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 Summar y 
 This new edition of the World Federation of Hemophilia ( WFH ) 
guidelines for the management of hemophilia comes at an exciting 
time in the evolution of the diagnosis and treatment of this condition. 
Since the publication of the second edition in 2012, tremendous ad-
vances have been made in several aspects of the management of he-
mophilia. These include genetic assessment as well as therapy with 
many innovative therapeutic products including extended half- life 
factor  VIII ( FVIII ) and factor  IX ( FIX ) products, a bi- specific antibody, 
and hemostasis rebalancing drugs now in clinical development. All 
of these allow for more effective hemostasis than was possible in 
the past. Laboratory monitoring of therapies is better defined and 
prophylaxis is accepted as the only way to change the natural his-
tory of bleeding. There are highly effective therapies for patients 
with inhibitors. Outcome assessment with validated clinimetric in-
struments is widely advocated and practiced. All these advances are 
reflected in this third edition of the  WFH guidelines, with new chap-
ters devoted to several of these topics along with a new chapter on 
principles of care that aims to provide a framework for development 
of a comprehensive healthcare system for hemophilia including ad-
vocacy and empowerment for people with hemophilia ( PWH ). The 
recommendations in this edition were all developed through a for-
mal evidence- informed and consensus- based methodology involving 
multidisciplinary healthcare professionals ( HCP s) and well- informed 
 PWH . While directed primarily at  HCP s, these guidelines should also 
be very useful for  PWH as well as advocacy organizations. 
 K E Y W O R D S 
bleeding disorders ,  hemophilia ,  management guidelines ,  novel 
hemostasis products ,  outcomes ,  treatment 
 This third edition of the WFH Guidelines for the Management of 
Hemophilia has been endorsed by the Asian- Pacific Society on 
Thrombosis and Hemostasis, European Haemophilia Consortium, 
and National Hemophilia Foundation (USA). 
 WFH Guidel ines Disc la imer 
 The World Federation of Hemophilia (WFH) does not endorse any 
particular treatment product or manufacturer; any reference to 
a product name is not an endorsement by the WFH. The WFH 
does not engage in the practice of medicine and under no circum-
stances recommends particular treatments for specific individu-
als. Guidelines are intended for general information only and are 
based on population level research, not for the care or treatment 
of any particular individual. Guidelines do not replace profes-
sional medical care and physician advice and/or product insert 
information, but should be used to educate and inform shared 
decision- making between patients, caregivers, and healthcare 
providers. 
 Furthermore, guidelines may not be complete or accurate be-
cause new research studies may have been published or treat-
ments, devices, or indications approved after the cut- off date for 
inclusion in these guidelines. Through a comprehensive and sys-
tematic literature review, WFH evidence- informed clinical practice 
guidelines incorporate data from the existing peer- reviewed litera-
ture. Although this literature met the pre- specified inclusion criteria 
for the guideline, and the WFH considered this scientific content to 
be the best evidence available for general clinical information pur-
poses at the time the guidelines were developed, this evidence is of 
varying quality and varying methodological rigor. 
 The WFH and its officers, committees, members, employees, 
and guideline authors and reviewers (“WFH Parties”) disclaim all 
liability for the accuracy or completeness and disclaim all warran-
ties, express or implied. The WFH Parties further disclaim all liability 
for any damages whatsoever (including, without limitation, direct, 
indirect, incidental, punitive, or consequential damages) arising out 
of the use, inability to use, or the results of use of a guideline, any 
references used in a guideline, or the materials, information, or pro-
cedures contained in a guideline, based on any legal theory whatso-
ever and whether or not there was advice on the possibility of such 
damages. 
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 With more than one million print and online distributions in six 
languages and more than 1000 citations in peer- reviewed articles 
since its publication in 2012, the World Federation of Hemophilia 
(WFH) clinical practice resource,  Guidelines for the Management of 
Hemophilia, 2nd edition , has served the community of hemophilia 
care providers and people with hemophilia extensively. Endorsed 
by the International Society on Thrombosis and Haemostasis (ISTH), 
the WFH guidelines were also the first hemophilia management 
guidelines to be accepted by the National Guideline Clearinghouse 
(NGC), formerly run by the Agency for Healthcare Research and 
Quality (AHRQ) of the United States Department of Health and 
Human Services ( https://www.ahrq.gov/gam/index.html ). 
 Over the past five years, unprecedented progress has been made 
not only in the development of newer therapeutics for hemophilia, 
but major paradigm shifts have also occurred in many of the princi-
ples governing the planning and philosophy of hemophilia treatment. 
Given the progress in genetic analysis technologies, in addition to 
much wider access, their applications in hemophilia have moved 
from the research arena to an increasingly greater role in the man-
agement of patients and their families. The advent of newer clotting 
factor concentrates (CFCs) with extended half- life has not only led to 
decreased burden of care for patients; more importantly, extended 
half- life CFCs have made it possible to maintain significantly higher 
factor trough levels on regular replacement therapy than has been 
possible with standard half- life CFCs. The bar of hemostatic safety 
was raised even higher with the introduction of non- CFC hemostatic 
agents such as the novel bispecific monoclonal antibody. This agent 
achieves hemostasis equivalent to approximately 15% FVIII levels, 
with subcutaneous administration and substantially less frequent 
dosing compared to CFCs. People with hemophilia treated with 
these newer therapies are now able to participate in many more ac-
tivities than ever before without fear of bleeding. In addition, struc-
tured outcome assessment has been a relatively unevolved aspect of 
the management of hemophilia. With greater emphasis over the past 
few years on its significance in routine management of hemophilia, 
several clinimetric instruments are now being used for the standard-
ized assessment and documentation of both hemostatic and muscu-
loskeletal outcomes. 
 To acknowledge these advances and establish them more firmly 
in clinical practice, several modifications have been made in the 
third edition of these guidelines. New chapters have been added to 
provide the required detail to the following topics: genetic assess-
ment; prophylaxis with hemostatic agents to prevent bleeding; man-
agement of inhibitors; and assessment of outcomes. An additional 
chapter defines the principles of management of hemophilia to pro-
vide aspirational benchmarks during the evolution of these services, 
within the local contexts of countries around the world. 
 Certain semantic changes introduced in this edition should be 
mentioned. The term “episodic” rather than “on demand” has been 
used to describe any hemostasis therapy after bleeding, as this 
term better reflects the concept of this practice. In keeping with 
the definition provided by the Scientific Standardization Committee 
of the ISTH, the term “exposure day” has been replaced with “expo-
sure” to encompass all CFC replacement doses administered within 
24 hours. 
 To ensure that bias was avoided as much as possible, a rigorous 
consensus- based methodology was adopted for formulating the 
final recommendations in these guidelines. An independent methods 
and process expert, unrelated to the field, was appointed alongside 
the content lead. All recommendations were informed by a compre-
hensive and systematic review of the relevant scientific literature 
and developed through an anonymous modified Delphi process re-
sulting in evidence- informed consensus- based recommendations. 
Importantly, in addition to the experts in hemophilia care and re-
lated clinical disciplines, the Delphi panels included well- informed 
patients who also had the opportunity to review the manuscripts 
and the literature, and vote on the recommendations. All these steps 
are described in detail in the Methodology chapter. 
 It is also important to note that the final chapter drafts were 
reviewed internally both by the full panel and within the WFH, as 
well as by external subject experts prior to submission for publica-
tion. All these reviewers have been acknowledged at the end of the 
guidelines along with many others whose contributions have been 
invaluable to their development. A final round of independent peer 
review was also conducted by the journal before publication. It is 
also important to note that these guidelines have been endorsed 
by the Asian-Pacific Society on Thrombosis and Hemostasis, 
European Haemophilia Consortium, and National Hemophilia 
Foundation (USA). 
 As a result of all these modifications, the guidelines have become 
more comprehensive than the previous edition. However, to pre-
serve their easy readability, the text remains structured using short 
sentences in bullet points. Detailed mechanistic explanations or 
descriptions of the original data underlying recommendations have 
been avoided. However, all relevant references have been cited and 
are listed at the end of each chapter. 
 It is hoped that the clinical care community, for whom these 
guidelines are primarily intended, will find them even more useful 
8  |    
than the previous editions. These guidelines may also serve as a 
resource to support education, advocacy, and decision- making re-
lated to hemophilia treatment and the delivery of care. In addition, 
they should help identify gaps in evidence upon which the recom-
mendations have been formulated to help direct appropriate clin-
ical research in these areas. As in the past, the electronic version 
of these guidelines is available on the WFH website ( http://www.
wfh.org ). These guidelines will be updated, added to, or modified as 
significant new data or evidence justifying change become available. 
This will keep the guideline content current and cognizant of the 
advances that are expected in the coming years, particularly in the 
area of gene therapy for hemophilia, which will need to be included 
in more detail once the ongoing clinical trials are over and products 
are registered. 
     |  9
 Chapter 1: Principles of Care 
 Alok  Srivastava 1   |    Gerard  Dolan 2   |    Lisa  Bagley 3   |    Margareth C.  Ozelo 4   |   
 Emna  Gouider 5   |    Debbie  Hum 6   |    Steven W.  Pipe 7   |    Bradley  Rayner 8   |    Alison  Street 9   |   
 Glenn F.  Pierce 6  
  1  Department of Haematology ,  Christian Medical College ,  Vellore ,  India 
  2  Guy ' s and St. Thomas’ Hospitals  NHS Foundation Trust ,  London ,  UK 
  3  London ,  UK 
  4  INCT do Sangue Hemocentro UNICAMP ,  University of Campinas ,  Campinas ,  SP ,  Brazil 
  5  Medical School, University of Tunis El Manar, Hemophilia Centre, Aziza Othmana Hospital, Tunis, Tunisia
  6  World Federation of Hemophilia ,  Montreal ,  QC ,  Canada 
  7  Departments of Pediatrics and Pathology ,  University of Michigan ,  Ann Arbor ,  Michigan ,  USA 
  8  Cape Town ,  South Africa 
  9  Monash University ,  Melbourne ,  Victoria ,  Australia 
 Introduction 
•  These principles of care aim to provide globally relevant guidance 
based on current science and best practices in hemophilia diag-
nosis and treatment, as identified by the guidelines panel of the 
World Federation of Hemophilia (WFH). They include core con-
cepts, requirements, and priorities in the delivery and manage-
ment of hemophilia care, which together constitute a framework 
for implementing and advancing hemophilia treatment programs. 
•  The principles build on the original tenets set out by the WFH 
and the World Health Organization (WHO) in 1990 1 and the up-
dated guidelines and recommendations developed collaboratively 
by the WFH, WHO, and International Society on Thrombosis and 
Haemostasis (ISTH) in 2002. 2 
•  The principles integrate core components of principled integrated 
care 3 and primary health care, including: meeting people ' s life-
time health needs through comprehensive preventive, curative, 
and rehabilitative services as well as palliative care; addressing 
the broader determinants of health through multisectoral policy 
and action that engages relevant stakeholders and enables local 
communities to strengthen primary health care; and empowering 
individuals, families, and communities to take charge of their own 
health. 4 
•  In addition, they align with the chronic care model ' s emphasis on 
the need to shift from acute, episodic, and reactive care towards 
care that embraces longitudinal, preventive, community-based, 
and integrated approaches. 5 
•  In addition to guiding clinical practice, principles of care can also 
serve as a common foundation of understanding for patient or-
ganizations, healthcare providers, healthcare administrators, and 
policymakers; this in turn enables better discussion and collab-
oration on decisions surrounding allocation of resources for he-
mophilia programs, and priorities for achieving the best standards 
possible within the available resources. 
•  Principles of care aim for ideal hemophilia management to en-
sure that patients have access to appropriate, sustained, and 
high-quality medical services and comprehensive care; however, 
it should also be recognized that the priorities and capabilities in 
each country determine what is practical at any point in time. 
 1.1  |  Principle 1: National coordination and 
delivery of hemophilia care 
•  A coordinated hemophilia care program, administered through a 
designated agency and integrated within the existing healthcare 
system, improves outcomes for people with hemophilia. 2,6-8 
•  Optimal hemophilia care within such a program requires the fol-
lowing key components 2 :
 ◦  comprehensive hemophilia care provided by a multidisci-
plinary team of specialists;  
 ◦  a national or regional network of hemophilia treatment cen-
tres (HTCs); 
 ◦  a national registry of patients with hemophilia; 
 ◦  robust processes for the procurement and distribution of safe 
and effective therapies, particularly clotting factor concen-
trates (CFCs) and other types of hemostasis products used in 
hemophilia treatment; 
 ◦  equitable access to these services and therapeutic products 9 ; 
and 
 ◦  recognition of the socioeconomic and cultural diversities 
within any given community, region, or country. 
 Comprehensive hemophilia care 
•  Treatment centres based on the multidisciplinary comprehen-
sive care model should be established to ensure that people with 
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hemophilia have access to the full range of clinical specialties and 
appropriate laboratory services. 6 
•  See Principle 7: Multidisciplinary care for hemophilia and Chapter 
2: Comprehensive Care of Hemophilia. 
 Network of hemophilia treatment centres 
•  Hemophilia care is best provided through designated diagnostic 
and treatment centres with clearly defined treatment protocols, 
standards of care, and quality and audit activities. 2 
•  Hospitals providing clinical care for people with hemophilia and 
related disorders are strongly encouraged to seek formal designa-
tion as a hemophilia treatment centre (HTC) or hemophilia com-
prehensive care centre (HCCC), as applicable, by the local health 
authorities 6,9 (see Table  1-1 ). 
•  Such centres can also serve the needs of patients with other con-
genital bleeding disorders. 
 National patient registry 
•  Each country should have a national registry of patients with 
hemophilia, with standardized data collection by all hemophilia 
centres and centralized administration by a nationally man-
dated authority, or participate in a multinational or international 
registry. 10-13 
•  The WFH ' s World Bleeding Disorders Registry (WBDR) provides 
an online platform for a network of HTCs around the world to col-
lect uniform and standardized data to track treatment and man-
agement of patients, monitor patient outcomes, and guide clinical 
practice. 13 The WBDR can be used as a patient registry for some 
or all HTCs within a country. 
•  Patient registries are used to collect accurate data on people with 
hemophilia in terms of their treatment and outcomes including 
disease severity, type of treatment, bleeding episodes, adverse 
events, joint status, inhibitor status, comorbidities, and quality of 
life. 
•  Registry data allow analysis of standards of care and can be used 
as a tool for auditing clinical and laboratory services; this in turn 
can support the development of better quality of care and facili-
tate resource planning and allocation. 6 
•  Patient registries can help to advance understanding of the vari-
ations in hemophilia treatment; describe care patterns, including 
appropriateness and disparities in the delivery and quality of care; 
indicate factors that influence prognosis and quality of life; and 
provide evidence on resource utilization. 14 
•  Adequate provision must be made for data privacy, confidenti-
ality, and respect for human rights 10 in compliance with national 
regulations and best ethical practices. 6 
•  It is important to ensure that the patient and/or the parent or legal 
guardian (in the case of minors) understands a registry ' s purpose 
and uses and provides informed written consent for the collection 
and sharing of data related to the patient ' s care. 10,15 
•  See Chapter 2: Comprehensive Care of Hemophilia and Chapter 
11: Outcome Assessment. 
 National or regional procurement of 
hemophilia therapies 
•  Sustained availability of CFCs in sufficient quantities is 
strongly correlated with better outcomes for people with he-
mophilia. 16 To ensure that people with hemophilia have reliable 
access to safe and effective CFCs and other hemostasis prod-
ucts, countries must establish a rigorous national or regional 
system for the procurement and distribution of hemophilia 
therapies. 2 
•  Hemophilia treatment relies on essential life-saving medicines 
that are relatively expensive compared to medications for other 
conditions. 
•  Setting up a national tender system or collaborating in a multi-
national system for the purchase of CFCs can help ensure that 
optimal products are selected at the best price. 17 
•  The decision-making process for such tenders under the contract-
ing authority (typically the Ministry of Health or other health au-
thority) should include both well-informed hemophilia clinicians 
and patient representatives. 9 
•  The WFH ' s  Guide to National Tenders for the Purchase of Clotting 
Factor Concentrates describes tender and procurement systems 
around the world and explains how to set up a national procure-
ment system and carry out tenders. 17 
•  See Chapter 2: Comprehensive Care of Hemophilia and Chapter 
5: Hemostatic Agents. 
 1.2  |  Principle 2: Access to safe CFCs, other 
hemostasis products, and curative therapies 
 Safe and effective CFCs 
•  People with hemophilia must have access to safe and effective 
treatment with optimal efficacy in the prevention of bleeding and 
treatment of any spontaneous, breakthrough, or trauma-related 
bleeding. For many, this involves treatment with specific CFCs or 
other hemostasis products. 
•  Both virus-inactivated plasma-derived and recombinant CFCs, as 
well as other hemostasis products when appropriate, can be used for 
treatment of bleeding and prophylaxis in people with hemophilia. 16 
•  Prophylaxis is the standard of care for people with severe he-
mophilia, and for some people with moderate hemophilia, or for 
those with another congenital bleeding disorder that is associated 
with a severe bleeding phenotype and/or a high risk of sponta-
neous life-threatening bleeding. 
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•  Episodic CFC replacement should not be considered a long-
term option for the management of hemophilia as it does not 
alter its natural history of spontaneous bleeding and related 
complications. 18,19 
•  The WFH ' s  Guide for the Assessment of Clotting Factor Concentrates 
should be carefully reviewed in the context of the healthcare sys-
tem in each country and incorporated into tender processes for 
procurement of hemophilia therapies. 16 
•  The  WFH Online Registry of Clotting Factor Concentrates lists all 
currently available plasma-derived and recombinant CFCs and 
their product details. 20 
•  See Chapter 5: Hemostatic Agents and Chapter 6: Prophylaxis in 
Hemophilia. 
 Emerging therapies and potential cures 
•  Emerging therapies in development with alternative modes of 
delivery (e.g., subcutaneous injection) and novel targets may 
overcome the limitations of standard CFC replacement therapy 
(i.e., need for intravenous administration, short half-life, risk of 
inhibitor formation). These emerging therapies offer markedly 
improved pharmacokinetic (PK) profiles with a very low burden 
of administration (e.g., up to monthly dosing); therefore, they 
may help reduce treatment burden and increase compliance. 
These therapies are discussed in Chapter 5: Hemostatic Agents, 
Chapter 6: Prophylaxis in Hemophilia, and Chapter 8: Inhibitors 
to Clotting Factor. 
•  The development of gene therapies for hemophilia has advanced 
significantly, with product registration likely in the near future. 
Several clinical trials in both people with hemophilia A and B 
have demonstrated success with a favourable safety profile to 
date. 21,22 
•  Gene therapy should make it possible for some people with he-
mophilia to aspire to and attain much better health outcomes and 
quality of life than that attainable with currently available hemo-
philia therapies. This will require evaluation through long-term 
follow-up as part of clinical trials and registries. 
•  Given the ongoing advances transforming the hemophilia treat-
ment landscape, it is important to establish systems to constantly 
monitor developments in emerging and gene therapies for hemo-
philia and make them available as soon as possible following ap-
proval by regulatory authorities. 
•  See Chapter 5: Hemostatic Agents, Chapter 6: Prophylaxis in 
Hemophilia, and Chapter 8: Inhibitors to Clotting Factor. 
 1.3  |  Principle 3: Laboratory services and genetic 
diagnosis of hemophilia 
 Laboratory diagnosis and testing 
•  The diagnosis and treatment of hemophilia require access to 
laboratory facilities that are equipped with appropriate re-
sources and expertise to accurately perform factor assays and 
other coagulation tests. 
 TA B L E   1 1     Roles of hemophilia comprehensive care centres and hemophilia treatment centres 6 
 Hemophilia comprehensive care centre (HCCC)  Hemophilia treatment centre (HTC) 
•  Provide 24- hour service with experienced staff •  Provide 24- hour, appropriate hematological cover 
•  Provide inhibitor care and immune tolerance services •  Operate inhibitor care and immune tolerance services in cooperation with a HCCC 
•  Provide safe and effective CFCs and other hemostasis 
products 
•  Provide safe and effective CFCs and other hemostasis products 
•  Provide community liaison, including school and home 
visits 
•  Provide access to nursing staff, physical therapy services, social workers, and 
obstetric and gynecological services 
•  Offer laboratory services with 24- hour assay cover •  Provide preliminary genetic counselling followed by referral to a HCCC for full 
review 
•  Provide access to hospital- based nursing staff, 
physical therapy services, social workers, dental 
services, obstetric and gynecological services, and 
psychosocial support 
•  Provide access to HIV and hepatitis C care, through a HCCC, if necessary 
•  Provide HIV and hepatitis C care •  Offer regular follow- up and home treatment in cooperation with a HCCC 
•  Provide access to a genetics laboratory and genetic 
counselling 
•  Provide prophylaxis in cooperation with a HCCC 
•  Provide home treatment •  Keep reliable records 
•  Keep reliable records •  Undertake medical education 
•  Undertake medical education •  Collaborate with other HTCs in research and exchange of best practices 
•  Initiate and participate in research  
 Abbreviations: CFC, clotting factor concentrate; HCCC, hemophilia comprehensive care centre; HIV, human immunodeficiency virus; HTC, 
hemophilia treatment centre.  
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•  Screening and testing for inhibitor development, now the most 
serious complication in hemophilia, is vital for any compre-
hensive hemophilia treatment program to be able to provide 
medical treatment and eradication of inhibitors 23 ; however, 
most centres around the world do not have inhibitor testing 
capacities. 
•  In many resource-constrained countries, centres and hospitals 
lack the appropriate technologies and capabilities for diagnosing 
hemophilia. Therefore, developing or enhancing existing labora-
tories with the capacity to perform coagulation tests with assured 
quality is an important priority in these countries. 8 
•  Coagulation laboratories must have well-trained laboratory staff 
and appropriate resources, including suitable and readily available 
reagents. 
•  Ideally, coagulation laboratories should be able to provide 24-
hour services for coagulation tests and factor assays and be able 
to perform inhibitor assays in a timely manner. 6 
•  It is essential to have good communication between the labora-
tory and the clinical team ordering the tests to ensure that the 
appropriate assays are carried out and that the results reported 
are correctly evaluated and well understood. 24 
•  All coagulation laboratories should include quality assurance pro-
grams and be subject to external quality assessment. 
•  See Chapter 3: Laboratory Diagnosis and Monitoring – Quality 
assurance. 
 Genetic assessment of hemophilia 
•  Genetic assessment of hemophilia is important to define disease 
biology, establish diagnosis in difficult cases, predict risk of in-
hibitor development, and provide prenatal diagnosis if desired. 
Wherever possible, genotype analysis should be offered to all pa-
tients with hemophilia. 9 (See Chapter 2: Comprehensive Care of 
Hemophilia and Chapter 3: Laboratory Diagnosis and Monitoring.) 
•  Genetic testing will not always identify the underlying variant as-
sociated with the phenotype. Genetic counselling of the person 
with hemophilia referred for genetic testing should highlight this 
possibility. 
•  The opportunity for discussion of the genetic analysis results be-
tween the clinical and the laboratory teams involved is an essen-
tial aspect of the genetic diagnostic service. 
•  Advances in molecular genetic technologies are becoming rou-
tinely integrated into many genetic diagnostic laboratories. Full  F8 
or  F9 gene screening is performed by polymerase chain reaction 
(PCR) and Sanger sequencing, or next-generation sequencing. 25-29 
Use of these techniques is evolving and increasing internation-
ally. The approach and use of a specific technique depend on the 
available technical expertise and resources. Genetic counselling 
must include comprehensive discussion about the possibility of 
incidental findings in genes other than  F8 or  F9, depending on the 
methods being used for the assessment. 
•  See Chapter 2: Comprehensive Care of Hemophilia, Chapter 
3: Laboratory Diagnosis and Monitoring, Chapter 4: Genetic 
Assessment, Chapter 8: Inhibitors to Clotting Factor, and Chapter 
9: Specific Management Issues. 
 1.4  |  Principle 4: Education and training in 
hemophilia care 
 Recruitment of medical specialists 
•  As hemophilia is a rare disorder in which the availability of spe-
cialized care is a critical determinant of burden of disease, 30 
recruitment and training of medical specialists in hemophilia 
management are key to establishing, maintaining, and advancing 
standards of care to reduce morbidity and mortality among peo-
ple with hemophilia in well-resourced and resource-constrained 
countries alike. 
•  Recruitment of physicians, hematologists, and scientists in the 
area of thrombosis and hemostasis to the field of hemophilia is 
essential to ensure sustained, high-quality medical care, together 
with recruitment of medical laboratory specialists, nurses, physi-
cal therapists, occupational therapists, and other musculoskeletal 
specialists (e.g., orthopedic surgeons, rheumatologists, and phys-
iatrists), dentists, and psychosocial counsellors. All are integral to 
multidisciplinary comprehensive care for hemophilia and require 
ongoing specialist education and development for practice in this 
field. 
•  Hemophilia education for allied specialists needed to help address 
specific medical and health-related issues that may arise in some 
patients is also important. 
•  Mentorship and fellowship opportunities are valuable and effec-
tive means to attract and retain new healthcare providers to the 
field of hemophilia. 
•  A coordinated approach to advancing clinical expertise in hemo-
philia (i.e., continued education, training, and fellowship programs) 
based on local, regional, and/or national needs and priorities will 
provide the foundation for sustaining and improving standards of 
care. 
•  Collaboration between hemophilia centres in re-
source-constrained and well-resourced countries and support 
from established expert bodies are effective avenues for ad-
vancing hemophilia knowledge, expertise, and standards of 
care. 8 
•  The WFH works in many countries around the world to help 
develop and expand local, regional, and national capacities in 
laboratory diagnosis and treatment of hemophilia through its 
medical twinning program, humanitarian aid program, 31 and mul-
tidisciplinary education and training workshops for healthcare 
providers. 32 
•  See Principle 7: Multidisciplinary care for hemophilia and Chapter 2: 
Comprehensive Care of Hemophilia. 
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 1.5  |  Principle 5: Clinical and epidemiological 
research 
•  Evidence-based research in hemophilia is greatly needed, but it 
is hampered by significant challenges due to the small size of the 
patient population. 
•  As most aspects of clinical management of hemophilia are empir-
ical and lack high-level evidence, well-designed studies to gen-
erate the necessary evidence to evaluate current practices are 
needed. 8 A mutual basic scheme, such as the WHO ' s International 
Classification of Functioning, Disability and Health (ICF), ensures 
that disciplines are connected by the same model. 
•  Given the differences in priorities in practice around the world, it 
is important to promote locally relevant clinical research. 
•  Standardization of outcome assessment will permit meaningful 
comparison across studies. 33 
•  Priority areas for clinical research in hemophilia include optimiza-
tion of clotting factor replacement therapy; better understanding 
and prevention of inhibitor formation; and clinical data collection 
on existing hemophilia therapies and clinical practices, newer 
therapies such as extended half-life CFCs and non-factor hemo-
stasis products, and potential gene therapies. 
•  Patient registries, with national and international collaboration 
between centres and countries, are an effective way to pool data 
to achieve the required sample size to conduct clinical research on 
rare disorders such as hemophilia. 
•  The WFH ' s World Bleeding Disorders Registry allows research-
ers to address important questions around patient care, compare 
country-specific levels of care, and use the evidence to advocate 
for better hemophilia care. 13 
•  See Chapter 5: Hemostatic Agents, Chapter 6: Prophylaxis in 
Hemophilia, Chapter 8: Inhibitors to Clotting Factor, and Chapter 
11: Outcome Assessment. 
 1.6  |  Principle 6: Acute and emergency care for 
bleeds 
•  In critical situations, people with hemophilia need immediate ac-
cess to emergency medicines and treatment as well as to special-
ist care at hospital emergency departments. 6 Lack of experience 
and knowledge of hemophilia management among medical pro-
fessionals, particularly in emergency departments, may lead to 
serious treatment-related complications. 8,34 
•  Therefore, it is essential to establish systems that are accessible 
around the clock for the management of acute life- or limb-threat-
ening complications of hemophilia. 8 
•  Treatment centres should develop protocols for emergency care for 
people with hemophilia, including those with inhibitors, that include 
management of serious acute complications such as intracranial 
hemorrhage (ICH) and other types of major internal hemorrhage and 
trauma. 8 (See Principle 9: Management of patients with inhibitors.) 
•  People with hemophilia should not be kept waiting in emergency 
departments and should be assessed immediately, even for 
less serious complications which can deteriorate while waiting. 
Prompt intervention is mandatory. 8 
•  Primary physicians and HTC staff must be prepared to attend to 
emergency situations and provide advice and specialist support 
without delay. 6 
•  The use of national online databases or the WBDR to capture 
treatment and health-related patient data allows for better 
acute and long-term management of people with hemophilia, 
and the use of digital mobile devices allows patients to record 
their bleeds and transmit their information to their HTC in real 
time. 8 
•  See Principle 7: Multidisciplinary care for hemophilia and Chapter 2: 
Comprehensive Care of Hemophilia. 
 1.7  |  Principle 7: Multidisciplinary care for 
hemophilia 
•  Optimal care of people with hemophilia, especially those with se-
vere forms of the disorder, requires treatment and comprehensive 
care provided by a multidisciplinary team of specialists. 
•  Priorities in treatment and care to ensure the best health and 
quality-of-life outcomes for people with hemophilia include 6,8 :
 ◦  prevention of bleeding and joint damage; 
 ◦  prompt management of bleeding episodes including follow-up 
physical therapy and rehabilitation; 
 ◦  appropriate emergency care; 
 ◦  appropriate pain management; 
 ◦  management of musculoskeletal complications and inhibitor 
development; 
 ◦  management of comorbidities; 
 ◦  regular psychosocial assessment and support as needed; and 
 ◦  ongoing education on treatment and self-care for people and 
families living with hemophilia. 
 Patient self- management and empowerment 
•  Self-management, i.e., the ability of patients to undertake 
daily management of their health and health care, 5 is essential 
in hemophilia. People with hemophilia must be competent in 
controlling bleeding symptoms to preserve their health, joint 
integrity, and functional independence. 2 Self-management al-
lows them to minimize the short- and long-term consequences 
of the disorder and can help provide a sense of normalcy and 
control. 35 
•  Key components of self-management in hemophilia include 35 : 
 ◦  bleed recognition; 
 ◦  record-keeping of bleeds and treatment; 
 ◦  self-administration of CFCs or other hemostasis products; 
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 ◦  self-care (i.e., nutrition and physical fitness) and medicines 
management (i.e., record-keeping, treatment routines, mainte-
nance of adequate treatment supply, proper storage, reconsti-
tution, and administration of treatment products); 
 ◦  pain management; 
 ◦  risk management; and 
 ◦  participation in outcome reporting and documentation. 
•  Patient advocacy organizations have played an important role in 
advancing hemophilia care around the world. Such organizations 
should therefore be encouraged and supported to cover those 
aspects of care which are not covered by the healthcare system, 
including emphasis on patient empowerment and working with 
other agencies to advance care. 
•  See Chapter 2: Comprehensive Care of Hemophilia, Chapter 7: 
Treatment of Specific Hemorrhages, Chapter 8: Inhibitors to 
Clotting Factor, Chapter 9: Specific Management Issues, and 
Chapter 10: Musculoskeletal Complications. 
 Transition from pediatric to adult care 
•  The transition from pediatric to adult care, during which adoles-
cents and young adults with hemophilia gradually assume respon-
sibility for their own health and hemophilia management, can be a 
challenge for patients and their families. 36 
•  Treatment adherence is a key challenge at two transition points: 
when young people with hemophilia switch to self-infusion, and 
again when they move away from home and assume the full re-
sponsibility of self-care. 37 
•  Comprehensive hemophilia care should therefore include a con-
scientious approach to transition of care that starts in early ad-
olescence 38 and supports the development of young people ' s 
self-efficacy and self-management skills, including psychosocial 
coping. 37 
•  Both pediatric and adult healthcare providers must be engaged in 
considering the individual needs of patients and families to ensure 
a smooth transition and to ensure the best care possible during 
this time. 36 
•  Engagement of adolescents and their caregivers early in the tran-
sition process allows time for acceptance and better understand-
ing of the transition from the pediatric to the adult model of care 
as well as the associated reallocation of health management and 
medical decision-making responsibilities. 39 
•  See Chapter 2: Comprehensive Care of Hemophilia – Transition 
from pediatric to adult care and Chapter 9: Specific Management 
Issues – Psychosocial issues. 
 1.8  |  Principle 8: Regular replacement therapy 
(prophylaxis) 
•  The standard of care for all patients with severe hemophilia is 
regular replacement therapy (prophylaxis) with CFCs, or other 
hemostasis products to prevent bleeding, started early in life (be-
fore age 3) to prevent musculoskeletal complications from recur-
rent joint and muscle bleeds. 40 
•  Episodic (“on demand”) clotting factor replacement therapy should 
no longer be considered to be a long-term treatment option. 
•  Implementation of home-based prophylaxis programs increases 
compliance and allows people with hemophilia to live relatively 
normal lives. These programs should be accompanied by educa-
tion of patients, families, and healthcare providers on the bene-
fits of prophylaxis and the importance of adherence to treatment 
regimens. 35,37,41 
•  Prophylaxis in young children may be the best way for a coun-
try to begin implementing universal prophylaxis for people with 
hemophilia. 8 
•  See Chapter 6: Prophylaxis in Hemophilia and Chapter 10: 
Musculoskeletal Complications. 
 1.9  |  Principle 9: Management of patients 
with inhibitors 
•  Systematic surveillance for inhibitors and comprehensive man-
agement of inhibitors should be implemented for people with he-
mophilia A, 23 particularly when patients are at highest risk during 
their first 20 exposures to CFCs (with one exposure defined as all 
CFCs administered within a 24-hour period 8,42 ), and thereafter up 
to 75 exposures. 43 
•  Eradication of inhibitors is currently best achieved through im-
mune tolerance induction (ITI) therapy. 
•  Patients who develop inhibitors should have access to ITI and to 
suitable hemostatic agents for control of bleeding as well as sur-
gical interventions, if needed, at specialized centres with relevant 
experience. 9,23 
•  Bypassing agents and other suitable treatment products should 
be available for patients who do not respond to enhanced factor 
dosages or ITI. 23,40,44 
•  Given the costs and other limitations of current treatment modal-
ities, research and innovation in the prevention and treatment of 
inhibitors are required. 8 
•  See Chapter 5: Hemostatic Agents and Chapter 8: Inhibitors to 
Clotting Factor. 
 1.10  |  Principle 10: Management of musculoskeletal 
complications 
•  The prevention and treatment of musculoskeletal complications 
in people with hemophilia are important to their health, auton-
omy, and quality of life. 
•  In all cases of musculoskeletal bleeding, adequate treatment gen-
erally requires a combination of clotting factor replacement ther-
apy and physical therapy with an experienced physical therapist 
to achieve complete functional recovery. 45 
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•  People with hemophilia should also have access to musculoskel-
etal specialists (i.e., physical therapist, occupational therapist, 
physiatrist, physical medicine/rehabilitation specialist, rheumatol-
ogist, orthopedist, orthopedic surgeon) with experience in hemo-
philia, with annual musculoskeletal assessments and longitudinal 
monitoring of their musculoskeletal outcomes and preventive or 
corrective measures as needed. 
•  Surgical interventions may become necessary for musculoskeletal 
complications if nonsurgical measures fail to provide satisfactory 
pain relief and improved function. Orthopedic surgeons should 
have specific training in surgical management of patients with 
hemophilia. 
•  See Chapter 2: Comprehensive Care of Hemophilia and Chapter 
10: Musculoskeletal Complications. 
 1.11  |  Principle 11: Management of specific 
conditions and comorbidities 
•  Specific complications and management issues may affect peo-
ple with hemophilia and their families at different life stages. 
Treatment and care for these conditions should be established as 
part of national hemophilia programs. 
 Carriers of hemophilia 
•  Some carriers of hemophilia experience bleeding problems, in-
cluding joint hemorrhages, similar to males; in addition, they may 
experience problems that are specific to women, such as pro-
longed or heavy menstrual bleeding. 46-49 Symptomatic carriers 
are considered to have mild or moderate hemophilia. It is there-
fore important to include a gynecologist in the comprehensive 
care team for the management of carriers. 
•  Carriers may experience a significant impact on various aspects of 
their lives and thus require specialist care specific to reproductive 
issues, including genetic counselling, genetic testing, prenatal diag-
nosis and planning, newborn testing, and psychosocial counselling. 
•  See Chapter 9: Specific Management Issues – Carriers. 
 Surgery and other invasive procedures 
•  Surgeries and other invasive procedures pose particular risks to 
patients with hemophilia; however, these procedures can be per-
formed safely with the provision of adequate laboratory support, 
careful preoperative planning, appropriate hemostasis with suffi-
cient quantities of CFCs and other hemostasis products during and 
after surgery, and optimal postoperative recovery and rehabilitation. 
•  Therefore, treatment centres and hospitals should establish pro-
tocols to ensure that people with hemophilia, with or without in-
hibitors, have ready access to these services, both in acute and 
elective surgery situations. 
•  See Chapter 9: Specific Management Issues – Surgery and inva-
sive procedures. 
 Management of comorbidities 
•  Improved life expectancy in hemophilia has led to a greater in-
terest in age-related disorders, with cardiovascular disease, hy-
pertension, and other cardiovascular risk factors increasingly 
reported in adults with hemophilia. 50-54 
•  The treatment of comorbidities, especially cardiovascular dis-
eases, is one of the most important challenges. 50 
•  Although most evidence suggests that hemophilia, at least the se-
vere form, partially protects against myocardial infarction, stroke, 
and venous thromboembolism, typical cardiovascular risk fac-
tors may still be present and cause disease despite the clotting 
defect. 50,55 
•  People with hemophilia are equally or even more prone to obesity, 
hypertension, and diabetes than the general population. 50 
•  Preventive strategies are needed to identify people with hemo-
philia who are at higher risk of developing cardiovascular disease 
in adulthood. 56 
•  See Chapter 9: Specific Management Issues – Comorbidities. 
 Medical issues with aging 
•  As they age, people with hemophilia require education and pre-
ventive strategies to reduce the risks and impacts of age-related 
morbidities. 
•  The hemophilia team should be closely involved in the planning 
and management of specialist care for people with hemophilia 
with comorbidities and any complications related to aging, to fa-
cilitate close consultation and agreement on treatment plans. 
•  Elderly patients with hemophilia should be managed in the same 
way as their peers in the general population, except for the nec-
essary additional correction of impaired hemostasis with CFCs. 50 
•  Specialist services should be well versed in bleed management and 
the specific treatment requirements of people with hemophilia. 8 
•  See Chapter 9: Specific Management Issues – Medical issues with 
aging. 
 Management of transfusion- transmitted infections 
•  Transfusion-transmitted infections, particularly those with the 
human immunodeficiency and hepatitis C viruses, have been 
major complications in the treatment of hemophilia in the past. 
•  It is absolutely imperative to ensure that current replacement 
therapy products are well tested and virally inactivated to avoid 
any chance of such infections being transmitted. 
•  While the management of these conditions will not be covered 
further in these guidelines, given the effectiveness of current 
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anti-viral therapies for both these conditions, it is important that 
relevant services be universally accessible to all patients with he-
mophilia who need them. 57 
 1.12  |  Principle 12: Outcome assessment 
•  In the management of hemophilia, outcome assessment refers to 
the use of specific tools designed to monitor an individual ' s dis-
ease course and to measure the consequences of the disease and 
its treatment (i.e., effectiveness of hemostatic therapy and asso-
ciated complications). 33 
•  To ensure that all consequences of the disorder are evaluated, 
outcome assessment should follow the WHO ' s ICF model. 58,59 
•  Standardized, validated outcome assessment is necessary for the 
clinical management of individual patients, to assess the quality of 
care provided, and for research or advocacy purposes. 33 
•  The most important indicator of the efficacy of hemostatic ther-
apy is frequency of bleeding, particularly joint and muscle bleeds. 
Bleeding frequency is the primary parameter for treatment deci-
sions and is also used as a predictor of long-term musculoskeletal 
outcomes. 6 
•  In hemophilia care, the impact of bleeding on the musculoskeletal 
and other systems is measured across several domains, including 
body structure and function and activities and participation. All 
of these domains may be affected by contextual factors including 
environmental, personal, and economic factors. 33 
•  Multiple clinical and radiological tools are used to assess the sta-
tus of joints and specific muscle groups. Measurements of activi-
ties and participation are either self-reported or observed. 6,60 
•  The ongoing development of hemophilia-specific measurement 
and assessment tools offers opportunities for clinicians and pa-
tients to better understand and evaluate the nature of the impair-
ments and functional limitations associated with the condition. 8,60 
•  Increasingly in recent years, health authorities, including health 
technology assessment bodies, are relying on patient-reported 
outcome data to evaluate the benefits of health interventions. 61 
•  Despite the availability of numerous assessment options, a core 
set of measures for outcome assessment in hemophilia remains 
to be defined. Such a core set should ideally be applicable to 
the clinical and cultural realities of hemophilia management 
worldwide. 12,13 
•  See Chapter 11: Outcome Assessment. 
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 All statements identified as recommendations are consensus based, 
as denoted by  CB . 
 2.1  |  Introduction 
•  Hemophilia is a rare X-linked congenital bleeding disorder char-
acterized by a deficiency of coagulation factor VIII (FVIII), called 
hemophilia A, or factor IX (FIX), called hemophilia B. The factor 
deficiencies are the result of pathogenic variants in the  F8 and  F9 
clotting factor genes. 
•  The best estimates of the prevalence of hemophilia, based on the 
most reliable national patient registry data available and recent 
World Federation of Hemophilia (WFH) annual global surveys, 
indicate that the expected number of males with hemophilia 
worldwide is 1,125,000, the majority of whom are undiagnosed, 
including an estimated 418,000 males with severe hemophilia. 1 
 Hemophilia A and B 
•  Hemophilia A is much more common than hemophilia B. 
Hemophilia A is estimated to account for 80%-85% of all hemo-
philia cases; hemophilia B is estimated to account for 15%-20% of 
all hemophilia cases. Estimated prevalence at birth is 24.6 cases 
per 100 000 males for all severities of hemophilia A (9.5 cases 
for severe hemophilia A) and 5.0 cases per 100 000 males for all 
severities of hemophilia B (1.5 cases for severe hemophilia B). 1 
•  Hemophilia is usually inherited through an X chromosome with an 
 F8 or  F9 gene mutation. However, both the  F8 and  F9 genes are 
prone to new mutations, and about 30% of all cases result from 
spontaneous genetic variants. Prospective studies report that 
over 50% of people newly diagnosed with severe hemophilia have 
no prior family history of hemophilia. 2,3 
•  Hemophilia usually affects only males who inherit an affected 
maternal X chromosome. Females with hemophilia (FVIII or FIX 
<40 IU/dL) are rare; in such cases, both X chromosomes are af-
fected or one is affected and the other is inactive. A female with 
one affected X chromosome is called a carrier of hemophilia. 4 
•  Hemorrhages, musculoskeletal complications, and other se-
quelae of hemophilia typically occur in males with hemophilia 
but may also occur in a proportion of female carriers. Since 
the baseline factor levels in carriers may be normal or variably 
reduced, the symptoms and complications of hemophilia are 
less common in females and are often overlooked and underdi-
agnosed; joint bleeds in carriers often remain unrecognized, 
leading to poorer joint outcomes due to undiagnosed joint prob-
lems. Better diagnosis and management of bleeding problems 
in carriers are needed. (See Chapter 9: Specific Management 
Issues – Carriers.) 
 Clinical diagnosis 
•  Hemophilia should be suspected in individuals presenting with a 
history of any of these symptoms: 
 ◦  easy bruising; 
 ◦  “spontaneous” bleeding (i.e., bleeding for no apparent/known 
reason), particularly into the joints, muscles, and soft tissues; 
 ◦  excessive bleeding following trauma or surgery. 
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•  Early symptoms of joint bleeds in children at a very young age are 
a key indicator of severe hemophilia. 5 (See also “Bleeding mani-
festations” below.) 
•  If hemophilia is suspected, the clinician should obtain the patient ' s 
bleeding history and family history of abnormal or unexplained 
bleeding experienced by any siblings or maternal male relatives 
(i.e., maternal cousin, uncle, or grandfather) to assess patterns of 
inheritance and assist with diagnosis. 
•  Accurate diagnosis of hemophilia is essential to inform appropri-
ate management. A definitive hemophilia diagnosis is based on a 
factor assay to demonstrate deficiency of FVIII or FIX. 
•  See Chapter 3: Laboratory Diagnosis and Monitoring and Chapter 
4: Genetic Assessment. 
 Bleeding manifestations 
•  The characteristic phenotype in hemophilia is the bleeding ten-
dency. The severity of bleeding manifestations in hemophilia gen-
erally correlates with the degree of the clotting factor deficiency 
(see Table  2-1 ). 
•  People with mild hemophilia may not necessarily have abnormal 
or prolonged bleeding problems until they experience serious 
trauma or undergo surgery. 
•  People with severe hemophilia most commonly experience bleeds 
into the joints, muscles, and internal organs (see Tables  2-2 and 
 2-3 ). 
•  In newborns and children with severe hemophilia less than 2 years 
of age, common types of bleeding include 6,7 : 
 ◦  soft tissue and intramuscular bleeding; 
 ◦  bleeding associated with a medical procedure (e.g., venipunc-
ture, central line placement, circumcision, neonatal heel prick); 
 ◦  mucocutaneous bleeding (e.g., oral, nasal); 
 ◦  extracranial bleeding. 
•  Some types of bleeds can be life-threatening and require immedi-
ate treatment and medical attention. 
•  See Table  2-2 and Chapter 7: Treatment of Specific Hemorrhages. 
 Patient/caregiver education 
•  People with hemophilia and family/primary caregivers must re-
ceive comprehensive education on hemophilia care, particularly 
on the prevention and treatment of bleeds and management of 
musculoskeletal complications, and training on essential skills for 
self-management, including bleed recognition, self-treatment, 
record-keeping, dental care, and risk management. 10,11 (See 2.5 
Home therapy – Self-management, below.) 
 2.2  |  Comprehensive care 
•  Comprehensive hemophilia care involves multidisciplinary medical 
services necessary for the diagnosis, treatment, and management 
of the condition and its complications. These services are typically 
delivered by a hemophilia treatment centre or hemophilia compre-
hensive care centre, as described in Chapter 1: Principles of Care 
– Principle 1: National coordination and delivery of hemophilia 
care. Comprehensive care promotes physical health, psychosocial 
well-being, and quality of life for people with hemophilia and re-
duces morbidity and mortality. 11-13 It should encompass family-cen-
tred care, particularly diagnosis and management of carriers. 11,14 
 Key components of comprehensive care 
•  Hemophilia is a rare inherited disorder that is complex to diagnose 
and to manage. Optimal care, especially for people with severe forms 
of the disorder, requires more than treatment of acute bleeding. 
•  Priorities in hemophilia treatment and care include 10,11 : 
 ◦  prevention of bleeding and joint damage; 
 ◦  prompt management of bleeding episodes including physical 
therapy and rehabilitation after joint bleeds; 
 ◦  pain management; 
 ◦  management of musculoskeletal complications; 
 ◦  prevention and management of inhibitors; 
 ◦  management of comorbidities; 
 ◦  dental care; 
 ◦  quality-of-life assessments and psychosocial support; 
 ◦  genetic counselling and diagnosis; 
 ◦  ongoing patient/family caregiver education and support. 
•  Emergency care should be available at all times, with the following 
essential services and resources 10,11 : 
 ◦  coagulation laboratory services with the capacity to per-
form accurate and precise clotting factor assays and inhibitor 
testing; 
 TA B L E   2 1     Relationship of bleeding severity to clotting factor level 8 
 Severity  Clotting factor level  Bleeding episodes 
 Severe  <1 IU/dL (<0.01 IU/mL) or <1% of normal •  Spontaneous bleeding into joints or muscles, predominantly in the absence 
of identifiable hemostatic challenge 
 Moderate  1- 5 IU/dL (0.01- 0.05 IU/mL) or 1- 5% of 
normal 
•  Occasional spontaneous bleeding; prolonged bleeding with minor trauma or 
surgery 
 Mild  5- 40 IU/dL (0.05- 0.40 IU/mL) or 5- <40% of 
normal 
•  Severe bleeding with major trauma or surgery; rare spontaneous bleeding 
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 ◦  provision of clotting factor concentrates (CFCs), either vi-
rus-inactivated plasma-derived or recombinant, as well as 
other hemostatic agents such as desmopressin (DDAVP) and 
antifibrinolytic agents (tranexamic acid or epsilon amino-
caproic acid [EACA]) where available; 
 ◦  provision of safe blood components such as fresh frozen 
plasma (FFP) and cryoprecipitate if adequately screened, 
tested, and/or virus-inactivated where CFCs are not available; 
 ◦  casting and/or splinting and mobility/support aids, as needed. 
•  See Chapter 5: Hemostatic Agents. 
 Comprehensive care team 
•  The wide-ranging needs of people with hemophilia and their 
families are best met by a multidisciplinary team of healthcare 
professionals with expertise and experience in hemophilia, in 
accordance with accepted protocols and practices and national 
standards of care, if available. 10,15,16 
 Patient/healthcare provider partnership and decision- making 
•  People with hemophilia are regarded as distinct core members of 
the comprehensive care team who through day-to-day self-man-
agement become experts and partners in their own hemophilia 
care. 
•  It is important to involve patients (and their parents/caregivers) 
in decision-making; incorporate their particular preferences, val-
ues, and personal experiences; 17 and obtain their concurrence 
with short- and long-term treatment and management plans. All 
parties should engage in truly shared decision-making through 
educated discussions about available healthcare options and 
anticipated outcomes, including evidence-informed guideline 
recommendations, benefits and risks of the various choices, 
and expressed concerns and values of the patient and care-
givers. 18 They should work together on the development and 
periodic updating of individualized treatment guidelines that 
the patient/caregiver can consult at will and share with others 
involved in care. 
•  Increasingly, patients are not only active members of their own 
healthcare team; they are becoming full partners in the health-
care team who are also involved in research, medical education, 
and student training in recognition of the value of their particular 
understanding and expertise. 17 
 Multidisciplinary team 
•  The core team typically consists of a medical director, nurse coor-
dinator, physical therapist, laboratory specialist, and psychosocial 
counsellor; all of whom should be specifically trained in the field. 
 ◦  The medical director (normally a pediatric and/or adult hema-
tologist or a physician with training and expertise in manag-
ing hemophilia and other bleeding disorders) oversees patient 
management including ordering diagnostic laboratory tests, 
prescribing treatment, and monitoring patient health and 
medical needs. 
 ◦  The nurse coordinator, who should have training in the man-
agement of patients with bleeding disorders, coordinates the 
provision of care by the multidisciplinary team, educates pa-
tients and their families, provides training for home therapy 
and other aspects of care, and assesses patients and institutes 
initial care where appropriate. 
 ◦  The physical therapist plays an important role in educating 
people with hemophilia and their caregivers on preventive 
measures, facilitating complete functional recovery after 
each bleed, and counselling individuals about preserving 
musculoskeletal health. 19 Other musculoskeletal specialists 
(i.e., occupational therapist, physiatrist, physical medicine/
rehabilitation specialist, rheumatologist, orthopedist, ortho-
pedic surgeon) provide treatment for specific musculoskele-
tal conditions. 
 ◦  The laboratory specialist performs specialized blood tests to 
establish the diagnosis and monitor therapy, including blood 
coagulation tests, factor assays, and inhibitor assays. 
 ◦  The psychosocial counsellor (preferably a social worker or 
psychologist) conducts psychosocial assessments and pro-
vides counselling and/or referrals to community resources. 
•  The roles assumed by core team members may differ at 
different centres, depending on the availability and expertise 
of trained staff and the organization of services within the 
centre. 
•  The comprehensive care team should also include or have access 
to dentists with hemophilia experience, and other specialists as 
 TA B L E   2 2     Sites of bleeding in hemophilia 9 
 Serious •  Joints (hemarthrosis) 
•  Muscles, especially deep compartments 
(iliopsoas, calf, forearm) 
•  Mucous membranes of the mouth, nose, 
and genitourinary tract 
 Life- threatening •  Intracranial 
•  Neck/throat 
•  Gastrointestinal 
 TA B L E   2 3     Approximate frequency of bleeding at different 
sites 
 Site of bleeding 
 Approximate 
frequency 
 Joints  70- 80% 
•  More common in hinged joints: ankles, knees, 
elbows 
•  Less common in multi- axial joints: shoulders, 
wrists, hips 
 Muscles  10- 20% 
 Other sites (major bleeds)  5- 10% 
 Central nervous system  <5% 
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needed to address specific medical and health-related issues 
that some people with hemophilia and carriers may encounter, 
including: 
 ◦  chronic pain specialist; 
 ◦  pharmacist; 
 ◦  geneticist; 
 ◦  hepatologist; 
 ◦  infectious disease specialist; 
 ◦  immunologist; 
 ◦  gynecologist/obstetrician; 
 ◦  vocational counsellor. 
•  Other medical specialists may be needed to address comorbid 
conditions related to age, lifestyle, or other circumstances. (See 
Chapter 9: Specific Management Issues – Comorbidities.) 
•  Detailed clinical management protocols are essential to ensure 
continuity of care in the event of personnel changes within the 
comprehensive care team. 10,15,16 
•  To foster the necessary expertise and experience in hemophilia, 
mentorships and fellowships can offer opportunities for re-
cruiting medical professionals to the field and advancing clinical 
knowledge. 
 Recommendation 2.2.1: 
•  For people with hemophilia, the WFH recommends coordinated 
delivery of comprehensive care by a multidisciplinary team 
of healthcare professionals with expertise and experience in 
hemophilia. 
•  REMARK : The core members of the comprehensive care team 
should consist of a medical director, nurse coordinator, muscu-
loskeletal specialists, medical laboratory specialist, psychosocial 
specialist, and the patient and family caregivers. The roles as-
sumed by the core team members may differ at different centres 
depending on the availability and expertise of trained staff and 
the organization of services within the centre.  CB 
 Recommendation 2.2.2: 
•  For people with hemophilia, the WFH recommends availability 
of and access to: 
 ◦  appropriate emergency care at all times; 
 ◦  a coagulation laboratory capable of performing clotting fac-
tor assays and inhibitor testing; 
 ◦  appropriate clotting factor concentrates (CFCs), either plas-
ma-derived or recombinant, as well as other hemostatic 
agents such as desmopressin (DDAVP), emicizumab, and 
antifibrinolytics; 
 ◦  safe blood components such as fresh frozen plasma (FFP) and 
cryoprecipitate that have been adequately screened, tested, 
and/or virus-inactivated if CFCs are not available; 
 ◦  casting and/or splinting for immobilization and mobility/sup-
port aids, as needed; 
 ◦  other specialists to address specific medical and 
health-related issues that some individuals may encounter, 
as needed.  CB 
 Recommendation 2.2.3: 
•  For all patients with hemophilia, the WFH suggests the prepara-
tion of written clinical management protocols to ensure continu-
ity of care in the event of changes in clinic personnel.  CB 
 Functions of a comprehensive care program 
•  A comprehensive care program helps put into operation the key 
principles of comprehensive care for hemophilia. The core func-
tions are described here. 
 Coordination and provision of care 
•  A comprehensive care program enables centralized coordination 
of care from across multidisciplinary specialities, services, and 
facilities, and the provision of inpatient care (hospital stays) and 
outpatient care (checkups and other clinic visits) to patients and 
their families. 
•  People with hemophilia require periodic monitoring and as-
sessment of their condition and circumstances. They should be 
evaluated at least once per year; those with mild or moderate he-
mophilia may require less frequent monitoring. 20 
•  Referrals to other services (e.g., dentistry, surgery, obstetrics/
gynecology) including communication of the care management 
plan to all treaters and care facilities are arranged through the 
program, which helps ensure that patients receive optimal care 
from specialists with appropriate hemophilia expertise. Planning 
and coordination of procedures must involve patients/family 
caregivers in consultation with all specialists required (e.g., for 
surgery, the anesthesiologist, surgeon, and surgical staff includ-
ing nurses). 20-22 
•  Ongoing collaboration with patients and family caregivers to de-
velop, audit, and refine the comprehensive care management plan 
is essential. 
 Recommendation 2.2.4: 
•  For people with hemophilia, the WFH recommends a multidis-
ciplinary checkup including hematologic, musculoskeletal, and 
quality-of-life assessments by the core comprehensive care team 
members at least yearly (every 6 months for children). 
•  REMARK : Smaller centres and family physicians can provide pri-
mary care and management of some complications of hemophilia, 
in frequent consultation with the hemophilia comprehensive 
care centre, especially for patients who live a long distance from 
the nearest hemophilia treatment centre. 
 Patient registry and data collection 
•  The comprehensive care program facilitates centralized patient 
data collection on sites of bleeds, types and doses of treatment 
administered, complications of treatment, and assessment of 
long-term musculoskeletal and other health outcomes and pa-
tient-reported outcomes (e.g., bleed-related activities, acute 
and chronic pain, days missed from school or work, impact 
     |  23
of hemophilia on activities of daily living). The WFH ' s World 
Bleeding Disorders Registry (WBDR) is an online platform for 
use by hemophilia treatment centres around the world to col-
lect such data to monitor patient outcomes and guide clinical 
practice. 23 
•  Patient records should be maintained in accordance with confi-
dentiality laws and other national regulations, ideally in a com-
puterized patient registry that is updated regularly by designated 
clinic staff with direct or indirect patient input. 
•  Systematic data collection also serves to facilitate the auditing of 
services provided by the hemophilia treatment centre with the 
goal of improving care delivery and to help the patient better 
manage their health condition. 
•  See Chapter 9: Specific Management Issues, Chapter 10: 
Musculoskeletal Complications, and Chapter 11: Outcome 
Assessment. 
 Recommendation 2.2.5: 
•  For all patients with hemophilia, the WFH recommends sys-
tematic data collection in patient registries, where possible, to 
inform allocation of resources, support improvement of care 
delivery services, and promote collaboration among centres in 
sharing data and conducting research.  CB 
 Clinical research 
•  Basic and clinical hemophilia research should be conducted where 
possible. Since the number of patients with hemophilia at indi-
vidual centres may be limited, clinical research is best conducted 
in collaboration with other hemophilia centres and national he-
mophilia patient groups such as national member organizations 
(NMOs) of the WFH. 
 Patient/caregiver education and support 
•  Education and training on home therapy should be provided 
where available and should ideally include supervision of adher-
ence to treatment. 
•  Ongoing support should be provided to families and caregivers 
including identifying resources and/or developing strategies to 
enable them to adapt to living with hemophilia. 
•  Potential challenges that patients and family members may en-
counter in everyday living, particularly those related to the man-
agement of bleeding, include: 
 ◦  changes associated with different stages of growth and devel-
opment (especially adolescence and aging); 
 ◦  adherence to a complex medical regimen requiring frequent 
IV infusions in the midst of other competing family needs 24 ; 
 ◦  issues with schooling and/or employment; 
 ◦  psychosocial and mental health issues; 
 ◦  bleeding problems and reproductive issues in carriers. 
•  In collaboration with hemophilia patient organizations, a compre-
hensive care program helps promote and/or facilitate hemophilia 
support groups, educational workshops, and recreational activi-
ties such as hemophilia camps. 
•  See 2.5 Home therapy and 2.8 Transition from pediatric to adult 
care, below, and Chapter 9: Specific Management Issues. 
 Recommendation 2.2.6: 
•  The WFH recommends that adequate education be provided to 
people with hemophilia, their family members, and other care-
givers to enable self-management and sufficient understanding 
of the disease for prevention of bleeds and related complications 
and for life planning.  CB 
 Recommendation 2.2.7: 
•  For people with hemophilia and their families, the WFH recom-
mends promotion and/or facilitation of educational and recre-
ational activities in collaboration with patient organizations, to 
provide them with opportunities to discover new interests and 
capabilities and build a support network with diverse members 
of the hemophilia community.  CB 
 2.3  |  Fitness and physical activity 
•  Physical activity is important to promote normal neuromuscular 
development and physical fitness. 19 
•  People with hemophilia may have an increased risk of low bone 
mineral density compared to the general population due to risk 
factors including hemophilia severity and hemophilic arthropathy 
and resulting immobility. 25 Ways to promote bone health include 
preventing hemarthrosis, regular exercise, and adequate vitamin 
D and calcium intake. 26,27 
•  For those with significant musculoskeletal dysfunction, 
weight-bearing activities that promote development and mainte-
nance of good bone density should be encouraged to the extent 
their joint health permits. 26 
•  The choice of activities should reflect the individual ' s prefer-
ences/interests, physical condition and ability, local contexts, and 
available resources. 
•  Non-contact sports such as swimming, walking, jogging, golf, bad-
minton, archery, cycling, rowing, sailing, and table tennis should 
be encouraged. 
•  High-contact and collision sports such as soccer, hockey, rugby, 
boxing, and wrestling, and high-velocity activities such as moto-
cross racing and skiing are not advised due to the potential for 
life-threatening injuries, unless the individual is on adequate pro-
phylaxis to cover such activities and is well educated on the po-
tential risks. 
•  Custom-made dental mouthguards should be used by individuals 
with hemophilia for all contact sports to prevent trauma and in-
jury to teeth and oral soft tissues. 28 
•  Organized sports programs should be encouraged over unstruc-
tured sports activities where protective equipment and supervi-
sion may be lacking. 
•  Ideally, individuals with hemophilia (or their family caregivers) 
should consult a physical therapist before engaging in new sports 
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and physical activities to discuss their appropriateness, required 
protective gear, prophylaxis (factor coverage and other measures), 
and required physical skills prior to beginning the activity. This is 
particularly important if the individual has any joint with recurrent 
bleeding (i.e., target joint). 29 
•  Ongoing patient/caregiver education on the physical implica-
tions of a given activity in relation to hemophilia (i.e., joint flex-
ion, joint or muscle trauma) is important so that they can make 
informed choices, adapt their self-management accordingly, and 
responsibly manage the way they participate in sports and phys-
ical activities. 
•  Target joints can be protected with braces or splints during physi-
cal activity, especially in the absence of factor coverage. 30,31 
•  See Chapter 7: Treatment of Specific Hemorrhages and Chapter 
10: Musculoskeletal Complications. 
 Recommendation 2.3.1: 
•  For people with hemophilia, the WFH recommends promotion 
of regular physical activity and fitness, with special attention on 
bone health maintenance, muscle strengthening, coordination, 
physical functioning, healthy body weight, and positive self-es-
teem.  CB 
 Recommendation 2.3.2: 
•  For people with hemophilia, the WFH recommends promotion 
of non-contact sports. High-contact and collision sports and 
high-velocity activities should be avoided unless the individual 
is on a prophylactic regimen that is adequate to cover such ac-
tivities and is properly educated on the potential risks and other 
required protective measures. 
•  REMARK : The choice of sports activities should take into consider-
ation the individual ' s physical condition and ability, preferences 
and interests, local customs, and available resources.  CB 
 Recommendation 2.3.3: 
•  For people with hemophilia, the WFH recommends consulta-
tion with a physical therapist or other musculoskeletal special-
ist before engaging in sports and physical activities to discuss 
their appropriateness specific to the individual ' s condition and 
their requirement for particular physical skills and/or protective 
gear.  CB 
 2.4  |  Adjunctive management 
•  Adjunctive therapies are important in the treatment of bleeds, 
particularly where coagulation therapies and hemostatic agents 
are limited (or unavailable), and may lessen the amount of treat-
ment product required. 
•  First-aid measures are a key component of adjunctive manage-
ment. In addition to CFCs to raise factor levels (or DDAVP in 
mild hemophilia A), the PRICE principles—protection, rest, ice, 
compression, and elevation—based on the conventional rest, 
ice, compression, and elevation (RICE) protocol for injuries, may 
be used for joint and muscle bleeds. Another approach, POLICE 
(protection, optimum loading, ice, compression, and eleva-
tion), replaces “rest” with “optimum loading” to focus attention 
on the need to balance rest with early mobilization and gradual 
weight-bearing to prevent complications associated with immobi-
lization. 32 It is important to consider the appropriateness of each 
of these measures for the particular situation. 
•  In recent years, there has been debate on the application of ice, 
which is believed to help manage acute pain from joint bleed-
ing and reduce blood flow to the injured tissue. 33 One study 
suggested that the cooling effect of ice may interfere with co-
agulation and slow the hemostasis process. 34 However, counter 
viewpoints note that many people with hemophilia appreciate 
ice for pain relief and that, for those without access to treatment 
products, ice for acute and chronic pain may be their only “treat-
ment” option. 35-37 
•  See Chapter 7: Treatment of Specific Hemorrhages – Joint hemor-
rhage – Adjunctive care. 
•  Physical therapy and rehabilitation are particularly important 
for functional improvement and recovery after musculoskeletal 
bleeds and for those with established hemophilic arthropathy. 38,39 
•  See Chapter 7: Treatment of Specific Hemorrhages – Joint 
hemorrhage – Physical therapy and rehabilitation and Chapter 
10: Musculoskeletal Complications – Hemophilic arthropa-
thy and joint contractures – Physical therapy for hemophilic 
arthropathy. 
•  Antifibrinolytic drugs are effective as adjunctive treatment for 
mucosal bleeds and invasive dental procedures. (See 2.7 Dental 
care and management, below, and Chapter 5: Hemostatic Agents 
– Other pharmacological options.) 
•  Certain selective COX-2 inhibitors may be used for joint inflam-
mation after an acute bleed and for chronic arthritis. 40 (See 2.6 
Pain management, below.) 
•  Complementary techniques for pain management (e.g., medita-
tion, distraction, mindfulness, or music therapy) may also be help-
ful for those with chronic hemophilic arthropathy. (See 2.6 Pain 
management, below.) 
 Recommendation 2.4.1: 
•  For people with hemophilia with a muscle or joint bleed, the 
WFH recommends following the PRICE principles (protection, 
rest, ice, compression, and elevation) in addition to increasing 
factor level.  CB 
 Recommendation 2.4.2: 
•  For people with hemophilia recovering from a joint or muscle 
bleed, the WFH recommends gradual re-initiation of physical 
activities under the supervision of a physical therapist with ex-
perience in hemophilia to assess resumption of normal motor de-
velopment and coordination. 
•  REMARK : For children with hemophilia recovering from a joint or 
muscle bleed, the physical therapist and family caregiver should 
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remain in close contact to discuss and decide on the appropriate 
sports and activities for the child ' s progressive rehabilitation.  CB 
 Recommendation 2.4.3: 
•  For people with hemophilia with established hemophilic arthrop-
athy or after recovery from musculoskeletal bleeding, the WFH 
recommends physical therapy and rehabilitation activities.  CB 
 Recommendation 2.4.4: 
•  For people with hemophilia, the WFH recommends the use of an-
tifibrinolytic drugs (e.g., tranexamic acid, epsilon aminocaproic 
acid [EACA]) alone or as adjuvant treatment, particularly in con-
trolling mucosal bleeds and for invasive dental procedures.  CB 
 2.5  |  Home therapy 
•  Home therapy gives people with hemophilia immediate access to 
CFCs or other coagulation therapies and hemostatic agents (e.g., 
emicizumab, DDAVP, antifibrinolytics) and hence enables optimal 
early treatment, resulting in less pain, dysfunction, and long-term 
disability, and significantly reduced hospitalization rates for he-
mophilic bleeding complications, especially for those on prophy-
laxis compared to episodic therapy. 41-43 
•  Home therapy also offers people with hemophilia substantially 
improved quality of life including less school/work absenteeism, 
the ability to safely participate in a larger variety of sports and 
physical activities, greater employment stability, and greater free-
dom to travel. 44 
•  Home therapy must be supervised closely by the comprehensive 
care team and should only be initiated after comprehensive pa-
tient/caregiver education and training. 41,42 
•  Education should focus on instilling essential knowledge of hemo-
philia and the basics of home therapy, including: 
 ◦  recognition of bleeds and common complications; 
 ◦  first-aid measures; 
 ◦  dosage calculation; 
 ◦  storage, preparation, and administration of CFCs and/or other 
treatment products; 
 ◦  aseptic techniques; 
 ◦  venipuncture (or access through a central venous catheter) 
and self-infusion/self-injection; 
 ◦  record-keeping; 
 ◦  proper storage and disposal of needles/sharps; 
 ◦  handling of blood spills. 
•  A patient/caregiver home therapy certification program is help-
ful for acknowledging and ensuring readiness to begin home 
therapy. 
•  Treatment adherence, level of education, and understanding of 
episodic and prophylactic treatment, infusion/injection tech-
niques, and bleed records should be reviewed and evaluated with 
patients and family caregivers at clinic checkups. 
•  See also “Self-management” below. 
 Clotting factor replacement therapy 
•  Home therapy with CFCs should ideally be achieved with prod-
ucts that are safe and are easily reconstituted. CFCs can be stored 
at room temperature or in a domestic refrigerator, depending on 
the product. People with hemophilia must be skilled in self-infu-
sion to minimize time to treatment and improve their joint health 
outcomes. 45 
•  Home therapy with CFCs can be started with young children 
with adequate venous access and motivated family caregivers 
who have undergone comprehensive training. Older children 
and teenagers can learn self-infusion with education and train-
ing from the hemophilia nurse coordinator (or home infusion 
nurse, where available) and family support. 
•  See “Self-management” below and Chapter 6: Prophylaxis in 
Hemophilia. 
 New coagulation therapies 
•  The use of new innovative therapies administered via different 
routes requires carefully planned patient/caregiver education, 
training, and supervision including specific training for those tran-
sitioning to another type of therapy (e.g., from intravenous factor 
replacement therapy to subcutaneous factor substitution therapy 
with emicizumab). 
•  Patients and their caregivers should understand the differences, 
benefits, and any risks associated with a particular treatment. 
Importantly, they should be taught how to monitor treatment 
and response, and under which circumstances they should con-
tact their healthcare provider and/or hemophilia treatment centre 
(e.g., breakthrough bleeding, upcoming surgery). 
 Emicizumab 
•  People with hemophilia A on prophylaxis with emicizumab may 
begin home therapy after proper training in subcutaneous injec-
tion technique. 46 
•  Emicizumab and those non-factor agents in development differ 
from conventional types of prophylaxis as they do not replace 
the missing coagulation factor, are administered subcutaneously 
and, in some cases, can be administered as infrequently as once 
or twice monthly. 47 Additionally, these agents are not associated 
with the peak and trough curves of protection that are now seen 
with factor prophylaxis regimens. 
•  Emicizumab ' s subcutaneous route of administration is already 
making it easier to start pediatric patients on prophylaxis at very 
young ages and without the need for central venous access de-
vices (CVADs). Emicizumab makes it feasible to initiate prophy-
laxis at birth to provide protection of newborns and infants newly 
diagnosed with severe hemophilia A; however, further research in 
infants less than 1 year of age is required. 48 
•  Emicizumab is not intended to treat acute bleeding episodes. 
Breakthrough bleeding is treated with doses of CFCs (or 
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bypassing agents in the case of patients with inhibitors) that are 
sufficient to achieve hemostasis. Caution is required when treat-
ing breakthrough bleeding episodes while on emicizumab as sev-
eral patients have developed either venous thromboembolism or 
thrombotic microangiopathy with concomitant administration of 
activated prothrombin complex concentrate (aPCC). 49 Consult 
the individual product inserts for precautions and risk manage-
ment guidance. 
•  See Chapter 5: Hemostatic Agents, Chapter 6: Prophylaxis in 
Hemophilia, and Chapter 8: Inhibitors to Clotting Factor. 
 Self- management 
•  Self-management focuses on patient empowerment and refers to 
a patient ' s ability to acquire the necessary skills and knowledge 
to become competent in their own care and apply it in their daily 
activities to keep their condition under control and minimize its 
impacts on their physical and psychological health. 45 For people 
with hemophilia, self-management requires concrete knowledge 
of bleeding mechanisms and treatment strategies (when and how 
to treat and what dose to give). 45 
•  The key self-management skills required for people with hemo-
philia include 45 : 
 ◦  bleed recognition; 
 ◦  self-infusion/self-treatment skills; 
 ◦  self-care (i.e., nutrition and physical fitness) and medicines 
management (i.e., record-keeping, treatment routines, mainte-
nance of adequate treatment supply, skills in storage, reconsti-
tution, and administration of treatment products); 
 ◦  pain management; and 
 ◦  risk management and conceptualizing preventive therapy. 
•  Knowledge of appropriate adjunctive therapies (e.g., 
antifibrinolytics, pain medications) and adjunctive man-
agement (e.g., the PRICE principles) are also important to 
self-management. 
•  See 2.3 Fitness and physical activity, 2.4 Adjunctive management, 
and 2.5 Home therapy, above, and 2.6 Pain management, below. 
 Bleed recognition 
•  Bleed recognition, especially of joint and muscle bleeds, is an es-
sential part of self-management so that prompt treatment can be 
initiated to minimize the short- and long-term impacts of bleeds. 
In hemophilia, a wait-and-see approach for potential bleeds or 
missed doses may result in the onset and progression of bleeding 
symptoms that are not only painful but ultimately lead to joint 
damage. 
•  It is important for family members/caregivers to be able to rec-
ognize subtle signs of bleeds in young children with hemophilia; 
in infants and young children, reluctance to use a limb may be 
indicative of a joint/muscle bleed. 50 The signs and symptoms of 
common types of hemorrhage in hemophilia 50 are described in 
Chapter 7: Treatment of Specific Hemorrhages and Chapter 11: 
Outcome Assessment. 
•  For those on prophylaxis with new types of coagulation therapy, it 
is important to monitor and assess the ability of patients/caregiv-
ers to recognize breakthrough bleeds and initiate prompt episodic 
treatment with CFCs or appropriate hemostatic agents. 
 Self- infusion/self- treatment 
•  In young children, injections or infusions are normally given by the 
parents and/or caregivers until the child is old enough to switch 
to self-treatment. 51 
•  Children with hemophilia typically learn to self-infuse or self-in-
ject in late childhood or early adolescence. Self-infusion requires 
skill and expertise developed through trial and error as well as 
education and support. 45 Becoming sufficient at self-infusion is 
complex as it requires a one-handed technique to perform all 
steps; however, most children self-infuse at least part of the time 
by 12 years of age. 45 
•  Establishing routines, such as self-infusing at the same time every 
day, can help significantly with treatment adherence. 45 
 Recommendation 2.5.1: 
•  Patients (or caregivers of children) with hemophilia should be 
taught how to manage their care at home and be able to demon-
strate understanding of how to recognize bleeds and the ability 
to infuse or self-infuse, with monitoring of venous access skills 
over the patient ' s lifetime.  CB 
 Self- care and medicines management 
•  Because people with hemophilia self-manage largely at home, 
healthcare providers have to depend on the patient/caregiver to 
inform them of their type of bleed episodes, bleeding frequency, 
and usage of treatment products. 52 
•  Therefore, it is important for patients/caregivers to keep accu-
rate bleed treatment records (paper or electronic) that include the 
date and site of bleeding, the dosage and lot number of the prod-
uct used, any adverse effects, bleed-related activities, and other 
outcomes to be reported as required. 
•  Hemophilia treatment centres now have the option to use 
electronic diaries (e-diaries) in the form of smartphone appli-
cations, handheld wireless monitoring systems, and online plat-
forms that allow real-time entries and direct data analysis. With 
these tools, healthcare providers no longer need to rely on pa-
tient visits to the hemophilia treatment centre to review paper 
diaries. 53-56 
•  Studies on e-diaries have demonstrated that their use increases 
the amount of information provided as well as the complete-
ness of data reporting. 53 Remote patient record management 
may also improve treatment compliance, increase patient qual-
ity of life, support healthcare providers in modifying treatment 
regimens, and improve communication with the healthcare 
team. 54-56 
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 Recommendation 2.5.2: 
•  For patients with hemophilia, a detailed record of all treatments 
administered (reason, batch number, number of units, etc.) should 
be documented and used to personalize treatment plans.  CB 
 Risk management and conceptualizing preventative therapy 
•  Risk management requires the ability to judge and balance 
chances and risks encountered in daily life, including controlling 
and navigating risks that arise and distinguishing between neg-
ative risk-taking and positive risk management. 45 In addition, it 
requires being able to self-advocate for appropriate hemophilia 
care with support from the hemophilia treatment centre such as 
emergency care, surgical management, or dental treatment. (See 
2.3 Fitness and physical activity, above, 2.7 Dental care and man-
agement, below, and Chapter 9: Specific Management Issues.) 
•  In addition, healthcare providers can educate and guide people 
with hemophilia in planning their daily lives to reduce bleeding 
risk. Strategies may include adapting the treatment regimen to fit 
within other priorities (e.g., school and sports), routines, activities, 
and events in their lives. 45 
 Central venous access devices 
•  An implanted central venous access device can enable stable, 
long-lasting venous access to make infusions easier and may be 
required for administering prophylaxis or immune tolerance in-
duction (ITI) therapy in young children with problematic venous 
access. 57,58 
•  The complications and risks associated with surgical implanta-
tion of CVADs (i.e., hospitalization, bleeding, catheter infection, 
thrombosis, breakage, and/or malfunction) need to be weighed 
against the advantages of early initiation of intensive prophy-
laxis. 59-61 Many pediatricians and hemophilia treaters are shifting 
from the use of CVADs to peripheral venous access for early initi-
ation of prophylaxis, starting with once-weekly prophylaxis then 
gradually escalating infusion frequency, 62 together with more in-
tensive caregiver training. 
•  Alternatively, the use of emicizumab obviates the need for CVADs, 
and it is increasingly among the treatment options for people with 
hemophilia A in many countries. (See Chapter 6: Prophylaxis in 
Hemophilia.) 
•  The protocol used for device care (using aseptic precautions), qual-
ity of patient/caregiver education, and user compliance may affect 
frequency of infections; therefore, careful guidelines and surveil-
lance protocols are important to reduce the risk of complications. 59 
•  Parents and caregivers must be taught to keep CVADs scrupu-
lously clean and to flush out the catheter properly after each 
therapy administration to prevent CVAD infection and clot forma-
tion. 59 Fibrinolytic agents may be helpful for preventing clotting 
and infections. 60 
•  It is essential to ensure that parents and caregivers have a thor-
ough understanding of all aspects of home therapy and are 
prepared and able to handle the issues and challenges that com-
monly arise in children with hemophilia at each development 
stage. (See 2.8 Transition from pediatric to adult care, below.) 
•  For patients in whom venous access is problematic, non-factor re-
placement therapy that can be administered subcutaneously (i.e., 
emicizumab) should be considered. (See Chapter 6: Prophylaxis in 
Hemophilia – Non-factor replacement therapy.) 
 Recommendation 2.5.3: 
•  For children with hemophilia, central venous access devices 
could be considered to facilitate early access to bleed treatment 
and prophylaxis.  CB 
 2.6  |  Pain management 
•  Acute and chronic pain are common in people with hemophilia. 
Proper assessment of the cause of pain is essential. 63 
•  See also Chapter 7: Treatment of Specific Hemorrhages. 
 Recommendation 2.6.1: 
•  For people with hemophilia with acute or chronic pain, the 
WFH recommends the use of age-appropriate pain assess-
ment tools to determine the cause and guide appropriate 
management.  CB 
 Pain caused by venous access 
•  In general, no pain medication is given. If required, application of 
a local anesthetic spray or cream at the site of venous access may 
be helpful. 64-66 
 Recommendation 2.6.2: 
•  For people with hemophilia with venous access pain, discomfort 
or anxiety, the WFH recommends the application of a local anes-
thetic spray or cream at the site of venous access.  CB 
 Pain caused by joint or muscle bleeding 
•  While hemostatic treatment should be administered as soon 
as possible to stop bleeding, additional medications are often 
needed for pain control (see Table  2-4 ). 
•  Other adjunctive measures may be required. 40 
•  See also Chapter 10: Musculoskeletal Complications. 
 Recommendation 2.6.3: 
•  For people with hemophilia with acute pain due to a joint or mus-
cle bleed, the WFH recommends immediate administration of 
clotting factor concentrates to stop bleeding, pain medication, 
and adjunctive measures such as immobilization, compression, 
and splinting to minimize pain, if appropriate.  CB 
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 Postoperative pain 
•  Intramuscular injection of analgesics should be avoided. 
•  Postoperative pain management should be coordinated with the 
anesthesiologist or pain specialist. 
•  Initially, narcotic analgesics can be given, followed by an oral opioid. 
•  When pain decreases, paracetamol/acetaminophen may be used. 
 Recommendation 2.6.4: 
•  For patients with hemophilia and postoperative pain, the WFH 
advises proportionate management of postoperative pain in co-
ordination with the anesthesiologist or pain specialist.  CB 
 Recommendation 2.6.5: 
•  For patients with hemophilia and postoperative pain, the WFH 
recommends analgesia similar to that used in patients without 
hemophilia including, as appropriate, the use of intravenous 
morphine or other narcotic analgesics, followed by an oral opioid 
(e.g., tramadol, codeine, hydrocodone, etc.) and paracetamol/ac-
etaminophen as pain decreases. 
•  REMARK : With the exception of selective COX-2 inhibitors, 
NSAIDs should not be used in patients with hemophilia. 
•  REMARK : The intramuscular route for administration of analgesia 
is not advised.  CB 
 Pain due to chronic hemophilic arthropathy 
•  Chronic hemophilic arthropathy develops in individuals who have 
not had adequate treatment and follow-up physical therapy and 
rehabilitation for joint and muscle bleeds. 
•  Pain management for chronic hemophilic arthropathy should in-
clude functional training and adaptation, and appropriate analge-
sics as detailed in Table  2-4 . 19,67-69 
•  Pain medications that may be used by people with hemophilia 
for chronic hemophilic arthropathy include paracetamol/acet-
aminophen, selective COX-2 inhibitors, tramadol, and opioid 
analgesics. 70,71 Other NSAIDs should be avoided in people with 
hemophilia. 72 Codeine should not be administered to children 
under 12 years of age. 
•  For individuals with disabling chronic pain due to hemophilic ar-
thropathy, orthopedic surgery may be indicated. 73 
•  See Chapter 10: Musculoskeletal Complications – Hemophilic 
arthropathy. 
 Recommendation 2.6.6: 
•  For people with hemophilia and chronic hemophilic arthropathy 
in need of pain management, the WFH recommends functional 
training and adaptations alongside appropriate analgesics.  CB 
 Recommendation 2.6.7: 
•  For people with hemophilia and chronic hemophilic arthropathy, 
the WFH recommends education on pain management including 
the use of complementary pain management techniques (e.g., 
meditation, distraction, mindfulness, or music therapy).  CB 
 Recommendation 2.6.8: 
•  For children and adults with hemophilia with pain due to chronic 
hemophilic arthropathy, the WFH recommends the use of parac-
etamol/acetaminophen, selective COX-2 inhibitors, tramadol, 
or morphine, and avoidance of other NSAIDs. Codeine may be 
used for children over 12 years of age but is contraindicated in 
younger children. 
•  REMARK : Prolonged use of these medications may have risks of 
dependence or addiction, as well as organ damage, and must be 
carefully monitored. 
•  REMARK : People with persistent pain should be referred to a spe-
cialized pain management team.  CB 
 Recommendation 2.6.9: 
•  For patients with hemophilia with disabling pain from chronic 
hemophilic arthropathy, the WFH recommends referral to an or-
thopedic specialist for consideration of orthopedic surgery.  CB 
 Dental pain 
•  People with hemophilia experiencing dental pain should always 
be referred for a professional dental consultation. Proportionate 
pain management measures should be applied (see Table  2-4 ). 
 Recommendation 2.6.10: 
•  For children and adults with hemophilia, the WFH recommends 
interim management of dental or orofacial pain according to a 
 TA B L E   2 4     Pain management strategies for people with 
hemophilia 
 1  Paracetamol/acetaminophen 
 If not effective 
 ↓ 
 2  COX- 2 inhibitor a  (e.g., celecoxib, meloxicam, 
nimesulide, and others) 
 or 
 paracetamol/acetaminophen plus codeine 
(3- 4 times/day) 
 or 
 paracetamol/acetaminophen plus tramadol 
(3- 4 times/day) 
 3  Morphine: Use a slow- release product with a rapid- 
release product as an escape analgesic. Increase 
use of the slow- release product if the rapid- 
release product is used more than 4 times/day. 
 Note :  If for any reason medications have been stopped for a period 
of time, individuals who have been taking and tolerating high- dose 
narcotic drugs should restart the drug at a lower dose, or use a less 
powerful painkiller, under the supervision of a physician. 
 aCOX- 2 inhibitors should be used with caution by people with 
hemophilia with hypertension and renal dysfunction. 
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proportionate approach for pain relief and referral to a dental 
care professional for assessment.  CB 
 2.7  |  Dental care and management 
•  Maintaining good oral health and preventing dental problems is 
of great importance in people with hemophilia to prevent oral 
diseases and conditions such as gingivitis, dental caries, and peri-
odontal diseases which may cause serious gum bleeding, espe-
cially in those with severe/moderate hemophilia, 74 and to avoid 
the need for major dental surgery. 75 
•  Since prolonged bleeding after dental treatment can cause severe 
or even life-threatening complications, people with hemophilia 
are a priority group for preventive dental and oral health care. 74 
•  It is important to ensure that people with hemophilia have access to 
dental treatment and regular preventive dental care at a designated 
dental care centre with expertise in the management of people 
with hemophilia according to evidence-based dental protocols. 75-77 
•  See also Chapter 7: Treatment of Specific Hemorrhages – Oral 
hemorrhage. 
 Recommendation 2.7.1: 
•  For children and adults with hemophilia, the WFH recommends 
provisions for access to regular preventive dental and oral health 
care as part of comprehensive hemophilia care.  CB 
 Recommendation 2.7.2: 
•  For children with hemophilia, the WFH recommends referral to a 
designated dental care centre at the time of the first tooth erup-
tion (around 6 months of age) or by age 1 in order to reduce the 
complications, morbidity, costs, and health and psychosocial im-
pacts associated with oral diseases in people with hemophilia.  CB 
 Recommendation 2.7.3: 
•  For adults with hemophilia, the WFH recommends facilitating 
access to appropriate adult dental services and procedures, with 
regular dental assessments throughout their lives to monitor and 
safeguard oral health using evidence-based and personalized 
preventive dental protocols.  CB 
 Recommendation 2.7.4: 
•  For people with hemophilia, the WFH recommends preventive 
dental and oral care as a priority to ensure optimal oral health 
and hygiene to prevent periodontal disease and dental caries, 
which predispose to gum bleeding, dental pain, tooth loss, chew-
ing difficulties, and social impacts.  CB 
 Oral care 
•  Optimal oral hygiene is essential to prevent periodontal disease and 
dental caries, which predispose to gum bleeding, dental pain, tooth 
loss, chewing difficulties, and social impacts (e.g., halitosis and low 
self-esteem). 76,78 This involves the use of oral hygiene products and 
toothbrushes which can be adapted based on individual needs. 79 
•  Dental pain occurring spontaneously or with facial swelling usu-
ally indicates the presence of advanced stages of oral disease and/
or infection and should trigger a professional dental consultation. 
Short-term pain control should be achieved as described (see 2.6 
Pain management, above), with paracetamol/acetaminophen as 
the drug of choice to manage toothache in children. 77 
 Recommendation 2.7.5: 
•  For all people with hemophilia, the WFH recommends education 
on the importance of good oral hygiene to prevent dental prob-
lems and complications, including instructions for twice-daily 
brushing of the teeth using a soft- or medium-texture tooth-
brush and fluoridated toothpaste to remove plaque deposits; the 
toothpaste should not be rinsed away but rather retained (“spit, 
but don ' t rinse”) after brushing to maximize fluoride benefit. 
•  REMARK : The use of dental floss or interdental brushes should be 
encouraged to ensure complete plaque removal. 
•  REMARK : Individuals with elbow or shoulder restrictions may ben-
efit from modified or electric toothbrushes and flossing aids.  CB 
 Recommendation 2.7.6: 
•  For children with hemophilia 6 years of age and younger, the 
WFH recommends parental/caregiver supervision of tooth-
brushing.  CB 
 Dental surgery and invasive procedures 
•  Before any dental surgery or other invasive procedure within 
the oral cavity, hemostasis management should be individually 
planned under the advisement of a hematologist. 80 
•  Systemic or topical antifibrinolytics (i.e., tranexamic acid or EACA) 
are effective as adjunct treatment in the management of dental 
interventions pre- and postoperatively and have the potential to 
reduce the need for factor replacement therapy. 76,81,82 
•  Antibiotics should only be prescribed if clinically indicated for 
management of infection. 
•  Local hemostatic measures such as wound suture, topical antifi-
brinolytics, oxidized cellulose, and fibrin sealant should be used as 
appropriate whenever possible following a dental extraction. 82,83 
•  Patients must be advised to immediately report any prolonged 
bleeding and/or difficulty speaking, swallowing, or breathing fol-
lowing dental surgery to the hematologist/dental surgeon as this 
can be life-threatening. Those who are not in hospital must report 
to the nearest emergency centre without delay. 
•  For many dental procedures, adequate local anesthesia is neces-
sary, and most dental injections can be delivered safely. 84,85 
•  Higher-risk intramuscular oral injections may require systemic he-
mostatic measures. These measures should be established preop-
eratively under advisement of a hematologist. 80 
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•  Alternative low-risk routes of delivery such as intraligamentary 
single-tooth anesthesia (STA) or buccal infiltration injections are 
effective alternatives to inferior alveolar nerve blocks (IDB). 84,86 
•  Other nonsurgical dental procedures carry variable levels of 
bleeding risk. Most restorative dental procedures such as dental 
fillings are low risk and can be carried out without the need for 
factor replacement therapy. 
•  Minimally invasive buccal infiltration or intraligamentary injec-
tions and techniques to protect soft tissues should be used, and 
standard local measures to aid mucosal hemostasis should be ap-
plied as appropriate. 
•  Professional dental cleanings can be provided with the use of an-
tifibrinolytic agents, if necessary. 82 
 Recommendation 2.7.7: 
•  For patients with hemophilia, the WFH recommends that den-
tal extraction or other invasive procedures within the oral cavity 
(e.g., dental implantation, periodontal surgery, or gum biopsy) be 
performed only with a personalized plan for hemostasis manage-
ment in consultation with a hematologist.  CB 
 Recommendation 2.7.8: 
•  For patients with hemophilia, the WFH recommends the use of 
systemic or topical tranexamic acid or epsilon aminocaproic acid 
(EACA) as adjunct treatment in the management of dental inter-
ventions pre- and postoperatively, to reduce the need for factor 
replacement therapy.  CB 
 Recommendation 2.7.9: 
•  For patients with hemophilia requiring dental extractions, the 
WFH recommends local hemostatic measures. Typical proce-
dures include wound suture, topical use of antifibrinolytics, oxi-
dized cellulose, and fibrin sealant, applied as appropriate. 
•  REMARK : Patients should be advised to maintain a soft diet and 
undertake careful brushing around the wound site for a mini-
mum of 3-5 days postoperatively to avoid disturbing the clot and 
wound healing within the tooth socket.  CB 
 Recommendation 2.7.10: 
•  For patients with hemophilia, the WFH recommends appropri-
ate local anesthesia for dental treatments as an essential part of 
pain and anxiety management. Most dental injections pose a low 
risk for patients with hemophilia when delivered by a dental care 
professional using local anesthesia with a vasoconstrictor, and 
when the agent is delivered slowly with a single-use fine-gauge 
needle.  CB 
 Recommendation 2.7.11: 
•  For patients with hemophilia requiring higher-risk intramuscular 
oral injections commonly associated with the provision of surgi-
cal dentistry (such as inferior alveolar dental block [IDB], supe-
rior alveolar nerve block, or injections in the floor of the mouth 
or vascular lingual tissues), the WFH recommends systemic 
hemostatic measures preoperatively to avoid the risk of hema-
toma. These measures should be established in consultation with 
the hematologist. 
•  REMARK : The availability and effectiveness of alternative low-
risk routes of local anesthetic delivery (such as intraligamentary 
single-tooth anesthesia, or buccal infiltration injections with 4% 
articaine) are effective alternatives to IDB and permit dental pro-
cedures in primary and permanent mandibular molar teeth.  CB 
 Recommendation 2.7.12: 
•  For patients with hemophilia, the WFH recommends the use of 
antifibrinolytic agents as effective adjunct treatment in the man-
agement of dental hygiene therapies that facilitates access to 
regular dental care delivered by a dental hygienist.  CB 
 Recommendation 2.7.13: 
•  In patients with hemophilia, the WFH asserts that the presence 
of blood-borne infections does not affect the safety of dental 
treatment as stringent universal cross-infection procedures are 
now mandatory across all disciplines of dentistry and recom-
mends the provision of full dental services regardless of infectiv-
ity or immunological status.  CB 
 2.8  |  Transition from pediatric to adult care 
•  At different life stages, people with hemophilia and their care-
givers go through transitions that involve transfer of care be-
yond the family, such as when a young person with hemophilia 
starts school, a new sport or leisure activities, and adolescence, 
and when moving from pediatric to adult medical care, moving 
away from home, starting new relationships, and making career 
choices. 51 
•  Parents and/or caregivers typically assume primary responsibility 
for the management of care for children and adolescents with he-
mophilia; in particular, for administering treatment and maintain-
ing adherence to therapeutic regimens. 51 
•  Two transition periods are particularly challenging for treatment 
adherence: when adolescents switch to self-treatment; and when 
young adults move away from home and assume full responsibil-
ity for self-care. 51 Many children and adolescents with hemophilia 
on prophylaxis who receive excellent comprehensive care do not 
experience the serious sequelae of their disorder, which may re-
sult in complacency in young adulthood. 87 
•  Ideally, young people with hemophilia should obtain the necessary 
knowledge and skills for self-management before transitioning to 
adult care; however, many young people still require parental as-
sistance with hemophilia care even in their later teenage years. 87 
•  Adherence to prophylaxis has been found to be suboptimal in 
many adolescents (13-17 years of age) and young adults (18-30 
years of age) with hemophilia. 51 
•  In general, the main barriers to adherence to prophylaxis include 
high perceived burden of treatment; no or low burden of bleeds 
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and symptoms; venous access difficulties; and viewing prophy-
laxis as complicated and time-consuming. 51 
•  In adolescents and young adults with hemophilia in particular, 
barriers to treatment adherence include 51 : 
 ◦  low symptom burden; 
 ◦  forgetfulness and lack of basic self-management skills such as 
treatment routines; 
 ◦  lack of knowledge about hemophilia, including low perceived 
benefit of prophylaxis; 
 ◦  inability to identify and act on bleeds; 
 ◦  disease denial; 
 ◦  the desire to be “normal”; 
 ◦  perceived negative impact on activities and social participation; 
 ◦  lack of transition planning; 
 ◦  difficulties with self-treatment; and 
 ◦  challenges communicating with a hemophilia treatment centre 
to receive optimal care. 
•  The transition to adulthood, with increased independence in 
living situations (e.g., living alone or away at college/university) 
and financial responsibilities, may be particularly challenging for 
young adults with hemophilia. 88 
•  Hemophilia treatment centres and healthcare providers can 
play an important role in helping young people with hemophilia 
maintain treatment adherence as they make the transition to 
adulthood, by ensuring that patient education encompasses 
knowledge and technical skills and development of self-ef-
ficacy and self-management skills including psychosocial 
coping. 51 
•  As no definitive systematic approach to transition from pediatric 
to adult care has yet been defined, the comprehensive care team 
should continuously assess and follow up on individual needs, 
preferences, and barriers to treatment adherence with age-ap-
propriate, tailored support. 51,89 
•  Key components of transition strategies include 51 : 
 ◦  development of a structured transition plan; 
 ◦  monitoring with systematic assessments of a patient ' s 
readiness; 
 ◦  individualized support; and 
 ◦  added support when switching to self-treatment or moving 
away from home. 
•  In addition, readiness self-assessment tools, such as the  HEMO-
Milestones tool, may be useful for promoting a standardized ap-
proach to assess self-management competency. 90 
•  Outcome indicators for assessing the effectiveness of transition 
from pediatric to adult hemophilia care include: 
 ◦  measurement of adherence; 
 ◦  any change in bleeding rate; 
 ◦  self-efficacy skills; 
 ◦  hemophilia knowledge; 
 ◦  patient and caregiver satisfaction; 
 ◦  time gap between last pediatric and first adult clinic visit; and 
 ◦  number of emergency room or hospital admissions. 91 
•  Self-management programs available on the Internet may also 
help to support young people with hemophilia in their transition 
to adult care. 87 
•  See Chapter 6: Prophylaxis in Hemophilia and Chapter 11: 
Outcome Assessment. 
 Recommendation 2.8.1: 
•  Children and adolescents with hemophilia should be supported 
with ongoing education and skills development, including the 
ability to self-infuse and other self-efficacy skills, to gain neces-
sary hemophilia knowledge for self-management of their condi-
tion before they make the transition from pediatric to adult care. 
•  REMARK : The comprehensive care team should support young 
patients and their families through the transition period. When 
possible, the first visit should be performed by both the pediatric 
and adult hematologists.  CB 
 Recommendation 2.8.2: 
•  For adolescents with hemophilia on prophylaxis, the WFH rec-
ommends individual education and training, ideally from a he-
mophilia nurse coordinator, to ensure adequate knowledge of 
hemophilia, and to support prophylaxis adherence and self-care 
management. This should include understanding measurements 
of adherence, as well as factors and risks that can lead to changes 
in bleeding rates.  CB 
 Recommendation 2.8.3: 
•  For adolescents 12-18 years of age with hemophilia, the WFH 
recommends age-specific hemophilia camps to foster peer group 
support and develop their self-infusion skills and understanding 
of the importance of adherence to treatment.  CB 
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 Chapter 3: Laboratory Diagnosis and Monitoring 
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 All statements identified as recommendations are consensus based, 
as denoted by  CB . 
 3.1  |  Introduction 
•  Different bleeding disorders may have very similar symptoms; 
therefore, a correct diagnosis is essential to ensure that a patient 
receives the appropriate treatment. 
•  An accurate diagnosis can only be made with the support of a 
comprehensive and reliable laboratory service. This is depen-
dent on the laboratory following strict protocols and procedures, 
which require: 
 ◦  knowledge and expertise in coagulation laboratory testing; 
 ◦  use of the correct equipment and reagents; and 
 ◦  quality assurance (QA). 
•  For detailed information on technical aspects and specific in-
structions on screening tests and factor assays, please consult 
 Diagnosis of Hemophilia and Other Bleeding Disorders: A Laboratory 
Manual , current edition, published by the World Federation of 
Hemophilia (WFH). 1 
 Recommendation 3.1.1: 
•  The WFH recommends that testing for diagnosis and monitoring 
of hemophilia must be carried out by staff with knowledge and 
experience in coagulation laboratory testing using equipment 
and reagents that have been validated for this specific purpose. 
•  REMARK : Details of laboratory tests for the diagnosis and mon-
itoring of hemophilia are described in the WFH laboratory 
manual.  CB 
 3.2  |  Coagulation laboratory testing 
 Principles of diagnosis 
•  Diagnosis of hemophilia is based on the following three 
principles: 
 ◦  understanding the clinical features of hemophilia and the ap-
propriateness of the clinical diagnosis; 
 ◦  using screening tests such as prothrombin time (PT) and acti-
vated partial thromboplastin time (APTT) or platelet function 
tests to identify the potential cause of bleeding (keeping in 
mind that normal screening test results do not exclude the 
possibility of a clinically relevant bleeding disorder being pres-
ent); and 
 ◦  confirming the diagnosis by factor assays and other appropri-
ate specific investigations. 
 Technical aspects 
 Preparation of the patient prior to taking a blood sample 
•  Fasting is not necessary before collection of blood for investiga-
tion of possible bleeding disorders. 
•  Whenever possible, patients should avoid medications that can 
affect test results such as acetylsalicylic acid (ASA), which can se-
verely affect platelet function for 7-10 days. 
•  Levels of factor VIII (FVIII) and von Willebrand factor (VWF) may 
be temporarily elevated by strenuous exercise, 2 stress, 3 or inflam-
mation enough to affect the accuracy of diagnosis. Factor VIII/
VWF levels increase during pregnancy. 4 
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 Recommendation 3.2.1: 
•  In preparation for collection of a blood sample for determination 
of prothrombin time (PT), activated partial thromboplastin time 
(APTT), or FVIII/FIX activity, the WFH advises that patients with 
hemophilia may maintain their regular diet—overnight fasting is 
not necessary prior to blood draw. 
•  REMARK : High levels of lipid in the plasma may affect the determi-
nation of clotting times when using coagulometers with optical 
systems.  CB 
 Recommendation 3.2.2: 
•  In preparation for collection of a blood sample for determina-
tion of APTT or FVIII/FIX activity, the WFH recommends that 
patients with hemophilia avoid strenuous exercise prior to blood 
draw. 
•  REMARK : Strenuous exercise or stress can temporarily elevate 
FVIII activity of patients with mild hemophilia A into the refer-
ence range; therefore, patients should be rested for a few min-
utes prior to venipuncture.  CB 
 Sample collection 
•  The blood sample should be collected as per standard guidelines. 5 
•  The sample should preferably be collected near the laboratory to en-
sure quick transport, and it should remain capped during transport. 
•  Results of tests can change according to the interval between col-
lection and testing and according to sample storage conditions. 6-8 
Higher temperatures (>25°C) lead to loss of FVIII activity over 
time, 9 whereas cold storage (2-8°C) may lead to cold activation 
of several proteolytic systems. 7,10 Storage of blood samples be-
fore processing at 2-8°C can lead to loss of FVIII and VWF suffi-
cient to cause unaffected patients to be misdiagnosed with von 
Willebrand disease (VWD). 11 
•  Specific guidance is available in relation to sample collection. 10 
Venipuncture must be aseptic, and the sample must be collected 
within 1 minute of tourniquet application without prolonged ve-
nous stasis. 
•  Blood should be withdrawn into a plastic syringe or an evacuated 
collection system. The needle should be 19-21 gauge for adults 
and 22-23 gauge for small children. Collection through peripheral 
venous catheters or non-heparinized central venous catheters 
can be successful for many hemostasis tests. 10,12 
•  Blood from an indwelling catheter should be avoided for some co-
agulation tests, particularly if platelet aggregation testing is being 
performed. 
•  Frothing of the blood sample should also be avoided. It is only 
necessary to discard the first 2 mL of blood collected if blood is 
collected through a catheter. 10 
•  The sample should be collected in citrate tubes containing 
0.105M-0.109M (c3.2%) aqueous trisodium citrate dihydrate, 
maintaining the proportion of blood to citrate at a 9:1 ratio. If the 
tube contains less than 90% of the target volume, results may be 
adversely affected, and prolongation of PT and APTT is expected 
when tubes contain less than 80% of target volume. 10 
•  Patients with an elevated hematocrit above 55% have a reduced 
plasma volume leading to an exponential increase in PT and APTT 
with increasing hematocrit, which can be avoided by adjusting the 
ratio of blood to anticoagulant. 13,14 
•  Results of some PT and APTT tests are different if samples are 
collected into 3.8% trisodium citrate. 10 The sample should be 
mixed promptly and adequately with citrate solution by gentle 
inversion 3 or 4 times. 10 
•  If platelet-poor plasma (PPP) is frozen for future testing, the stor-
age conditions affect the stability of the frozen material. 7 If the 
sample is frozen at −70°C, it may be stored for up to six months. 7,15 
Storage at −20°C is usually inadequate. 
•  Frozen samples must be thawed rapidly in a water bath for 
4-5 minutes at 37°C to avoid formation of cryoprecipitate. 
 Preparation of platelet- poor plasma (PPP) 
•  Most coagulation tests require the use of PPP. 
•  PPP should be prepared as per standard guidelines. 5,7 
•  The residual platelet count in PPP depends on the centrifugation 
conditions including adverse effects on platelet function test-
ing if refrigerated centrifuges are used since cold can activate 
platelets. 7,10 
•  PPP may be kept at room temperature (20-25°C) prior to testing. 
•  Plasma that has been hemolyzed during collection and processing 
should not be used for platelet function testing, APTT testing, or 
related testing, irrespective of which method and instrument are 
used for analysis. 7,16,17 PT and fibrinogen testing are less affected, 
and only gross in vitro hemolysis may be relevant. 10,16 Adding he-
molysate to plasma in vitro may give misleading results. 16,18 
•  Sample acceptance criteria should take into account the risks from 
rejection (and delayed or missing test results) against the risks of 
acceptance and testing (and the degree to which sample artefacts 
may or may not influence clinical management). 
 Recommendation 3.2.3: 
•  For the diagnosis and monitoring of hemophilia A and B, the 
WFH recommends that blood samples be labelled immediately 
with the patient ' s first and last name, an identification number or 
date of birth, and the date and time of specimen collection. This 
should be done before leaving the side of the patient. 
•  REMARK : There is no consensus on whether the tube should 
be labeled immediately before or immediately after blood 
collection.  CB 
 Recommendation 3.2.4: 
•  The WFH recommends that blood samples for determination of 
PT, APTT, or FVIII/FIX activity be collected in citrate tubes con-
taining 0.105-0.109M (around 3.2%) aqueous trisodium citrate 
dihydrate, capped during processing, and kept at 18-25°C during 
transport and storage. Blood samples should be centrifuged 
at ambient temperature for a minimum of 1700 g for at least 
10 minutes, and either be analyzed within 8 hours of collection 
(4 hours for FVIII:C) or stored deep frozen at − 35°C or lower. 
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•  REMARK : Storage of citrated whole blood samples at 2-8°C should 
be avoided as this may result in loss of FVIII activity. 
•  REMARK : Platelet poor plasma (PPP) samples can be stored at 
− 35°C for up to 3 months and at − 70°C for up to 6 months prior 
to determination of FVIII/FIX activity. Storage of PPP at − 20°C 
is usually inadequate. Freezers with auto-defrost should not be 
used to store PPP prior to determination of PT, APTT, or FVIII/
FIX activity.  CB 
 Recommendation 3.2.5: 
•  The WFH recommends that blood samples for determination of 
PT, APTT, or FVIII/FIX activity should be rejected and replaced 
if the collection tube contains less than 80% of the target fill 
volume. 
•  REMARK : If the collection tube contains between 80% and 90% of 
its target fill volume, the results obtained using certain methods 
may have minor artefactual prolongation of PT and APTT and 
minor artefactual reduction in FVIII/FIX activity.  CB 
 Recommendation 3.2.6: 
•  The WFH recommends that blood samples for determination of 
APTT or FVIII/FIX activity should be rejected and replaced if in 
vitro hemolysis or clotting have occurred during the collection 
and processing of the sample. 
•  REMARK : The impact of in vitro hemolysis on PT is insufficient to 
affect patient management. 
•  REMARK : Samples from patients with in vivo hemolysis that have 
been collected for determination of PT, APTT, or FVIII/FIX activ-
ity can be accepted and tested.  CB 
 Endpoint detection 
•  Many laboratories now have some form of semi- or fully auto-
mated coagulation analyzers. Accurately detecting the clotting 
endpoint using a manual technique requires considerable exper-
tise, particularly if clotting time is prolonged or if fibrinogen con-
centration is low, and the clot is thin and wispy. 
•  For manual testing, the tube should be tilted 3 times every 5 sec-
onds through an angle of approximately 90° during observation. 
The tube should be immersed in a water bath at 37°C between 
tilting. 
 Screening tests 
•  Platelet count, PT, and APTT may be used to screen a patient sus-
pected of having a bleeding disorder. 19 
•  The sensitivity of both PT 20 and APTT tests 21,22 to factor defi-
ciencies are influenced by the type of reagents used to perform 
the test. 
 Recommendation 3.2.7: 
•  For laboratory investigation of patients being assessed due to 
clinical suspicion of hemophilia A, the WFH recommends that 
prothrombin time testing also be performed using a laboratory 
reagent containing human tissue factor. 
•  REMARK : Hemophilia A is sometimes excluded despite clinical 
suspicion of its presence. Such cases may have other factor de-
ficiencies. Some patients with certain FVII defects may have 
symptoms similar to mild hemophilia but may display normal PT 
and FVII activity if the laboratory reagent contains non-human 
tissue factor so that the diagnosis would be missed.  CB 
 Recommendation 3.2.8: 
•  For laboratory investigation of patients being assessed due to 
clinical suspicion of hemophilia, the WFH recommends that an 
APTT result within the reference range not be used to rule out 
the presence of mild hemophilia A or B. 
•  REMARK : In some cases of mild hemophilia A or B, APTT may be 
within the normal range.  CB 
•  Bleeding time testing lacks sensitivity and specificity, and it is 
also prone to performance-related errors. Therefore, other tests 
of platelet function such as platelet aggregometry are preferred 
when available. 23,24 
•  Based on the results of these tests, the category of bleeding dis-
order may be partially characterized to guide subsequent analysis 
(see Table  3-1 ). 
•  These screening tests may not detect abnormalities in patients 
with mild bleeding disorders, including some variants of VWD, 
some cases of genetically confirmed mild hemophilia A or B, de-
fects of platelet function, FXIII deficiency, and those rare de-
fects of fibrinolysis which may be associated with a bleeding 
tendency. 
 Correction studies 
•  Abnormal screening tests may be further investigated using cor-
rection or mixing studies. 
•  Correction or mixing studies using pooled normal plasma (PNP) 
may help to define whether prolonged coagulation times are due 
to factor deficiency or circulating anticoagulants or inhibitors. 
•  The APTT of a patient/normal plasma mix may initially be normal 
and then progressively prolonged on incubation in the presence 
of a time-dependent inhibitor (e.g., many acquired autoantibodies 
against FVIII), although this pattern can be variable in cases with 
complex kinetics. 
 TA B L E   3 1     Interpretation of screening tests 
 Possible diagnosis  PT  APTT  Platelet count 
 Normal  Normal  Normal  Normal 
 Hemophilia A or B  Normal  Prolonged a   Normal 
 VWD  Normal  Normal or 
prolonged a  
 Normal or reduced 
 Platelet defect  Normal  Normal  Normal or reduced 
 Abbreviations: APTT, activated partial thromboplastin time; PT, 
prothrombin time; VWD, von Willebrand disease. 
 a The same pattern can occur in the presence of FXI, FXII, prekallikrein, 
or high molecular weight kininogen deficiencies.  
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•  Correction studies with FVIII/FIX-deficient plasma may be used to 
identify the particular deficiency if a factor assay is not available. 
 Recommendation 3.2.9: 
•  The WFH recommends that an APTT result within the normal 
range obtained in a sample containing an equal volume mixture 
of patient and pooled normal plasma that was analyzed immedi-
ately after preparation of that mixture should not be used to rule 
out the possible presence of an FVIII inhibitor. 
•  REMARK : The APTT of an equal volume mixture of patient and 
pooled normal plasma becomes substantially prolonged over a 
period of 1 to 2 hours of incubation at 37°C if the patient sample 
contains a neutralizing anti-FVIII inhibitor.  CB 
 Factor assays 
•  Several types of FVIII assay including chromogenic and fluoro-
genic clotting assays are available. 25-30 One-stage clotting assays 
based on APTT are the most commonly used techniques in most 
regions. 26,27 
•  FVIII- and FIX-deficient plasma must completely lack FVIII and 
FIX, respectively, i.e., it must contain < 1 IU/dL and have normal 
levels of other clotting factors. 1 
•  The level of clotting factors in pooled normal plasma varies sub-
stantially between pools, 31,32 therefore, a system of international 
units (IUs) has been established for continuity and traceabil-
ity. 31,33 Factor levels are reported in international units, either per 
mL or per decilitre (IU/dL). If IU/dL is used, then results are not 
interchangeable with percentage (%) of pooled normal plasma. 34 
•  Use of a single test plasma dilution leads to assay inaccuracy in 
the presence of some inhibitors, including lupus anticoagulants 
(LA), 35 specific high-responding factor inhibitors, and some anti-
coagulant drugs, 36 and leads to assay imprecision. 
•  Assay calibration method can affect the quality of results. 37,38 
When assaying test samples from patients with moderate or se-
vere hemophilia, an extended or separate calibration curve may 
be needed. It is not acceptable to simply extend the calibration 
curve by extrapolation without analyzing additional dilutions of 
the calibration plasma. 
•  Some cases of genetically confirmed mild hemophilia A show nor-
mal FVIII activity when a one-stage assay is used for diagnosis 
but reduced activity in chromogenic and two-stage clotting as-
says. 39-46 The reverse can also occur. 40,47,48 This means that more 
than one type of FVIII assay is needed to detect all forms of mild 
hemophilia A. 
•  All patients with reduced FVIII activity and a possible diagno-
sis of hemophilia A should have a full laboratory assessment to 
rule out VWD. This is especially important to differentiate VWD 
Normandy from mild hemophilia A since both have a normal level 
of VWF antigen usually associated with a reduced FVIII activity. 49 
•  Chromogenic FIX assays are becoming more available, 50-54 and 
one study has reported that a chromogenic FIX assay may cor-
relate better with the clinical picture than a one-stage assay in 
some hemophilia B cases. 53 
•  Thrombin generation tests have been used in characterizing he-
mophilia 55-57 but are not in widespread use. 
 Recommendation 3.2.10: 
•  For laboratory investigation of patients being assessed due to 
clinical suspicion of hemophilia A, the WFH recommends the use 
of both the one-stage FVIII assay and the chromogenic FVIII:C 
assay in the initial diagnostic workup. 
•  REMARK : Both assays should be performed even if the result of 
one of the two assays shows FVIII activity within the normal 
range. 
•  REMARK : The one-stage FVIII assay requires the use of FVIII-
deficient plasma containing less than 1 IU/dL (<1%) FVIII activ-
ity and normal levels of other clotting factors that can influence 
APTT (fibrinogen, FII, FV, FIX, FX, FXI, FXII, prekallikrein, and 
HMWK).  CB 
 Recommendation 3.2.11: 
•  For laboratory investigation of patients being assessed due to 
clinical suspicion of hemophilia B, the WFH recommends the use 
of the one-stage FIX assay in the initial diagnostic workup. 
•  REMARK : Data are currently insufficient to make recommenda-
tions on the role of the chromogenic FIX assay in the initial diag-
nostic workup of hemophilia B. 
•  REMARK : The one-stage FIX assay requires the use of FIX-
deficient plasma containing less than 1 IU/dL (<1%) FIX activity 
and normal levels of other clotting factors that can influence 
APTT (fibrinogen, FII, FV, FVIII, FX, FXI, FXII, prekallikrein, and 
HMWK).  CB 
 Recommendation 3.2.12: 
•  For one-stage or chromogenic FVIII/FIX assays, the reference/
standard plasma used for calibration, whether commercially or 
locally prepared, must be traceable to a WHO international stan-
dard, and results should be reported in international units (IUs). 
•  REMARK : Results should be reported as IU/mL or IU/dL. 
•  REMARK : In principle, percentage is the appropriate unit of activity 
only when the assay is performed using pooled normal plasma as 
the reference plasma whose activity is not traceable back to a 
WHO international standard.  CB 
 Recommendation 3.2.13: 
•  For laboratory investigation due to clinical suspicion of hemo-
philia using one-stage FVIII/FIX assays, the WFH recommends 
analysis using 3 different dilutions of test plasma samples. 
•  REMARK : The results of the test and standard plasma dilutions 
should be compared by parallel-line analysis. One way to as-
sess this is to calculate the coefficient of variation (CV) of 
the 3 results using the equation CV = ([standard deviation/
mean] × 100). If the CV of the 3 results is less than 15%, then 
the average of the 3 results should be reported. If the CV is 
greater than 15%, the results should be scrutinized. Presence of 
pathological inhibitors against specific clotting factors or lupus 
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anticoagulants can interfere with some one-stage FVIII and FIX 
assays. Some therapeutic anticoagulants can also show this 
interference effect. In all of these settings, factor activity in-
creases in the assay as the plasma is increasingly diluted. Factor 
activity is underestimated when the plasma is diluted less, and 
a more accurate activity result is obtained when the test plasma 
is diluted more.  CB 
 Recommendation 3.2.14: 
•  In populations where lupus anticoagulant occurs, the WFH rec-
ommends the use of an APTT reagent insensitive to lupus antico-
agulant to perform one-stage FVIII/FIX assays.  CB 
 Recommendation 3.2.15: 
•  For all one-stage FVIII/FIX assays, only the clotting times of test 
sample dilutions that are within the range covered by the calibra-
tion curve should be used to calculate FVIII/FIX activity in the 
test sample. 
•  REMARK : When assaying test samples from patients with moder-
ate or severe hemophilia A or B, an extended or additional cali-
bration curve may be needed. It is not acceptable to extend the 
calibration curve by extrapolation without analyzing additional 
dilutions of the reference/calibration plasma.  CB 
 Recommendation 3.2.16: 
•  For all types of FVIII and FIX assays, an internal quality control 
(IQC) sample should be included with each batch of test samples 
analyzed. Results should only be released for patient manage-
ment purposes after confirmation that the IQC result is within 
the target range for that material. 
•  REMARK : A description of how to set target ranges for IQC mate-
rials and handle out-of-range IQC results is available in the WFH 
laboratory manual.  CB 
 Recommendation 3.2.17: 
•  For internal quality control samples with FVIII/FIX activity in the 
range of 50-150 IU/dL, the between-assay coefficient of varia-
tion should be less than 10%. 
•  REMARK : Some studies have shown use of a stored calibration 
curve to be associated with higher between-assay CVs than 
use of a new calibration curve generated alongside patient 
samples.  CB 
 Post- FVIII/FIX infusion monitoring 
•  Lower than expected recovery and/or reduced half-life of infused 
clotting factor concentrates (CFCs) may be an early indicator of 
the presence of inhibitors. 
•  For samples containing FVIII or FIX CFCs, results of FVIII or FIX 
assays may vary according to whether a one-stage or chromo-
genic assay is used for analysis and sometimes according to the 
specific reagents or kits used in the assay. 
•  If factor assays are used to confirm efficacy of treatment or to 
make dose adjustments, bear in mind that some assays are unsuit-
able for monitoring some products. 58 
•  Using an assay that markedly overestimates activity compared to 
the expected results from the labelled potency of the concentrate 
could lead to undertreatment and clinical risk. 
•  A full consensus on the tolerable degree of difference in results 
from different assays before patient management is adversely 
affected has not been established at the time of this writing; in 
the meantime, assays that give results that differ by more than 
25-30% from the labelled potency of the concentrate vial are best 
avoided or, in any case, should not be used without taking account 
of such differences. 
•  Routine in-house assays can be used for post-infusion monitor-
ing, provided that the local assay system (method and reference/
calibrator) is included in the manufacturer ' s guidance. 59 Any local 
assay should be verified for use with the specific CFC being used. 60 
•  A number of articles have reviewed the published evidence re-
lated to use of specific assays for monitoring specific extended 
half-life (EHL) and unmodified CFCs. 58,60,61 
•  One-stage assays used to monitor the single-chain recombinant 
FVIII molecule lonoctocog alfa (Afstyla ® ) underestimated relative 
potency by 45% whereas chromogenic assay recovered the ex-
pected values 62 which led to a recommendation that chromogenic 
assay is preferred, and that one-stage assay results should be mul-
tiplied by a conversion factor of 2 to determine the patient ' s FVIII 
activity level. 63 Such an approach did not fully correct for reagent 
differences, 64 and some experts have specifically recommended 
against using an assay known to give discrepant values and mul-
tiplying the result by a correction factor in this way. 65 Since there 
may be lot-to-lot variation in reagents used for factor assays, any 
such conversion factor should be verified for the lot numbers in use. 
•  There are numerous published assay studies comparing results 
in samples containing CFCs including EHL FVIII and FIX concen-
trates. Despite this, there are a number of one-stage and chro-
mogenic assay reagents that have not been studied for use with 
some CFCs at the time of this writing. The reader is referred to 
the references in Table  3-2 (FVIII) and Table  3-3 (FIX) to see the 
evidence supporting the recommendations below. 
 Recommendation 3.2.18: 
•  For monitoring replacement therapy with FVIII or FIX concen-
trates, the WFH recommends that laboratories use a FVIII/FIX 
assay that has been validated for use with the specific concen-
trate used for treatment. 
•  Remark: This recommendation is particularly important for mod-
ified molecular forms of FVIII and FIX.  CB 
 Recommendation 3.2.19: 
•  For monitoring replacement therapy with plasma-derived FVIII 
concentrates, the WFH recommends use of a one-stage or chro-
mogenic FVIII assay calibrated with a plasma standard traceable 
to a WHO international standard.  CB 
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 Recommendation 3.2.20: 
•  For monitoring replacement therapy with clotting factor concen-
trates containing full-length recombinant FVIII, the WFH recom-
mends use of a one-stage or chromogenic FVIII assay calibrated with 
a plasma standard traceable to a WHO international standard.  CB 
 Recommendation 3.2.21: 
•  For monitoring replacement therapy with efmoroctocog alfa (re-
combinant FVIII fused with human immunoglobulin G1 [rFVIIIFc]; 
Elocta  ®  /Eloctate  ®  ), the WFH recommends use of a one-stage or 
chromogenic FVIII assay calibrated with a plasma standard trace-
able to a WHO international standard.  CB 
 Recommendation 3.2.22: 
•  For monitoring replacement therapy with turoctocog alfa pegol 
(recombinant B-domain-truncated FVIII with a site-specific 40-
kDa polyethylene glycol group [N8-GP]; Esperoct  ®  ), the WFH 
recommends use of a chromogenic FVIII assay or APTT-based 
one-stage FVIII assay with validated reagents, including some 
ellagic acid activator reagents (Actin  ®  , Actin  ®   FS, SynthAFax  ™  , 
DG Synth  ™  ) and some silica activator reagents (Pathromtin  ®   SL, 
SynthASil  ™  ), calibrated with a plasma standard traceable to a 
WHO international standard. 
•  REMARK : One-stage FVIII assays with APTT-SP  ™  , STA  ®  -PTT 
Automate, or TriniCLOT  ™   APTT HS reagents significantly 
 TA B L E   3 2     Publications with data related to the use of different FVIII assays in the presence of recombinant and modified factor VIII 
concentrates 
 Product type  Brand name 
 International non- 
proprietary name  References 
 Full- length recombinant  Advate ® , Kogenate ®  FS, 
Kovaltry ®  
 Octocog alfa  Church (2018) 66  , Kitchen (2016) 67  , Kitchen 
(2016) 68  , Turecek (2016) 69  
 BDD FVIII  NovoEight ®   Turoctocog alfa  Viuff (2011) 70  
 BDD FVIII  ReFacto AF ®   Moroctocog alfa  Kitchen (2016) 68  , Jacquemin (2018) 71  , Cauchie 
(2013) 72  , Morfini (2003) 73  , Ingerslev (2004) 74  , 
Santoro (2009) 75  
 BDD FVIII fused to Fc portion of 
IgG1 
 Elocta ® /Eloctate ®   Efmoroctocog alfa  Powell (2012) 76  , McCue (2015) 77  , Sommer 
(2014) 78  , Kitchen (2019) 79  
 B- domain- truncated FVIII with 
site- specific 40 kDa polyethylene 
glycol moiety 
 Esperoct ®   Turoctocog alfa pegol  Hillarp (2017) 80  , Pickering (2016) 81  , Persson 
(2019) 82  , Ezban (2019) 83  , Hegemann (2019) 84  , 
Tiefenbacher (2019) 85  
 BDD FVIII with site- specific 60 kDa 
polyethylene glycol 
 Jivi ®   Damoctocog alfa pegol  Church (2018) 66  , Gu (2014) 86  
 Full- length recombinant FVIII 
with non- site- specific 20 kDa 
pegylation 
 Adynovate ® /Adynovi ®   Rurioctocog alfa pegol  Turecek (2016) 69  , Bulla (2017) 87  , Weber 
(2017) 88  
 Single- chain recombinant FVIII  Afstyla ®   Lonoctocog alfa  St Ledger (2018) 62  , Bowyer (2017) 64  
 Recombinant BDD porcine FVIII  Obizur ®   Susoctocog alfa  Turecek (2016) 69  , Vanguru (2018) 89  
 Note :  Therapeutic products are denoted by both their international non- proprietary name and their brand name because of the latter ' s more common 
usage and recognition by the community.  
 Abbreviations: BDD, B- domain- deleted; FVIII, factor VIII; kDA, kilodalton. 
 TA B L E   3 3     Publications with data related to the use of different FIX assays in the presence of recombinant and modified factor IX 
concentrates 
 Product type  Brand name 
 International non- proprietary 
name  References 
 Recombinant  Not identified  Not identified  Wilmot (2014) 90  
 Recombinant FIX fused to Fc 
portion of IgG1 
 Alprolix ®   Eftrenonacog alfa  Kershaw (2018) 54  , Sommer (2014) 91  , 
Bowyer (2019) 92  
 Recombinant fusion protein linking 
FIX to albumin 
 Idelvion ®   Albutrepenonacog alfa  Horn (2019) 51  , Bowyer (2019) 92  
 Recombinant FIX with site- directed 
40 kDa pegylation 
 Refixia ® /Rebinyn ®   Nonacog beta pegol  Bowyer (2016) 52  , Rosen (2016) 93  , 
Tiefenbacher (2017) 94  , Ezban (2019) 95  
 Note :  Therapeutic products are denoted by both their international non- proprietary names and their brand names because of the latter ' s more 
common usage and recognition by the community.  
 Abbreviations: FIX, factor IX; IgG1, immunoglobulin G1; kDA, kilodalton. 
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underestimate true FVIII activity of N8-GP and should not 
be used.  CB 
 Recommendation 3.2.23: 
•  For monitoring replacement therapy with damoctocog alfa pegol 
(recombinant B-domain-deleted FVIII with a site-specific 60 kDa 
branched polyethylene glycol group [BDD-rFVIII]; Jivi  ®  ), the 
WFH recommends use of a chromogenic FVIII assay or APTT-
based one-stage FVIII assay with validated reagents, including 
the ellagic acid activator reagent Actin  ®   FSL and some silica ac-
tivator reagents (Pathromtin  ®   SL, SynthASil  ™  ), calibrated with a 
plasma standard traceable to a WHO international standard. 
•  REMARK : One-stage FVIII assays with the ellagic acid activator 
reagent Actin  ®   FS or the kaolin activator reagent C.K. Prest  ®  
 significantly overestimate true FVIII activity and should not 
be used. One-stage FVIII assays with APTT-SP  ™   and STA  ®-  PTT 
Automate reagents significantly underestimate true FVIII activ-
ity and should not be used.  CB 
 Recommendation 3.2.24: 
•  For monitoring replacement therapy with rurioctocog alfa pegol 
(full-length recombinant FVIII with non-site-specific 20-kDa 
polyethylene glycol; Adynovate  ®  /Adynovi  ®  ), the WFH advises 
that more laboratory assay studies are required to inform recom-
mendations about laboratory monitoring. 
•  REMARK : There are conflicting findings in the literature assessing 
the use of one-stage and chromogenic FVIII assays in samples 
containing rurioctocog alfa pegol.  CB 
 Recommendation 3.2.25: 
•  For monitoring replacement therapy with lonoctocog alfa (sin-
gle-chain recombinant FVIII [rVIII-SingleChain]; Afstyla  ®  ), the 
WFH recommends use of a chromogenic FVIII assay calibrated 
with a plasma standard traceable to a WHO international 
standard. 
•  REMARK : The summary of product characteristics recommends 
chromogenic assays. It also states that the one-stage FVIII assay 
result underestimates the FVIII activity level by approximately 
45% compared to the chromogenic assay result, and suggests 
that if the one-stage assay is used, the result should be multiplied 
by a factor of 2.  CB 
 Recommendation 3.2.26: 
•  For monitoring replacement therapy with plasma-derived FIX 
concentrates, the WFH recommends use of a one-stage or chro-
mogenic FIX assay calibrated with a plasma standard traceable to 
a WHO international standard.  CB 
 Recommendation 3.2.27: 
•  For monitoring replacement therapy with clotting factor con-
centrates containing unmodified recombinant FIX, the WFH rec-
ommends use of a one-stage FIX assay calibrated with a plasma 
standard traceable to a WHO international standard. 
•  REMARK : Chromogenic FIX assays have been reported to underes-
timate the FIX activity of recombinant FIX concentrate.  CB 
 Recommendation 3.2.28: 
•  For monitoring replacement therapy with eftrenonacog alfa (re-
combinant FIX fused with human immunoglobulin G1 [rFIXFc]; 
Alprolix  ®  ), the WFH recommends use of a chromogenic FIX assay 
or APTT-based one-stage FIX assay with validated reagents, in-
cluding some ellagic acid activator reagents (Actin  ®  , Actin  ®   FS, 
Actin  ®   FSL), some silica activator reagents (Pathromtin  ®   SL, 
SynthASil  ™  ), and a polyphenol activator reagent (Cephascreen  ®  ), 
calibrated with a plasma standard traceable to a WHO interna-
tional standard. 
•  REMARK : One-stage FIX assays with STA  ®  -PTT Automate or ka-
olin activator (C.K. Prest  ®  ) reagents significantly underestimate 
true rFIXFc (Alprolix  ®  ) activity and should not be used.  CB 
 Recommendation 3.2.29: 
•  For monitoring replacement therapy with albutrepenonacog 
alfa (recombinant FIX fused with recombinant human albumin 
[rFIX-RFP]; Idelvion  ®  ), the WFH recommends use of an APTT-
based one-stage FIX assay with validated reagents, including 
some silica activator reagents (Pathromtin  ®   SL, SynthASil  ™  ), cali-
brated with a plasma standard traceable to a WHO international 
standard. 
•  REMARK : One-stage FIX assays with the ellagic acid activator re-
agent Actin  ®   FS or the kaolin activator reagent C.K. Prest  ®   sig-
nificantly underestimate true rFIX-RFP (Idelvion  ®  ) activity and 
should not be used. One-stage assays with the ellagic acid activa-
tor SynthAFax  ™   reagent or chromogenic FIX assays significantly 
overestimate true rFIX-RFP (Idelvion  ®  ) activity and should not 
be used.  CB 
 Recommendation 3.2.30: 
•  For monitoring replacement therapy with nonacog beta pegol 
(recombinant FIX with a 40-kDa polyethylene glycol moiety 
[N9-GP]; Refixia  ®  /Rebinyn  ®  ), the WFH recommends use of a 
chromogenic FIX assay or APTT-based one-stage FIX assay with 
validated reagents, including the ellagic acid activator reagent 
SynthAFax  ™   or the polyphenol activator Cephascreen  ®  , cali-
brated with a plasma standard traceable to a WHO international 
standard . 
•  REMARK : Most one-stage FIX assays significantly overestimate 
or underestimate true FIX activity of N9-GP and should not be 
used. One-stage assays using the ellagic acid activator reagent 
SynthAFax  ™   or the polyphenol activator reagent Cephascreen  ®  , 
are suitable for monitoring therapy with N9-GP.  CB 
 Emicizumab 
•  Emicizumab is an engineered bispecific antibody that binds 
both human FIX/FIXa and FX/FXa and which is not regulated 
by the mechanisms that regulate FVIII but which acts as a FVIII 
mimetic. 96,97 
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•  The APTT is considerably shortened by emicizumab to within or 
below the reference range irrespective of reagents used, which 
means that emicizumab affects all APTT-based laboratory tests 
and assays. 98-100 
•  Emicizumab significantly interferes in chromogenic FVIII assays 
utilizing human FIXa and FX but not those using FIXa and FX of 
bovine origin. Local verification is needed for chromogenic kits 
containing bovine FX and human FIXa. 98,99 
•  Emicizumab can be measured and reported in μg/mL using a mod-
ified one-stage assay with higher test sample dilution (in assay 
buffer) and calibrated with emicizumab-specific calibrators. 99 
 Recommendation 3.2.31: 
•  For patients receiving emicizumab in whom confirmation of ex-
pected emicizumab levels is required, the WFH recommends use 
of a modified one-stage assay including an additional pre-dilu-
tion step of test plasma and assay calibration with specific emi-
cizumab calibrators. 
•  REMARK : Even at subtherapeutic levels of emicizumab, APTT may 
be normal or subnormal in patients with severe hemophilia A 
with or without inhibitors.  CB 
 Recommendation 3.2.32: 
•  For determination of FVIII activity in patients with hemophilia A 
receiving emicizumab, the WFH recommends use of a chromo-
genic FVIII assay containing bovine FX. 
•  REMARK : At therapeutic levels, emicizumab affects any chromo-
genic FVIII assay containing FX of human origin. Emicizumab may 
also affect chromogenic FVIII assays containing FIXa of human 
and FX of bovine origin but only at emicizumab levels higher than 
those expected in patients receiving recommended doses.  CB 
 Recommendation 3.2.33: 
•  For determination of FVIII inhibitor levels in patients receiving 
emicizumab, the WFH recommends use of a chromogenic FVIII 
assay containing bovine FX.  CB 
 Recommendation 3.2.34: 
•  For patients with a suspected neutralizing anti-emicizumab anti-
body, the WFH recommends measuring emicizumab levels using 
a modified one-stage assay including an additional pre-dilution 
step of test plasma and assay calibration with specific emici-
zumab calibrators. 
•  REMARK : Validated anti-drug antibody assays may also be used for 
this purpose, if available.  CB 
 Inhibitor testing 
•  The most frequently encountered functional inhibitors of hemo-
stasis are lupus anticoagulants, which are not directed against 
specific clotting factors and whose presence should be excluded 
prior to specific factor inhibitor testing. 
•  Results of APTT testing on mixtures of test and normal plasma can 
be difficult to interpret, particularly since in acquired hemophilia 
there may initially be a full correction of APTT even in the pres-
ence of a potent specific anti-FVIII antibody. If anti-FVIII anti-
body is present, the APTT of this mixture will be prolonged with 
incubation. 
•  Most FVIII inhibitors that develop secondary to replacement ther-
apy in patients with hemophilia A show a characteristic pattern: 
the APTT of a patient/PNP mixture is intermediate, i.e., between 
the APTTs of the two materials, and it is further prolonged when 
the mixture is incubated at 37°C for 1-2 hours. 
•  Confirmation that an inhibitor is directed against a specific clot-
ting factor requires a specific inhibitor assay. 
•  Quantification of the inhibitor titer is performed in the labora-
tory, preferably using the Nijmegen-modified Bethesda assay 
for FVIII inhibitor testing, 1 because this modification offers 
improved specificity and sensitivity over the original Bethesda 
assay. 101-109 
•  The results of Bethesda inhibitor assays can be affected by the 
use of different dilutions of test sample before those dilutions are 
mixed with normal plasma. 110 
•  For patients treated with FVIII or FIX, washout is no longer nec-
essary if a heat neutralization modification of the Nijmegen-
Bethesda assay is used, which inactivates FVIII/FIX in the sample 
to allow detection of the inhibitor. 109,111-113 This is not required if 
FVIII/FIX is <5 IU/dL in the test sample since this low level will not 
have a significant effect on inhibitor titer calculations. 
•  Different types of FVIII assays can be used to determine the FVIII 
during the Nijmegen-Bethesda inhibitor assay. 114-118 The proto-
col for the US national inhibitor program requires a chromogenic 
assay to be used when positive FVIII inhibitor results below 2.0 
BU are observed. 108 If there is suspicion of lupus anticoagulant 
or if the sample contains therapeutic anticoagulants such as hep-
arin or direct FXa or FIIa inhibitors, it may be useful to confirm 
inhibitor presence using a chromogenic assay to measure residual 
factor activity (instead of a one-stage assay). 
•  An inhibitor titer of ≥ 0.6 BU/mL should be considered clinically 
significant. 119,120 
•  Some non-neutralizing anti-FVIII antibodies which are not de-
tected by the Nijmegen-Bethesda assay may be clinically relevant 
because they may increase the clearance of FVIII and can be mea-
sured by ELISA. 121-128 
 Recommendation 3.2.35: 
•  For determination of anti-FVIII inhibitors in a sample containing 
greater than 5 IU/dL FVIII activity, the WFH recommends that 
prior to testing, the sample be heated to 56°C for 30 minutes and 
centrifuged at ambient temperature for a minimum of 1700 g for 
at least 5 minutes. 
•  REMARK : The quantification limit of the Nijmegen-Bethesda FVIII 
inhibitor assay is around 0.6 BU/mL. 
•  REMARK : The Nijmegen-Bethesda FVIII inhibitor assay requires 
use of buffered pooled normal plasma as a source of FVIII, which 
is then mixed with an equal volume of FVIII-deficient plasma to 
prepare the control mixture.  CB 
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 Recommendation 3.2.36: 
•  For determination of anti-FIX inhibitors in a sample containing 
greater than 5 IU/dL FIX activity, the WFH recommends that 
prior to testing, the sample be heated at 56°C for 30 minutes and 
centrifuged at ambient temperature for a minimum of 1700 g for 
at least 5 minutes.  CB 
 Recommendation 3.2.37: 
•  For quantification of anti-FVIII inhibitors, the WFH recommends 
that the Nijmegen-Bethesda assay be used. 
•  REMARK : Bethesda assays detect neutralizing antibodies. A small 
proportion of anti-FVIII antibodies are non-neutralizing, shorten 
the half-life of infused FVIII, and are not detected by Bethesda 
assays. 
•  REMARK : The Nijmegen modification describes a specific method 
for buffering pooled normal plasma; other buffering methods 
may be suitable.  CB 
 Recommendation 3.2.38: 
•  For quantification of FVIII and FIX inhibitors, the WFH recom-
mends that only residual FVIII/FIX activity between 25% and 
75% of the FVIII/FIX in the control mixture be used to calculate 
inhibitor concentrations. 
•  REMARK : The most accurate inhibitor results are obtained when 
the residual FVIII/FIX activity is close to 50% of the level in the 
control mixture.  CB 
 Recommendation 3.2.39: 
•  For quantification of low-titer anti-FVIII inhibitors (<2 BU/mL), 
the WFH recommends use of a chromogenic Nijmegen-Bethesda 
FVIII assay to measure residual FVIII activity. 
•  REMARK : Use of a chromogenic Nijmegen-Bethesda FVIII assay 
instead of a one-stage FVIII assay provides greater specificity 
and reduces possible variability in measurement of residual FVIII 
leading to underestimation to the extent that a false positive in-
hibitor is reported when no inhibitor is present. 
 Gene therapy 
•  Discrepancies between results of one-stage and chromogenic as-
says have been reported after both FVIII and FIX gene therapy. 
•  Results of one-stage FVIII assays were approximately 1.65-fold 
higher 129 and 1.5-fold higher 130 than chromogenic assays for two 
different therapies with B-domain–deleted (BDD) FVIII, which is 
in contrast to CFC-containing BDD FVIII where chromogenic re-
sults are higher than one-stage assay results. 58,75 
•  Results of one-stage FIX assays varied according to reagents used 
but were higher than results obtained in chromogenic FIX assays 
in patients who had received FIX gene therapy with a high specific 
activity FIX Padua variant. 131 
 Recommendation 3.2.40: 
•  For quantification of FVIII activity in recipients of gene transfer, 
the WFH advises that more research is necessary to determine 
the relative accuracy of chromogenic and one-stage assays in 
predicting hemostatic protection. 
•  REMARK : The one-stage assay appears to consistently produce 
FVIII activity results that are approximately 1.6-fold greater than 
those obtained with the chromogenic assay for multiple FVIII 
transgene products. Correlation with both plasma and recombi-
nant FVIII-specific activity and clinical response may be needed 
for accurate determination of FVIII activity in recipients.  CB 
 Recommendation 3.2.41: 
•  For quantification of FIX activity in recipients of gene transfer, 
the WFH advises that more research is necessary to determine 
the relative accuracy of chromogenic and one-stage assays in 
predicting hemostatic protection. 
•  REMARK : FIX Padua (R338L) has been utilized for FIX gene therapy 
because it has a higher specific activity than native FIX. The one-
stage assay appears to consistently produce FIX Padua activity 
results that are approximately 1.6-fold greater than those ob-
tained with the chromogenic assay. Correlation with both plasma 
and recombinant FIX-specific activity is needed for accurate de-
termination of FIX Padua activity in recipients.  CB 
 Trained personnel 
•  A laboratory scientist/technologist with an interest in coagula-
tion must have an in-depth understanding of the tests in order to 
achieve accurate results. 
•  In some cases, it may be beneficial to have a laboratory scientist/
technologist who has had further training in a specialist centre. 
 3.3  |  Use of correct equipment and reagents 
 Equipment 
•  The basic laboratory equipment requirements include a 
37°C ± 0.5°C water bath for rapid thawing of frozen samples and 
for performing manual tests on any samples where automated 
analysis has failed, and calibrated automated pipettes. 
•  Plastic and glass consumables used in coagulation testing should 
not be re-used. 
•  Automated coagulometers offer significant advantages over man-
ual methods of some semi-automates including improved accu-
racy precision, repertoire and in some cases automatic detection 
of pre-analytical problems. 
 Selection of coagulometers 
•  Important considerations in the selection of coagulometers 
include: 
 ◦  test repertoire; 
 ◦  operational requirements including service and breakdown 
response; 
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 ◦  throughput; 
 ◦  comparability between the results on the primary analyzer 
and any back-up methods; 
 ◦  compatibility with blood sample tubes and plasma storage 
containers in local use; and 
 ◦  safety. 
•  Information is required in relation to the performance characteris-
tics of the system. This can be obtained from a variety of sources 
including the published literature and manufacturers’ data, but it 
may also require some form of local assessment. Detailed guid-
ance on selection and assessment of analyzers is available. 132,133 
 Reagents 
•  It is good practice to ensure continuity of the supply of a cho-
sen reagent, with attention paid to continuity of batches and long 
shelf life. This may be achieved by asking the supplier to batch 
hold for the laboratory, if possible. 
•  Different reagent brands may have different sensitivities and should 
not be run side by side, unless this is done for a specific purpose. 
•  A normal reference range should be defined for all methods. 
Practical guidance on this is published, 1 and for APTT must take 
into account the sample collection and processing conditions 
used locally. 
 3.4  |  Quality assurance 
•  Quality assurance covers all aspects of the diagnosis process from 
sample taking, separation and analysis, and internal quality con-
trol (IQC) through to reporting of the result and ensuring that it 
reaches the appropriate clinician within an appropriate time. 
 Internal quality control 
•  Internal quality control is used to establish whether a series of 
techniques and procedures is being performed consistently over 
a period of time. 
•  IQC measures are taken to ensure that the results of laboratory 
investigations are reliable enough to assist clinical decision-mak-
ing, monitor therapy, and diagnose hemostatic abnormalities. 
•  Graphical display of quality control results, for example in the 
form of Levey-Jennings charts, may facilitate review of trends in 
IQC results. 
 External quality assessment 
•  External quality assessment (EQA) helps to identify the degree 
of agreement between the local laboratory results and those ob-
tained by other centres. 
•  The WFH International External Quality Assessment Scheme 
(IEQAS) is specifically designed to meet the needs of hemophilia 
treatment centres worldwide. This scheme includes analyses rel-
evant to the diagnosis and management of bleeding disorders. 
Details of this scheme, which is operated in conjunction with the 
U.K. National External Quality Assessment Service (UK NEQAS) 
for Blood Coagulation in Sheffield, U.K., can be obtained from the 
WFH. 134 
•  In order for a laboratory to attain a high level of testing reliability 
and to participate successfully in an external quality assessment 
program, the laboratory must have access to appropriate reagents 
and techniques and an appropriate number of adequately trained 
staff. 
 Recommendation 3.4.1: 
•  The WFH strongly recommends that coagulation laboratories im-
plement quality assurance programs for all laboratory systems to 
ensure quality adherence and the reliability of laboratory blood 
testing procedures and reporting for the diagnosis and treatment 
of hemophilia.  CB 
 Recommendation 3.4.2: 
•  For hemostasis screening tests, the WFH recommends perform-
ing internal quality controls with at least two levels of internal 
quality control samples (normal and abnormal plasma samples) 
for all test batches at least daily.  CB 
 Recommendation 3.4.3: 
•  The WFH strongly recommends that clinical laboratories rou-
tinely participate in external quality assessment for each assay 
used for the diagnosis and treatment of hemophilia. 
•  REMARK : Participation in the WFH International External Quality 
Assessment Scheme (IEQAS) enables laboratories to improve 
and standardize laboratory testing for hemophilia.  CB 
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 All statements identified as recommendations are consensus based, 
as denoted by  CB . 
 4.1  |  Introduction 
•  Genetic assessment of hemophilia is important in defining disease 
biology, establishing diagnosis in difficult cases, predicting risk of 
inhibitor development, identifying female carriers, and providing 
prenatal diagnosis, if desired. 1 
•  Genotype analysis should be offered to all people with hemophilia 
and their “at-risk” female family members. 
•  Genetic testing strategies are led by the phenotypic parame-
ters measured by the coagulation laboratory in addition to the 
family pedigree. Therefore, it is essential that the data are made 
available to the genetic testing laboratory. An accurate inter-
pretation of the underlying variant(s) detected is dependent 
on the supporting phenotypic data and family history for the 
patient. 2–5 
•  Genetic counselling for people with hemophilia and their fami-
lies is an essential requirement prior to genetic testing. This in-
cludes obtaining informed consent from the patient, parent, or 
legal guardian, requiring both permission to carry out testing as 
well as education to ensure that they fully understand the testing 
procedure, the benefits and limitations of the test, and possible 
consequences of the test results. 6,7 
•  Genetic counselling should also provide information and advice 
about prenatal diagnosis (PND), management of pregnancy and 
delivery in hemophilia carriers, and pre-implantation genetic diag-
nosis (PGD). It is important to be aware of and follow the relevant 
laws governing such procedures in the country where the service 
is being provided. 
•  Genetic testing will not always identify the underlying variant 
associated with the hemophilia phenotype. Genetic counselling 
should highlight this possibility to the individual referred for 
genetic testing. (See Chapter 9: Specific Management Issues – 
Carriers – Genetic counselling – Psychosocial support.) 
•  Genetic diagnostic laboratories should adhere to strict protocols 
and procedures, which require: 
 ◦  knowledge and expertise in genetic laboratory testing; 
 ◦  use of the correct investigative platforms; 
 ◦  knowledge and expertise in the interpretation of the genetic 
variants identified in association with hemophilia; 
 ◦  use of the correct interpretative platforms for investigation of 
variants; 
 ◦  use of the correct nomenclature for description of variants 
and the correct classification systems for determining patho-
genicity of variants; 
 ◦  internal quality control procedures; 
 ◦  participation in periodic accreditation, where available; and 
 ◦  participation in external quality assessment schemes (EQAS), 
where available. 
•  The interpretation of the results of genetic testing should be per-
formed by scientists who have knowledge and expertise in hemo-
philia genetics. 
•  The opportunity for discussion of the genetic results between the 
ordering clinician and reporting scientist is an essential provision 
of the genetic diagnostic service. 
 Recommendation 4.1.1: 
•  For people with hemophilia, the WFH recommends that genetic 
testing be offered to identify the specific underlying genetic 
variant associated with their disorder.  CB 
 Recommendation 4.1.2: 
•  For obligate carriers of hemophilia and “at-risk” female relatives 
of people with hemophilia or potential carriers of hemophilia, the 
WFH recommends that genetic testing be offered for the previ-
ously identified genetic variant in the  F8  or  F9  gene.  CB 
 Recommendation 4.1.3: 
•  For females with low phenotypic coagulation FVIII or FIX levels, 
the WFH recommends that investigation of the genetic/epigene-
tic basis of the phenotype be offered.  CB 
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 Recommendation 4.1.4: 
•  For obligate carriers of hemophilia and “at-risk” female relatives 
of people with hemophilia or potential carriers of hemophilia, the 
WFH recommends the inclusion of a detailed family pedigree to 
support the genetic testing referral.  CB 
 Recommendation 4.1.5: 
•  For individuals with suspected hemophilia and potential carriers 
of hemophilia, the WFH strongly recommends that phenotypic 
screening for FVIII or FIX levels, von Willebrand factor (VWF) 
antigen, and VWF activity testing be performed prior to referral 
for genetic testing.  CB 
 Recommendation 4.1.6: 
•  For people with hemophilia, obligate carriers of hemophilia, “at-
risk” female relatives, or individuals with low coagulation factor 
levels, the WFH strongly recommends detailed genetic counsel-
ling prior to offering genetic testing. 
•  REMARK : Genetic counselling should include a discussion of the 
experimental limits of the molecular results according to the 
availability of practical approaches. 
•  REMARK : Genetic counselling should include a discussion of the 
possibility of incidental findings in genes other than  F8  or  F9 , 
if the methodology used by the investigating laboratory (e.g., 
next generation sequencing [NGS]) may detect such genetic 
variations. 
•  REMARK : Genetic counselling should be performed by a genetic 
counsellor when available. If no genetic counsellor is available, 
a medical professional with knowledge of genetics in hemophilia 
can provide genetic counselling.  CB 
 Recommendation 4.1.7: 
•  For all patients referred for genetic testing, the WFH strongly 
recommends that informed consent be obtained from the pa-
tient, parent, or legal guardian. This requires both permission to 
carry out testing and education to ensure that they fully under-
stand the testing procedure, the benefits and limitations of the 
test, and possible consequences of the test results. 
•  REMARK : Written informed consent may need to be obtained and 
documented by the clinician or genetic counsellor in compliance 
with local policies and practices.  CB 
 4.2  |  Indications for genetic assessment 
•  Genetic testing is generally sought in all affected cases (probands) 
and “at-risk” female relatives within the family. 
•  Ideally, the disease-causing variant should first be identified in the 
proband or the obligate carrier. All other potential carriers may 
subsequently be screened for this variant to confirm or exclude 
the carrier status. 
•  If neither the proband nor the obligate carrier are available for 
testing, the genetic assessment may still be performed in potential 
carriers; however, when a disease-causing variant is not detected, 
it should be clearly mentioned in the report that failure to detect 
genetic variants with the existing techniques does not exclude the 
carrier status. 
•  Carriers of hemophilia exhibit a wide range of factor levels, 
with approximately 30% having levels <40 IU/dL. 8 Women and 
girls with low or borderline levels can experience a range of 
bleeding symptoms, usually consistent with mild hemophilia, 
but hemarthrosis and more severe bleeding symptoms can 
occur. 9,10 
•  Besides the heterozygosity for the disease-causing variant, low 
factor levels in carriers of hemophilia may be attributed to other 
epigenetic factors such as X-chromosome inactivation (XCI) 11,12 
or the ABO blood group system. 13 
•  Pregnant women who are confirmed carriers of an  F8 or  F9 
variant may be offered non-invasive testing to determine the 
sex of the fetus they are carrying in order to inform subse-
quent options for prenatal diagnosis in a male fetus. This is 
achieved through analysis of cell-free fetal DNA in the maternal 
plasma. 14–16 
•  Prenatal diagnosis may be offered to all confirmed carriers of an 
 F8 or  F9 variant who are carrying a male fetus in early pregnancy 
by chorionic villus sampling or in late pregnancy by late-gestation 
amniocentesis, in order to guide the management of the delivery 
or to terminate the pregnancy in case of an affected fetus. 17–20 
Genetic counselling should include a discussion of the risk of the 
PND procedure to the pregnancy. 
•  Pre-implantation genetic diagnosis may be offered to confirmed 
carriers of an  F8 or  F9 variant in order to select an embryo that 
will not result in the birth of a male with hemophilia. 21,22 
•  It is important to be aware of and follow the relevant laws govern-
ing genetic counselling and pre-implantation genetic diagnosis in 
the country where the services are being provided. 
•  Among all the genetic risk factors, the nature of disease-causing 
variants in both  F8 and  F9 has been found to be the strongest 
risk factors for inhibitor development. Null variants, i.e., vari-
ants which result in total absence of the protein (large deletions, 
duplications, insertions, inversions, nonsense mutations, and 
splice-site variants), have shown the strongest association with 
inhibitors as compared to other variants (small in-frame deletions, 
duplications, insertions, missense mutations). 23–33 The response 
to immune tolerance induction (ITI) therapy has also been re-
ported to be associated with the disease-causing variants with 
the latter group showing good response to ITI as compared to pa-
tients carrying null variants. 34 
•  Some of the gene manipulation techniques (e.g., nonsense muta-
tion suppression and gene editing) may require prior information 
of the disease-causing variants. 
•  Genetic assessment may be offered to: 
 ◦  all cases with clinically suspected hemophilia or hemophilia 
cases with confirmed laboratory diagnosis; 
 ◦  all obligate carriers to identify the molecular variant for possi-
ble future prenatal diagnosis; 
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 ◦  all at-risk female family members to establish carrier status, 
which is critical for optimal prenatal counselling and testing if 
indicated, or to offer pre-implantation genetic diagnosis; 
 ◦  all symptomatic females (with low FVIII or FIX levels) with no 
family history; 
 ◦  predict the risk of inhibitor development in individuals with 
hemophilia; 
 ◦  predict the response to ITI therapy; 
 ◦  ascertain the feasibility of some gene manipulation techniques. 
•  See Chapter 3: Laboratory Diagnosis and Monitoring. 
 Recommendation 4.2.1: 
•  For people with suspected or established hemophilia undergoing 
genetic testing, the WFH recommends that the index case (pro-
band) be genotyped to identify the underlying genetic variant.  CB 
 Recommendation 4.2.2: 
•  For obligate carriers of hemophilia and “at-risk” female relatives 
of the affected proband or potential carrier of hemophilia, the 
WFH recommends genetic counselling about their risk of being 
a carrier.  CB 
 Recommendation 4.2.3: 
•  For all obligate carriers of hemophilia and “at-risk” female rel-
atives of people with hemophilia or potential carriers of hemo-
philia, the WFH recommends that phenotypic coagulation factor 
levels be measured.  CB 
 Recommendation 4.2.4: 
•  For all obligate carriers of hemophilia and “at-risk” female rel-
atives of people with hemophilia, the WFH recommends that 
genetic testing be offered for the previously identified genetic 
variant in the  F8  or  F9  gene.  CB 
 Recommendation 4.2.5: 
•  For females with low phenotypic coagulation FVIII or FIX levels, 
the WFH recommends that investigation of the genetic/epigene-
tic basis of the phenotype be offered.  CB 
 Recommendation 4.2.6: 
•  For pregnant females who are carriers of an  F8  or  F9  variant and 
are carrying a male fetus, the WFH recommends that prenatal 
diagnosis (PND) be offered to determine the hemophilia status 
of the fetus. 
•  REMARK : Genetic counselling should include a discussion of the 
risk of the PND procedure to the pregnancy. 
•  REMARK : It is important to be aware of and follow the relevant 
laws governing such procedures in the country where the service 
is being provided.  CB 
 Recommendation 4.2.7: 
•  For families who wish to be prepared for a child with hemophilia 
before birth or who wish to terminate an affected fetus, the WFH 
recommends that prenatal diagnosis (PND) by chorionic villus 
sampling or amniocentesis be offered. 
•  REMARK : It is important to be aware of and follow the relevant 
laws governing such procedures in the country where the service 
is being provided. 
•  REMARK : PND may be offered in early pregnancy or in late preg-
nancy by late-gestation amniocentesis in order to guide the man-
agement of the delivery of an affected child.  CB 
 Recommendation 4.2.8: 
•  For people with suspected or established hemophilia, the WFH 
recommends that genetic testing be performed; knowledge of 
the genetic variant may help predict the risk of inhibitor develop-
ment, response to immune tolerance induction (ITI), and depth of 
phenotype severity, as well as determine the availability of gene 
manipulation techniques.  CB 
 4.3  |  Strategy for genetic testing of probands 
•  Worldwide, approximately 30-45% of patients with severe hemo-
philia A show an unusual type of structural variant (SV), a large 
DNA inversion affecting the  F8 intron 22 (i.e., the intron 22 inver-
sion, Inv22). 35,36 
•  The  F8 intron 22 inversion originates almost exclusively from male 
germ cells 37 by an event of homologous recombination between 
large inverted repeated sequences. 38 Reported evidence in the 
literature supports the fact that almost all mothers of patients 
with the Inv22 are carriers 39 and that the Inv22 is the most preva-
lent cause for severe hemophilia A worldwide. 40–44 
•  A second recurrent inversion event causing approximately 2% of 
severe hemophilia A phenotypes worldwide is the  F8 intron 1 in-
version (Inv1). 45 
•  The remaining patients with severe, moderate, or mild hemophilia 
A (i.e., uninformative for the common  F8 inversions), as well as 
all patients with hemophilia B, generally have small variants in 
 F8 or  F9 , such as single nucleotide substitutions, small insertions, 
duplications or deletions, or, less frequently, large copy number 
variations (CNVs). 
•  Information about  F8 and  F9 variants is compiled in internationally 
accessible databases, such as those developed by the Centers for 
Disease Control and Prevention (CDC), named CDC Hemophilia 
A Mutation Project (CHAMP) and CDC Hemophilia B Mutation 
Project (CHBMP;  http://www.cdc.gov/ncbdd d/hemop hilia/ 
champs.html ), and by the European Association for Haemophilia 
and Allied Disorders (EAHAD) for  F8 and  F9 . 
 Recommendation 4.3.1: 
•  For male probands, the WFH recommends that genetic testing 
be directed by the proband ' s baseline phenotypic coagulation 
factor level, which indicates the severity of the disorder. 
 ◦  In patients with severe hemophilia A (FVIII:C <1 IU/dL) 
or moderate hemophilia A with lower-borderline factor 
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activity levels (FVIII:C 1-3 IU/dL), analysis of the  F8  intron 
22 inversion and the  F8  intron 1 inversion should be per-
formed first. 
 ◦  Patients with severe hemophilia A in whom recurrent inver-
sions (i.e.,  F8  intron 22 and intron 1 inversions) cannot be 
detected should undergo screening and characterization of 
small variants, including single nucleotide variants (SNV) and 
small insertion, duplication, or deletion variants covering the 
essential regions of  F8  including the 26 exons, exon/intron 
boundaries, and 5ʹ and 3ʹ untranslated regions. If these tests 
are still uninformative, patients should be screened for copy 
number variants (CNV) including large  F8  deletions, duplica-
tions, or complex rearrangements. 
 ◦  In patients with moderate (FVIII:C 1-5 IU/dL) or mild (FVIII:C 
5-40 IU/dL) hemophilia A, screening and characterization of 
small variants (i.e., SNV and small insertions, duplications, or 
deletions) covering the essential regions of  F8  including the 
26 exons, exon/intron boundaries, and 5ʹ and 3ʹ untranslated 
regions should be performed first. If these tests are still unin-
formative, patients should be screened for  F8  CNV. 
 ◦  In all patients with hemophilia B (i.e., patients with severe 
[FIX:C <1 IU/dL], moderate [FIX:C 1-5 IU/dL], and mild [FIX:C 
5-40 IU/dL] hemophilia B), screening and characterization of 
small variants (i.e., SNV and small insertions, duplications, or 
deletions) covering the essential regions of  F9  including the 
8 exons, exon/intron boundaries, and 5ʹ and 3ʹ untranslated 
regions should be performed first. If these tests are still unin-
formative, patients should be screened for  F9  CNV.  CB 
 4.4  |  Techniques for genetic assessment 
•  The  F8 gene is localized to the long arm of the X chromosome at 
Xq28.  F8 spans 187 kb of genomic DNA and consists of 26 exons 
encoding a mRNA of 9.0 kb. The mature FVIII protein has 2,332 
amino acids. 
•  The  F9 gene is localized to the long arm of the X chromosome at 
Xq27.  F9 spans 33 kb of DNA and comprises 8 exons.  F9 mRNA 
is 2.8 kb and encodes a pre-pro-protein of 461 amino acids that 
is post-translationally processed to yield a mature protein of 415 
amino acids. 
•  Different techniques (e.g., Southern blot, long-range and in-
verse-shifting polymerase chain reaction [PCR]) can be used for 
detection of the recurrent  F8 intron 22 inversion. 35,46–55 The re-
current  F8 intron 1 inversion can be detected by double PCR 56 
or by inverse-shifting PCR. 50 The approach and use of a specific 
technique depend on the available technical expertise and re-
sources. All results should be confirmed by repeat analytical test-
ing of the DNA sample. 
•  Depending on the availability of resources, full  F8 or  F9 gene 
screening is performed by PCR and Sanger sequencing, or 
next-generation sequencing (NGS), for the detection of missense, 
nonsense, splice-site, small and large deletions, duplications, and 
insertions. 46,57–61 Where resources are limited, laboratories may 
choose a cost-effective screening approach prior to Sanger se-
quencing, 62 e.g., by heteroduplex analysis using conformation 
sensitive gel electrophoresis (CSGE). 
•  When choosing an analytical technique, laboratories must be 
aware of the sensitivity and specificity of the approach used and 
the turn-around time for producing an interpretive report. All re-
sults should be confirmed by repeat analytical testing of the DNA 
sample. 
•  The presence of a variant should be confirmed in both 5ʹ (forward) 
and 3ʹ (reverse) directions, specifically in heterozygous carriers, 
when analyzing variants detected using Sanger sequencing. 
•  In case of no amplification in a particular exon or in a contiguous 
stretch during PCR, a large DNA deletion may be suspected. This 
should be confirmed by standard approaches such as gap-PCR or 
techniques which can detect gene dosage or CNVs such as multi-
plex ligation-dependent probe amplification (MLPA) or quantita-
tive real-time PCR on the deleted region. 63–71 The conventional 
Sanger sequencing techniques are not sensitive to pick up CNVs 
in the case of carriers. 
•  When a disease-causing variant is not detected, large duplications 
or insertions may be suspected. These can be detected by apply-
ing the same methods as those employed for identifying large de-
letions, as described above. 
•  The technical approach for CNV analysis may depend on the re-
sources available to the laboratory. According to the practical 
limitations of the technique, results should be provided with an 
estimation of error, if applicable. 
•  High-throughput sequencing techniques, e.g., NGS, should only 
be used after it is established that structural variants can be de-
tected by the technique. 72 
•  All results of genetic testing should be confirmed by indepen-
dent testing of the DNA sample. This may be accomplished either 
through a repeat of the original assay or by using a different meth-
odology, e.g., using Sanger sequencing to confirm an NGS result. 
•  During the technical process of taking a sample for prenatal di-
agnosis, the fetal sample may get contaminated with maternal 
blood which can lead to misdiagnosis. Different techniques can 
be used for maternal cell contamination testing depending on the 
available technical expertise and resources. For example, multiple 
autosomal short tandem repeat (STR) markers may be used. 73–76 
When choosing an analytical technique, laboratories must be 
aware of the sensitivity and specificity of the approach used and 
the turn-around time for producing an interpretive report. 
 Recommendation 4.4.1: 
•  For people with severe hemophilia A, or moderate hemophilia A 
with lower-borderline factor activity levels (FVIII:C 1-3 IU/dL), 
the WFH recommends testing for the  F8  intron 22 inversion and 
 F8  intron 1 inversion in the first line of genetic testing. 
•  REMARK : Different techniques can be used for detection of the 
 F8  intron 22 inversion and intron 1 inversion depending on the 
available technical expertise and resources. 
     |  53
•  REMARK : All results should be confirmed by independent analyti-
cal testing of the DNA sample.  CB 
 Recommendation 4.4.2: 
•  For people with severe hemophilia A who are negative for the 
common  F8  intron 22 inversion and  F8  intron 1 inversion vari-
ants, the WFH recommends full gene screening of the essential 
regions of  F8 , including the 26 exons, splice boundaries, pro-
moter, and 5ʹ and 3ʹ untranslated regions. 
•  REMARK : For example, depending on the availability of resources, 
full  F8  gene screening may take the form of polymerase chain re-
action (PCR) and Sanger sequencing or next generation sequenc-
ing (NGS). Where resources are limited, laboratories may choose 
a cost-effective screening approach prior to Sanger sequencing. 
•  REMARK : When choosing an analytical technique, laboratories must 
be aware of the sensitivity and specificity of the approach used 
and the turn-around time for producing an interpretive report. 
•  REMARK : The presence of a variant should be confirmed in both 
5ʹ (forward) and 3ʹ (reverse) directions, specifically in hetero-
zygous carriers, when analyzing variants detected using Sanger 
sequencing. 
•  REMARK : All results should be confirmed by independent analyti-
cal testing of the DNA sample.  CB 
 Recommendation 4.4.3: 
•  For people with hemophilia B, the WFH recommends full gene 
screening of the essential regions of  F9 , including the 8 exons, 
splice boundaries, promoter, and 5ʹ and 3ʹ untranslated regions. 
•  REMARK : For example, depending on the availability of resources, 
full  F9  gene screening may take the form of polymerase chain re-
action (PCR) and Sanger sequencing or next generation sequenc-
ing (NGS). Where resources are limited, laboratories may choose 
a cost-effective screening approach prior to Sanger sequencing. 
•  REMARK : When choosing an analytical technique, laboratories must 
be aware of the sensitivity and specificity of the approach used 
and the turn-around time for producing an interpretive report. 
•  REMARK : The presence of a variant should be confirmed in both 
5ʹ (forward) and 3ʹ (reverse) directions, specifically in hetero-
zygous carriers, when analyzing variants detected using Sanger 
sequencing. 
•  REMARK : All results should be confirmed by independent analyti-
cal testing of the DNA sample.  CB 
 Recommendation 4.4.4: 
•  For people with hemophilia A or B in whom no variant is de-
tectable on inversion analysis or full gene sequencing, the 
WFH recommends that a large deletion or duplication event be 
investigated. 
•  REMARK : Copy number variation (CNV) analysis may be performed 
using various validated techniques dependent on the resources 
available to the laboratory. According to the practical limitations 
of the technique, results should be provided with an estimation 
of error, if applicable. 
•  REMARK : All results should be confirmed by independent analyti-
cal testing of the DNA sample.  CB 
 Recommendation 4.4.5: 
•  For prenatal testing, the WFH recommends maternal cell con-
tamination testing of the fetal sample. 
•  REMARK : Different techniques can be used for maternal cell 
contamination testing depending on the available technical ex-
pertise and resources. For example, multiple autosomal short 
tandem repeat (STR) markers may be used. 
•  REMARK : When choosing an analytical technique, laboratories 
must be aware of the sensitivity and specificity of the approach 
used and the turn-around time for producing an interpretive re-
port.  CB 
 4.5  |  Classification and description of variants 
•  The American College of Medical Genetics and Genomics (ACMG) 
guidelines were developed to provide a standardized approach 
and terminology for classification of genetic variants in Mendelian 
disorders. 77 When applied across laboratories, they provide cli-
nicians with useful information on the likelihood that the variant 
impacts gene function. 6 
•  Genetic diagnostics are critically dependent on accurate and stan-
dardized descriptions and sharing of genetic variants. The Human 
Genome Variation Society (HGVS) maintains a sequence variant 
nomenclature system for this purpose ( http://www.HGVS.org/
varno men) . 78 Providing corresponding  F8 or  F9 legacy nomencla-
ture can be helpful to the clinician for comparison to prior patient 
or family clinical reports. 
 Recommendation 4.5.1: 
•  The WFH recommends that variants be classified per the 
American College of Medical Genetics and Genomics (ACMG) 
guidelines. 
•  REMARK : ClinGen, a U.S. National Institutes of Health-funded re-
source dedicated to building a central resource that defines the 
clinical relevance of genes and variants, has assembled an inter-
national expert committee to apply ACMG recommendations to 
 F8  and  F9  variants, which should produce more hemophilia-spe-
cific recommendations.  CB 
 Recommendation 4.5.2: 
•  The WFH recommends that variants be described using the 
Human Genome Variation Society (HGVS) nomenclature.  CB 
 4.6  |  Interpretive reports 
•  Clinical laboratory reports should include information to allow 
correct identification of the patient and specimen, report the vari-
ant using standardized nomenclature with a genome reference, 
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note limitations of the assay, and provide an interpretation 
of the findings in a manner that will be helpful to the ordering 
clinician. 6,79,80 
 Recommendation 4.6.1: 
•  The WFH recommends that interpretive reports contain: 
 ◦  patient information including patient name, date of birth, or-
dering clinician, date of specimen collection, diagnosis, base-
line factor level, and family pedigree; 
 ◦  description of the assay(s), references to the literature (if ap-
plicable), limitations of the test, and the genome reference 
sequence used for analysis; 
 ◦  results including DNA variant(s) in Human Genome Variation 
Society (HGVS) nomenclature and American College of 
Medical Genetic and Genomics (ACMG) variant classification; 
and 
 ◦  interpretation of test results in a format useful to the order-
ing clinician, including recommendations for follow-up test-
ing if indicated, implications of test results for patients and 
family members, and the role of genetic counselling.  CB 
 Recommendation 4.6.2: 
•  For all interpretive reports for all individuals undergoing genetic 
testing for hemophilia, the WFH recommends that the ordering 
clinician and reporting scientist be available to discuss the po-
tential phenotypic consequences of the reported genotype, as 
required.  CB 
 4.7  |  Strategies if causative variant is not detected 
•  Approximately 0.6% of patients with severe hemophilia A and 
2.9% of patients with moderate or mild hemophilia A will have no 
identifiable genetic variant in  F8 genomic DNA using current di-
agnostic methods, i.e., covering all coding and regulatory regions 
of  F8 but not deep intronic sequences. 67 
•  Approximately 1.1% of patients with moderate or mild hemophilia 
B will have no identifiable genetic variant in  F9 genomic DNA 
using current diagnostic methods that exclude the screening of 
deep intronic sequences. 67 
•  In patients with a clear diagnosis of hemophilia A and no patho-
genic variant identified in the  F8 coding sequences, analysis of 
intronic regions by sequencing or targeted massively parallel se-
quencing (MPS) to the whole  F8 is an option to detect and analyze 
deep intronic variants involved in splicing defects, which are sus-
pected to account for most of these patients’ phenotypes. 81–86 
Deep intronic variants should be interpreted with caution, and 
functional analysis of these variants would be desirable to demon-
strate their pathogenicity. 
•  NGS platforms have been designed to cover different needs. 
Among them, the My Life, Our Future platform ( https://www.
mylif eourf uture.org ) simultaneously analyzes all small variants 
and the prevalent inversions causing hemophilia A and B 72 ; the 
ThromboGenomics platform ( http://throm bo.cambr idged nadia 
gnosis.org.uk ) analyzes 63 genes associated with thrombotic, co-
agulation, and platelet disorders 87 ; and the 23-gene NGS panel for 
inherited bleeding coagulation disorders analyzes 23 genes known 
to be associated with inherited bleeding disorders. 88 The latter 
two approaches complement the variant screening with a separate 
testing of  F8 inversions. Due to the wide range of genes under anal-
ysis, the latter two platforms are particularly useful to investigate 
the hidden cause of bleeding in a patient lacking a proper diagnosis. 
•  Whole-genome sequencing (WGS) can be considered noting any 
limitations in detecting structural variation. Linkage analysis may 
be considered for family studies. 89 
•  Complex genomic rearrangements may be considered in some 
individuals who present with an atypical phenotype. These pa-
tients, in whom a large genomic deletion including part or all of  F8 
or  F9 is suspected, should be referred to a geneticist to evaluate 
the possible utility of a pangenomic study. The presence of a con-
tiguous gene syndrome can be analyzed by cytogenetic microar-
ray analysis. 90–93 
•  In patients with a confirmed diagnosis of hemophilia A and no 
 F8 exonic or intronic pathogenic variant detected, identification 
of specific micro-RNA expression imbalances, either by ncRNA 
microarrays or RNA-seq (MPS-based transcriptome), may repre-
sent the cause for  F8 downregulation and hemophilia A expres-
sion. 94–96 However, further research is still necessary to determine 
the actual role of microRNAs in the pathogenesis of hemophilia A. 
•  Germline and somatic mosaicism may complicate any genetic as-
sessment in hemophilia. 97,98 
•  In some cases, when testing for the familial variant in the mother 
of a patient with hemophilia, the variant will not be detected. In 
this instance, the possibility of mosaicism should be considered. 
•  In hemophilia A-affected probands where the mode of inher-
itance is not conclusive, or in low-level female probands, other 
potential diagnoses that need to be investigated include: 
 ◦  type 2N VWD if only low FVIII:C level on the phenotypic 
screen has been assessed; 
 ◦  combined FV and FVIII deficiency caused by pathogenic vari-
ants affecting  LMAN1 or  MCFD2 genes 99 ; 
 ◦  other types of VWD. 100 
•  See Chapter 3: Laboratory Diagnosis and Monitoring. 
•  As X-chromosome-linked recessive disorders, hemophilia A and 
B affect hemizygous males while heterozygous females (carriers) 
do not typically express hemophilia symptoms. However, in cases 
of symptomatic carriers, abundant evidence has indicated that 
non-random and extremely skewed X-chromosome inactivation 
plays central roles in hemophilia pathogenesis. 11,101 Furthermore, 
hemophilia expression in female heterozygous carriers is caused 
by the phase of the X-chromosome inactivation skewing, prefer-
entially silencing the normal  F8 allele. 12 
 Recommendation 4.7.1: 
•  For people in whom a strong diagnosis of hemophilia is certain 
but no  F8  or  F9  variant is detected using current diagnostic 
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genetic testing, the WFH recommends that other genetic causes 
be considered (e.g., deep intronic variants). 
•  REMARK : Current testing techniques are expected to evolve in 
the near future to include next generation sequencing (NGS) and 
whole genome sequencing (WGS). 
•  REMARK : NGS and WGS techniques should only be used after it is 
established that structural variants can be detected by the tech-
nique.  CB 
 Recommendation 4.7.2: 
•  For “at-risk” female relatives of people with hemophilia in whom 
the familial variant is not detected using standard diagnostic ge-
netic testing, particularly in females with one affected child, the 
WFH recommends that the possibility of mosaicism be consid-
ered and discussed during genetic counselling.  CB 
 Recommendation 4.7.3: 
•  For people with hemophilia A in whom the mode of inheritance 
is not conclusive, and in whom no inversion or variant is de-
tected by current diagnostic testing, the WFH recommends that 
other potential diagnoses be investigated, including type 2N von 
Willebrand disease (VWD), combined FV and FVIII deficiency, or 
other types of VWD.  CB 
 Recommendation 4.7.4: 
•  For symptomatic females with low phenotypic coagulation 
FVIII or FIX levels in whom just one pathogenic variant is found, 
the WFH recommends performing investigative tests for an 
X-chromosome inactivation pattern, if locally available.  CB 
 4.8  |  Quality assurance 
•  Quality assurance (QA), as described in Chapter 3: Laboratory 
Diagnosis and Monitoring – Quality assurance, is an umbrella 
term used to describe all measures taken to ensure the reliability 
of laboratory testing and reporting. In genetic testing, this covers 
all aspects of the diagnostic process from nucleic acid extraction 
and genetic analysis, to the description and classification of the 
variant(s) detected, and the production of an interpretive report 
to the ordering clinician. 
•  Internal Quality Control (IQC) of genetic tests should routinely be 
performed to ensure the validity of any variant(s) detected. 
•  Genetics laboratories are strongly advised to participate in 
External Quality Assessment Schemes (EQAS) to ensure that 
the quality of their results identified, classified, and interpreted, 
are in agreement with those obtained by other laboratories. This 
may be by a formal EQAS or an informal sample exchange be-
tween laboratories. Formal EQAS for genomics are provided by, 
for example, Genomics Quality Assessment (GenQA), and spe-
cifically for hemophilia genetic assessment by the U.K. National 
External Quality Assessment Service (UK NEQAS) for Blood 
Coagulation. 
•  Genetic diagnostic laboratories should undergo periodic accred-
itation, if available, by an approved body. Accreditation assesses 
the laboratory against internationally agreed standards to ensure 
high-quality provision of the genetic diagnostic service. 
•  The formation of Genetics Laboratory Networks for those provid-
ing genetic assessment of hemophilia, either within countries or 
between those in regions of the world, enables an opportunity for 
sharing of good practice and expertise. 
 Recommendation 4.8.1: 
•  The WFH recommends that genetic diagnostic laboratories 
should undergo periodic accreditation, if available, by an ap-
proved body.  CB 
 Recommendation 4.8.2: 
•  The WFH recommends that internal quality control (IQC) of ge-
netic tests be performed and recorded routinely within the lab-
oratory.  CB 
 Recommendation 4.8.3: 
•  The WFH recommends that laboratories participate in external 
quality assessment schemes (EQAS) for the genetic tests they 
provide. 
•  REMARK : Participation in an EQAS ensures the provision of a test 
that is robust and reliable. This may be through participation in 
a formal EQAS or an informal sample exchange between labora-
tories.  CB 
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 5.1  |  Introduction 
•  Different types of hemostatic agents and coagulation therapies 
are available for the management of hemophilia. The wide range 
of product classes and types in use around the world reflects the 
evolution of hemophilia treatment products and the variations in 
local healthcare resources and capacities. 
•  Clotting factor concentrates (CFCs) are the treatment of choice 
for people with hemophilia as they are very safe and effective 
for treating and preventing bleeds. There are two main types of 
CFCs: virally inactivated plasma-derived products made from 
plasma donated by human blood donors; and recombinant prod-
ucts manufactured using genetically engineered cells and recom-
binant technology. 
•  The development of non-factor replacement therapies such as 
emicizumab has recently begun to offer an alternative treatment 
approach as such products become available in clinical practice. 
•  However, access to CFCs and emicizumab is limited in many parts 
of the world; in some countries, healthcare providers often rely 
on locally produced blood products such as cryoprecipitate and 
fresh frozen plasma (FFP) for hemophilia treatment. However, 
these blood products are less effective than CFCs and may con-
tain viral and bacterial pathogens. 1,2 For this reason, where avail-
able, viral-inactivated plasma-derived or recombinant CFCs are 
preferred over cryoprecipitate and FFP. 
•  Although advances have been made in the safety of such blood 
products, the WFH ' s position is that the products of choice 
for hemophilia treatment are industrially manufactured CFCs 
where they fulfill the requirements for pharmaceutical Good 
Manufacturing Practice (GMP). 2 
•  The comprehensive  WFH Guide for the Assessment of Clotting 
Factor Concentrates describes the key elements that affect the 
quality, safety, efficacy, licensing, and regulation of factor prod-
ucts and the important principles involved in selecting suitable 
products for the treatment of hemophilia. 2 
•  The WFH also publishes and regularly updates the  WFH Online 
Registry of Clotting Factor Concentrates , which lists all currently 
available products and their manufacturing details. 3 
 Recommendation 5.1.1: 
•  For patients with hemophilia, the WFH does not express a pref-
erence for recombinant over plasma-derived clotting factor 
concentrates. 
•  REMARK : The choice between these classes of product must be 
made according to local criteria including availability, cost, and 
patient preferences.  CB 
 5.2  |  Product selection 
•  Product selection should evaluate key requirements including 
product safety and quality, purity, viral inactivation, and efficacy. 2 
 Safety and quality 
•  Currently manufactured plasma-derived CFCs produced to 
GMP standards have an exemplary safety record with respect to 
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lipid-enveloped viruses, such as human immunodeficiency virus 
(HIV) and hepatitis C virus (HCV). 
•  Product safety is the result of comprehensive measures and im-
provements in several areas including: 
 ◦  donor selection (exclusion of at-risk donors); 
 ◦  screening of donations, including nucleic acid testing (NAT); 
 ◦  a number of in-process viral inactivation and/or removal steps, 
notably solvent-detergent and heat treatment, and nanofiltra-
tion for the removal of some non-enveloped viruses and pri-
ons; and 
 ◦  post-marketing surveillance. 2 
•  As new information evolves in this field, decision-makers need to 
always be aware of current scientific recommendations regarding 
choice of CFCs for people with hemophilia. 
•  When selecting plasma-derived CFCs, both plasma quality and 
the manufacturing process need to be considered. The WFH em-
phasizes the importance of assessment by the official agencies re-
sponsible for protecting and promoting public health (i.e., national 
regulatory authorities, health agencies, or ministries of health) to 
ensure the quality, safety, and efficacy of plasma-derived treat-
ment products for hemophilia. 2 
•  Two issues require special consideration: 
 ◦  purity of product; and 
 ◦  viral inactivation/elimination. 
 Purity 
•  Purity of CFCs refers to the percentage of the desired ingredient 
(i.e., factor VIII [FVIII] or factor IX [FIX]) relative to the other in-
gredients in the product. 
•  There is no universally accepted classification of products based 
on purity, and CFCs on the market vary widely in their purity. 
Their “specific activity” may be expressed in international units 
(IU) per milligram (mg) and, for example, can range from 10 to 
>100 IU/mg for FVIII. 4 
•  Some products have high or very high purity at one stage in the 
production process but are subsequently stabilized by albumin, 
which decreases their final purity. 
•  In rare cases, lower-purity CFCs may give rise to adverse or al-
lergic reactions. 5,6 Patients who experience repeated allergic 
reactions with a particular product may benefit from the adminis-
tration of an antihistamine immediately prior to infusion or from 
the use of a higher-purity CFC. 
•  Plasma-derived FVIII CFCs may contain variable amounts of von 
Willebrand factor (VWF). Therefore, it is important to ascertain 
a product ' s VWF content (as most commonly measured by VWF 
activity assay) if it is used for the treatment of von Willebrand 
disease (VWD) and not hemophilia A. 7 
•  For treatment of FIX deficiency, a product containing only FIX is 
more appropriate than prothrombin complex concentrates (PCCs). 
PCCs also contain other clotting factors such as factors II, VII, and 
X, some of which may become activated during manufacture and 
may predispose the patient to thromboembolism. Current PCCs 
are considered safer than earlier products due to the inclusion of 
coagulation inhibitors such as heparin, antithrombin, and proteins 
C, S, and Z. 8,9 Nevertheless, with intensive treatment (e.g., during 
perioperative management), prothrombotic clotting factors may 
accumulate in the plasma and increase the risk for thromboem-
bolic complications. 
•  The viral safety of CFCs is not related to their purity, provided 
that adequate viral elimination measures are in place. 
 Viral inactivation/elimination 
•  In-process viral inactivation is the single largest contributor to the 
safety of plasma-derived CFCs. 10 
•  Typically, two complementary or orthogonal-specific viral reduc-
tion steps are incorporated into the CFC manufacturing process. 
These measures should follow the regulations set by official reg-
ulatory agencies. 
•  Solvent-detergent treatment is highly effective against lipid-en-
veloped viruses such as hepatitis B virus (HBV), HCV, and HIV, but 
this treatment does not inactivate non-lipid-enveloped viruses 
such as hepatitis A virus (HAV) and human parvovirus B19. 
•  Heat treatment is generally effective against a broad range of vi-
ruses, both with and without a lipid envelope, including HAV and 
human parvovirus B19. However, the degree of inactivation is de-
pendent upon the temperature, time, and whether heating occurs 
in the dry or wet state. 
•  As non-enveloped viruses currently pose a greater challenge than 
enveloped viruses to viral elimination during the manufacturing 
process, 11 any viral reduction/inactivation process should ideally 
inactivate both lipid-enveloped and non-lipid-enveloped viruses. 
•  Inactivation of prions in plasma-derived CFCs is not possible be-
cause the necessary techniques denature coagulation factors; nor is 
there a reliable screening test for variant Creutzfeldt–Jakob disease 
(vCJD). The risk of prion-mediated disease through plasma-derived 
products is currently being addressed by exclusion of at-risk donors, 
leukoreduction of donations, and plasma fractionation manufactur-
ing steps including precipitation, chromatography, and filtration. 10 
 Recommendation 5.2.1: 
•  For people with hemophilia, the WFH recommends the use of prod-
ucts that have been accepted by the official regulatory agencies 
responsible for protecting and promoting public health with con-
sideration given to the plasma quality (i.e., purity of the product) 
and the manufacturing process (i.e., viral inactivation/elimination). 
•  REMARK : A plasma-derived product created by a process that in-
corporates two viral reduction steps should not automatically be 
considered better than one that only has one specific viral inac-
tivation step. If only one step is used, this step should preferably 
inactivate viruses with and without lipid envelopes. Most re-
cently, licensed products use two orthogonal viral inactivation/
elimination steps. 
•  REMARK : Current prothrombin complex concentrates should be 
considered safer than earlier products due to the inclusion of co-
agulation inhibitors such as heparin, antithrombin, and proteins 
C, S, and Z.  CB 
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 Efficacy 
•  Product potency (the biological activity in terms of the concentra-
tion or amount of the drug required to produce a defined effect) 
and efficacy (the ability of a drug to produce a desired therapeutic 
effect in patients) are also important features for consideration in 
product selection. 2 
•  Plasma-derived and conventional recombinant FVIII and FIX CFCs 
with standard half-life (SHL) have been proven to have similarly 
high clinical efficacy. 2 
•  Recombinant CFCs with extended half-life (EHL) are engineered 
to provide longer-lasting therapy than SHL CFCs. (See “ Extended 
half-life products ” below.) 
 5.3  |  Clotting factor concentrates (CFCs) 
•  The main treatment for severe hemophilia is CFC replacement 
therapy with plasma-derived or recombinant CFCs as they pro-
vide convenient high doses of clotting factor for the treatment 
and prevention of bleeds. 
•  See also Chapter 2: Comprehensive Care of Hemophilia, Chapter 
6: Prophylaxis in Hemophilia, Chapter 7: Treatment of Specific 
Hemorrhages, and Chapter 9: Specific Management Issues. 
 FVIII CFCs 
•  All currently marketed plasma-derived and recombinant FVIII 
products are listed in the  WFH Online Registry of Clotting Factor 
Concentrates. 3 Consult the individual product inserts for details. 
 Dosage/administration 
•  FVIII CFCs are available in vials labelled with the product potency 
expressed in IU, ranging from approximately 250-3000 IU per vial. 
•  In the absence of an inhibitor, each IU of plasma-derived or re-
combinant SHL FVIII per kilogram of body weight infused intrave-
nously will raise the plasma FVIII level by approximately 2 IU/dL. 12 
This raise (also called recovery) is dependent on several individual 
factors; most importantly, the body mass index (BMI). It is higher 
in patients with a high BMI and lower in those with a low BMI. 13 
•  The half-life of SHL FVIII is approximately 12 hours in adults; its 
half-life is shorter in younger children and increases with age. 
•  To calculate dosage, multiply the patient ' s weight in kilograms by 
the FVIII level in IU/dL desired, then multiply by 0.5. 
 ◦  Example: 50 kg × 40 (IU/dL level desired) × 0.5 = 1000 IU of 
FVIII. 
•  See Chapter 7: Treatment of Specific Hemorrhages and refer to 
Table 7-2 for CFC replacement for different types of hemorrhage. 
•  FVIII CFCs should be infused slowly over several minutes as spec-
ified in the product insert. 14 The patient ' s peak factor level should 
be measured 15-30 minutes after the infusion to verify the ex-
pected FVIII activity level of the dose given. 12 
•  For patients undergoing surgery or those with severe bleeds that 
require frequent infusions, laboratory monitoring of FVIII levels is 
necessary, including measurement of FVIII trough level to aid in 
the calculation of subsequent doses. (See Chapter 3: Laboratory 
Diagnosis and Monitoring – Factor assays, and Chapter 9: Specific 
Management Issues – Surgery and invasive procedures.) 
•  Subsequent doses should ideally be based on the FVIII half-life 
and on the factor recovery in the individual patient for a partic-
ular product. However, the half-life in individual patients cannot 
be predicted simply from patient characteristics such as age and 
body weight and typically requires empiric determination. 
•  Guidelines for pharmacokinetic (PK) studies on new FVIII CFCs 
include 10-11 blood samplings taken over a period of 32-48 hours 
(additional samplings over up to 96 hours or longer for EHL FVIII). 
However, for dose tailoring in routine practice, useful PK param-
eters can be estimated from population PK models which enable 
Bayesian estimation of individual PK from limited samples. 15 
•  See Chapter 6: Prophylaxis in Hemophilia and Chapter 7: 
Treatment of Specific Hemorrhages. 
 Recommendation 5.3.1: 
•  For people with hemophilia receiving FVIII concentrates who 
would benefit from optimization of prophylaxis, the WFH rec-
ommends individualized pharmacokinetic monitoring. 
•  REMARK : Peak factor level should be measured 15-30 minutes 
after the infusion to verify calculated dose. Plasma half-life can 
be determined via full PK (10-11 blood samplings taken over a 
period of 32-96 hours), or with limited sampling in combination 
with population PK estimates.  CB 
•  Continuous infusion of CFCs avoids peaks and troughs and may 
be advantageous and more convenient in certain clinical situa-
tions (e.g., major surgery or severe bleeding episodes in patients 
with low-responding inhibitors). However, the use of specifically 
designated pumps and knowledge of the stability of the particular 
CFC after reconstitution within the infusion device are required. 16 
•  Continuous infusion may allow a reduction in factor clearance, dos-
age, and the total quantity of CFCs used. 17 It can potentially be more 
cost-effective for patients with severe hemophilia, depending on 
the doses used for continuous and intermittent bolus infusions. 18 
However, caution should be exercised if considering continuous in-
fusion for patients with mild hemophilia as this has been associated 
with an increased risk of the development of inhibitors, 19,20 although 
the contribution of continuous infusion alone may be confounded by 
the presence of high-risk pathogenic variants in mild hemophilia A. 
•  Doses for continuous infusion should be adjusted based on 
frequent factor assays (usually once a day) and calculation of 
clearance, noting that clearance of factor may be increased im-
mediately after surgery or with severe bleeding (e.g., blood loss of 
>500 mL), whereby additional boluses of CFCs may be required to 
maintain effective levels. For some CFCs, stability can be demon-
strated for up to 12 hours after preparing the solution; thus, con-
tinuous infusion over several hours is possible. 21 
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 Recommendation 5.3.2: 
•  For patients with hemophilia receiving FVIII concentrates where 
steady-state hemostatic correction is necessary for a prolonged 
period of time (e.g., perioperative management or in the case of a 
severe bleeding episode in a patient with a low-responding inhib-
itor), the WFH recommends consideration for use of continuous 
infusion. 
•  REMARK : Continuous infusion may lead to a reduction in the total 
quantity of clotting factor concentrates used and can be more 
cost-effective in patients with severe hemophilia. However, this 
cost-effectiveness comparison can depend on the doses used for 
continuous and intermittent bolus infusions. 
•  REMARK : Continuous infusion requires the use of specifically des-
ignated pumps and knowledge of the stability of the particular 
clotting factor concentrate after reconstitution within the infu-
sion device, and patients must be monitored frequently for pump 
failure.  CB 
 FIX CFCs 
•  All currently marketed plasma-derived and recombinant FIX 
products are listed in the  WFH Online Registry of Clotting Factor 
Concentrates. 3 Consult the individual product inserts for details. 
•  FIX CFCs are categorized into two classes: 
 ◦  Pure FIX CFCs, which may be plasma-derived or recombinant 
(see below for information on EHL FIX CFCs); 
 ◦  FIX CFCs that also contain factors II, VII, IX, and X, known as 
prothrombin complex concentrates (PCCs), which are nowa-
days only rarely used. 
•  Whenever possible, the use of pure FIX concentrates is preferable 
for the treatment of hemophilia B 8,9 as they are associated with a 
reduced risk of thrombosis and disseminated intravascular coag-
ulation compared to PCCs, particularly in the following instances: 
 ◦  surgery; 
 ◦  liver disease; 
 ◦  intensive exposure, i.e., prolonged therapy at high doses; 
 ◦  previous thrombosis or known thrombotic tendency; 
 ◦  concomitant use of drugs known to have thrombogenic poten-
tial, including antifibrinolytic agents. 
•  See Chapter 9: Specific Management Issues – Surgery and inva-
sive procedures. 
 Recommendation 5.3.3: 
•  For treatment of FIX deficiency in patients with hemophilia B, 
the WFH recommends a product containing only FIX rather than 
prothrombin complex concentrates (PCCs), which also contain 
other clotting factors, such as factors II, VII, and X, some of which 
may become activated during manufacture and may predispose 
the patient to thromboembolism. 
•  REMARK : Pure FIX products have reduced risk of thrombosis or 
disseminated intravascular coagulation, compared to what was 
observed with large doses of older-generation PCCs. 
•  REMARK : Current PCCs are considered safer than earlier products 
due to the inclusion of coagulation inhibitors such as heparin, 
antithrombin, and proteins C, S, and Z. Nevertheless, in cases 
of intensive treatment (e.g., perioperative management), pro-
thrombotic clotting factors may accumulate in plasma and may 
increase the risk for thromboembolic complications. When PCCs 
are used in high doses in order to normalize FIX levels, thrombo-
prophylaxis should be considered.  CB 
 Recommendation 5.3.4: 
•  For hemophilia B patients requiring prolonged therapy at high 
doses, the use of pure FIX concentrates is recommended over 
prothrombin complex concentrates.  CB 
 Recommendation 5.3.5: 
•  For hemophilia B patients undergoing surgery, the use of pure 
FIX concentrates is recommended over prothrombin complex 
concentrates.  CB 
 Recommendation 5.3.6: 
•  For hemophilia B patients with liver disease, the use of pure FIX 
concentrates is recommended over prothrombin complex con-
centrates.  CB 
 Recommendation 5.3.7: 
•  For hemophilia B patients with previous thrombosis or known 
thrombotic tendency, the use of pure FIX concentrates is recom-
mended over prothrombin complex concentrates.  CB 
 Recommendation 5.3.8: 
•  For hemophilia B patients concomitantly using drugs known to 
have thrombogenic potential, including antifibrinolytic agents, 
the use of pure FIX concentrates is recommended over pro-
thrombin complex concentrates.  CB 
 Dosage/administration 
•  FIX CFCs are available in vials labelled with the product potency, 
ranging from approximately 250-4000 IU per vial. 
•  In the absence of an inhibitor, each IU of plasma-derived or re-
combinant SHL FIX per kilogram of body weight infused intrave-
nously will raise the plasma FIX level by approximately 1 IU/dL. 12 
•  The half-life of SHL FIX is approximately 18-24 hours. Guidelines 
for PK studies on FIX CFCs include at least 8 blood samplings 
taken over a period of 72 hours (additional samplings over up to 
2 weeks for EHL FIX). However, for dose tailoring in routine prac-
tice, useful PK parameters can be estimated from population PK 
models which enable Bayesian estimation of individual PK from 
limited samples. 15 
 Recommendation 5.3.9: 
•  For patients with hemophilia B receiving FIX concentrates who 
would benefit from optimization of prophylaxis, the WFH recom-
mends pharmacokinetic monitoring. 
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•  REMARK : Peak factor level should be measured 15-30 minutes 
after the infusion to verify calculated dose. Plasma half-life can 
be determined via full PK (10-11 blood samplings taken over a 
period of 1-2 weeks), or with limited sampling in combination 
with population PK estimates.  CB 
•  Unmodified recombinant FIX (rFIX) CFCs have a lower recovery 
than plasma-derived FIX CFCs, such that each unit of FIX infused 
per kilogram of body weight will raise FIX activity by approxi-
mately 0.8 IU/dL in adults and 0.7 IU/dL in children under 15 years 
of age. 22 
•  To calculate dosage, multiply the patient ' s weight in kilograms by 
the FIX level in IU/dL desired. 
 ◦  Example: 50 kg body weight × 40 (IU/dL level de-
sired) = 2000 IU of plasma-derived FIX. 
 ◦  For rFIX, the dose is calculated as 2000 IU ÷ 0.8 (or 
2000 IU × 1.25) = 2500 IU for adults, and 2000 IU ÷ 0.7 (or 
2000 IU × 1.43) = 2860 IU for children. 
•  See Chapter 7: Treatment of Specific Hemorrhages and refer to 
Table 7-2 for practice patterns with CFCs for different types of 
hemorrhage. 
•  FIX CFCs should be infused slowly over several minutes as speci-
fied in the product insert. 14 The patient ' s peak FIX level should be 
measured approximately 15-30 minutes after infusion to verify 
the expected FIX activity of the dose given. 12 
•  For patients undergoing surgery or those with severe bleeds that 
require frequent infusions, laboratory monitoring of FIX levels 
is required including measurement of FIX trough level to aid in 
the calculation of subsequent doses. (See Chapter 3: Laboratory 
Diagnosis and Monitoring – Factor assays, and Chapter 9: Specific 
Management Issues – Surgery and invasive procedures.) 
•  Purified FIX CFCs may also be administered by continuous infu-
sion (as with FVIII CFCs). 
•  Allergic reactions may occur with infusions of both recombinant 
and plasma-derived FIX CFCs (in approximately 2%-4% of cases). 
These are often associated with anti-FIX inhibitors. 
 Extended half- life products 
 Rationale for development of EHL CFCs 
•  The frequency of infusions using SHL CFCs is associated with an 
increased burden of treatment and often leads to poor adherence 
to prophylaxis regimens. 23 Annualized bleeding rates (ABRs) are 
not always zero with prophylaxis with SHL CFCs, and joint dis-
ease can still appear in young adults. 24,25 EHL products were de-
veloped to address the need to reduce the treatment burden of 
prophylaxis and to maintain higher factor trough levels to improve 
bleed prevention. 
 Mechanisms of half- life extension 
•  Fusion technologies and PEGylation are successful half-life exten-
sion strategies in hemophilia. 26 
•  Fusion technologies rescue endocytosed proteins from intracel-
lular degradation pathways through interaction with the neonatal 
Fc receptor. 
•  PEGylation reduces interaction with clearance receptors. 
•  All currently marketed EHL products are listed in the  WFH Online 
Registry of Clotting Factor Concentrates. 3 Consult the individual 
product inserts for details. 
•  Different types of recombinant and modified forms of FVIII and 
FIX are summarized in Chapter 3: Laboratory Diagnosis and 
Monitoring – Tables 3-2 and 3-3. 
•  The WFH recommendations on EHL products were structured 
accordingly: 
 ◦  The emphasis was on the absence of “clinical safety issues” 
and not on preclinical observations from animal models with 
unclear implications. 
 ◦  The WFH recognizes that evaluation of both clinical and pre-
clinical observations of EHL products has led to divergence in 
regulatory approval for some PEGylated products, which has 
impacted their licensing for prophylaxis and pediatric applica-
tion in some geographies. 
 ◦  Regarding allergic reactions, these are, albeit rarely, observed 
for all infusion treatment products and have been observed 
with fusion proteins as well. 27 
 ◦  Regarding anti-PEG antibodies, there is no published evidence 
to support that these have clinical safety implications in pa-
tients with hemophilia. 28 
 Recommendation 5.3.10: 
•  For patients with hemophilia A or B, there is no evidence for any 
clinical safety issues in persons with hemophilia to recommend 
a preference among the various mechanisms of action (e.g., 
PEGylation, Fc-fusion, albumin-fusion) used to extend the half-
life of clotting factor concentrates.  CB 
 Pharmacokinetic properties of EHL products 
•  For EHL FVIII products, half-life extension has been limited to 1.4- 
to 1.6-fold (or approximately 19 hours) that of SHL FVIII products. 
EHL FIX products have a much longer half-life at 3- to over 5-fold 
that of SHL FIX products. 
•  The prolonged half-life of EHL products translates to dosing twice 
per week or every 3 days in most cases for FVIII, and once every 
7-14 days for FIX. 
•  Clearance of EHL products in adolescents and adults is similar, as 
was observed for SHL products, and half-life is shorter in pediatric 
populations. 29 
•  EHL FIX products do not demonstrate the lower factor recovery 
observed with standard rFIX products. Some EHL FIX products 
show much higher recovery, suggesting extravascular distribu-
tion of a lower proportion of EHL FIX. 30,31 Accordingly, clinical 
assessment of efficacy should supplement assessment of plasma 
PK measurements. 
•  Modification of these molecules has introduced variations in 
their activity measurements in routine coagulation assays. Thus, 
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clinicians should follow the recommendations accompanying a 
product ' s regulatory approval regarding the optimal assays to 
be used for laboratory monitoring. (See Chapter 3: Laboratory 
Diagnosis and Monitoring – Factor assays.) 
 Safety and efficacy of EHL products 
•  All registered EHL products have been shown to be efficacious in 
the prevention and treatment of bleeds in children, adolescents, 
and adults. Over 90% of bleeds were successfully treated with 
a single administration, and the efficacy in bleed prevention re-
sulted in ABRs <4-5 across all EHL products. Hemostatic efficacy 
was demonstrated in a variety of minor and major surgeries. 32 
•  In previously treated children, adolescents, and adults, no in-
creased risk of new inhibitor development has been observed in 
those receiving EHL FVIII/FIX products; all clinical trials in pre-
viously treated patients (PTPs) have demonstrated either no in-
hibitor development or very low incidence rates that were within 
regulatory safety limits. 
•  EHL products have been given to previously untreated patients 
(PUPs), either as part of clinical PUP studies or outside of stud-
ies. Although inhibitor development has been reported in such 
settings, no substantial difference in levels of inhibitor develop-
ment has been observed with EHL compared to SHL products. 
However, no completed trial in PUPs has yet been published in 
full. 
 Approaches to dosing with EHL products 
•  Although EHL CFCs extend the time until patients reach the mini-
mum trough levels required to avoid spontaneous bleeds, there is 
significant interpatient variability related to age, body mass, blood 
group, VWF level, bleeding phenotype, physical activity level, 
joint status, and compliance. Accordingly, there is no consensus 
on standardized dosing with EHL CFCs nor management of pa-
tients receiving EHL products. 23,33 
•  Each of the following approaches has established efficacy in clin-
ical trials with EHL CFCs: 
 ◦  fixed programmatic prophylaxis (fixed dose and interval, e.g., 
once weekly for FIX, twice weekly for FVIII); 
 ◦  PK-tailored prophylaxis (dose tailored to target trough level, 
given at fixed intervals); 
 ◦  phenotypic-tailored prophylaxis (variable dose and interval 
tailored according to bleeding pattern and activity); 
 ◦  dose/frequency-tailored prophylaxis (dose and/or frequency 
tailored according to target trough level and interval, e.g., 
higher dose and longer interval). 
•  To transition from SHL to EHL factor replacement therapy, dose 
frequency is typically lowered from 3 to 2 times weekly for FVIII, 
and from twice weekly to once every 7-10 days for FIX. 
•  PK-driven dosing allows more individualized prophylaxis. 
Population PK tools are in development to aid the implementation 
of individualized prophylaxis in clinical practice. Once an individ-
ual ' s PK profile is generated, the dose and treatment frequency 
required to obtain a desired trough level can be estimated. The 
target trough level needs to be customized to the needs of the 
individual patient within their healthcare system ' s parameters and 
flexibilities. 
•  See Chapter 6: Prophylaxis in Hemophilia – Extended half-life fac-
tor prophylaxis. 
 Recommendation 5.3.11: 
•  Patients with hemophilia who are transitioning from standard 
half-life clotting factor concentrates to extended half-life clot-
ting factor concentrates would typically require decreased dose 
frequencies, but EHL products may also be used to maintain 
higher trough levels to optimize prophylaxis. 
•  REMARK : Pharmacokinetic-guided dosing as per Recommendations 
5.3.1 and 5.3.9 provides for more individualized prophylaxis.  CB 
 5.4  |  Bypassing agents 
•  Bypassing agents are used for the treatment and prevention of 
bleeding complications in patients with hemophilia A or B who 
develop FVIII or FIX alloantibodies (called inhibitors) that typically 
neutralize the function of infused CFCs. 34 These agents are based 
on different mechanisms of action to achieve hemostasis, thereby 
bypassing the need for FVIII or FIX replacement to treat and pre-
vent bleeds. 35 
 Recombinant activated factor VIIa (rFVIIa) 
•  Recombinant activated factor VIIa (rFVIIa) is a bypassing agent 
that promotes coagulation through tissue factor-dependent 
and independent pathways. 35 rFVIIa binds to tissue factor to 
activate FX and FIX and allows the coagulation cascade to 
resume. 36,37 
 Activated prothrombin complex concentrate (aPCC) 
•  Activated prothrombin complex concentrate (aPCC) is used to 
treat patients with hemophilia A with inhibitors. aPCC contains 
mainly non-activated FII (prothrombin), FIX, FX, and mainly acti-
vated FVII. 38-40 
•  See Chapter 8: Inhibitors to Clotting Factor for more information 
on bleed management for patients with inhibitors. 
 Recommendation 5.4.1: 
•  For people with hemophilia A with an inhibitor requiring treat-
ment for acute bleeding complications or surgery, the WFH rec-
ommends that a bypassing agent be used. 
•  REMARK : Bypassing agents include recombinant activated factor 
VIIa or activated prothrombin complex concentrate.  CB 
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 Recommendation 5.4.2: 
•  For patients with hemophilia B and an inhibitor with a history 
of anaphylaxis to FIX-containing clotting factor concentrates, 
recombinant activated factor VIIa must be administered as acti-
vated prothrombin complex concentrate cannot be used.  CB 
 Recommendation 5.4.3: 
•  The WFH recommends that patients with hemophilia with an in-
hibitor should be considered for regular prophylaxis to prevent 
bleeding events.  CB 
•  In addition to bypassing agents, non-factor replacement therapies 
(e.g., emicizumab) are becoming available that offer new treat-
ment paradigms including for the treatment of inhibitors. 
•  See  5.7 Non-factor replacement therapies, below; and Chapter 6: 
Prophylaxis in Hemophilia – Prophylaxis using non-factor replace-
ment therapies. 
 5.5  |  Other plasma products 
•  Cryoprecipitate and FFP are not normally subjected to viral in-
activation procedures (such as heat or solvent-detergent treat-
ment) and consequently carry an increased risk of transmission 
of viral pathogens, which is significant with repeated infusions. 1,41 
However, the WFH recognizes the necessity of the continued use 
of cryoprecipitate and FFP in some parts of the world where they 
are the only available or affordable treatment options. 1,2 
•  Certain steps can be taken to minimize the risk of transmission of 
viral pathogens. These include: 
 ◦  quarantining plasma until the donor has been tested or even re-
tested for antibodies to HIV, HCV, and the surface antigens of 
the hepatitis B virus (HBsAg)—a practice that is difficult to imple-
ment in countries where the proportion of repeat donors is low; 
 ◦  NAT testing to detect viruses—a technology that has a po-
tentially much greater relevance for the production of cryo-
precipitate than for CFCs, as the latter are subjected to viral 
inactivation steps. 42 
•  Allergic reactions are more common following infusion of cryo-
precipitate than CFC. 41 (For use of antihistamine prophylaxis, see 
“ Safety and quality ” above.) 
 Recommendation 5.5.1: 
•  For patients with hemophilia, the WFH strongly recommends the 
use of viral-inactivated plasma-derived or recombinant clotting 
factor concentrates in preference to cryoprecipitate or fresh fro-
zen plasma. 
•  REMARK : The WFH supports the use of CFCs in preference to 
cryoprecipitate or FFP due to concerns about quality, safety, and 
efficacy. However, the WFH recognizes the reality that they are 
still widely used in countries around the world where they are 
the only available or affordable treatment options.  CB 
 Fresh frozen plasma (FFP) 
•  As fresh frozen plasma contains all coagulation factors, it is some-
times used to treat coagulation factor deficiencies. 
•  Cryoprecipitate is preferable to FFP for the treatment of hemo-
philia A. 43 However, as FFP and cryo-poor plasma contain FIX, 
albeit in low concentrations, they can be used for the treatment 
of hemophilia B in countries unable to afford plasma-derived FIX 
CFCs. 
 Recommendation 5.5.2: 
•  For patients with hemophilia, fresh frozen plasma is not recom-
mended due to concerns about the safety and quality. 
•  REMARK : However, the WFH recognizes the as yet unavoidable re-
ality of their continued use in some parts of the world where it is 
the only available or affordable treatment option.  CB 
•  It is possible to apply some forms of virucidal treatment to packs 
of FFP (including solvent-detergent treatment). The use of treated 
packs is recommended; however, virucidal treatment may have 
some impact on coagulation factors. The large-scale preparation 
of pooled solvent-detergent–treated plasma has also been shown 
to reduce the proportion of the largest multimers of VWF, 44,45 
which is important for VWD, but is irrelevant for treatment of 
hemophilia A. 
 Dosage/administration 
•  One mL of FFP contains 1 unit of factor activity. 
•  It is generally difficult to achieve FVIII levels higher than 30 IU/
dL with FFP alone. 
•  FIX levels above 25 IU/dL are difficult to achieve. A starting FFP 
dose of 15-20 mL/kg is acceptable. 43 
 Cryoprecipitate 
•  Cryoprecipitate is the insoluble concentrate of high molecular 
weight plasma proteins that precipitate when frozen plasma is 
slowly thawed at 1-60°C. 
•  Cryoprecipitate contains significant quantities of FVIII (about 
3-10 IU/mL), VWF, fibrinogen, and FXIII but not FIX nor FXI. The 
resultant supernatant is called cryo-poor plasma and contains 
other coagulation factors such as factors VII, IX, X, and XI. 
•  The use of viral inactivation procedures is strongly 
encouraged. 1,43,46,47 
•  The manufacture of small pool, viral-inactivated (solvent-deter-
gent–treated) cryoprecipitate has been described, although this 
provides safety only for lipid-enveloped viruses. 47 
 Recommendation 5.5.3: 
•  For patients with hemophilia, cryoprecipitate is not recom-
mended due to concerns about the safety and quality. 
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•  REMARK : The use of cryoprecipitate can only be justified in sit-
uations where clotting factor concentrates are not available 
as there is no proven advantage for their use over CFCs. It is 
strongly encouraged that viral-inactivation procedures be used, 
if available.  CB 
 Dosage/administration 
•  A bag of cryoprecipitate made from 1 unit of FFP (200-250 mL) 
may contain 70-80 units of FVIII in a volume of 30-40 mL. 
 5.6  |  Other pharmacological options 
•  In addition to CFCs, other agents can be of great value in a signif-
icant proportion of cases. These include: 
 ◦  desmopressin (DDAVP); 
 ◦  tranexamic acid; and 
 ◦  epsilon aminocaproic acid (EACA). 
•  See also Chapter 2: Comprehensive Care of Hemophilia, Chapter 
7: Treatment of Specific Hemorrhages, and Chapter 9: Specific 
Management Issues. 
 Desmopressin (DDAVP) 
•  Desmopressin (1-deamino-8-D-arginine vasopressin, also known 
as DDAVP) is a synthetic analogue of vasopressin that boosts 
plasma levels of FVIII and VWF. 48 
•  DDAVP may be the treatment of choice for patients with mild 
or moderate hemophilia A when FVIII can be raised to an appro-
priate therapeutic level because it avoids the expense and po-
tential hazards of using CFC including the risk of FVIII inhibitor 
development. 48-51 
•  DDAVP does not affect FIX levels and is of no value in hemophilia B. 
•  There are significant differences in individual patient response to 
DDAVP. The response to intranasal DDAVP is more variable and 
therefore less predictable. 48,49 
•  DDAVP is particularly useful in the treatment and prevention of 
bleeding in carriers of hemophilia A. 52 
•  DDAVP is not licensed for use in pregnancy, but it has been used 
with caution in pregnant carriers during labour and delivery. Its 
use should be avoided in preeclampsia and eclampsia because 
of the already high levels of VWF. 53,54 (See Chapter 9: Specific 
Management Issues – Carriers.) 
•  The decision to use DDAVP must be based on both the patient ' s 
baseline FVIII activity, the increment achieved, and the duration 
of treatment required. 
 Dosage/administration 
•  Though DDAVP may be given subcutaneously, it is primarily ad-
ministered by intravenous infusion or nasal spray. It is important 
to choose the correct preparation of DDAVP because some low-
er-dose preparations are used for other medical purposes. 
•  Appropriate preparations include: 
 ◦  4 μg/mL for intravenous use; 
 ◦  15 μg/mL for intravenous and subcutaneous use; 
 ◦  150 μg per metered dose as nasal spray. 
•  A single dose of 0.3 μg/kg body weight, either via intravenous or 
subcutaneous administration, can be expected to boost the FVIII 
level 3- to 6-fold. 48,55 
•  For intravenous use, DDAVP is usually diluted in at least 50-
100 mL of physiological saline and given by slow infusion over 
20-30 minutes. 
•  The peak response is seen approximately 60 minutes after either 
intravenous or subcutaneous administration. 
•  Children should generally not be given DDAVP more than once 
per day; in adults under close supervision, twice-daily dosing may 
be considered. With subsequent dosing, therapeutic response de-
creases (tachyphylaxis) and the risk of complications rises; thus, in 
general, DDAVP should not be used for more than 3 consecutive 
days. 
•  CFCs may be needed when higher factor levels are required for a 
prolonged period. 56 
•  Rapid DDAVP infusion may result in tachycardia, flushing, tremor, 
and abdominal discomfort. 
•  A single metered intranasal DDAVP spray of 1.5 mg/mL in each 
nostril is appropriate for an adult. For patients with a body weight 
of less than 40 kg, a single dose in one nostril is sufficient. 57,58 
•  Some patients may find the intranasal preparation of DDAVP 
difficult to use, and it may be less efficacious than DDAVP given 
subcutaneously. 
•  Because DDAVP is an antidiuretic agent, water retention, hypo-
natremia, and even seizures may occur in patients receiving large 
amounts of hypotonic intravenous or oral fluids, necessitating 
fluid restriction during DDAVP treatment. 59 This is especially im-
portant in the context of home treatment of minor bleeding epi-
sodes and peri-operatively, when large quantities of infusions are 
used—patients/caregivers should be instructed to restrict fluids 
after DDAVP use. 59 
•  DDAVP should be used with caution in young children, and it is 
contraindicated in children under 2 years of age. For young pediat-
ric inpatients (i.e., postoperative patients), hypotonic intravenous 
fluids should be avoided and total fluid intake should be reduced 
to 75% of maintenance requirements in the 24 hours after use of 
DDAVP. 59 Plasma osmolality and sodium levels should be mea-
sured before and after DDAVP use in young children, especially if 
more than one dose is used over a 24-hour period. 48,59-61 
•  Hyponatremia is uncommon in most adults treated with DDAVP. 
However, hypotension is commonly observed in both children and 
adults, and children under 2 years of age have an increased risk of 
seizures secondary to cerebral edema caused by water retention/
hyponatremia. 61,62 Other side effects of DDAVP include headache, 
flushing, fatigue, and tachycardia. Given the vasoactive effect of 
DDAVP, caution should be exercised if it is used in patients with hy-
pertension that is not completely controlled by therapy. These side 
effects may occur more often after intravenous administration. 63,64 
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•  There are case reports of thrombosis (including myocardial infarc-
tion) after infusion of DDAVP. It should be used with caution in 
patients with a history or risk of cardiovascular disease. 55 
 Recommendation 5.6.1: 
•  For patients with mild or moderate hemophilia A and carriers of 
hemophilia A, the WFH recommends considering desmopressin 
(DDAVP) as an option for treatment. 
•  REMARK : The WFH recommends testing DDAVP prior to thera-
peutic use to evaluate the individual FVIII response. The deci-
sion to use DDAVP must be based on the patient ' s baseline FVIII 
activity, the increment achieved, and the duration of treatment 
required. 
•  REMARK : In general, the most common adverse events observed 
are tachycardia, flushing, tremor, abdominal discomfort, and 
headache, especially during rapid infusion, and are mostly mild 
and transient. However, hypotension and/or severe hyponatre-
mia can also occur. 
•  REMARK : For pregnant women during labour and delivery, the 
WFH recommends caution in the use of DDAVP, and it should be 
avoided in pre-eclampsia and eclampsia. 
•  REMARK : With more than 3 consecutive days of dosing, the ther-
apeutic response may decrease (tachyphylaxis) and the risk of 
complications rises; thus, clotting factor concentrates may be 
needed when higher factor levels are required for a prolonged 
period.  CB 
 Recommendation 5.6.2: 
•  For adults, the WFH recommends DDAVP not be used for more 
than 3 consecutive days and only under close supervision. If 
DDAVP is administered twice in a single day, subsequent daily 
dosing should be limited to once per day. 
•  REMARK : In general, the most common adverse events observed 
are tachycardia, flushing, tremor, abdominal discomfort, and 
headache, especially during rapid infusion. However, hypoten-
sion and/or hyponatremia can also occur. 
•  REMARK : With more than 3 consecutive days of dosing, the thera-
peutic response may decrease (tachyphylaxis) and the risk of com-
plications rises; thus, clotting factor concentrates may be needed 
when higher factor levels are required for a prolonged period.  CB 
 Recommendation 5.6.3: 
•  For children, the WFH recommends using no more than 1 dose of 
DDAVP per day for no more than 3 consecutive days. 
•  REMARK : In general, the most common adverse events observed 
are tachycardia, flushing, tremor, abdominal discomfort, and 
headache, especially during rapid infusion. However, hypoten-
sion and/or hyponatremia can also occur. 
•  REMARK : With more than 3 consecutive days of dosing, the ther-
apeutic response may decrease (tachyphylaxis) and the risk of 
complications rises; thus, clotting factor concentrates may be 
needed when higher factor levels are required for a prolonged 
period.  CB 
 Recommendation 5.6.4: 
•  For children under 2 years of age, the WFH alerts that DDAVP 
is contraindicated due to increased risk of seizures as conse-
quences of water retention and hyponatremia.  CB 
 Recommendation 5.6.5: 
•  For patients at risk of cardiovascular disease or thrombosis, the 
WFH recommends that DDAVP should be used with caution due 
to the risk of thromboembolism and myocardial infarction.  CB 
 Tranexamic acid 
•  Tranexamic acid is an antifibrinolytic agent that competitively in-
hibits the activation of plasminogen to plasmin. It promotes clot 
stability and is useful as adjunctive therapy for some types of he-
mophilic bleeding. 65 
•  Treatment with tranexamic acid alone is of no value in the preven-
tion of hemarthroses in hemophilia. 65 
•  Tranexamic acid is useful for treating superficial soft tissue and mu-
cosal bleeds (e.g., oral bleeding, epistaxis, and menorrhagia). 66-68 
•  Tranexamic acid is particularly valuable in the setting of dental 
surgery and may be used to control oral bleeding associated with 
eruption or shedding of teeth. 67,69 
•  See also Chapter 2: Comprehensive Care of Hemophilia and 
Chapter 7: Treatment of Specific Hemorrhages. 
 Dosage/administration 
•  Tranexamic acid is usually given as oral tablets (25 mg/kg/dose) 
3-4 times daily. It can also be given by intravenous infusion 
(10 mg/kg/dose) 2-3 times daily. It is also available as an oral 
rinse. 
•  Gastrointestinal upset (nausea, vomiting, or diarrhea) may rarely 
occur as a side effect of tranexamic acid, but these symptoms usu-
ally resolve if the dosage is reduced. When administered intrave-
nously, tranexamic acid must be infused slowly as rapid injection 
may result in dizziness and hypotension. 
•  A syrup formulation of tranexamic acid is also available for pedi-
atric use. If this is not obtainable, a tablet can be crushed finely 
and dissolved in clean water for topical use on bleeding mucosal 
lesions. 
•  Tranexamic acid is commonly prescribed for 7 days following den-
tal extractions to prevent postoperative bleeding. 
•  Tranexamic acid is excreted by the kidneys, and the dose must 
be reduced if there is renal impairment in order to avoid toxic 
accumulation. 
•  The use of tranexamic acid is contraindicated for the treatment of 
hematuria as its use may prevent dissolution of clots in the ureter, 
leading to serious obstructive uropathy and potentially perma-
nent loss of renal function. 
•  Tranexamic acid is also contraindicated in the setting of thoracic 
surgery where it may result in the development of insoluble 
hematomas. 
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•  Tranexamic acid may be given alone or together with standard 
doses of CFCs including bypassing agents such as aPCC and 
rFVIIa. 70-72 
•  Tranexamic acid is contraindicated in patients with hemophilia B 
receiving PCCs, as it increases the risk of thromboembolism. 73 
 Recommendation 5.6.6: 
•  For patients with hemophilia, the WFH recommends that an-
tifibrinolytics are a valuable alternative to use alone or as ad-
juvant treatment, particularly in controlling mucocutaneous 
bleeding (e.g., epistaxis, oral and gastrointestinal bleeding, and 
menorrhagia) and for dental surgery and eruption or shedding 
of teeth. 
•  REMARK : Antifibrinolytics can be used with standard doses of clot-
ting factor concentrates, including bypassing agents. However, 
they should not be used with prothrombin complex concentrates 
due to the increased risk of thromboembolism.  CB 
 Recommendation 5.6.7: 
•  For patients with hematuria, the WFH recommends against the 
use of antifibrinolytics, as it is contraindicated in these patients 
due to increased risk of obstructive uropathy.  CB 
 Recommendation 5.6.8: 
•  For patients with renal impairment, the WFH recommends re-
duced dosing of antifibrinolytics and close monitoring.  CB 
 Epsilon aminocaproic acid 
•  Epsilon aminocaproic acid is similar to tranexamic acid but is less 
widely used as it has a shorter plasma half-life, lower potency, and 
higher toxicity. 65 
•  See also Chapter 2: Comprehensive Care of Hemophilia and 
Chapter 7: Treatment of Specific Hemorrhages. 
 Dosage/administration 
•  In adults, EACA is typically administered orally (100 mg/kg/dose 
up to a maximum of 2 g/dose) or intravenously (100 mg/kg/dose 
up to a maximum of 4 g/dose) every 4-6 hours up to a maximum 
of 24 g/day. 
•  A 250 mg/mL syrup formulation of EACA is also available. 
•  Gastrointestinal upset is a common complication with EACA use; 
reducing the dose often alleviates this side effect. 
•  Myopathy is a rare adverse reaction specifically reported in 
association with EACA therapy (but not tranexamic acid) and 
typically occurs after administration of high doses for several 
weeks. 
•  The myopathy associated with EACA use is often painful and as-
sociated with elevated levels of creatine kinase and even myoglo-
binuria. Full resolution may be expected once EACA treatment is 
stopped. 
 5.7  |  Non- factor replacement therapies 
•  For the past five decades, the focus of hemophilia therapies has 
been on replacing the missing clotting factor protein; however, 
recombinant technology combined with improved basic under-
standing of coagulation biochemistry is currently shifting the 
treatment paradigm. 
 Rationale and mechanisms of action 
•  New and emerging innovative therapeutics have been developed 
with alternative modes of delivery (e.g., subcutaneous), targets 
that overcome the limitations of current clotting factor replace-
ment therapy (i.e., intravenous administration, short half-life, risk 
of inhibitor formation), and markedly improved PK profiles with 
a very low burden of administration (e.g., up to monthly dosing), 
which may increase compliance. 
 Substitution therapy 
•  Substitution therapy differs from factor replacement therapy in that 
it is based on the use of an alternative hemostatic agent to substi-
tute for clotting factor. The factor mimetic, emicizumab, is the first 
and only licensed substitution therapy at the time of this publication. 
•  Emicizumab is a chimeric bispecific antibody directed against 
the enzyme FIXa and the zymogen FX that mimics the cofactor 
function of FVIII in patients with hemophilia A, with or without 
inhibitors. Emicizumab binds to FIX, FIXa, FX, and FXa; however, 
it is its affinity to FIXa and FX that promotes FIXa-catalyzed FX 
activation and tenase formation. 74,75 
•  The key benefits of emicizumab are its subcutaneous route of ad-
ministration, long half-life, high efficacy in bleed prevention, and 
reduction of the frequency of bleeding episodes in patients with 
or without FVIII inhibitors. 
•  As emicizumab differs biochemically from FVIII, many questions 
remain regarding its long-term impact on joint pathology and im-
munogenicity in non-inhibitor patients. 
•  Emicizumab is not intended to treat acute bleeding episodes. 
Caution is required when treating breakthrough bleeding epi-
sodes while on emicizumab as several patients have developed 
either venous thromboembolism or thrombotic microangiopathy 
with concomitant administration of aPCC. 76 Consult the hemo-
philia treatment centre and risk management guidance. 
 Recommendation 5.7.1: 
•  For patients with hemophilia A with an inhibitor, the WFH recom-
mends that emicizumab should be used for regular prophylaxis. 
•  REMARK : For patients with hemophilia A with no inhibitor, the 
WFH recommends that emicizumab can be used for regular pro-
phylaxis.  CB 
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 Hemostatic rebalancing agents 
•  The hemostatic system regulates the balance between procoag-
ulants (e.g., clotting factors) and natural anticoagulants (e.g., an-
tithrombin, tissue factor pathway inhibitor [TFPI], and activated 
protein C). Bleeding disorders result from a deficiency of the pro-
coagulants, whereas deficiencies of the natural anticoagulants are 
associated with increased thrombotic risk. 
•  Hemophilia has typically been treated by replacing the missing 
procoagulant protein or with bypassing agents (i.e., when inhib-
itors are present). However, inhibiting the natural anticoagulants 
can also restore hemostasis. This has been observed naturally as 
co-inheritance of thrombophilic risk factors can moderate the 
clinical phenotype of severe hemophilia A. In addition, thrombin 
generation is increased with co-inheritance of hemophilia with 
some forms of thrombophilia (e.g., protein C deficiency). 
•  Fitusiran is an RNA interference therapy that specifically targets 
antithrombin messenger RNA to suppress the production of anti-
thrombin in the liver. 77 This therapy has the advantage of subcu-
taneous administration, prolonged duration of action and, due to 
its mechanism of action, it could be used in both hemophilia A and 
B patients with or without inhibitors. 
•  For prevention of bleeding, suppression of antithrombin by 75% 
is most effective. Breakthrough bleeding can be treated with 
FVIII/FIX replacement or with bypassing agents, but lower doses 
must be used to minimize the risk of excessive procoagulant 
activity. 
•  Anti-TFPI antibodies represent another modality in clinical trials. 
Different anti-TFPI antibodies are currently in development, all of 
which bind to the K2 domain or to both the K1 and K2 domains 
of TFPI, thus rescuing FXa and FVIIa from inhibition. 78 These 
therapies may also be administered subcutaneously and restore 
hemostasis in both hemophilia A and B patients with or without 
inhibitors, but their duration of action is limited by target-medi-
ated drug disposition. The use of fitusiran requires close monitor-
ing to minimize risk of thrombosis. Two anti-TFPI clinical programs 
are ongoing, while two others have seen evidence of thrombotic 
complications. One clinical program has been stopped and one 
halted due to these adverse events. 
•  See also Chapter 2: Comprehensive Care of Hemophilia, Chapter 
6: Prophylaxis in Hemophilia, Chapter 8: Inhibitors to Clotting 
Factor, and Chapter 9: Specific Management Issues. 
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 This chapter discusses prophylaxis for people with hemophilia in the ab-
sence of inhibitors to factor VIII or IX. For prophylaxis for patients with 
inhibitors, see Chapter 8: Inhibitors to Clotting Factor. 
 All statements identified as recommendations are consensus based, 
as denoted by  CB . 
 6.1  |  Introduction 
•  Prophylaxis in hemophilia consists of regular administration of 
therapeutic products aimed at maintaining hemostasis to pre-
vent bleeding, especially joint hemorrhages, which would lead 
to arthropathy and disability. Prophylaxis should enable people 
with hemophilia to lead healthy and active lives including par-
ticipation in most physical and social activities (at home, school, 
work, and in the community), similar to the non-hemophilic 
population. 
•  Prophylaxis with clotting factor concentrates (CFCs) is referred 
to as regular replacement therapy; it stands in contrast to epi-
sodic replacement therapy (also known as on-demand therapy), 
which is defined as the administration of CFCs only at the time 
of a bleed. 1 Episodic therapy, regardless of the doses used, while 
essential in reducing the pain and debilitating impact of individ-
ual bleeds, does not alter the bleeding profile significantly and 
hence does not change the natural history of hemophilia lead-
ing to musculoskeletal damage and other complications due to 
bleeding. 
•  Therefore, the use of prophylaxis is always recommended over 
episodic therapy. In countries with healthcare constraints and for 
patients with limited access to CFCs, less intensive prophylaxis 
regimens may be used. (See 6.9 Health economics of prophylaxis.) 
Still, in all countries the ideal is for patients to not experience any 
bleeds (i.e., achieve “zero” bleeds). 
•  With the advent of innovative non-factor replacement therapies, 
which for the most part can be administered subcutaneously, 
prophylaxis is being redefined as the regular administration (intra-
venously, subcutaneously, or otherwise) of a hemostatic agent/
agents to enhance hemostasis and effectively prevent bleeding in 
people with hemophilia. 2,3 
 Recommendation 6.1.1: 
•  For patients with hemophilia A or B with a severe phenotype 
(note that this may include patients with moderate hemophilia 
with a severe phenotype), the WFH strongly recommends that 
such patients be on prophylaxis sufficient to prevent bleeds at 
all times, but that prophylaxis should be individualized, taking 
into consideration patient bleeding phenotype, joint status, 
individual pharmacokinetics, and patient self-assessment and 
preference. 
•  REMARK : Individualizing prophylaxis means that if patients con-
tinue to experience bleeds, their prophylaxis regimen should be 
escalated (in dose/frequency or both) to prevent bleeding. 
•  REMARK : In countries with significant healthcare constraints, the 
WFH still advocates for the use of prophylaxis over episodic 
therapy but recognizes that less intensive prophylaxis may be 
used.  CB 
•  See 6.9 Health economics of prophylaxis and 6.10 Low-dose pro-
phylaxis for patients with limited access to CFCs. 
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 Standard half- life factor replacement therapy 
•  Prophylaxis has conventionally been defined as the regular in-
travenous (IV) infusion of the missing clotting factor VIII (FVIII) 
in people with hemophilia A and factor IX (FIX) in people with 
hemophilia B, given in order to increase the FVIII/FIX level with 
the intent to prevent bleeding. 1 The focus of this conventional 
definition of prophylaxis has been on preventing joint bleeds and 
maintaining musculoskeletal health. 
•  The objective of prophylaxis has been to convert a person with 
severe hemophilia (baseline FVIII/FIX level <1 IU/dL [1%]) to a 
bleeding phenotype typical of moderate or mild hemophilia by 
maintaining factor levels above 1 IU/dL (1%) at all times. 4 
•  This was based on the observation that people with moderate 
hemophilia seldom experienced spontaneous bleeding and had 
much better preservation of joint function. 
•  However, there has been increasing recognition and evidence that 
factor trough levels of 1-3 IU/dL (1%-3%) are insufficient to totally 
prevent bleeds in all people with hemophilia and allow occasional 
clinical and subclinical bleeds, resulting in gradual progression of 
joint disease over a lifespan. 5 
•  In general, the higher the factor levels at all times, the less the 
bleeding. For every 1% increase in baseline factor levels (in peo-
ple with hemophilia not on prophylaxis), there is a decrease in 
bleeding frequency, and when baseline FVIII:C levels are above 
15 IU/dL (15%), spontaneous bleeding is uncommon. 6-8 The same 
is thought to apply with FIX:C levels, although this has been less 
well studied. Similarly, it has been shown that the more time spent 
with FVIII levels below 1 IU/dL (1%), the higher the rate of break-
through bleeds during prophylaxis. 6 
 Extended half- life factor replacement therapy 
•  The use of extended half-life (EHL) CFCs fits within the definition 
of conventional factor prophylaxis but allows for more ambitious 
prophylaxis than simply converting an individual from a severe to 
a moderate phenotype. 
•  This is particularly the case with some EHL FIX products which 
allow individuals to have FIX levels in a non-hemophilic range 
(>40 IU/dL [40%]) for a substantial proportion of time and levels 
in the mild hemophilia range (5-40 IU/dL [5%-40%]) just prior to 
the next infusion. 9 
•  While prophylaxis with CFCs has been the mainstay of hemophilia 
treatment for many decades, the treatment landscape is changing 
with the development of new types of therapies. 
 Non- factor replacement therapy 
•  Non-factor replacement therapy differs from clotting factor re-
placement therapy in that it provides hemostasis through a differ-
ent mechanism than FVIII/FIX replacement. The first, and at the 
time of this publication, the only licensed non-factor replacement 
therapy for hemophilia A is emicizumab. 10 Emicizumab mimics the 
cofactor activity of FVIII. It is administered subcutaneously once 
weekly, and in some cases can be administered as infrequently as 
once every 2 or 4 weeks. 11 (See 6.5 Prophylaxis with non-factor 
replacement therapy.) 
 Basic definitions and concepts in prophylaxis 
with CFCs 
•  Prophylaxis has been characterized according to when it is initi-
ated and according to its intensity. These definitions apply to both 
hemophilia A and B. (See Tables  6-1 and  6-2 .) 
 Initiation of prophylaxis: timing and approach 
•  Age at initiation of prophylaxis has been a strong predictor of 
long-term clinical outcomes. 
•  People with hemophilia initiated on early prophylaxis (i.e., primary 
or secondary prophylaxis) have shown the best long-term out-
comes. 12 (See Table  6-1 for prophylaxis definitions.) Furthermore, 
early initiation of prophylaxis also reduces the risk and incidence 
of intracranial hemorrhage (ICH), which is highest in very young 
children. 13 
•  Long-term cohort studies have shown that a small number 
of joint bleeds occurring early in life prior to the start of pro-
phylaxis may (in some patients) ultimately result in hemophilic 
arthropathy. 14-16 
•  Regular prophylaxis begun at a young age and given in appropri-
ate doses should therefore be considered the standard of care to 
treat hemophilia until an alternate long-term therapy such as gene 
therapy is available. 
•  There have been various approaches regarding how to initiate 
conventional prophylaxis with IV factor replacement therapy. The 
two main ways (high-dose prophylaxis and low-dose escalating 
prophylaxis) are mainly differentiated in the frequency of CFC ad-
ministration and less so in the doses used. 17 
•  Escalating frequency prophylaxis, which starts with less intense 
prophylaxis (e.g., once-weekly infusions), followed by an increase 
in frequency, has enabled young children and their families to 
gradually adapt to the burdens of prophylaxis (e.g., peripheral 
venous infusion). 18,19 Young children commenced on low-dose 
escalating prophylaxis need to be followed closely, and strong 
consideration should be given to escalating prophylaxis quickly 
(either all patients or according to bleeding symptoms) in order to 
prevent bleeding and resulting morbidity. 
•  Starting with less intense prophylaxis and then gradually esca-
lating may improve family acceptance of starting prophylaxis 
early and may improve adherence to prophylaxis. This approach 
also appears to result in less need for placement of central ve-
nous access devices (CVADs). However, patients on less intense 
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prophylaxis are at a higher risk of bleeding until escalation of pro-
phylaxis occurs. 20,21 
•  For people with hemophilia A, starting with small doses of FVIII 
CFC therapy may have the additional (unproven) benefit of de-
creasing inhibitor development, as large and frequent doses of 
FVIII early on have been associated with an increase in the rate of 
inhibitor development. 22 
•  People with severe/moderate hemophilia who have had a 
life-threatening bleed in early childhood should, however, not be 
placed on escalating dose prophylaxis but instead be started im-
mediately on high-dose prophylaxis. 
•  How to start and when to start prophylaxis with either standard 
half-life (SHL) or extended half-life (EHL) CFCs is not signifi-
cantly different. In both cases, prophylaxis should be commenced 
early by starting with a high-dose/high-frequency approach or a 
low-frequency approach, followed by escalation of frequency. 
•  With EHL CFCs, less frequent infusions (e.g., once weekly) may 
be sufficient for many individuals, particularly those with severe 
hemophilia B receiving EHL FIX CFCs. As EHL CFCs must still be 
given intravenously, they remain difficult to administer in very 
young children with poor peripheral venous access. 17 
•  Time to initiation of prophylaxis with non-factor replacement 
agents has not been well studied. Since emicizumab is adminis-
tered subcutaneously, challenges of venous access are mitigated. 
It may be started at a similar time as CFC prophylaxis initiation, 
or perhaps earlier, although data are still very limited. 23 Further 
research on initiation of emicizumab in newborns is needed. 24 
•  See Tables  6-1 and  6-2 , above, and Chapter 3: Laboratory 
Diagnosis and Monitoring – Inhibitor testing. 
 Recommendation 6.1.2: 
•  For pediatric patients with severe hemophilia A or B, the WFH 
recommends early initiation of prophylaxis with clotting factor 
concentrates (standard or extended half-life FVIII/FIX) or other 
hemostatic agent(s) prior to the onset of joint disease and ide-
ally before age 3, in order to prevent spontaneous and break-
through bleeding including hemarthroses which can lead to 
joint disease.  CB 
 Recommendation 6.1.3: 
•  For adolescents and adults with hemophilia who show evidence 
of joint damage and have not as yet been on prophylaxis, the 
WFH recommends commencing tertiary prophylaxis in order to 
reduce the number of hemarthroses, spontaneous and break-
through bleeding, and slow down the progression of hemophilic 
arthropathy.  CB 
 Intensity of prophylaxis 
•  Although intensity of prophylaxis has generally been referred to 
as high, intermediate, and low dose, it should be appreciated that 
intensity is a function of both dose and frequency and that high 
dose usually refers to a combination of both high doses and high 
frequencies, while low dose usually refers to a combination of 
lower doses and lower frequencies, although not always. 
•  See 6.6 Fixed/non-tailored factor prophylaxis regimens, below, 
and 6.7 Tailored factor prophylaxis regimens, below. 
 6.2  |  Benefits of prophylaxis 
 Prophylaxis using clotting factor concentrates 
•  All forms of prophylaxis (high/intermediate/low dose with 
CFCs or prophylaxis with non-factor replacement agents, e.g., 
 TA B L E   6 1     Conventional factor prophylaxis for hemophilia A and B defined according to when prophylaxis is initiated 1 
 Primary prophylaxis •  Regular continuous prophylaxis started in the absence of documented joint disease, determined by physical 
examination and/or imaging studies, and before the second clinically evident joint bleed and 3 years of age 
 Secondary prophylaxis •  Regular continuous prophylaxis initiated after 2 or more joint bleeds but before the onset of joint disease; this 
is usually at 3 or more years of age 
 Tertiary prophylaxis •  Regular continuous prophylaxis initiated after the onset of documented joint disease. Tertiary prophylaxis 
typically applies to prophylaxis commenced in adulthood 
 TA B L E   6 2     Conventional factor prophylaxis with standard half- life clotting factor defined according to its intensity 
 Prophylaxis intensity  Hemophilia A  Hemophilia B 
•  High- dose prophylaxis 4  •  25- 40 IU FVIII/kg every 2 days 
(>4000 IU/kg per year) 
•  40- 60 IU FIX/kg twice per week 
(>4000 IU/kg per year) 
•  Intermediate- dose prophylaxis •  15- 25 IU FVIII/kg 3 days per week 
(1500- 4000 IU/kg per year) 
•  20- 40 IU FIX/kg twice per week 
(2000- 4000 IU/kg per year) 
•  Low- dose prophylaxis (with escalation of 
dose intensity, as needed) a  
•  10- 15 IU FVIII/kg 2- 3 days per week 
(1000- 1500 IU/kg per year) 
•  10- 15 IU FIX/kg 2 days per week 
(1000- 1500 IU/kg per year) 
 Abbreviations: FIX, factor IX; FVIII, factor VIII; IU, international unit; kg, kilogram. 
 a Should only be taken as the starting point of replacement therapy to be tailored, as possible, to prevent bleeding.  
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emicizumab) provide superior benefits over episodic therapy. 
Conventional high-dose and intermediate-dose prophylaxis, initi-
ated early in life, have been associated with over 90% reduction in 
joint bleeding rates, annualized joint bleeding rates (AJBRs) below 
3 per year, and a significant reduction in joint deterioration and 
degenerative joint disease. 12,25 
•  Prophylaxis also provides protection from other types of hemor-
rhages in hemophilia, including preventing or substantially reduc-
ing the risk of intracranial hemorrhage. 13 
•  Longer-term benefits include reduction of chronic musculoskel-
etal pain, functional limitations and disability, need for orthope-
dic surgery, hospitalization, emergency room visits, and reduced 
length of hospital stays; all of this leads to greater participation 
(i.e., regular attendance) in educational, recreational, and profes-
sional activities, with improved quality of life. 26 
•  Because of these benefits, the World Health Organization (WHO), 
the World Federation of Hemophilia (WFH), and many national and 
international hemophilia organizations have endorsed early pro-
phylaxis as the standard of care for children with a severe pheno-
type hemophilia 27 and recommend that prophylaxis be continued 
lifelong. Additionally, adults with severe phenotype hemophilia (if 
not already on prophylaxis) should initiate prophylaxis as well. 22 
 Prophylaxis using non- factor replacement therapies 
•  Emicizumab prophylaxis in a number of clinical trials has been 
shown to be associated with very low rates of bleeding (an an-
nualized bleeding rate [ABR] of 1.5) and ABRs lower than what 
patients previously reported while on prophylaxis with CFCs. 2 
More research is needed regarding long-term outcomes with emi-
cizumab. Data on the use of other non-factor therapies for pro-
phylaxis are at present much more limited. 
 Recommendation 6.2.1: 
•  For patients with severe phenotype hemophilia A or B, especially 
children, the WFH recommends regular long-term prophylaxis 
as the standard of care to prevent hemarthrosis and other spon-
taneous and breakthrough bleeding, maintain musculoskeletal 
health, and promote quality of life. When prophylaxis is not fea-
sible, episodic therapy is essential treatment for acute hemor-
rhages, but it will not prevent long-term joint damage. 
•  REMARK : In the long term, early and regular prophylaxis for chil-
dren reduces hemarthrosis and other hemophilic bleeding, pro-
duces better health and joint outcomes, reduces the number of 
hospital visits and admissions, and may avert the need for ortho-
pedic interventions, including surgery, in the future.  CB 
 6.3  |  Standard half- life factor prophylaxis 
•  All SHL CFCs (i.e., plasma-derived and recombinant) have essen-
tially similar pharmacokinetic properties. The short half-life of 
SHL CFCs results in the need for frequent venipunctures for pro-
phylaxis (3-4 times per week for FVIII and 2-3 times per week for 
FIX); this often leads to the need for CVADs in young children and 
to reduced adherence in older children/adults. 28 
•  With SHL CFCs, it is difficult to achieve factor trough levels much 
higher than 1 IU/dL (1%); to do so would require very frequent 
infusions (possibly daily) that many patients are likely unwilling or 
unable to do. 
•  Individual factor levels in people with hemophilia on prophylaxis 
are determined by: 
 ◦  the prophylaxis regimen (dose and frequency) that individuals 
are on; 
 ◦  their individual pharmacokinetic (PK) handling of factor (factor 
recovery and half-life/clearance); and 
 ◦  the PK characteristics of the CFC product used. (See Table  6-3 .) 
 Recommendation 6.3.1: 
•  For patients with severe phenotype hemophilia A or B, pro-
phylaxis with clotting factor concentrates (either standard or 
extended half-life) is recommended at a dose and dosing inter-
val (dependent on the pharmacokinetic [PK] properties of the 
clotting factor concentrate) that allow them to at all times have 
sufficient circulating factor to prevent hemarthrosis, and spon-
taneous and breakthrough bleeding, based on their individual 
needs and lifestyles and preserve musculoskeletal function. 
•  REMARK : In the past, a trough factor level of 1 IU/dL (1%) was 
deemed an adequate goal. Now recognizing that with a 1% 
trough level, patients remain at risk of bleeding, most clinicians 
would prefer to target higher trough levels (>3%-5%, or higher). 
Recent studies show that such trough levels achieve less bleed-
ing. However, the trade-off is that higher trough levels may re-
quire higher doses or more frequent infusions of clotting factor 
concentrates. This should therefore be personalized based on 
the individual ' s activities, lifestyle, and PK handling of factor.  CB 
 Time of day dosing for SHL CFCs 
•  Timing of prophylactic doses is important particularly for conven-
tional CFCs with shorter half-lives (i.e., SHL FVIII/FIX). Due to the 
short half-life of SHL CFCs, conventional prophylaxis produces a 
sinusoidal curve of factor peaks and troughs, corresponding to 
times when patients can safely be more active and times when 
they cannot. 
•  As people are more likely to be active during the day, it makes 
logical sense for most to infuse SHL CFCs in the mornings rather 
than in the evenings. 
 Recommendation 6.3.2: 
•  For patients who are adherent to their prescribed prophylaxis 
regimen but still experience breakthrough bleeds, the WFH rec-
ommends escalation of prophylaxis with measurement of trough 
levels and, if required, orthopedic interventions as appropriate. 
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•  REMARK : Any patient who fails to respond to adequate factor re-
placement therapy after past responsiveness should be tested 
for inhibitor development prior to escalation of therapy.  CB 
 6.4  |  Extended half- life factor prophylaxis 
•  The limitations of prophylaxis with SHL CFCs led to the recent 
development, introduction, and increasing use of EHL CFCs. 
 Half- life/clearance 
•  Current EHL FVIII CFCs show modest improvement (1.4- to 
1.6-fold) in half-life/clearance in comparison to SHL FVIII CFCs, 
with no significant differences in PK properties between these 
EHL FVIIIs. (Note that there is one EHL FVIII still in clinical trials 
[BIVV001] that shows a 3- to 4-fold half-life extension.) By con-
trast, EHL FIX CFCs show greatly improved half-lives (3- to 5-fold 
longer) in comparison to SHL FIX, but unlike with EHL FVIIIs, 
there are significant differences in the PK properties between 
EHL FIX CFCs. 9,30-32 
 Dose 
•  It is not as yet determined what constitutes high-, intermediate-, 
and low-dose prophylaxis with EHL CFCs and whether these defi-
nitions should be revised, given that much higher factor trough lev-
els can be obtained with EHL CFCs, particularly with EHL FIXs. For 
the most part, EHL FVIIIs have similar recoveries as SHL FVIIIs, and 
hence doses used for prophylaxis will be similar. Certain EHL FIX 
products show higher recoveries on the basis of less extravascular 
distribution than SHL FIX; for these products, lower doses might 
be used for prophylaxis. 9,31 It has been hypothesized that differ-
ences in extravascular distribution of FIX between various EHL and 
SHL FIX CFCs may be important in the protective effect that these 
CFCs deliver. 33,34 Further research into this is necessary. 
 Frequency of dosing 
•  Overall, EHL CFCs allow people with hemophilia to reduce the 
number of infusions needed to still achieve levels of protection 
similar to SHL CFCs, or allow them to increase their factor trough 
levels and achieve higher levels of bleed protection with a similar 
number of infusions, or a combination of both. Modest reductions 
in infusion frequency or modest increases in factor trough levels 
(likely not both) may be accomplished with EHL FVIII concentrates. 
•  Some (but not all) EHL FIX concentrates permit patients to infuse 
much less frequently (e.g., once every 7-14 days) and still maintain 
FIX trough levels of ≥10%-20% 9,31,32,35 or infuse weekly or more 
frequently and achieve FIX trough levels of 20%, 30%, or poten-
tially higher levels. The only caveat to this is that differences in 
extravascular distribution of FIX may be important in the protec-
tive effect of FIX. 36 
 Time of day dosing for EHL CFCs 
•  The longer the half-life of a product, the less critical the timing of 
infusions. This is particularly the case with some EHL FIX concen-
trates. 37-39 (See Table  6-4 .) 
 Recommendation 6.4.1: 
•  For patients with severe phenotype hemophilia A or B using EHL 
FVIII or FIX concentrates, the WFH recommends prophylaxis 
with EHL clotting factor concentrates at sufficient doses and 
 TA B L E   6 3     Variables that affect factor levels (applies to both SHL and EHL clotting factors) in people with hemophilia 
 Variables  Impacts on factor levels 
 Most important 
 Frequency of dosing a  •  Doubling frequency of infusions (without changing the dose/infusion) provides on average 5 half- lives of 
additional coverage 
 Half- life/clearance b  •  Doubling half- life provides on average 5 half- lives of additional coverage 
 Least important 
 Dose •  Doubling dose provides 1 half- life of additional coverage 
 Recovery •  Doubling recovery provides 1 half- life of additional coverage 
 Note :  This table is adapted from Carcao (2015). 29  
 Abbreviations: CFC, clotting factor concentrate; EHL, extended half- life; FIX, factor IX; SHL, standard half- life. 
 a Frequent small doses of CFC are generally much more efficient than infrequent large doses. Daily prophylaxis would be the most efficient 
prophylaxis regimen with SHL CFCs, as it would allow for use of relatively small doses of CFC and yet permit high factor levels to be maintained. 
However, such a regimen may be very difficult to adhere to, particularly for younger patients.  
 b Known variables that impact half- life/clearance of FVIII include blood group (O vs non- O) and von Willebrand factor levels; less is known as to what 
contributes to individual differences in pharmacokinetic handling of FIX. For the most part, individual factor recovery and half- lives increase with age. 
This may result in older patients needing a lower dose per infusion to maintain similar factor trough levels.  
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dosing intervals to prevent hemarthroses and spontaneous and 
breakthrough bleeding and preserve joint function.  CB 
 6.5  |  Prophylaxis with non- factor 
replacement therapy 
•  Note: Emicizumab is the only licensed non-factor replacement 
product available at the time of publication. 
•  The development of new non-factor hemostatic therapies in he-
mophilia is causing a reconsideration of the concepts and defi-
nitions of prophylaxis. These new non-factor therapies include 
emicizumab, a FVIII mimetic already in clinical use for hemophilia 
A, 10 and others still in development including agents that inhibit 
natural endogenous anticoagulants (antithrombin, tissue factor 
pathway inhibitor [TFPI], and activated protein C). 
•  Emicizumab and those non-factor agents in development differ 
from conventional types of prophylaxis as they do not replace the 
missing coagulation factor, are administered subcutaneously, and 
in some cases can be administered as infrequently as once every 
2 or 4 weeks. 11 Additionally, these agents are not associated with 
the peak and trough curves of protection that we now see with 
factor prophylaxis regimens. 
•  There have already been extensive clinical trials of emicizumab in 
patients with hemophilia A with and without inhibitors that attest 
to the safety and bleed protection with this agent. 2,32,40 (For emi-
cizumab use in patients with inhibitors, see Chapter 8: Inhibitors 
to Clotting Factor.) 
•  Emicizumab is already making it easier to start patients on pro-
phylaxis at an earlier age and without the need for CVADs. This 
may cause a re-evaluation of what constitutes primary prophy-
laxis (see Table  6-1 ), as perhaps prophylaxis can be commenced 
much earlier than usual. This could reduce the risk of bleeding 
that now occurs in very young children (ages 6-12 months) prior 
to the usual commencement of prophylaxis. 12,30,41 Further re-
search on the safety of emicizumab in this very young population 
is required. 24 
•  Non-factor products should allow for less burdensome prophylaxis, 
which might improve adherence and might lead to increased uptake 
of prophylaxis among patients not currently on prophylaxis (includ-
ing those with moderate hemophilia), permitting them increased 
participation in social and sports activities. The above is already 
demonstrated by the increasing uptake and usage of emicizumab. 
•  All of these developments are transforming the concepts of pro-
phylactic intensity. No longer can one refer to high-dose prophy-
laxis as prophylaxis that results in factor trough levels of 1%-3%. 3 
 Recommendation 6.5.1: 
•  For patients with severe phenotype hemophilia A without inhib-
itors, prophylaxis with emicizumab will prevent hemarthrosis, 
spontaneous, and breakthrough bleeding. 
•  REMARK : The WFH however notes that there are very little long-
term data on patient outcomes with such an approach and rec-
ommends that such data be obtained.  CB 
•  See also Chapter 5: Hemostatic Agents and Chapter 8: Inhibitors 
to Clotting Factor. 
 6.6  |  Fixed/non- tailored factor prophylaxis regimens 
•  Many factor prophylaxis regimens have been developed and pro-
mulgated by different groups. These regimens can, in general, be 
categorized as non-tailored/fixed-dose (“one size fits all”) or tai-
lored prophylaxis regimens. 
 “One size fits all” SHL factor prophylaxis regimens 
 High- dose and intermediate- dose prophylaxis 
•  The high-dose prophylaxis approach involves the administration 
of usually 25-40 IU/kg per dose given every other day or 3 times 
per week (for SHL FVIII concentrates) or twice per week (for SHL 
FIX concentrates) in order to ensure protection from spontaneous 
 TA B L E   6 4     Documented benefits of EHL CFCs 
 Benefits of lower infusion frequency  Benefits of higher factor trough levels 
•  Fewer clinic visits or home care nurse visits when commencing 
patients on prophylaxis, possibly leading to earlier start of 
prophylaxis 
•  More effective prophylaxis—higher level of prevention of bleeds (both 
clinically evident and subclinical microbleeds) while maintaining similar 
dosing schedules 
•  Less need for CVADs leading to some cost savings and reduced 
morbidity 
•  Potentially greater level of sports participation (possibly including 
sports that have traditionally been discouraged) without incurring a 
substantially increased risk of bleeding 
•  Less burdensome infusion schedules (dosing days and times): 
 ◦  fewer morning infusions 
 ◦  fewer infusions on work/school days 
 
•  Increased uptake of prophylaxis among patients not currently on 
prophylaxis 
 
 Note :  This table is adapted from Carcao (2015). 29  
 Abbreviations: CFC, clotting factor concentrate; CVADs, central venous access devices; EHL, extended half- life. 
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and breakthrough bleeds. Intermediate-dose prophylaxis is differ-
entiated from high-dose prophylaxis mainly in that lower doses 
are used (15-25 IU/kg) but generally at similar or almost similar 
infusion frequencies. (See Tables  6-2 and  6-5 .) 
•  High-dose regimens are associated with a higher need for CVADs 
in children. These can empower parents to be able to manage their 
child ' s hemophilia at home such that they no longer rely on regular 
trips to the hospital. They also make treatment less stressful for 
young patients, potentially improving adherence. However, there 
is expense and discomfort associated with the insertion of CVADs, 
and there is an appreciable frequency of complications (i.e., infec-
tion, thrombosis, and mechanical device failure) which often lead to 
hospitalization and CVAD replacement. 28,42 Consequently, CVADs 
should be viewed as a temporary aid and kept in place only for the 
minimum time possible to transition to using peripheral veins. 
•  As a result of a greater appreciation of CVAD complications, there 
has been a shift away from starting high-dose prophylaxis imme-
diately in young children. More and more young children with se-
vere phenotype hemophilia have been commenced on escalating 
prophylaxis regimens that start with once-weekly prophylaxis 
and then gradually escalate frequency of infusions regardless of 
bleeding phenotype. 22 
•  In patients who have experienced a life-threatening bleed, doses 
of CFC or non-factor therapy used for prophylaxis should be ad-
equate to prevent further bleeding; however, optimal doses to 
achieve this goal remain to be defined. 
 Recommendation 6.6.1: 
•  For patients with moderate/severe hemophilia A or B, especially 
those who have experienced a life-threatening bleed (e.g., intra-
cranial hemorrhage [ICH]), the WFH recommends prophylaxis 
with FVIII or FIX concentrates or with a non-factor therapy (e.g., 
emicizumab for hemophilia A) in order to prevent a recurrent 
life-threatening bleed. This is particularly important during the 
first 3-6 months following an ICH as the risk of recurrence is 
highest during this period. 
•  REMARK : As inhibitor development is associated with intense 
exposure as would occur in the setting of an ICH, such patients 
require good clinical monitoring of treatment response and fre-
quent laboratory testing for inhibitors.  CB 
 Recommendation 6.6.2: 
•  For patients with hemophilia and venous access difficulties that 
impede regular clotting factor concentrate infusions, the WFH 
recommends insertion of a central venous access device (CVAD) 
to facilitate prophylactic clotting factor concentrate infusions. 
Another currently available option is the use of emicizumab 
while in the future there may be other subcutaneous non-factor 
therapies that become available.  CB 
 Low- dose prophylaxis 
•  Low-dose prophylaxis involves the administration of factor re-
placement therapy at either less frequent intervals (generally 
 TA B L E   6 5     Advantages and disadvantages of fixed “one size fits all” SHL factor prophylaxis regimens 
 Regimen  Advantages  Disadvantages 
 High dose/high frequency •  Ensures that, on average, patients with hemophilia will 
have at all times measurable FVIII/FIX levels; i.e., levels 
above 1 IU/dL (1%) 
•  Ensures that virtually all individuals receive enough 
treatment to prevent virtually all bleeds 
•  Achieves lowest AJBRs and best long-term joint outcomes 
•  Offers benefits for very active individuals 
•  May be associated with adherence and 
convenience issues due to increased 
infusion demands on patients 
•  Is associated with highest factor utilization 
and consequently highest cost 
•  Results in high need for CVADs or AVFs 
•  May overtreat some individuals who have 
a milder phenotype which may negatively 
impact adherence 




•  Reduces AJBRs by approximately 90% to <1 per year 
•  Is less expensive than high-dose prophylaxis and 
consequently affordable in more countries 
•  Provides quality of life and activity participation rates 
comparable to high-dose prophylaxis 
•  Might be best for adolescents and adults 
•  Results in undertreatment of some patients 
•  Leads to slightly worse long-term MSK 
outcomes 
 Low dose/low frequency •  Is the least expensive of the fixed regimens and 
consequently affordable in more countries 
•  Reduces the incidence of bleeding by ~80% or more in 
comparison to episodic therapy and can achieve AJBRs of 
around <3 per year 20  
•  Has unknown long-term effect on MSK 
outcomes which are likely worse than those 
achieved with intermediate-/high-dose 
regimens 
 Note :  This table is adapted from Carcao (2015). 29  
 Abbreviations: AJBR, annual joint bleeding rate; AVF, arteriovenous fistula; CVAD, central venous access device; FIX, factor IX; FVIII, factor VIII; 
MSK, musculoskeletal; SHL, standard half- life. 
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once-weekly or twice-weekly prophylaxis) or using lower doses 
or a combination of both. 
•  In well-resourced countries, low-dose prophylaxis tends to be 
low-frequency prophylaxis with usual doses. This often is used as 
a way of initiating prophylaxis and is then followed by escalation 
of frequency to a higher degree of protection. 
•  Some centres choose to escalate only those patients who demon-
strate breakthrough bleeds on less intense prophylaxis (escalation 
tailored to bleeding phenotype approach); other centres choose 
to escalate all patients rapidly to more intense prophylaxis regard-
less of bleeding phenotype (escalation regardless of bleeding phe-
notype approach) to provide greater protection. 
•  In resource-constrained countries, low-dose prophylaxis tends to 
focus on the use of smaller doses. This is a way for patients in 
these countries to start receiving prophylaxis but at lower cost. To 
minimize cost, the focus tends to be on minimizing the doses used 
while keeping infusion frequencies similar. 20,43-46 
•  This allows replacement therapy with annual consumption similar 
to episodic treatment but with a much lower rate of spontaneous 
bleeds. 
•  Advantages and disadvantages of fixed “one size fits all” SHL fac-
tor prophylaxis regimens are shown in Table  6-5 . 
 6.7  |  Tailored factor prophylaxis regimens 
•  Tailored prophylaxis regimens are individualized to the needs of 
each patient; this means that individuals get a prophylaxis regi-
men tailored to their needs rather than a generic regimen received 
by all. Ideally, this allows for the “right amount of prophylaxis to 
be given to the right patient.” This has the potential to more ef-
ficiently allocate CFCs such that they will not be “wasted” on 
patients who may not require as much and yet not be denied to 
patients who require more. (See 6.9 Health economics of prophy-
laxis, below.) 
•  Prophylaxis can be tailored in different ways. This applies to both 
hemophilia A and B. (See Tables  6-2 and  6-6 ). 
•  Differences in disease phenotype as well as differences in indi-
vidual PK handling of factor form the basis of the rationale for 
tailoring prophylaxis to the individual. 
•  Advantages and disadvantages of both fixed prophylaxis regimens 
and tailored prophylaxis regimens are shown in Table  6-5 (fixed-
dose regimens) and Table  6-6 (tailored regimens). There is likely 
no one regimen that is best for all patients and for all economies. 
•  The ultimate goal of all prophylaxis therapy should be the same—
to have no spontaneous bleeding. 
•  See Chapter 11: Outcome Assessment. 
 Variables that affect bleeding phenotype 
•  People with hemophilia exhibit significant phenotypic hetero-
geneity in bleeding; this inter-individual variability is seen even 
among people with severe hemophilia with comparable baseline 
factor levels. 6,17,30 
•  The bleeding phenotype results from the combined effect of the 
individual patient ' s genotypic profile (including hemophilia geno-
type, genetic profiles for all other hemostatic factors, and other 
genetic traits), joint health status, and behavioral characteristics. 
(See Table  6-7 .) 
•  It has been noted that people with hemophilia who suffer recur-
rent bleeds at a young age and develop joint damage (target joints) 
will usually require much higher factor trough levels to prevent 
bleeding in the future. 
•  Inter-individual differences in the balance between positive and 
negative regulators of coagulation lead to differential bleeding 
risks. 49 
•  Furthermore, activity levels can vary greatly over a person ' s life-
time. Young children may be constantly and unpredictably active 
while older children and adults may be much less active and when 
active may engage in planned physical activities less likely to 
cause bleeding. 
•  Consequently, a patient ' s prophylaxis regimen may need to 
change over time, particularly with changes in activity levels. 
Hence, prophylaxis may be individualized over a person ' s lifetime. 
•  Some of this individualization might have to do with individual 
lifestyle; some people who tend to be more sedentary may opt 
for fewer infusions leading to a lower degree of protection, while 
more active individuals may opt for more frequent infusions and 
a higher level of protection. This leads to increased inter-patient 
and intra-patient individualization of prophylaxis as patients age. 
•  All of the factors described above contribute to the wide vari-
ability in clinical phenotype among people with hemophilia. This 
variability in inherent bleeding phenotype is demonstrated in the 
wide range of ages at which children experience their first joint 
bleed, which may vary from <1 year to about 6 years with a me-
dian of around 2 years of age. 50 Age at first joint bleed has been 
shown in several studies to predict bleeding phenotype in later 
years as reflected in subsequent annual clotting factor utilization 
and arthropathy rates, wherein patients who had their first joint 
bleed at a later age required less treatment and developed less 
arthropathy. 50-53 
 6.8  |  Adherence and patient/caregiver education 
•  Despite the benefits of prophylaxis, adherence has traditionally 
been a significant problem. There are many reasons for reduced 
adherence to prophylaxis. The main reason is likely the burden 
of administering CFCs both intravenously and frequently. This 
results in venous access difficulties (particularly in young chil-
dren but also in older adults with significant arthropathy and 
potentially extinguished veins) and child/family resistance to the 
time-consuming nature of conventional prophylaxis. 
•  Another reason for reduced adherence stems from the fact that 
prophylaxis is designed mainly to prevent long-term complications 
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from hemophilia. There may be a lack of comprehension on the 
part of the patient/caregiver of the long-term complications of 
hemophilia that can occur if prophylaxis is not commenced at a 
young age and a lack of appreciation of the benefits of prophy-
laxis. 54 (See Chapter 2: Comprehensive Care of Hemophilia – 
Transition from pediatric to adult care.) 
•  The consequences of reduced adherence are reduced effective-
ness of prophylaxis; in the extreme, reduced adherence leads to 
cessation of prophylaxis and places the patient at significant risk 
of bleeding. This problem of reduced adherence is seen in both 
well-resourced countries as well as in countries with more con-
strained resources. 
•  With SHL CFCs, missed or delayed prophylaxis doses immediately 
increase the bleeding risk; thus missed/delayed doses account 
for a substantial proportion of breakthrough bleeds. 6 With EHL 
CFCs, the consequences of a missed dose may be even greater; 
however, there is much more margin for a dose to be simply de-
layed rather than missed. 
•  EHL CFCs may improve adherence by allowing treatment to be 
administered less often and at less burdensome times (evenings 
rather than mornings and weekends rather than weekdays). This 
is particularly the case with some EHL FIX CFCs. 
•  Emicizumab, which may be administered weekly, biweekly, or 
every 4 weeks, should improve adherence even further; this 
needs to be studied. The impact of other non-factor therapies, 
if they are found to be effective and safe and become clinically 
available, will also need to be studied. 
•  Prophylaxis is a team effort that relies on ongoing patient/care-
giver education and consultation. The hemophilia treatment 
centre care team plays a key role in teaching the patient/family 
about prophylaxis, about the importance of maintaining a paper 
or electronic diary of bleeding episodes and amount of CFC or 
 TA B L E   6 6     Tailoring prophylaxis to patient needs 
 Tailoring approach  Advantages  Disadvantages 
 Pharmacokinetics 
 
•  Involves undertaking at least a minimal PK 
evaluation of patients and then adjusting 
the dose/frequency of factor infusions 
in order to achieve in each patient a 
predetermined factor trough level. 
•  Can be estimated with population PK 
modeling (e.g., WAPPS-Hemo) a  using 
Bayesian analysis 
•  Recognizes that hemophilia patients have 
different PK handling of factor which will 
impact on prophylaxis needs. 
•  Matches the amount of CFCs given to a 
patient with their PK perceived needs, 
ensuring that every patient is receiving a 
sufficient amount of treatment to attain 
similar factor levels. 
•  Does not force patients to experience 
bleeds in order to declare their prophylaxis 
needs. 
•  May result in substantial savings in factor 
consumption as patients would receive 
targeted amounts needed to achieve certain 
factor trough levels. 
•  Allows for individualizing prophylaxis with 
aging as PKs change with patient age. PK 
assessments will require repeating with 
aging 48  
•  Requires patients to undergo at least a 
minimal PK evaluation. 
•  Requires expertise in interpreting results 
of PK. 
•  Focuses solely on one attribute that 
contributes to bleeding (PK handling of 
factor) and ignores other differences 
between patients, including physical activity 
levels. Sports participation may be better 
supported by attention to factor levels at 
the time of participation rather than by 
factor trough levels alone. 
•  May lead to overtreatment in some patients 
who might do well with lower factor trough 
levels, and may lead to undertreatment of 
some patients (e.g., very active patients) 
who might need higher factor trough levels 
 Clinical factors (bleeding phenotype and 
physical activity patterns) 
 
•  Involves selection of a starting regimen, 
which can be of any frequency, and 
patients are carefully monitored for 
bleeding. Dose and frequency are adjusted 
(escalated or de-escalated) as needed to 
suppress excessive clinical bleeding with 
the minimum intensity of prophylaxis 
•  Recognizes that patients with hemophilia 
are heterogeneous, not just in PK handling 
of factor but in many other aspects (some 
unknown) that contribute to bleeding and 
MSK outcomes. 
•  Better matches the amount of prophylaxis 
to the needs of the patient, potentially 
saving at a population level a certain 
amount of CFCs. 
•  Suited to transitional stages in life, e.g., 
escalating prophylaxis in early childhood; 
de-escalating prophylaxis in adulthood. 
•  Allows very young children to become 
accustomed to receiving IV infusions when 
escalating prophylaxis and might allow the 
avoidance of CVADs 
•  Forces patients to experience bleeds to 
declare their bleeding phenotype and 
prophylaxis needs 
•  Depends heavily on the bleeding criteria 
used to adjust treatment. Although some 
patients may tolerate some bleeds without 
long-term joint damage, other patients 
(particularly young children) are much more 
susceptible; in these patients, even one or 
a few bleeds might contribute to long-term 
joint damage. 
•  Puts patients at risk of a serious bleed (e.g., 
ICH) while escalating prophylaxis. 
•  Requires constant adaptation of prophylaxis 
to physical activity patterns which may be 
difficult if physical activity patterns are 
frequently changing 
 Note :  This table is adapted from Carcao (2015). 29  
 Abbreviations: CFC, clotting factor concentrate; CVADs, central venous access devices; ICH, intracranial hemorrhage; IV, intravenous; MSK, 
musculoskeletal; PK, pharmacokinetic. 
 aAvailable at:  http://www.wapps-hemo.org . 47  
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other therapy administered, and about the importance of adher-
ing to the treatment plan. 
•  A key component of prophylaxis has been teaching patients/
families how to infuse intravenous therapies at home; this is re-
ferred to as home therapy. (See Chapter 2: Comprehensive Care 
of Hemophilia – Home therapy.) 
•  Regular checkups throughout a lifetime at the hemophilia treat-
ment centre are important to review the prophylaxis plan to-
gether, including the type of therapy, dosage, and frequency, with 
adjustments according to the patient ' s body weight, bleeding pat-
terns, or other factors. 
•  The above are integral requirements for effective prophy-
laxis. Other requirements for effective prophylaxis are noted in 
Table  6-8 . 
 Recommendation 6.8.1: 
•  For patients with severe phenotype hemophilia A or B on pro-
phylaxis, the WFH recommends that patients/caregivers be 
taught to maintain timely and accurate records of bleeding ep-
isodes and treatment and be followed in hemophilia treatment 
centres. 
 6.9  |  Health economics of prophylaxis 
•  CFCs have generally been quite expensive and have usually ac-
counted for over 90% of the cost of hemophilia care. This has his-
torically led to prophylaxis in the short term being considerably 
more expensive than episodic factor replacement therapy. 
•  Cost of prophylaxis is very sensitive to the cost of CFCs and to 
the intensity (frequency and dose) of prophylaxis. In the long 
term, some of the cost of early and routine prophylaxis may be 
mitigated by decreased healthcare costs in adulthood due to bet-
ter joint health outcomes which may diminish hemarthroses and 
other hemophilic bleeding and therefore reduce the number of 
hospital visits and admissions over the years as well as diminish 
or eliminate the need for costly orthopedic surgery in the future. 
•  By contrast, the direct costs of episodic therapy increase over time 
because numerous joint bleeds lead to joint damage and greater 
susceptibility to bleeding, often resulting in greater need for epi-
sodic CFC infusions and for orthopedic surgery in later years. 
•  There are considerable long-term personal and societal indirect 
costs stemming from people with hemophilia not being on prophy-
laxis, including absenteeism from school or work and limitations in 
vocational opportunities for adults with hemophilic arthropathy. 
•  The development of new therapies for hemophilia will likely have 
considerable economic ramifications. Historically, when new 
therapies are introduced, they tend to be more expensive than 
existing available “older therapies.” 
•  However, they often lead to a drop in the price of “older thera-
pies.” This may lead to the increased uptake of prophylaxis (and 
possibly high-dose prophylaxis) with older CFCs where their re-
duced prices may make conventional prophylaxis much more af-
fordable and more widely available. 
•  Furthermore, many countries have achieved substantial decreases 
in CFC prices through national and regional tenders. 55 
 6.10  |  Low- dose prophylaxis for patients with 
limited access to CFCs 
•  For over two decades, prophylaxis has been the standard of care 
in most well-resourced countries but was seldom undertaken in 
resource-constrained countries as it was deemed to not be af-
fordable at the doses conventionally used. 56 In the early 2000s, 
a number of observational studies showed the benefits of low-
dose factor prophylaxis (i.e., reduced bleeds and better preser-
vation of joint health) over episodic factor replacement therapy, 
without a dramatic increase in cost. 20,57 Consequently, it became 
recognized that low-dose factor prophylaxis should also be the 
preferred way of managing patients even in resource-constrained 
countries. 
 TA B L E   6 8     Basic requirements for effective prophylaxis 
•  Reliable, uninterrupted supply of prophylactic treatments 
(clotting factor concentrates and/or non- factor therapies) 
•  Consistent, expert monitoring (clinical and laboratory) of 
prophylaxis and its effectiveness 
•  Home therapy, preferably administered by the patient/caregiver 
•  Good patient understanding of the value of prophylaxis 
•  Good patient adherence to prophylaxis 
 TA B L E   6 7     Factors that affect bleeding phenotype and contribute to inter- patient phenotypic variability 
 Genetic differences  Non- genetic differences 
•  Hemophilic variants •  Levels and patterns of activity 
•  Levels of other procoagulant and anticoagulant 
proteins 
•  Functional ability and physical coordination (i.e., strength, flexibility, balance, 
stability, mobility) 
•  Inflammatory responses that might impact a person ' s 
susceptibility to joint damage from bleeding 
•  Risk- taking behaviors 
 •  Body build (i.e., muscle status) 
 •  Presence or absence of existing target joints or established hemophilic arthropathy 
 •  Occurrence of trauma 
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•  Showing the benefits of low-dose prophylaxis regimens over 
episodic therapy can be an important step in convincing 
stakeholders in resource-constrained countries to gradually 
transition patients with hemophilia from episodic therapy to 
prophylaxis. 20,43-46,58,59 
•  For those countries with healthcare constraints where prophy-
laxis may potentially be instituted gradually, the WFH ' s position 
is that it is most essential to initiate prophylaxis in young children 
since prevention of target joint development may offer marked 
long-term joint health benefits. 
 Recommendation 6.10.1: 
•  For patients with severe phenotype hemophilia A or B in coun-
tries with healthcare constraints, the WFH still strongly recom-
mends prophylaxis (even when the only option is using lower 
factor doses) over episodic factor therapy to reduce hemar-
throses and other spontaneous and breakthrough bleeding and 
better preserve joint function. 
 6.11  |  New definitions of prophylaxis 
•  With emicizumab and potentially with other non-factor therapies 
in the future, as well as with EHL CFCs (particularly EHL FIX), 
new definitions for prophylaxis are required. Modern prophylaxis 
definitions will need to be inclusive of a wide variety of hemo-
static agents with diverse mechanisms of action and modes of 
administration. 
•  The WFH proposes the following as a new definition of prophy-
laxis based on outcomes rather than doses of therapeutic prod-
ucts or time for initiation of the treatment regimen: the regular 
administration of a hemostatic agent/agents with the goal of pre-
venting bleeding in people with hemophilia while allowing them to 
lead active lives and achieve quality of life comparable to non-he-
mophilic individuals. 
 6.12  |  Future research questions to be addressed 
•  Prophylaxis in the future will create new challenges and need for 
research studies, including: 
 ◦  how to assess the pharmacodynamic effects and pharmacoki-
netics of new therapies, considering that monitoring is more 
complex than simply measuring FVIII or FIX levels; 
 ◦  how to assess the intensity of prophylaxis with emicizumab 
and potentially other non-factor therapies, especially given 
current challenges in monitoring such therapies; 
 ◦  how to manage breakthrough bleeds and surgical procedures 
in patients on prophylaxis with emicizumab and potentially 
other non-factor therapies; 
 ◦  how best to monitor short- and long-term clinical outcomes 
and adverse events with these new products as they may be 
associated with outcomes and adverse events not previously 
encountered; 
 ◦  how to approach inhibitor development (traditionally the 
greatest threat to managing hemophilia) and inhibitor eradica-
tion in the face of emicizumab and potentially other non-fac-
tor therapies; 
 ◦  how best to select a hemostatic therapy or a combination of 
therapies tailored to an individual patient. 
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 7.1  |  Introduction 
•  The primary clinical hallmarks of hemophilia are prolonged spon-
taneous and/or traumatic hemorrhages, most commonly within 
the musculoskeletal system and predominantly intra-articular 
bleeding into the large synovial joints, i.e., the ankles, knees, and 
elbows, and frequently into the shoulder, wrist, and hip joints. 
Hemophilic bleeding is also common in muscle and mucosal soft 
tissues, and less common in other soft tissues, the brain, and inter-
nal organs. Without adequate treatment, such internal bleeds may 
lead to serious complications and even become life-threatening. 
•  Bleeding symptoms and tendencies depend on the patient ' s he-
mophilia severity and clotting factor level. 
•  People with mild hemophilia may not necessarily have abnormal or 
prolonged bleeding problems requiring clotting factor replacement 
therapy until they experience serious trauma or undergo surgery. 
Those with moderate hemophilia may experience occasional spon-
taneous bleeding and/or prolonged bleeding with minor trauma 
or surgery. (See Chapter 2: Comprehensive Care of Hemophilia – 
Table 2-1: Relationship of bleeding severity to clotting factor level.) 
•  In general, the main treatment for bleeding episodes in patients 
with severe hemophilia is prompt clotting factor replacement 
therapy and rehabilitation. However, different types of bleeds 
and bleeding at particular anatomical sites may require more 
specific management with additional measures. It is important to 
consult the appropriate specialists for the management of bleeds 
related to specific sites. (For discussion and recommendations on 
muscle hemorrhages and acute and chronic complications related 
to musculoskeletal bleeding, see Chapter 10: Musculoskeletal 
Complications – Muscle hemorrhage.) 
•  The aim of management of specific hemorrhages is not only to treat 
the bleed, but also to prevent bleed recurrence, limit complications, 
and restore tissue and/or organ function to a pre-bleed state. 
•  Diagnosing a specific bleed correctly is the first step and may re-
quire a combination of clinical evaluation, laboratory assessment, 
and imaging investigations. 
•  In most instances in hemophilia care, therapeutic intervention 
may precede diagnostic workup of the patient. The objective of 
early intervention is to limit the extent of bleeding and to reduce 
bleeding complications. 
•  The amount of hemostatic agent used for bleed treatment and du-
ration of treatment depends on the site and severity of bleeding. 
•  More and more hemophilia A patients are being treated with emi-
cizumab prophylaxis; this therapy is not intended for treatment 
of acute bleeding episodes and breakthrough bleeding (bleeding 
that occurs between prophylactic doses). 
•  For breakthrough bleeding in patients without inhibitors on emi-
cizumab, factor VIII (FVIII) infusion at doses expected to achieve 
hemostasis should be used. To date, no cases of thrombosis or 
thrombotic microangiopathy have been reported in this setting. 1 
•  Patients with inhibitors on emicizumab experiencing acute bleeds 
should be treated with recombinant activated factor VIIa (rFVIIa) 
at doses expected to achieve hemostasis. The use of activated 
prothrombin complex concentrate (aPCC) should be avoided in in-
hibitor patients on emicizumab experiencing breakthrough bleed-
ing. If the use of aPCC is not avoidable, lower doses of aPCC can 
be used with close monitoring of the patient for development of 
thrombosis and/or thrombotic microangiopathy. 2 
•  For inhibitor patients not on emicizumab, standard doses of rFVIIa 
or aPCC should be used. 
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 Patient/caregiver education 
•  Since most bleeds in hemophilia occur outside of hemophilia 
treatment centres, ongoing patient/family caregiver education is 
an essential component of bleed management. 
•  It is important for healthcare providers to educate patients and 
caregivers on bleed recognition and treatment, on hemophilia 
self-care and self-management, and on potential bleeding risks 
and complications associated with different circumstances and at 
different stages of development. (See Chapter 2: Comprehensive 
Care of Hemophilia – Home therapy – Self-management.) 
•  Patient and caregiver education should include instruction on the 
limitations and potential side effects of hemostatic agents and on 
when to consult healthcare providers for guidance and further 
intervention. 
 7.2  |  Joint hemorrhage 
•  The onset of bleeding into a joint is often experienced by pa-
tients as a sensation “aura”, 3 described as a tingling sensation and 
tightness within the joint that precedes the appearance of clinical 
signs. A joint hemorrhage (hemarthrosis) is defined as an episode 
characterized by a combination of any of the following 3 : 
 ◦  increasing swelling or warmth of the skin over the joint; 
 ◦  increasing pain; or 
 ◦  progressive loss of range of motion or difficulty in using the 
limb as compared with baseline. 
•  The loss of range of motion associated with joint hemorrhage lim-
its both flexion and extension. 
 Clotting factor replacement therapy 
•  The goal in the treatment of acute hemarthrosis is to stop the 
bleeding as soon as possible. Treatment should ideally be given as 
soon as the patient suspects a bleed and before the onset of overt 
swelling, loss of joint function, and pain. 4 
•  Clotting factor concentrate (CFC) should be administered imme-
diately at a dose sufficient to raise the patient ' s factor level high 
enough to stop the bleeding. 5-8 (See Table 7-2.) 
•  In the acute setting, bleeding evaluation should include bleeding 
history assessment, physical examination, and pain assessment. 
Ultrasound may be a useful tool to aid in the assessment of early 
hemarthrosis. 5 
•  Response to treatment is demonstrated by a decrease in pain and 
swelling, and an increase in range of motion of the joint. The defi-
nitions listed in Table  7-1 are recommended for the assessment of 
response to treatment of an acute hemarthrosis. 3 
 Recommendation 7.2.1: 
•  Hemophilia patients with severe hemarthrosis should be treated 
immediately with intravenous clotting factor concentrate re-
placement infusion(s) until there is bleed resolution.  CB 
 Recommendation 7.2.2: 
•  Hemophilia patients with moderate or mild joint bleeding should 
be given 1 intravenous infusion of clotting factor concentrate, 
repeated if clinically indicated, depending on the resolution of 
the bleed.  CB 
•  If bleeding continues over the next 6-12 hours, a revised plan 
of assessment including further diagnostic assessment (i.e., fac-
tor assays) and/or intensification of factor replacement therapy 
should be adopted. 
•  Depending on the response to the first dose of treatment, a fur-
ther dose(s) 12 hours after the initial loading dose for hemophilia 
A (if using standard half-life FVIII) or after 24 hours for hemophilia 
B (if using standard half-life factor IX [FIX]) may be required to 
achieve full resolution. 7 (See Table  7-2 .) 
•  The need for a further dose of extended half-life FVIII or FIX will 
also depend on the product half-life. 
•  After an initial moderate to excellent response to hemostatic 
treatment, a new bleed is defined as a bleed occurring over 
72 hours after stopping treatment for the original bleed for which 
treatment was initiated. 3 
 TA B L E   7 1     Definitions of response to treatment 
 Excellent •  Complete pain relief and/or complete resolution of signs of continuing bleeding after the initial infusion within 8 h and not 
requiring any further factor replacement therapy within 72 h after onset of bleeding 
 Good •  Significant pain relief and/or improvement in signs of bleeding within approximately 8 h after a single infusion but 
requiring more than 1 dose of factor replacement therapy within 72 h for complete resolution 
 Moderate •  Modest pain relief and/or improvement in signs of bleeding within approximately 8 h after the initial infusion and requiring 
more than 1 infusion within 72 h but without complete resolution 
 None •  No or minimal improvement, or condition worsens, within approximately 8 h after the initial infusion 
 Notes :  The above definitions of response to treatment of an acute hemarthrosis refer to treatment with standard half- life products in inhibitor- 
negative individuals with hemophilia. These definitions may require modification for inhibitor patients receiving bypassing agents as hemostatic 
coverage and patients who receive extended half- life clotting factor concentrates. Modifications may be required for studies where patients receive 
 a priori multidose clotting factor concentrate infusions for treatment of acute joint/muscle bleeds as part of an enhanced episodic treatment program. 
Adapted from Blanchette et al. (2014). 3 
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•  A target joint is a single joint in which three or more sponta-
neous bleeds have occurred within a consecutive 6-month 
period. 3 
•  If symptoms and signs of bleeding persist despite normally ap-
propriate and adequate interventions, the presence of inhibi-
tors or alternative diagnoses such as septic arthritis or fracture 
should be considered. (See Chapter 8: Inhibitors to Clotting 
Factor.) 
 Pain management 
•  Acute hemarthrosis may be extremely painful, and prompt admin-
istration of clotting factor replacement and effective analgesia 
are key aspects of pain management. 
•  Analgesics for use in people with hemophilia include parac-
etamol/acetaminophen, selective COX-2 inhibitors (but not other 
NSAIDs), tramadol, or opioids. 9-11 (See Chapter 2: Comprehensive 
Care of Hemophilia – Pain management.) 
•  Many patients may require opioid analgesia; any usage of opioids 
should be under the guidance of a pain specialist, as even well-in-
tentioned efforts may lead to medication addiction. 
•  Long-term use of opioid analgesics should be carefully monitored 
but preferably avoided because of the chronic nature of bleeding 
episodes in people with severe hemophilia and the risks of medi-
cation addiction. 
•  See Chapter 2: Comprehensive Care of Hemophilia – Pain 
management. 
 Recommendation 7.2.3: 
•  In hemophilia patients with hemarthrosis, severity of pain 
should be graded and monitored according to the World Health 
Organization (WHO) pain scale.  CB 
 Recommendation 7.2.4: 
•  Hemophilia patients with pain due to hemarthrosis should be given 
analgesic medication according to the severity of the pain.  CB 
 Recommendation 7.2.5: 
•  In hemophilia patients with severe pain, management of such 
pain should include opioids based on clinical symptoms to an 
extent that the patient is comfortable to weight bear or use the 
joint as much as possible without any pain.  CB 
 Adjunctive care 
•  A key element of managing the symptoms of hemarthrosis is 
RICE (rest, ice, compression, elevation). In hemophilia care, im-
mobilization is also considered to be an aspect of this approach; 
therefore, PRICE, which includes the concept of “protection” of 
the injured area, is often recommended. Compression may help 
to reduce the risk of rebleeding. However, as prolonged rest 
can negatively affect joint function through reduction in mus-
cle strength, the acronym POLICE, which replaces “rest” with 
“optimal loading”, has been put forward to encourage clinicians 
to establish a balance between rest, early mobilization, and 
weight-bearing to prevent unwanted complications associated 
with immobilization, while minimizing rebleeding leading to sy-
novitis and cartilage damage. 12 
•  The application of ice has been shown to reduce acute hemarthro-
sis-related pain; however, it has been suggested that a decrease 
in intra-articular temperature could interfere with coagulation in 
the presence of acute tissue lesions. 13,14 The use of ice without 
direct skin contact for short periods of 15-20 minutes soon after 
bleeding occurs is considered acceptable but should not exceed 
6 hours. 13 (See Chapter 2: Comprehensive Care of Hemophilia – 
Adjunctive management.) 
•  During a joint bleed, semi-flexion is usually the most comfortable 
position, and any attempt to change this position often exacer-
bates pain. 15 
•  Depending on the site of the joint bleed, elevating the affected 
joint, if tolerated and comfortable, may help reduce hemarthro-
sis-related swelling. 13 
•  Rest, in the case of a hip, knee, or ankle bleed, or the use of a sling 
for an elbow, shoulder, or wrist bleed, is advisable to immobilize a 
joint with severe bleeding until pain resolves. 
•  As soon as the pain and swelling begin to subside, the patient can 
change the position of the affected joint from a position of rest to 
a position of function, gently and gradually increasing mobiliza-
tion of the joint. 
•  Patients with hip, knee, or ankle joint bleeds should be re-
stricted from weight-bearing until complete pre-bleed joint 
range of motion and function are restored and acute pain 
and inflammation symptoms have dissipated. It is advisable 
to avoid weight-bearing for 1 week, with the use of walking 
aids (e.g., crutches, walker) to assist progressive weight-bear-
ing under the guidance of a member of the comprehensive 
care team with experience in musculoskeletal rehabilitation 
after a bleed. 13 Pain can also be used to guide resumption of 
weight-bearing. 
•  These adjunctive measures will not stop joint bleeding but can 
help manage and reduce symptoms of pain and inflammation. 7 
•  See also Chapter 2: Comprehensive Care of Hemophilia – 
Adjunctive management. 
 Recommendation 7.2.6: 
•  Hemophilia patients with hemarthrosis should be managed using 
the RICE approach (Rest, Ice, Compression, and Elevation) in ad-
dition to clotting factor concentrate replacement. 
•  REMARK : The WFH recognizes that in some regions of the world, 
RICE may be the only initial treatment available or the best treat-
ment available in the absence of an adequate supply of CFCs or 
other hemostatic agents.  CB . 
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 Recommendation 7.2.7: 
•  In hemophilia patients with hemarthrosis, weight-bearing 
should be avoided until the symptoms improve to an ex-
tent that the patient is comfortable to weight bear without 
significant pain.  CB 
 Recommendation 7.2.8: 
•  In hemophilia patients, use of opioid analgesia in managing pain 
should be limited in duration, as much as possible.  CB 
 Physical therapy and rehabilitation 
•  Physical therapy and rehabilitation for the management of pa-
tients with hemophilia refers to the use of flexibility and strength 
training, proprioceptive/sensorimotor retraining, and balance 
and functional exercises to restore or preserve joint and muscle 
function. 16 
•  Thorough assessment of acute joint bleeding followed by physical 
therapy tailored to the individual ' s clinical situation is essential to 
achieve a significant degree of success. 16 
•  Ideally, physical therapy should be undertaken under adequate 
factor or hemostatic coverage. If hemostatic coverage is not avail-
able, physical therapy should be applied cautiously and exercises 
should be initiated judiciously. 
•  It is important to carefully monitor the affected joint throughout 
physical therapy and assess whether hemostatic treatment is 
needed to prevent recurrence of bleeding. 7,17 
•  Rehabilitation should include both active and passive range of 
motion exercises. 
•  The patient should continue active exercises and proprioceptive 
training until complete pre-bleed joint range of motion and func-
tioning are restored and signs of acute synovitis have dissipated. 18 
 Recommendation 7.2.9: 
•  In hemophilia patients with hemarthrosis, physical therapy exer-
cises performed under clotting factor coverage should begin as 
soon as the pain symptoms stop.  CB 
 Recommendation 7.2.10: 
•  In hemophilia patients with hemarthrosis, the aim of physical 
therapy should be to return joint function to the pre-bleed 
state.  CB 
 Arthrocentesis 
•  Arthrocentesis (removal of blood from a joint) may be considered 
for patients with hemophilia experiencing prolonged or worsen-
ing bleeding symptoms including: 
 ◦  tense, painful hemarthrosis that shows no improvement 
within 24 hours of the initial infusion (this is particularly 
the case for bleeding into the hip joint due to the particular 
anatomy of the hip joint); or 
 ◦  clinical suspicion of infection/septic arthritis. 7,19,20 
•  Inhibitors should be considered as a possible reason for persistent 
bleeding despite adequate factor replacement therapy, and the 
presence of inhibitors should be assessed before arthrocentesis 
is attempted. 
•  For hemophilia patients with inhibitors, other appropriate he-
mostatic agents should be used to provide hemostatic coverage 
for the procedure, as needed. 7 (See “Management of bleeding” in 
Chapter 8: Inhibitors to Clotting Factor.) 
•  Arthrocentesis should always be done under strictly aseptic con-
ditions to avoid introducing intra-articular infections. 
•  When necessary, arthrocentesis should only be performed 
under factor coverage, with factor activity levels of at least 
30-50 IU/dL maintained for 48-72 hours. Arthrocentesis should 
not be done in circumstances where such factor coverage 
(or equivalent coverage with other hemostatic agents) is not 
available. 21 
•  A large-bore needle, at least 16 gauge, should be used. The 
joint should be immobilized with mild compression following 
arthrocentesis, and weight-bearing should be restricted until 
the remaining blood is absorbed or absence of pain permits 
mobilization. 
•  Arthrocentesis should be followed by carefully supervised physi-
cal therapy and rehabilitation. 
•  See also Chapter 10: Musculoskeletal Complications. 
 Recommendation 7.2.11: 
•  For hemophilia patients without inhibitors on factor replacement 
therapy presenting with joint hemorrhage and persistent pain, 
arthrocentesis is recommended only if there is a tense, painful 
hemarthrosis or suspicion of infection. Routine arthrocentesis is 
not advised. 
•  REMARK : In many healthcare settings, arthrocentesis is not com-
mon practice because of fear of introducing intra-articular infec-
tion.  CB 
 7.3  |  Central nervous system and 
intracranial hemorrhage 
•  All head injuries, confirmed or suspected, significant headaches 
including headaches lasting for several hours, and somnolence in 
some instances, must be treated as possible intracranial bleeds. 
Sudden severe back pain may be a symptom of bleeding around 
the spinal cord. 
•  In the event of significant head trauma or clinical suspicion of 
central nervous system and/or intracranial hemorrhage, imme-
diate treatment with CFC infusion is required without waiting 
for further symptoms to develop or for laboratory or radiologic 
evaluation. 
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 Recommendation 7.3.1: 
•  In hemophilia patients presenting with suspected central ner-
vous system bleeds or bleed-related symptoms, clotting factor 
replacement therapy should be administered immediately before 
investigations are performed.  CB 
•  Immediately administer appropriate clotting factor replacement 
therapy as soon as significant trauma or symptoms occur, before 
any other intervention, and maintain factor level until etiology is 
defined. If a bleed is confirmed, maintain the appropriate factor 
level for 10-14 days. 22,23 (See Table  7-2 .) 
•  Immediate medical evaluation and hospitalization are required, in-
cluding a computed tomography (CT) scan or magnetic resonance 
imaging (MRI) of the brain and neurological consultation as soon as 
possible. 24,25 Ultrasound examination may be considered in children. 
 Recommendation 7.3.2: 
•  In patients with hemophilia presenting with suspected central 
nervous system bleeding that could be life-threatening, clotting 
factor replacement therapy should be administered immediately 
before investigations are performed and continued until the 
bleed resolves. 
•  REMARK : In patients with hemophilia who have been treated for 
central nervous system bleeding, secondary prophylaxis is rec-
ommended to prevent bleed recurrence.  CB 
•  Intracranial hemorrhage may be an indication for secondary pro-
phylaxis (short-term prophylaxis for 3-6 months or even lifelong), 
especially where a relatively high risk of bleed recurrence has 
been observed (e.g., in the presence of human immunodeficiency 
virus [HIV] infection). 22,26,27 
 7.4  |  Throat and neck hemorrhage 
•  Bleeding into the throat or neck may be due to local pathology, 
trauma, or severe coughing, and may present with swelling or 
pain. This is a medical emergency because it can lead to airway 
obstruction. If indicated, gently elevate the head to help reduce 
airway obstruction due to the hemorrhage. 
•  Treat immediately with CFC to raise the patient ' s factor level 
when significant trauma or bleeding symptoms occur in the throat 
and neck area, without any delay that could occur while awaiting 
full evaluation. (See Table  7-2 .) 
•  Immediate hospitalization and medical evaluation by a specialist 
otolaryngologist is required. 28 
•  Protective factor levels should be maintained until symptoms re-
solve. 28-30 (See Table  7-2 .) 
 Recommendation 7.4.1: 
•  In hemophilia patients with throat and neck bleeding, clotting 
factor replacement therapy should be administered immediately 
and critical care evaluation sought.  CB 
 Recommendation 7.4.2: 
•  In hemophilia patients with throat and neck bleeding, including 
injury of the tongue, clotting factor replacement therapy should 
continue until the bleeding symptoms have resolved.  CB 
•  To prevent oral hemorrhage in patients with severe tonsillitis, 
prophylaxis with CFCs, desmopressin (DDAVP; for those with 
mild or moderate hemophilia A), or antifibrinolytics (epsilon 
aminocaproic acid [EACA] and tranexamic acid) are advised in 
addition to bacterial culture and treatment with appropriate 
antibiotics. 
 Recommendation 7.4.3: 
•  In hemophilia patients with throat and neck bleeding and local 
infection, antifibrinolytics should be started to treat the bleed 
and antibiotics to treat the infection.  CB 
 7.5  |  Gastrointestinal/abdominal hemorrhage 
•  Acute gastrointestinal (GI) hemorrhage may present as hemate-
mesis, hematochezia (rectal passage of fresh blood), or melena. 
•  In a patient with liver disease, the first sign of GI bleeding may 
be hepatic encephalopathy, as the failing liver cannot process the 
high protein load of GI bleeding. 
•  Any sign of GI bleeding and/or acute hemorrhage in the abdomen 
requires immediate medical evaluation. All patients with GI bleeds 
should be hospitalized. 
 Recommendation 7.5.1: 
•  In hemophilia patients with gastrointestinal bleeding, factor lev-
els should be raised immediately and the underlying etiology of 
the bleed identified and treated.  CB 
•  GI bleeds must be treated as soon as possible following injury 
and/or the onset of the earliest symptoms with clotting factor re-
placement therapy to raise the patient ' s factor level, with factor 
levels maintained until hemorrhaging has stopped and the etiol-
ogy of the hemorrhage is defined. 31,32 (See Table  7-2 .) 
 Recommendation 7.5.2: 
•  Hemophilia patients with gastrointestinal bleeding should be 
prescribed antifibrinolytics.  CB 
•  Antifibrinolytics are often effective adjunctive therapy for both 
patients with hemophilia A and hemophilia B. Concurrent use 
with aPCC or prothrombin complex concentrate (PCC) may be 
used with caution in some patients. 
•  Treat the origin of the hemorrhage as indicated. 
•  Monitor hemoglobin levels regularly and treat anemia or shock as 
needed. Perform endoscopy, if clinically indicated, in any patient 
with dropping hemoglobin levels. In GI bleeding, the investigation 
of choice is endoscopy. 
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•  In patients with advanced liver disease, ammonia levels should be 
monitored, and treatment to prevent clinical encephalopathy with 
lactulose or a similar agent should be initiated. 
 Recommendation 7.5.3: 
•  In hemophilia patients with gastrointestinal bleeding, endo-
scopic and radiologic imaging should be performed to identify all 
sites of bleeding.  CB 
 Recommendation 7.5.4: 
•  In hemophilia patients with gastrointestinal bleeding, hemoglo-
bin levels should be monitored regularly.  CB 
•  An acute abdominal (including retroperitoneal) hemorrhage can 
present with abdominal pain and distension and can be mistaken 
for a number of infectious or surgical conditions. It may also pres-
ent as a paralytic ileus. 
•  Abdominal bleeds must be treated immediately to raise and 
maintain the patient ' s factor levels until the etiology can be 
defined. 
•  Perform a clinical assessment of the patient with a physical ex-
amination, pain assessment, and history taking including bleed 
history. An ultrasound and/or CT scan can identify the site and 
extent of abdominal bleeding. 
•  Determine appropriate treatment in consultation with a special-
ist. 28-30 (See Table  7-2 .) 
 7.6  |  Renal hemorrhage 
•  Bleeding in the kidneys (renal hemorrhage) can occur sponta-
neously or following injury. 
•  Urinary tract bleeding may be the first sign of malignancy in the 
bladder, particularly in older patients. 
•  Symptoms may include abdominal pain and swelling, severe flank 
and back pain, and hematuria. 
•  Patients with mild painless hematuria can be treated with com-
plete bed rest and vigorous hydration (3 L/m 2 body surface area/
day), with or without clotting factor replacement as feasible, for 
48 hours unless there is concurrent renal or cardiac impairment. 
Avoid DDAVP when hydrating intensively. 33 
•  All renal bleeding should be treated as urgent. 
 Recommendation 7.6.1: 
•  For hemophilia patients with urinary tract hemorrhage, the site 
of bleeding should be identified and clotting factor replacement 
therapy should be administered immediately.  CB 
 Recommendation 7.6.2: 
•  Hemophilia patients with renal bleeding should be given 
adequate hydration and prescribed bed rest until bleeding 
stops.  CB 
•  If there is pain or persistent gross hematuria, it is important to 
watch for clots and urinary obstruction. 33,34 Avoid use of antifi-
brinolytic agents. 33 
 Recommendation 7.6.3: 
•  In hemophilia patients with renal bleeding, antifibrinolytics 
should not be administered.  CB 
 Recommendation 7.6.4: 
•  In hemophilia patients with renal bleeding, clotting factor re-
placement therapy should continue until the bleeding is re-
solved.  CB 
•  Refer the patient to a urologist for evaluation of a local cause if 
hematuria (gross/macroscopic or microscopic hematuria) persists 
or if there are repeated episodes. (See Table  7-2 .) 
 7.7  |  Ophthalmic hemorrhage 
•  Bleeding in the eye (ophthalmic hemorrhage) is uncommon unless 
associated with trauma or infection of the eye. 
•  Eye bleeds should be treated immediately to raise the patient ' s 
factor level, with factor levels maintained until the etiology of the 
bleed can be defined, followed by appropriate treatment in con-
sultation with a specialist. 28-30 
 Recommendation 7.7.1: 
•  In hemophilia patients with ophthalmic bleeding, clotting factor 
levels should be raised immediately and the patient evaluated by 
an ophthalmologist.  CB 
 Recommendation 7.7.2: 
•  In hemophilia patients with ophthalmic bleeding, regular physical 
examination should be carried out every 6-8 hours for the dura-
tion of the ophthalmic bleed. 
•  REMARK : Imaging may be included as clinically indicated.  CB . 
 Recommendation 7.7.3: 
•  In hemophilia patients with ophthalmic bleeding, treatment 
and monitoring should be continued until the bleeding is 
resolved.  CB 
•  Refer the patient for evaluation by an ophthalmologist as soon as 
possible. (See Table  7-2 .) 
 7.8  |  Oral hemorrhage 
•  The most common causes of bleeding in the mouth (oral hemor-
rhage) are dental extraction, gingival bleeding (often due to poor 
oral hygiene), and trauma. 
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•  Gum bleeding is a sign of inflammatory gum disease (gingivitis) 
and is preventable and treatable in people with hemophilia. It 
is not caused by the underlying congenital bleeding disorder 
itself. 
•  Early referral to a dental professional for assessment and ap-
propriate periodontal treatment and advice will reduce bleeding 
after brushing, prevent progression of gum disease, and reduce 
the likelihood of early tooth loss and risk of associated systemic 
effects. 
•  Other less common causes of bleeding from the mouth may 
include: self-injury, shedding of deciduous (baby) teeth, and re-
cent dental surgery without appropriate hemostatic measures in 
place. 
•  Bleeding following loss of baby teeth is not usually prolonged 
if recognized and treated early. Direct pressure should be ap-
plied on the tooth socket using a damp gauze swab and main-
tained for at least 15-30 minutes. Parents/caregivers should be 
advised that if bleeding persists for longer than 6 hours, they 
should consult their hemophilia treatment centre for additional 
support. 
•  A carefully planned preoperative hemostatic care plan is ad-
vised for patients with hemophilia about to undergo oral sur-
gery or invasive dental procedures to avoid postoperative 
bleeding. 
 Recommendation 7.8.1: 
•  In hemophilia patients with oral bleeding, the site of bleeding 
should be identified and direct pressure and/or sutures applied, 
if possible.  CB 
 Recommendation 7.8.2: 
•  In hemophilia patients with oral bleeding, antifibrinolytics should 
be prescribed and administered at appropriate dosages.  CB 
•  Antifibrinolytic agents should be used with caution in pa-
tients with hemophilia B who are being treated with large 
doses of PCC or in patients with inhibitors being treated with 
aPCC. 35,36 
 Recommendation 7.8.3: 
•  In hemophilia patients with persistent oral bleeding, clotting fac-
tor replacement therapy should be administered along with local 
measures such as sutures and topical adrenaline application to 
stop the bleeding.  CB 
•  Patients who experience prolonged bleeding from the mouth 
should seek early consultation with their hemophilia team in asso-
ciation with the dentist or oral and maxillofacial surgeon to deter-
mine the source and severity of bleeding. 
•  If there has been unexpected bleeding following a carefully 
planned invasive dental procedure, laboratory tests should be 
performed alongside management of oral bleeding to identify 
possible causes, e.g., the presence of an inhibitor or platelet func-
tion defect due to medication. 
•  Persistent oral bleeding should be managed using staged local 
and/or systemic measures including: 
 ◦  direct pressure on the area using a damp gauze swab, main-
tained for at least 15-30 minutes; 
 ◦  local anesthesia with adrenaline/epinephrine to aid local 
vasoconstriction; 
 ◦  sutures for wound closure; 
 ◦  application of local hemostatic agents, e.g., oxidized cellulose, 
thrombin, fibrin sealant, or similar; 
 ◦  use of oral or topical antifibrinolytics as a mouthwash or 
paste 29,30 ; 
 ◦  systemic treatment of choice, e.g., CFC replacement, DDAVP, 
or antifibrinolytic therapy as directed by the hemophilia team; 
and 
 ◦  monitoring of vital signs and treatment for anemia, if required. 
•  Once hemostasis is achieved, stringent postoperative manage-
ment will reduce risk of rebleeding. 
•  Patients with hemophilia should be advised to: 
 ◦  use systemic and/or topical antifibrinolytic agents for 
5-7 days; 
 ◦  refrain from sports and intensive exercises for 3-5 days; 
 ◦  eat a soft diet with no vigorous mouth rinsing for 3-5 days; 
 ◦  refrain from or reduce smoking for at least 24 hours; and 
 ◦  consider use of a soft splint to protect the wound longer term, 
if required. 
•  See also Chapter 2: Comprehensive Care of Hemophilia – Dental 
care and management. 
 7.9  |  Epistaxis 
•  Bleeding from the nose (epistaxis) can occur with injury or irrita-
tion to the nasal mucous membrane. 
•  People with hemophilia may experience frequent and pro-
longed nosebleeds which can be minor nuisances or major events 
that require medical attention in the hospital or emergency room. 
•  Clotting factor replacement therapy is often not necessary unless 
bleeding is severe or recurrent. 28,29 
 Recommendation 7.9.1: 
•  In hemophilia patients with epistaxis, the head should be el-
evated and cold compression applied to the Little ' s area of the 
nose.  CB 
 Recommendation 7.9.2: 
•  In hemophilia patients with epistaxis, nasal packing should be 
avoided as it can cause bleeding when removed. However, in 
practice, nasal packing is used extensively.  CB 
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 Recommendation 7.9.3: 
•  In hemophilia patients with epistaxis, gauze soaked in an anti-
fibrinolytic agent may be used in addition to clotting factor re-
placement therapy.  CB 
•  Patients with acute epistaxis must receive first aid treatment as 
follows: 
 ◦  Place the patient ' s head in a forward position to avoid swal-
lowing of blood and have the patient gently blow out weak 
clots. 
 ◦  Apply firm continuous pressure with a gauze soaked in 
ice water to the anterior nasal septum, i.e., Little ' s area, for 
5-10 minutes. 
 ◦  An antifibrinolytic agent applied locally using a soaked gauze 
is helpful. 
•  Nasal packing is contraindicated because the vascular endo-
thelial lining is destroyed upon removal of the packing material, 
and hemostasis will be challenged. Cauterization is an effective 
alternative. 
•  For epistaxis specifically related to allergies, upper respiratory 
infections, or seasonal changes, administer antihistamines and 
decongestant medications if indicated. 
•  For epistaxis caused by infection, administer antibiotics if 
indicated. 
•  If epistaxis is prolonged or occurs frequently, evaluate for anemia 
and treat appropriately. 
•  For patients with severe and recurrent nosebleeds, special-
ist consultation and preventative measures are recommended. 
Consultation with an otolaryngologist is advisable if nosebleeds 
are persistent or recurrent. 
•  In severe or persistent cases, therapeutic occlusion of the arterial 
supply to the nose may be indicated. 
•  Preventive measures to reduce risk of epistaxis include: 
 ◦  increasing the humidity of the environment; 
 ◦  applying gels (e.g., petroleum jelly or saline drops/gel) to the 
nasal mucosa to preserve moisture, or administering saline 
spray; 
 ◦  adhering to prescribed medications such as antihistamines, 
decongestant medications, and antibiotics as directed. 
 Recommendation 7.9.4: 
•  In hemophilia patients with persistent epistaxis, vital signs and 
hemoglobin levels should be monitored until the bleeding stops 
(usually within 24-48 hours).  CB 
 Recommendation 7.9.5: 
•  In hemophilia patients with recurrent epistaxis, the underly-
ing pathology should be identified immediately and treated. 
Decongestants and antihistamines should help if bleeding is 
related to allergy, and antibiotics should be administered if 
bleeding is related to infection.  CB 
 7.10  |  Lacerations and abrasions 
•  Lacerations and abrasions are external bleeds caused by superfi-
cial or deep cuts or scrapes to the surface of the skin. 
•  Superficial lacerations should be treated with first aid. 
•  For deep lacerations, raise the patient ' s factor level, then suture 
the wound if appropriate. 28-30 (See Table  7-2 .) 
 Recommendation 7.10.1: 
•  In hemophilia patients with lacerations and abrasions, clotting 
factor replacement therapy should be administered and the 
wound sutured immediately, if appropriate, in consultation with 
appropriate surgeons.  CB 
•  Hemostatic coverage should be considered for suture removal, if 
the risk of bleeding is considered high. 
 7.11  |  Soft tissue hemorrhage 
•  A soft tissue hemorrhage (hematoma) occurs in muscles, liga-
ments, tendons, and subcutaneous spaces. 
•  Common soft tissue injuries are often caused by a sprain or strain, 
a blow resulting in a contusion, or overuse of a particular body 
part. Symptoms depend on the site of hemorrhage. 
•  Clotting factor replacement therapy may not be necessary for 
most superficial soft tissue bleeding. The application of firm pres-
sure and ice may be helpful. 
•  Open compartmental hemorrhage, such as in the retroperitoneal 
space, scrotum, buttocks, or thighs, can result in extensive blood 
loss. If this situation is suspected, immediate clotting factor re-
placement therapy is required to decrease bleeding as well as ice 
and adjunct treatment to reduce pain, tissue metabolism, edema, 
and inflammation. 13 
•  Evaluate the patient for severity of hemorrhage and possible dis-
tal neurovascular involvement. Rule out possible trauma to spaces 
containing vital organs, such as the head or abdomen. 
•  Continued evaluation should be considered to avoid compart-
ment syndrome. 28,29 
•  Monitor hemoglobin levels and vital signs regularly until bleeding 
has stopped and/or function is restored. 
•  See also Chapter 10: Musculoskeletal Complications. 
 7.12  |  Practice patterns in CFC replacement 
•  The desired peak plasma factor levels shown in Table  7-2 reflect 
the range of practice in the community and have been part of 
the WFH guidelines since 2005. Over this long period, they have 
helped guide clinical care as well as research, particularly for sur-
gical hemostasis, without any reported safety concerns. More re-
search is needed to critically evaluate these practices. 
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 TA B L E   7 2     Practice patterns: peak plasma factor levels and duration of administration 
 Type of hemorrhage 
 Hemophilia A  Hemophilia B 
 Lower- dose practice 
pattern 
 Higher- dose practice 
pattern 
 Lower- dose practice 
pattern 
 Higher- dose practice 
pattern 
















 Joint  10- 20  1- 2 a   40- 60  1- 2 a   10- 20  1- 2 a   40- 60  1- 2 a  
 Superficial muscle/
no NV compromise 
(except iliopsoas) 
 10- 20  2- 3 a   40- 60  2- 3 a   10- 20  2- 3 a   40- 60  2- 3 a  
 Iliopsoas or deep muscle with NV injury or substantial blood loss 
 Initial  20- 40  1- 2  80- 100  1- 2  15- 30  1- 2  60- 80  1- 2 
 Maintenance  10- 20  3- 5 b   30- 60  3- 5 b   10- 20  3- 5 b   30- 60  3- 5 b  
 Intracranial 
 Initial  50- 80  1- 3  80- 100  1- 7  50- 80  1- 3  60- 80  1- 7 
 Maintenance  20- 40 
 30- 50 
 8- 14 
 4- 7 
 50 
 – 
 8- 21 
 – 
 20- 40 
 30- 50 
 8- 14 
 4- 7 
 30 
 – 
 8- 21 
 – 
 Throat and neck 
 Initial  30- 50  1- 3  80- 100  1- 7  30- 50  1- 3  60- 80  1- 7 
 Maintenance  10- 20  4- 7  50  8- 14  10- 20  4- 7  30  8- 14 
 Gastrointestinal 
 Initial  30- 50  1- 3  80- 100  7- 14  30- 50  1- 3  60- 80  7- 14 
 Maintenance  10- 20  4- 7  50   10- 20  4- 7  30  
 Renal  20- 40  3- 5  50  3- 5  15- 30  3- 5  40  3- 5 
 Deep laceration  20- 40  5- 7  50  5- 7  15- 30  5- 7  40  5- 7 
 Surgery (major) 
 Pre- op  60- 80   80- 100   50- 70   60- 80  
 Post- op c   30- 40 
 20- 30 
 10- 20 
 1- 3 
 4- 6 
 7- 14 
 60- 80 
 40- 60 
 30- 50 
 1- 3 
 4- 6 
 7- 14 
 30- 40 
 20- 30 
 10- 20 
 1- 3 
 4- 6 
 7- 14 
 40- 60 
 30- 50 
 20- 40 
 1- 3 
 4- 6 
 7- 14 
 Surgery (minor) 
 Pre- op  40- 80   50- 80   40- 80   50- 80  
 Post- op d   20- 50  1- 5  30- 80  1- 5  20- 50  1- 5  30- 80  1- 5 
 Notes :  In this table, the desired peak factor levels of CFC replacement shown for treatment of hemorrhages at different anatomical sites represent 
the ranges in global practice patterns depending on available resources. Importantly, it should be recognized that the goal of such treatment is 
effective control of bleeding and should be the same everywhere in the world. Lower CFC replacement levels require much closer observation for 
effectiveness of bleeding control, with a potentially greater chance of requiring additional CFC replacement to achieve the target plasma level as well 
as the hemostatic and musculoskeletal outcomes. 
 Abbreviations: CFC, clotting factor concentrate; NV, neurovascular. 
 a May be longer if response is inadequate.  
 b Sometimes longer as secondary prophylaxis during physical therapy.  
 c The duration of treatment refers to sequential days post-surgery. Type of CFC and patient's response to CFC should be taken into account.  
 d Depending on procedure; the number of doses would depend on the half-life of the CFC used.  
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 All statements identified as recommendations are consensus based, 
as denoted by  CB . 
 This chapter describes inhibitor formation, one of the most serious com-
plications in hemophilia treatment, and provides key definitions and 
guidance on inhibitor screening, testing, and treatment. The manage-
ment of hemophilia A inhibitors and hemophilia B inhibitors is discussed 
separately given the differences in inhibitor incidence and treatment. 
 All recommendations on product use in this chapter are made under 
the assumption that a specific product is available in a particular coun-
try, region, or healthcare system. 
 8.1  |  Introduction 
•  “Inhibitors” in hemophilia are IgG alloantibodies to exogenous 
clotting factor VIII (FVIII) or factor IX (FIX) that neutralize the 
function of infused clotting factor concentrates (CFCs). 1 Inhibitors 
are detected and quantified by the Nijmegen-modified Bethesda 
assay. 
•  The presence of a new inhibitor should be suspected in any pa-
tient with hemophilia who fails to respond clinically to CFC re-
placement therapy, particularly in previously responsive patients. 
(See 8.2 Inhibitor screening, below.) 
•  Inhibitors are more frequently encountered in patients with se-
vere disease than in those with moderate or mild hemophilia, 
and more commonly in patients with hemophilia A than in those 
with hemophilia B. Controlling bleeds is a greater challenge in 
hemophilia patients with inhibitors than in those without inhibi-
tors. Inhibitors to FVIII or FIX are associated with a higher disease 
burden, including increased risk of musculoskeletal complications, 
pain, physical limitations, and treatment challenges, all of which 
may impact a patient ' s physical functioning, capacity for physical 
activities, and quality of life. 
•  In addition, the immune response to FVIII and FIX products is 
poorly understood and, in the absence of evidence, there remain 
areas of evolving and sometimes ambiguous or conflicting infor-
mation on inhibitor management. 
•  Furthermore, while new therapies and strategies for inhibitor 
treatment and eradication are emerging that may offer benefits, 
the long-term clinical outcomes remain unknown. 
•  Significant differences exist between hemophilia A and hemo-
philia B regarding inhibitor incidence, management, and response 
to immune tolerance induction (ITI) and alternative hemostatic 
agents. Therefore, in this chapter, hemophilia A inhibitors and he-
mophilia B inhibitors are discussed separately. 
 Patient/caregiver education 
•  Ongoing patient and family caregiver education and psychoso-
cial support are essential components of the management of 
hemophilia patients with inhibitors given the complexity and 
challenges of this serious complication. It is vital for clinicians, 
patients, caregivers, and the hemophilia treatment centre team 
to maintain good communication through a well-coordinated 
plan of care. 
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 8.2  |  Inhibitor screening 
•  Inhibitors are measured by the Bethesda assay or the Nijmegen-
modified Bethesda assay. 2,3 
•  The definition of a positive inhibitor is a Bethesda titer of 
>0.6 Bethesda units (BU) for FVIII and ≥0.3 BU for FIX. 1,4 
•  Inhibitor measurement may be performed during replacement 
therapy by assays utilizing heat treatment techniques. 5 (See 
Chapter 3: Laboratory Diagnosis and Monitoring – Coagulation 
laboratory testing – Inhibitor testing.) 
•  A low-responding inhibitor is an inhibitor <5.0 BU, whereas a 
high-responding inhibitor is an inhibitor ≥5.0 BU. 
•  Low-responding inhibitors tend to be transient; a transient inhib-
itor is defined as a positive inhibitor that drops below the defini-
tion threshold within 6 months of initial documentation without 
any change in treatment regimen and despite antigenic challenge 
with CFCs. 1 A suspected inhibitor should be confirmed by repeat 
laboratory testing, documenting poor factor recovery and/or 
shortened half-life ( t ½ ) of less than 6 hours in hemophilia A (in the 
case of standard half-life FVIII CFCs 6 ) and 9 hours in hemophilia B 
(in the case of standard half-life FIX CFCs). 7 
•  High-responding inhibitors tend to be persistent and may fall or 
become undetectable after a long period without CFC exposure; 
however, they increase 3-5 days after re-challenge with CFCs (an-
amnestic response). 8 
•  It is critical to detect inhibitors early to ensure appropriate treat-
ment. At least half of inhibitor cases are detected by routine in-
hibitor screening after initial exposures to CFCs, while the rest are 
detected after there is poor clinical response to CFC replacement 
therapy (i.e., when factor recovery and/or half-life are not as ex-
pected) when treating or preventing a bleed. 9 
•  Inhibitor testing should be performed before major surgery and 
if there is suboptimal response to CFC replacement therapy in 
the post-operative period 7,10,11 ; and in any patient who fails to 
respond to adequate CFC replacement therapy after past respon-
siveness. 7,12-14 (See Table  8-1 .) 
•  It is particularly important to perform routine inhibitor screening 
during the time of greatest risk for inhibitor development, at least 
every 6-12 months after CFC replacement therapy is initiated, and 
annually thereafter. While some advocate more frequent screen-
ing, 8 this remains controversial with few data to support the ben-
efit of this approach. 
•  Screening should be performed in any patient, regardless of 
age or disease severity, who is intensively treated (i.e., for more 
than 5 consecutive days) 7,15 and within 4 weeks of the last 
infusion. 
•  See also 8.3 Hemophilia A and FVIII inhibitors – Inhibitor incidence 
and 8.4 Hemophilia B and FIX inhibitors – Inhibitor incidence, 
below; and Chapter 3: Laboratory Diagnosis and Monitoring – 
Coagulation laboratory testing – Inhibitor testing. 
 Recommendation 8.2.1: 
•  For patients with newly diagnosed hemophilia A, the WFH rec-
ommends regular inhibitor screening at least every 6-12 months, 
and then annually. 
•  REMARK : In general, more frequent screening should be consid-
ered for recurrent bleeds or target joints that occur despite stan-
dard factor replacement. 
•  REMARK : This recommendation places greater value on early in-
hibitor diagnosis in patients with severe hemophilia and late di-
agnosis in adulthood in patients with less severe disease, such 
as after intensive exposure to clotting factor concentrate, for 
example after surgery. 
•  REMARK : The requirement for frequent blood draws was consid-
ered in relationship to the potential morbidity of uncontrolled or 
life-threatening bleeds.  CB 
 Recommendation 8.2.2: 
•  For patients with hemophilia A who receive clotting fac-
tor concentrate for more than 5 consecutive days, the WFH 
suggests inhibitor screening within 4 weeks of the last 
infusion.  CB 
 Recommendation 8.2.3: 
•  For patients with hemophilia A who have poor or no response to 
adequate clotting factor replacement therapy, or who have lower 
than expected factor recovery or half-life, the WFH suggests in-
hibitor screening.  CB 
 Recommendation 8.2.4: 
•  For patients with hemophilia A who undergo surgery, the WFH 
suggests inhibitor screening preoperatively in order to deter-
mine if an inhibitor is present which, if present, may require 
non-FVIII-containing therapy.  CB 
 Recommendation 8.2.5: 
•  For patients with newly diagnosed hemophilia B, the WFH rec-
ommends regular inhibitor screening at least every 6-12 months, 
and then annually. 
 TA B L E   8 1     Indications for inhibitor testing 
•  After initial factor exposure 
•  After intensive factor exposure, e.g., daily exposure for more than 
5 days 7,15  
•  For recurrent bleeds or target joint bleeds, despite adequate CFC 
replacement therapy 7,12-14  
•  For failure to respond to adequate CFC replacement therapy 7,12,14  
•  For lower than expected factor recovery or half- life after CFC 
replacement therapy 7,12-14  
•  For suboptimal clinical or laboratory response to CFC 
replacement therapy 9  
•  Before surgery 1,7,11  
•  For suboptimal post- operative response to CFC replacement 
therapy 7,12-14  
 Abbreviation: CFC, clotting factor concentrate. 
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•  REMARK : In general, more frequent inhibitor screening should be 
considered when recurrent bleeds or target joints occur despite 
adequate factor replacement. 
•  REMARK : Because inhibitor incidence is much lower in hemophilia 
B than in hemophilia A, experience and evidence are limited. 
•  REMARK : This recommendation places greater value on early in-
hibitor diagnosis to avoid uncontrolled bleeds and bleeding 
complications. The requirement for frequent blood draws was 
considered in relationship to the potential morbidity of uncon-
trolled or life-threatening bleeds.  CB 
 Recommendation 8.2.6: 
•  For patients with hemophilia B who are treated with clotting 
factor concentrate for more than 5 consecutive days, the 
WFH suggests inhibitor screening within 4 weeks of the last 
infusion.  CB 
 Recommendation 8.2.7: 
•  For patients with hemophilia B who fail to respond to adequate 
clotting factor replacement therapy or who have lower than ex-
pected factor recovery or half-life, the WFH suggests inhibitor 
screening.  CB 
 Recommendation 8.2.8: 
•  For patients with hemophilia B who develop an allergic reaction 
to FIX therapy, including anaphylaxis or nephrotic syndrome, the 
WFH suggests inhibitor screening to determine if an inhibitor is 
present.  CB 
 Recommendation 8.2.9: 
•  For patients with severe hemophilia B who undergo major sur-
gery, the WFH suggests preoperative inhibitor screening.  CB 
 8.3  |  Hemophilia A and FVIII inhibitors 
 Genetic and environmental risk factors 
•  Inhibitors are more frequently encountered in persons with se-
vere hemophilia A than in those with moderate or mild forms of 
the disease. 
•  Other risk factors for inhibitor formation in hemophilia A include 
family history of inhibitors, black African ancestry, Hispanic an-
cestry, genetic variants such as type of mutation and polymor-
phic immune regulatory genes, and high-intensity factor exposure 
(e.g., intensive CFC replacement therapy for a severe early bleed, 
central nervous system bleed, surgery, or trauma). 6,9,10,12,14-20 (See 
Table  8-2 .) 
•  Product type (i.e., plasma-derived FVIII CFCs with or without von 
Willebrand factor or recombinant FVIII CFCs) may contribute to 
inhibitor risk in hemophilia A patients; however, this is not well 
understood and remains controversial. 6,16,21 
 Inhibitor incidence 
•  Inhibitory antibodies develop with a cumulative incidence of 
approximately 30% among previously untreated patients with 
hemophilia A, 16,22 of which 79% occur within the first 20 expo-
sures and the remainder, 21%, within the first 75 exposures. 22 An 
exposure is defined as any 24-hour period in which a FVIII/FIX-
containing product is given. 1,22 
•  Inhibitor rates vary by study and may be underestimated in stud-
ies in which not all subjects are previously untreated patients 
(PUPs) and in whom follow-up is incomplete. 6 
•  The incidence of inhibitors in mild and moderate hemophilia A 
patients is 5%-10%, lower than in those with severe hemophilia. 
These inhibitors typically occur at an older age and often after 
intensive FVIII exposure, e.g., for surgery or severe bleeds. 12,23 In 
most cases, these are low-responding inhibitors; high-responding 
inhibitors are less common in such patients. 24 
•  Most cases of mild and moderate hemophilia A are caused by mis-
sense mutations, which in general are associated with a low rate 
of inhibitor development, although there are a few exceptions. 25 
 Disease burden 
•  Children and adults with persistent FVIII inhibitors typically 
have higher rates of hospitalization, 25 greater treatment costs, 19 
and higher mortality rates than those without inhibitors. 26 
Development of new non-factor replacement therapies may re-
duce this burden in the future. 
•  Bleeding manifestations in mild and moderate hemophilia A pa-
tients with inhibitors are predominantly mucocutaneous, uro-
genital, and gastrointestinal bleeding, reminiscent of bleeding 
symptoms in patients with acquired hemophilia A (due to auto-
antibodies to FVIII). 19 Consequently, the risk of severe complica-
tions or even death from serious bleeding may still be significant 
in these patients. The mortality rate among mild and moderate 
hemophilia A patients with inhibitors is reported to be five times 
greater than among those without inhibitors. 26 
•  Despite the availability of non-factor replacement therapies for 
hemophilia patients who develop inhibitors, there has been a con-
sensus that patients with inhibitors should undergo a trial of ITI, 
when possible, in order to eradicate the inhibitor. 27 
 TA B L E   8 2     Potential risk factors for inhibitors 
•  Race 9,10,15  
•  Family history 9,10,15  
•  Genotype, immune regulatory genes 9,16,17,20,25  
•  Hemophilia severity 9,10,12,14,19,25  
•  CFC replacement intensity 9,12,14-16,18,20  
•  CFC type 6,16,21  
 Abbreviation: CFC, clotting factor concentrate. 
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•  The availability of non-factor replacement therapies (e.g., emi-
cizumab) that are effective in bleed prevention in patients with 
FVIII inhibitors has raised questions about whether such agents 
should be used before, during, after, or in place of ITI. This remains 
controversial, however, as there are insufficient data to resolve 
this question. 
 Management of bleeding 
•  Management of bleeding in hemophilia patients with inhibitors 
must be carried out in consultation with a hemophilia treatment 
centre and staff experienced in inhibitor treatment. 7,28 (See 
Table  8-3 .) 
•  Choice of treatment product should be based on inhibitor titer, 
clinical response to the product, site and nature of the bleed, 7,29 
and product availability by country. 
 Recommendation 8.3.1: 
•  For patients with hemophilia A and FVIII inhibitors who 
develop an acute bleed, the WFH recommends that treat-
ment be based on whether the inhibitor is low-responding or 
high-responding.  CB 
 Therapeutic options for FVIII inhibitor patients 
 CFC replacement therapy 
•  For low-responding inhibitors, FVIII CFC replacement ther-
apy is preferred for acute bleeds if measurable factor levels are 
achieved. 7,29,30 Careful monitoring for clinical efficacy is needed, 
as higher doses may be required to achieve hemostasis. 
•  In the absence of a rational and validated dosing algorithm, the 
following formula is used to estimate the amount of FVIII needed 
as a loading dose to neutralize the inhibitor 31 : 
 ◦  [body weight (kg) × 80 × [(1 − hematocrit) × antibody titer 
(BU)] 
•  An additional 50 IU/kg above the calculated loading dose is added 
to achieve a measurable FVIII activity. 31 
•  FVIII levels should be measured 15 minutes after completion of 
the bolus, and adjustment to reach target levels is necessary be-
cause there is substantial individual variation. 31 
•  For high-responding inhibitors, bypass agent therapy (recombi-
nant activated factor VIIa [rFVIIa] or activated prothrombin com-
plex concentrate [aPCC]) or porcine FVIII should be used to treat 
bleeds. 
 Recommendation 8.3.2: 
•  For patients with hemophilia A and inhibitors who have acute 
bleeds, the WFH recommends FVIII concentrate for those with 
low-responding inhibitors, and a bypassing agent (recombinant 
factor VIIa [rFVIIa] or activated prothrombin complex concen-
trate [aPCC]) for those with high-responding inhibitors. 
•  REMARK : In those receiving non-factor therapy for prophylaxis 
(e.g., emicizumab), the WFH prefers rFVIIa over aPCC because of 
the risk of thrombotic microangiopathy when aPCC is used with 
emicizumab. 
•  REMARK : In patients receiving emicizumab who receive FVIII con-
centrate, the WFH recommends bovine reagent chromogenic 
FVIII assays (bovine FX in kit reagent) to measure plasma FVIII:C 
activity and inhibitor titer levels. 
•  REMARK : Caution is urged when rFVIIa is used in patients re-
ceiving emicizumab who have risk factors for thrombosis (e.g., 
past venous thromboembolism, obesity, smoking, chronic in-
fection, inflammation) due to the risk of acute non-ST segment 
elevation myocardial infarction (non-STEMI) and pulmonary 
embolism.  CB 
•  For patients with high-responding inhibitors whose titers have 
fallen to undetectable or low levels, standard FVIII CFC replace-
ment may be used in an emergency for up to 3-5 days, at more 
frequent dosing due to the shorter half-life, until an anamnestic 
response occurs. When the latter occurs, further treatment with 
FVIII CFCs is typically no longer effective, 7,29 and bypass agent 
therapy is needed. This underscores the need for close FVIII 
monitoring. 
•  The factor substitution therapy, emicizumab, is increasingly used to 
prevent hemorrhage in FVIII inhibitor patients. 32,33 This agent is ef-
fective for  preventing bleeds (prophylaxis) in hemophilia A inhibitor 
patients but is not indicated for  treating bleeds. Thus, breakthrough 
bleeds require treatment with FVIII CFCs (for low-responding in-
hibitors) as described above, or hemostatic bypassing agents (for 
 TA B L E   8 3     Treatment of acute bleeds in hemophilia A patients 
with inhibitors 
 Hemophilia A 
 Low- responding 
inhibitors 
 High- responding 
inhibitors 
 Agent •  FVIII 31  , a  •  rFVIIa or aPCC 33,40,47  , b  
or FVIII 39  , c  
 Monitoring •  FVIII activity 
(FVIII:C) assay 
•  Thromboelastography 
or thrombin generation 
assay 46  , d  
 Abbreviations: aPCC, activated prothrombin complex concentrate; 
FVIII, factor VIII; FVIII:C, FVIII activity; rFVIIa, recombinant activated 
factor VIIa. 
 a Will require higher, more frequent dosing if half- life is shortened.  
 b In patients on emicizumab prophylaxis, aPCC should be avoided 
or used with caution at lower doses because of the thrombotic 
microangiopathy risk (black box warning). Caution is also urged when 
rFVIIa is used in patients on emicizumab who have risk factors for 
thrombosis because of risk of myocardial infarction or pulmonary 
embolism.  
 c In patients with high- responding inhibitors with a currently low 
inhibitor titer, FVIII may be considered, with close monitoring for an 
anamnestic response.  
 d The thrombin generation assay is not state- of- the- art monitoring and 
is unavailable in most laboratories, but increasingly being used to assess 
response.  
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high-responding inhibitors), as described below. Conventional by-
passing agents include rFVIIa and aPCC, which have been shown to 
be effective as prophylaxis 34,35 and for treatment of bleeds. 
 Conventional hemostatic bypassing agents 
•  Treatment with bypassing agents typically consists of one dose of 
aPCC or two doses of rFVIIa. The efficacy of two doses of rFVIIa 
(90-270 μg/kg) or one dose of aPCC (75-85 unit/kg) is compa-
rable in the management of joint bleeding. 36 Notably, however, 
some patients may respond better to one agent than the other, 
highlighting the need to individualize therapy. 30,36 (See Table  8-3 .) 
•  However, if hemostasis is unsatisfactory with rFVIIa or aPCC as 
single agents, each may be alternated every 6 hours. 37,38 (See 
Table  8-4 .) 
•  Combination/sequential bypass agent treatment should be used 
only in treatment centres with extensive experience in managing 
hemophilia patients with inhibitors; close monitoring for throm-
bosis and disseminated intravascular coagulation is required. 
•  It is estimated that aPCC leads to an anamnestic response in ap-
proximately 30% of patients with FVIII inhibitors due to the pres-
ence of FVIII in aPCC. 39 
•  While rFVIIa or aPCC may be used to treat bleeds in both hemo-
philia A and B patients with inhibitors, there has been concern 
about using aPCC, which contains FIX, in patients with FIX inhib-
itors who manifest anaphylaxis to FIX. This, however, is not an 
issue for patients with FVIII inhibitors. 
•  Caution : Thrombosis or thrombotic microangiopathy may occur in 
patients receiving emicizumab who are also receiving aPCC. 33,40 
Thus, aPCC should be avoided in patients on emicizumab except 
in patients unresponsive to rFVIIa or when rFVIIa is unavailable, 
and with aPCC dosing not above 50 IU/kg and no more than 
100 IU/kg total per day. 
 Recommendation 8.3.3: 
•  For patients with hemophilia A and low-responding inhibitors 
who develop an acute bleed, the WFH recommends a FVIII-
containing product or, if the hemostatic response is poor, 
the WFH recommends rFVIIa or aPCC. For those receiving 
emicizumab prophylaxis who develop an acute bleed, the WFH 
prefers rFVIIa over aPCC to avoid the risk of thrombotic 
microangiopathy. 
•  REMARK : Caution is urged when rFVIIa is used in patients receiv-
ing emicizumab who have risk factors for thrombosis (e.g., past 
venous thromboembolism, obesity, smoking, chronic infection, 
inflammation) due to the risk of acute non-STEMI and pulmonary 
embolism. 
•  REMARK : The WFH recommends bovine reagent-based chromo-
genic FVIII assays (bovine FX in kit reagent) to measure plasma 
FVIII:C activity and inhibitor titer levels.  CB 
 Recommendation 8.3.4: 
•  For patients with hemophilia A and high-responding FVIII in-
hibitors receiving emicizumab who develop an acute bleed, the 
WFH prefers rFVIIa over aPCC to avoid the risk of thrombotic 
microangiopathy. 
•  REMARK : Caution is urged when rFVIIa is used in patients receiv-
ing emicizumab who have risk factors for thrombosis (e.g., past 
venous thromboembolism, obesity, smoking, chronic infection, 
inflammation) due to the risk of arterial thromboembolism, e.g., 
acute non-STEMI and pulmonary embolism. 
•  REMARK : The WFH recommends bovine reagent-based chromo-
genic FVIII assays (bovine FX in kit reagent) to measure plasma 
FVIII:C activity and inhibitor titer levels.  CB 
 Emicizumab 
•  The factor substitution therapy, emicizumab, a bispecific mono-
clonal antibody and FVIII mimic, has been licensed for bleed pre-
vention in patients with hemophilia A with and without inhibitors. 
Patients on emicizumab who experience breakthrough bleeds 
require episodic treatment with FVIII CFCs or with hemostatic 
bypassing agents, as described above. 
•  Several phase 3 clinical trials and post-marketing experience have 
shown that emicizumab is effective prophylaxis in adults and chil-
dren with inhibitors. 33,41–43 As emicizumab is injected subcutane-
ously every 1, 2, or 4 weeks, the burden of prophylaxis is much 
less than with bypassing agents. Emicizumab reduces morbidity, 
complications, and hospitalization, and is cost-effective. 41 
•  Prophylaxis dosing with emicizumab consists of an induction pe-
riod of 3.0 mg/kg/week for 4 weeks by subcutaneous injection. 
This is followed thereafter by 1.5 mg/kg/week or alternative dos-
ing schedules including 3 mg/kg every 2 weeks or 6 mg/kg every 
4 weeks. 41–44 
•  As emicizumab interferes with the measurement of FVIII:C and 
FVIII inhibitors using the one-stage FVIII assay, a specific chro-
mogenic assay using bovine reagents is used to detect inhibitors 
to FVIII. 45,46 
 Recommendation 8.3.5: 
•  For patients with hemophilia A and inhibitors who receive emi-
cizumab, the WFH recommends bovine chromogenic assays (bo-
vine FX in kit reagent) to monitor inhibitor levels.  CB 
 TA B L E   8 4     Sequential bypass agent therapy alternating rFVIIa 
and aPCC 37 
 6:00  AM  90 μg/kg rFVIIa 
 9:00  AM  50 U/kg aPCC 
 12:00  PM  90 μg/kg rFVIIa 
 3:00  PM  50 U/kg aPCC 
 6:00  PM  90 μg/kg rFVIIa 
 9:00  PM  50 U/kg aPCC 
 12:00  AM  90 μg/kg rFVIIa 
 3:00  AM  50 U/kg aPCC 
 6:00  AM  90 μg/kg rFVIIa 
 Abbreviations: aPCC, activated prothrombin complex concentrate; 
rFVIIa, recombinant factor VIIa. 
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•  Close monitoring of clinical response to emicizumab and labora-
tory monitoring of inhibitor titer level is advised with a chromo-
genic Bethesda assay using bovine reagents. 
•  In patients receiving emicizumab who have risk factors for throm-
bosis, e.g., past venous thromboembolism, obesity, smoking, chronic 
infection, or inflammation, rFVIIa should be used with caution due 
to the potential risk of acute non-STEMI and pulmonary embolism. 47 
 Recommendation 8.3.6: 
•  For patients with hemophilia A and inhibitors receiving emi-
cizumab, the WFH recommends close clinical monitoring for 
thrombosis, adverse reactions, and thrombotic microangiopathy. 
•  REMARK : Caution is urged when rFVIIa is used in patients receiv-
ing emicizumab who have risk factors for thrombosis (e.g., past 
venous thromboembolism, obesity, smoking, chronic infection, 
inflammation) due to the risk of acute non-STEMI and pulmonary 
embolism.  CB 
 Recommendation 8.3.7: 
•  As emicizumab is used to prevent, but not treat, acute bleeds in 
patients with hemophilia A and inhibitors, the WFH recommends 
clotting factor replacement therapy for acute bleeds.  CB 
 Recommendation 8.3.8: 
•  For patients with hemophilia A and inhibitors receiving emici-
zumab who have an acute bleed, the WFH recommends clotting 
factor replacement therapy including FVIII for those with low-re-
sponding inhibitors; the WFH prefers rFVIIa over aPCC for those 
with high-responding FVIII inhibitors due to the risk of throm-
botic microangiopathy. 
•  REMARK : Caution is urged when rFVIIa is used in patients receiv-
ing emicizumab who have risk factors for thrombosis (e.g., past 
venous thromboembolism, obesity, smoking, chronic infection, 
inflammation) due to the risk of acute non-STEMI and pulmonary 
embolism.  CB 
 Recommendation 8.3.9: 
•  For patients with hemophilia A and inhibitors receiving emici-
zumab who have an acute bleed, the WFH prefers rFVIIa over 
aPCC, because of the risk of thrombotic microangiopathy. 
•  REMARK : The WFH suggests following black box warnings for emi-
cizumab and maintaining vigilance as new evidence develops. 
•  REMARK : Caution is urged when rFVIIa is used in patients receiv-
ing emicizumab who have risk factors for thrombosis (e.g., past 
venous thromboembolism, obesity, smoking, chronic infection, 
inflammation) due to the risk of acute non-STEMI and pulmonary 
embolism. Thrombotic risks may last for up to 6 months during 
which plasma levels of emicizumab may persist.  CB 
 Therapies in clinical trials 
•  Extended half-life rFVIIa may have a role in the management of 
bleeds in hemophilia patients with inhibitors, although investiga-
tions have been in vitro and early-phase clinical trials. 48,49 
•  Non-factor therapies such as fitusiran, an investigational RNA 
interference agent that targets antithrombin (siRNA-AT), 50 and 
tissue factor pathway inhibitors (anti-TFPI), 51 are in clinical trials 
on bleed prevention in patients with inhibitors. These are not ex-
pected to be effective in episodic treatment of bleeds. 
 Surgery and invasive procedures 
•  Inhibitor testing of patients with hemophilia of all types of 
severity is advised prior to surgery and invasive procedures. 
Special precautions must be taken in hemophilia patients with 
inhibitors undergoing surgery: factor coverage, bypass agent 
treatment, and follow-up must be determined and planned in 
advance. 
•  Close monitoring of clinical response to bypass agent therapy 
is required, specifically monitoring for safety, i.e., thrombosis or 
consumptive coagulopathy. 
•  Once hemostasis is achieved and maintained on a selected regi-
men for 3-5 days, these agents may be tapered over 1-3 weeks. 
However, it is recognized that the dose and taper schedule must 
be individualized for each patient, as variability exists in individual 
response to bypass agent therapy. 
•  Adjusted-dose continuous infusion is another option in surgery 
and invasive procedures, for which clearance should be calculated 
every day with dose adjustment accordingly. 52 
•  Combination/sequential bypass agent treatment should be con-
sidered in those with poor response to one bypassing agent. 
Sequential use (i.e., alternating rFVIIa and aPCC every 3 hours) 
has been shown to improve efficacy over single bypass agent 
therapy and allows for lower total daily dose of aPCC, 37,38 po-
tentially reducing thrombotic risk. Sequential regimens should be 
used only in treatment centres with extensive experience in man-
aging hemophilia patients with inhibitors, with close monitoring 
for thrombosis and disseminated intravascular coagulation. (See 
Table  8-4 .) 
 Recommendation 8.3.10: 
•  For patients with hemophilia A and low-responding FVIII inhib-
itors who undergo surgery or an invasive procedure, the WFH 
suggests higher, more frequent FVIII product dosing than usual 
due to the short half-life of FVIII. 
•  REMARK : The WFH also recognizes adjusted-dose FVIII continu-
ous infusion as an option.  CB 
 Recommendation 8.3.11: 
•  For patients with hemophilia A and high-responding FVIII inhib-
itors who undergo surgery or an invasive procedure, the WFH 
recommends bypass agent therapy (rFVIIa or aPCC) at the dis-
cretion of the clinician. If single-agent bypass fails, sequential 
bypass agent treatment, i.e., rFVIIa alternating with aPCC, is 
another therapeutic approach. The WFH also recommends close 
clinical monitoring for thrombosis.  CB 
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 Recommendation 8.3.12: 
•  For patients with hemophilia A and inhibitors receiving emi-
cizumab who undergo major surgery or an invasive procedure, 
the WFH recommends a FVIII-containing product for those 
with low-responding inhibitors. The WFH prefers rFVIIa over 
aPCC for those with high-responding inhibitors due to the risk 
of thrombotic microangiopathy. The WFH makes no recommen-
dations on specific dose, frequency, or duration as there are in-
sufficient data. 
•  REMARK : Caution is urged when rFVIIa is used in patients receiv-
ing emicizumab who have risk factors for thrombosis (e.g., past 
venous thromboembolism, obesity, smoking, chronic infection, 
inflammation) due to the risk of acute non-STEMI and pulmonary 
embolism.  CB 
 Recommendation 8.3.13: 
•  For patients with hemophilia A and inhibitors receiving emici-
zumab who undergo minor surgery or an invasive procedure, the 
WFH recommends either low-dose or no clotting factor replace-
ment therapy. 
•  REMARK : Caution is urged when rFVIIa is used in patients receiv-
ing emicizumab who have risk factors for thrombosis (e.g., past 
venous thromboembolism, obesity, smoking, chronic infection, 
inflammation) due to the risk of acute non-STEMI and pulmonary 
embolism.  CB 
 Recommendation 8.3.14: 
•  For patients with hemophilia A and inhibitors receiving emi-
cizumab who undergo major surgery or an invasive pro-
cedure, the WFH recommends close clinical monitoring 
for thrombosis, consumptive coagulopathy, or thrombotic 
microangiopathy.  CB 
 Recommendation 8.3.15: 
•  For patients with hemophilia A and inhibitors who use bypass 
agent therapy, the WFH recommends clinical monitoring and 
consideration for laboratory monitoring with thrombin genera-
tion and other coagulation tests, but more data are needed to 
recommend the latter.  CB 
 Immune tolerance induction 
•  Inhibitor eradication by immune tolerance induction therapy is 
successful in 70%-80% of patients with severe hemophilia A. 53-55 
•  Response to ITI may be less favourable in patients with moderate/
mild hemophilia A. 7,17 
 Recommendation 8.3.16: 
•  For patients with hemophilia A who develop persistent low-re-
sponding inhibitors, the WFH suggests that immune tolerance 
induction (ITI) be considered.  CB 
•  Successful ITI is defined as a persistently negative Bethesda titer, 
accompanied by normal pharmacokinetics, including factor recov-
ery >66% and half-life >6 hours for standard FVIII CFCs. Once 
successful ITI is achieved, FVIII prophylaxis may be initiated or 
resumed. 
•  There is general consensus that failure of ITI is the inability to 
achieve successful tolerance within 2-3 years of initiation of an 
ITI regimen. 27 
 Recommendation 8.3.17: 
•  For patients with hemophilia A and persistent inhibitors who fail 
immune tolerance induction (ITI) or never underwent ITI, the 
WFH recommends emicizumab prophylaxis over bypass agent 
prophylaxis (rFVIIa or aPCC), as emicizumab is more effective in 
bleed prevention and simpler to administer, as it is given weekly 
and subcutaneously.  CB 
•  When to initiate ITI has been a topic of debate. Registry data from 
the 1990s and 2000s showed success was highest when ITI was 
begun in patients with low inhibitor titers (<10 BU). Thus, clini-
cians adopted a policy of waiting to start ITI until inhibitor titers 
had fallen to <10 BU; however, more recently, clinicians have 
begun to initiate ITI immediately after inhibitor detection no mat-
ter the titer, with good response. 56 
•  The optimal regimen (product or dose) for ITI remains to be de-
fined. In the International ITI Trial, there was no difference in 
efficacy between a low-dose/low-frequency regimen (50 IU/kg 
FVIII 3 times weekly) and a high-dose/high-frequency regimen 
(200 IU/kg daily), but the low-dose/low-frequency regimen re-
quired a longer time to achieve tolerance and more bleeds oc-
curred during that period, particularly in the first 3-6 months of 
ITI. For this reason, the trial was stopped early, 57 with subsequent 
clinician preference for the high-dose/high-frequency regimen. 
•  While on ITI, if patients experience frequent bleeding, bypass 
agent prophylaxis (rFVIIa, aPCC) or emicizumab prophylaxis may 
be instituted. Emicizumab prophylaxis has been associated with a 
significantly greater reduction in bleeding rates than bypass agent 
prophylaxis. 33 
•  It may be possible to delay or avoid ITI altogether with emici-
zumab prophylaxis, given the very low bleeding rates seen with 
this agent, but controversy continues and data are scarce. (See 
“Therapeutic options for FVIII inhibitor patients – Emicizumab” 
above.) 
•  Few data exist on the use of extended half-life factor therapies or 
ancillary non-factor therapies for ITI. Preliminary data from small 
case series and observational studies have shown that extended 
half-life CFCs are effective in some patients with inhibitors, in-
cluding those with high-responding inhibitors and those who have 
previously failed ITI with standard half-life CFCs or were never 
tolerized, and may shorten duration of ITI. 17,59,60 Data from a 
small case series found FVIII 100 IU/kg three times weekly plus 
emicizumab prophylaxis is safe and associated with a decline in 
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inhibitor titer. 61 Larger, randomized studies are needed to confirm 
these findings. 
•  Because ITI requires frequent infusions (up to once daily), it gen-
erally requires good venous access. In young children with small 
veins and/or poor access, a central venous access device (CVAD) 
is usually required for ITI. However, CVAD use is associated with 
complications such as infection and/or thrombosis. For this rea-
son, emicizumab, which is administered subcutaneously and re-
quires no IV access, has been considered a simpler option than 
standard ITI and, it may allow for lower dose/lower frequency 
FVIII CFC infusions when used with ITI or instead of ITI, although 
this is unproven. This remains controversial as there are no data 
regarding inhibitor risk if episodic CFC replacement therapy is re-
quired for breakthrough bleeds during emicizumab prophylaxis. 
•  Whether emicizumab should be initiated before, during, after, or in-
stead of ITI is unknown, 62 and answering this question will require 
clinical trials. As emicizumab differs biochemically from FVIII, many 
questions remain regarding its long-term impact on joint pathology, 
immunogenicity, and cost-effectiveness in non-inhibitor patients. 
•  Although there has been interest in the use of immunosuppres-
sive and immunomodulatory therapies in hemophilia patients 
with inhibitors, the role of these agents is not yet defined, and as 
there is no consensus regarding these agents in the management 
of inhibitor patients, clinical trials are needed. 
 FVIII prophylaxis after immune tolerance induction 
•  After successful ITI in hemophilia A patients with inhibitors, FVIII 
prophylaxis with close monitoring of clinical response should be 
initiated. 
•  At least one extended half-life CFC, rFVIIIFc, has been evaluated 
for its tolerogenic potential in the prevention of inhibitor forma-
tion and in the induction of immune tolerance. At this time, data 
on the impact of extended half-life therapies are limited. 58,60,63 
 Product switching 
•  While there is controversy regarding inhibitor development in 
those switching CFC products, including rare case reports, data 
from large studies indicate there is no evidence supporting in-
creased risk. 64-66 
 Recommendation 8.3.18: 
•  For patients with hemophilia A who switch to another type 
or brand of factor product, the WFH has no preference for 
the choice of specific type of therapy, as current evidence in-
dicates product switching does not increase risk of inhibitor 
development. 
•  REMARK : The WFH encourages product choice based on potential 
advantages, such as simpler administration, safety, efficacy, and 
personal preferences. 
•  REMARK : The WFH supports prospective data collection on inhib-
itor formation by product, particularly before and after switching 
products.  CB 
 Recommendation 8.3.19: 
•  For patients with severe hemophilia A and inhibitors, the WFH 
recommends emicizumab over bypass agent prophylaxis to re-
duce bleeding episodes, as emicizumab appears to be superior to 
bypass prophylaxis.  CB 
 8.4  |  Hemophilia B and FIX inhibitors 
 Genetic and environmental risk factors 
•  FIX inhibitors are almost exclusively seen in patients with severe 
hemophilia B and very rarely in the milder forms. 67 
•  Inhibitors in patients with severe hemophilia B are rare and occur 
most commonly in those with null variants, in which no endoge-
nous clotting factor is produced, in most cases due to large dele-
tion, frame-shift, and nonsense variants. 67,68 There is no known 
ancestral predilection to inhibitor development in hemophilia B. 
•  Inhibitor formation in hemophilia B is not thought to be related 
to type of FIX CFC, and it has been reported in those receiving 
plasma-derived and recombinant FIX CFCs alike. 
 Inhibitor incidence 
•  Inhibitor formation in patients with hemophilia B occurs infre-
quently, with a cumulative incidence of up to 5%. 69,70 
•  The development of an FIX inhibitor is considered the most seri-
ous complication in patients with hemophilia B, 9 due not only to 
loss of response to FIX replacement, but also to the associated 
risks of anaphylaxis and nephrotic syndrome. 67 
•  Inhibitor detection in hemophilia B is similar to that in hemophilia 
A, with most inhibitors occurring after a median of 9-11 expo-
sures, and before 20 exposures, typically before 2 years of age. 18 
•  Treatment strategies for FIX inhibitors are similar to those for 
FVIII inhibitors; specifically, they focus on controlling hemostasis 
and eradicating the inhibitor. 
•  It is recommended that because of the severity of complica-
tions, patients with hemophilia B should be followed closely and 
screened for inhibitors every 6-12 months after initiating CFC re-
placement therapy, and annually thereafter. 
 Disease burden 
 Anaphylaxis to FIX 
•  Inhibitor formation in patients with hemophilia B is overall asso-
ciated with a similar disease burden as in hemophilia A but may 
also be associated with allergic reaction to FIX CFCs. Anaphylaxis 
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occurs in 50% of hemophilia B patients with inhibitors, 20 and 
more frequently in those with null mutations. Such reactions may 
be the first symptom of FIX inhibitor development. 67 
•  Newly diagnosed severe hemophilia B patients, particularly those 
with a family history of severe hemophilia B with inhibitors and/
or with genetic variants predisposing to inhibitor development, 
should be treated in a clinic or hospital setting capable of manag-
ing severe allergic reactions for the initial 10-20 exposures to FIX 
CFCs, with emergency equipment available to treat anaphylaxis. 67 
Reactions may also occur later but may be less severe. 20,71 
 Recommendation 8.4.1: 
•  For patients with hemophilia B who develop anaphylaxis to FIX ther-
apy, the WFH recommends screening for an inhibitor to FIX, as an 
allergic reaction may be the first sign of inhibitor development.  CB 
 Recommendation 8.4.2: 
•  For patients with hemophilia B and a family history of inhibitors 
or risk factors for inhibitor development, the WFH recommends 
monitoring initial infusions in a clinic or hospital setting capable 
of managing severe allergic reactions.  CB 
 Recommendation 8.4.3: 
•  For patients with hemophilia B who develop anaphylaxis to FIX 
therapy, the WFH recommends screening for nephrotic syn-
drome, as it is more common in FIX inhibitor patients with aller-
gic reactions to FIX.  CB 
 Recommendation 8.4.4: 
•  For patients with hemophilia B and inhibitors and an allergic re-
action/anaphylaxis to FIX therapy, the WFH recommends rFVIIa 
to treat acute bleeds but is against use of aPCC as it contains FIX 
and may cause or worsen an allergic reaction. 
•  REMARK : For patients with hemophilia B and inhibitors and allergic 
reaction to FIX therapy, the WFH indicates there are insufficient 
data to recommend desensitization by small, repeated doses of 
FIX, intravenously or subcutaneously, and recognizes that in 
some, this approach may worsen an allergic reaction or cause ana-
phylaxis. If undertaken, FIX desensitization should be performed 
with caution and under close supervision by experts only.  CB 
 Recommendation 8.4.5: 
•  For patients with hemophilia B and inhibitors who develop ana-
phylaxis to FIX therapy, the WFH recommends bypass therapy 
with rFVIIa over aPCC, as aPCC contains FIX and may cause or 
worsen an allergic reaction.  CB 
 Management of bleeding 
•  Management of bleeding in hemophilia patients with inhibitors 
must be carried out in consultation with a hemophilia treatment 
centre and staff experienced in inhibitor treatment. 7,28 
•  Treatment of bleeding in hemophilia B patients with inhibitors 
should be individualized. 67 Choice of treatment product should be 
based on inhibitor titer, clinical response to the product, previous 
infusion reactions, site and nature of the bleed, 7,29 and product 
availability by country. 
 Recommendation 8.4.6: 
•  For patients with hemophilia B and inhibitors who develop an 
acute bleed, the WFH recommends treatment based on whether 
the inhibitor is low-responding or high-responding and whether 
there is a history of allergic reactions.  CB 
 Therapeutic options for patients with FIX inhibitors 
 CFC replacement therapy 
•  For those with low-responding inhibitors, specific FIX CFC re-
placement therapy may be used if there is adequate inhibitor 
neutralization to control bleeding. Because allergic reactions and 
anaphylaxis may occur in up to 50% of hemophilia B patients with 
inhibitors, 20 close monitoring is essential. 
 Recommendation 8.4.7: 
•  For patients with hemophilia B and low-responding FIX inhib-
itors, the WFH recommends use of a FIX-containing product 
to treat acute bleeds, as long as there is no allergic reaction to 
FIX.  CB 
•  For hemophilia B patients with high-responding inhibitors or 
those with low-responding inhibitors who develop allergic reac-
tions or anaphylaxis, the bypassing agent rFVIIa may be used to 
control bleeding. As aPCC contains FIX, it may trigger or worsen 
an allergic or anaphylactic response; for that reason, aPCC should 
be avoided in hemophilia B patients. However, in the absence of 
such a reaction, aPCC has shown similar efficacy in controlling 
acute bleeding. 27 
 Recommendation 8.4.8: 
•  For patients with hemophilia B and high-responding FIX inhib-
itors, the WFH prefers rFVIIa over aPCC to treat acute bleeds, 
as aPCC contains FIX and may cause or worsen an allergic 
reaction.  CB 
 Conventional hemostatic bypassing agents 
•  Alternative hemostatic agents for prevention of spontaneous or 
traumatic bleeds (prophylaxis) in hemophilia B inhibitor patients 
include rFVIIa, or, in the absence of an allergic/anaphylactic reac-
tion to FIX, aPCC. 34,47,60,72,73 
•  Bypass agent prophylaxis in inhibitor patients is not as effective 
nor as convenient as standard factor prophylaxis is in patients 
without inhibitors. 72 
•  For hemostasis, bypass agent therapy with rFVIIa constitutes 
the standard approach. In general, aPCC may increase risk of 
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anaphylaxis because of FIX content and should be avoided in 
those with hemophilia B inhibitors (see above). Both agents are 
effective in treating 90% of musculoskeletal bleeds and can be 
used in major and minor prophylaxis. 34,72 (See Table  8-5 .) 
•  As there are no reliable laboratory assays to monitor bypass 
agent therapy, careful monitoring of hemoglobin levels, blood 
loss, wound healing, and clinical response to treatment is ad-
vised, including patient-reported outcomes and subjective patient 
feedback. 
 Recommendation 8.4.9: 
•  For patients with hemophilia B and inhibitors who use bypass 
agent therapy, the WFH recommends clinical monitoring and 
consideration for laboratory monitoring with thrombin genera-
tion and other coagulation tests, although more data are needed 
to recommend the latter.  CB 
 Therapies in clinical trials 
•  Several emerging non-factor therapies are in clinical trials 
for bleed prevention in hemophilia B patients with inhibitors, 
including fitusiran (siRNA-AT3) 50 and anti-TFPI. 51,74 These 
therapies may provide a less invasive route and/or lower fre-
quency of dosing and, if safe and effective, may be adopted into 
use. 
•  An extended half-life rFVIIa with in vitro hemostasis 48 is in early 
clinical trials for bleed prevention in patients with hemophilia B 
and inhibitors. 49 This therapy may reduce the frequency of dosing 
and, if safe and effective, may be adopted into use. 49 
 Immune tolerance induction 
•  Because inhibitor prevalence is low in hemophilia B, experi-
ence with ITI is limited. The principles of treatment are similar 
to those in hemophilia A, but the success rate is lower, espe-
cially in patients with an allergic reaction to FIX. The latter may 
require FIX desensitization before attempting ITI, although 
few data are available regarding the efficacy or safety of this 
approach. 
•  Hemophilia B inhibitor patients with a history of severe allergic 
reactions to FIX may develop nephrotic syndrome, which may be 
irreversible. In some patients undergoing ITI, nephrotic syndrome 
may develop; close monitoring is required even after ITI is com-
pleted, as nephrotic syndrome may persist. 
•  There is little evidence regarding when or whether to initiate ITI 
in hemophilia B patients after inhibitor detection; however, some 
have initiated a high-dose/high-frequency FIX regimen until toler-
ance is achieved, i.e., the inhibitor titer is persistently negative and 
factor recovery and half-life return to normal. However, there is 
no supporting evidence, and this approach is based on experience 
with hemophilia A inhibitor management. Clinical and laboratory 
monitoring is important, especially for development of allergic re-
actions or nephrotic syndrome. 
•  Little is known about the role of immunosuppressive agents in he-
mophilia B patients with inhibitors, as few data are available; thus, 
there is no consensus regarding their use in these patients. 
 Recommendation 8.4.10: 
•  For patients with hemophilia B and inhibitors, the WFH is unable 
to make a recommendation on the use of immune tolerance in-
duction, as experience with ITI in hemophilia B is limited. 
•  REMARK : In patients with hemophilia B and inhibitors in whom 
ITI is attempted, high-dose factor replacement protocols should 
be followed similar to what is recommended for hemophilia A, 
with strong consideration for the use of immunosuppression. It 
should be noted the risk of nephrotic syndrome may increase 
with high-dose ITI.  CB 
 FIX prophylaxis after immune tolerance induction 
•  After successful immune tolerization in hemophilia B patients 
with inhibitors (defined as the return to a persistently negative 
inhibitor titer), FIX prophylaxis with close monitoring of clinical 
response should be initiated. 7 
 Surgery and invasive procedures 
•  Inhibitor testing is advised in patients with hemophilia B prior to 
surgery and invasive procedures. Special precautions, as noted 
above in the “Management of bleeding” section, must be taken 
in hemophilia B patients with inhibitors, including monitoring for 
allergic reactions and nephrotic syndrome. 
•  In those with low-responding inhibitors, standard FIX CFC cov-
erage may be considered if high enough levels are achieved. In 
 TA B L E   8 5     Treatment of acute bleeds in hemophilia B patients 
with inhibitors 
 Hemophilia B 
 Low- responding 
inhibitors 
 High- responding 
inhibitors 
 Agents •  FIX 20  , a  •  rFVIIa or aPCC 27  , b  or 
porcine FVIII 
 Monitoring •  FIX activity 
(FIX:C) assay 
•  Thromboelastography 
or thrombin generation 
assay 46  , c  
 Abbreviations: aPCC, activated prothrombin complex concentrate; FIX, 
factor IX; FVIII, factor VIII; rFVIIa, recombinant activated factor VIIa. 
 a Will require higher, more frequent dosing if half- life is shortened.  
 b In patients with FIX inhibitors, there is high risk for allergic reaction 
and nephrotic syndrome with FIX- containing products, e.g., aPCC, 
and caution is urged; however, in those with an allergic reaction or 
nephrotic syndrome with FIX- containing products, aPCC should be 
avoided since it contains FIX.  
 c The thrombin generation assay is not state- of- the- art monitoring and 
is unavailable in most laboratories, but increasingly being used to assess 
response.  
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those with high-responding inhibitors or in those with a history 
of allergic reactions to FIX CFCs, treatment with the bypassing 
agent rFVIIa is advised, recognizing the risk of an allergic reaction 
or worsening of such a reaction in those who experience allergic 
reactions to FIX when treated with aPCC due to its FIX content. 
•  If hemostasis is unsatisfactory with rFVIIa or aPCC used as sin-
gle agents, these agents may be alternated, 37 recognizing this is 
based on a small observational study and also recognizing the 
risk for allergic reaction or worsening of an allergic reaction with 
aPCC due to FIX content. 
•  Close perioperative monitoring of clinical response to bypass 
agent therapy is required, particularly for thrombosis or consump-
tive coagulopathy. (See Recommendation 8.4.9 on clinical moni-
toring of bypass agent therapy, above.) 
•  Once hemostasis is achieved and maintained on a bypass agent 
regimen for 3-5 days, use of these agents may be tapered over a 
week or more. 
 Recommendation 8.4.11: 
•  For patients with hemophilia B and low-responding FIX inhibi-
tors who undergo surgery, the WFH has no preference for type 
of FIX products, but recommends more frequent dosing due to 
the short FIX half-life.  CB 
 Recommendation 8.4.12: 
•  For patients with hemophilia B and FIX inhibitors who undergo 
surgery, the WFH recommends rFVIIa over aPCC, as aPCC con-
tains FIX and may cause or worsen an allergic reaction.  CB 
 Recommendation 8.4.13: 
•  For patients with hemophilia B and inhibitors and an allergic re-
action to FIX who undergo surgery, the WFH prefers rFVIIa over 
aPCC as aPCC contains FIX and may cause or worsen an allergic 
reaction.  CB 
 Recommendation 8.4.14: 
•  For patients with hemophilia B and inhibitors who undergo sur-
gery or an invasive procedure, the WFH recommends close clini-
cal monitoring for thrombosis or consumptive coagulopathy.  CB 
 Product switching 
•  While there is controversy regarding risk of inhibitor development 
in patients with hemophilia B switching FIX CFC products, including 
rare case reports, there is a lack of evidence supporting this risk. 64 
 Recommendation 8.4.15: 
•  For patients with hemophilia B who switch to another type 
or brand of factor product, the WFH has no preference in the 
choice of specific type of therapy, as current evidence indicates 
product switching does not increase the risk of inhibitor develop-
ment, but rigorous controlled trials are lacking.  CB 
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 All statements identified as recommendations are consensus based, 
as denoted by  CB . 
 9.1  |  Introduction 
•  People with hemophilia and their families may experience a number 
of health- or hemophilia-related conditions or management issues 
over the course of their lives. These include bleeding and reproduc-
tive complications that may affect carriers, specific requirements 
for surgery and other invasive procedures, psychosocial matters, a 
range of comorbidities due to lifestyle and aging, and other issues. 
•  As the management of these conditions can sometimes be com-
plex, education aimed at preventing and/or appropriately treating 
the issues discussed in this chapter should be a primary and ongo-
ing focus of collaboration between people and family members af-
fected by hemophilia and their multidisciplinary healthcare team. 
 9.2  |  Carriers 
•  The most severe forms of hemophilia typically affect males; fe-
males have conventionally been designated as “carriers.” 
•  Carriers often do not show symptoms of hemophilia because, 
although they have an abnormal  F8 or  F9 gene on one X chro-
mosome, their other X chromosome contains a normal  F8 or  F9 
gene that generally works as normal to produce factor levels in 
the lower limit of the normal range. 
•  A proportion of carriers have low factor VIII (FVIII) or factor IX 
(FIX) activity due to lyonization (the random suppression of one 
of the two X chromosomes; also called X inactivation), which 
can result in mild, moderate, or even severe hemophilia in rare 
instances. Symptomatic females should be designated as having 
hemophilia of a specified severity, like males with hemophilia. 
 Inheritance of hemophilia 
•  A female who has an  F8 or  F9 pathogenic variant is called an ob-
ligate carrier of hemophilia. Obligate carriers can be identified as 
having a hemophilia gene based on analysis of their family history 
of hemophilia. 
•  Obligate carriers include: 
 ◦  any biological daughter of a father with hemophilia; 
 ◦  any biological mother of a child with hemophilia who also has 
at least one other family member with hemophilia (i.e., her 
brother, maternal grandfather, uncle, nephew, or male cousin) 
or who is a known carrier of hemophilia (i.e., her mother, sister, 
maternal grandmother, aunt, niece, or female cousin); 
 ◦  any biological mother of two or more children with hemophilia. 
•  Potential carriers include: 
 ◦  any biological daughter, sister, mother, maternal grandmother, 
aunt, niece, or female cousin of a carrier of hemophilia; 
 ◦  a biological mother of a child with hemophilia and no known 
family history of hemophilia or carriers of hemophilia. 
 Factor levels in carriers 
•  Carriers with FVIII/FIX levels in the normal range may never re-
quire factor replacement therapy. However, some carriers with 
factor levels in the lower range of normal (i.e., below 50 IU/dL) 
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experience bleeding problems similar to males with mild hemo-
philia (e.g., hemorrhaging after dental extraction, surgery, or 
trauma) as well as problems that are specific to women, such as 
prolonged or heavy menstrual bleeding. 1 
•  Carriers who exhibit a greater bleeding tendency than would be 
predicted by their factor level, as in males, may have a second 
coagulation defect, such as a von Willebrand factor (VWF) gene 
variant or a congenital platelet defect. 
 Recommendation 9.2.1: 
•  Carriers of hemophilia, irrespective of factor level, should be reg-
istered at a hemophilia treatment centre.  CB 
 Recommendation 9.2.2: 
•  Carriers of hemophilia with low factor levels should be treated 
and managed the same as males with hemophilia.  CB 
 Carrier factor level testing 
•  All immediate female relatives (mother, sister, or daughter) of a 
person with hemophilia should have their factor levels measured, 
especially prior to any invasive procedure, childbirth, or as soon as 
any abnormal bleeding symptoms occur. 1,2 
•  In potential carriers, the diagnosis should be confirmed by genetic 
testing, if available, as factor levels may be above 50 IU/dL. 3,4 
•  In some carriers, levels consistent with moderate or even severe 
hemophilia may be found on factor level testing as a result of ly-
onization. 5 (See Chapter 2: Comprehensive Care of Hemophilia 
– Table 2-1.) 
 Recommendation 9.2.3: 
•  All potential and obligate carriers of hemophilia should have 
their FVIII/FIX levels measured to establish their baseline levels 
prior to major procedures, surgery, or pregnancy.  CB 
 Bleeding symptoms 
•  The most common manifestations among symptomatic carriers 
include 1 : 
 ◦  menorrhagia (heavy menstrual bleeding); 
 ◦  dysmenorrhea (pain during menstrual bleeding); 
 ◦  postpartum hemorrhage; 
 ◦  perimenopausal bleeding (abnormal bleeding during the 
pre-menopause transition); 
 ◦  abnormal bleeding alone, following trauma, or after medical 
interventions (e.g., dental extraction or surgery). 
•  Hormonal therapy is useful in managing heavy menstrual bleed-
ing. 6,7 Options include: 
 ◦  oral, subcutaneous, or transdermal formulations containing 
estrogen/progesterone/progestin; 
 ◦  the levonorgestrel intrauterine device (IUD). 
•  Oral antifibrinolytics, e.g., tranexamic acid (15-25 mg/kg every 
6-8 hours), may also be helpful in managing heavy menstrual 
bleeding. 8 
 Genetic counselling 
•  Genetic counselling is an essential but complex component of 
comprehensive care for individuals and families with a diagnosis 
of hemophilia and for those at risk. 9 
•  While the scope and availability of services vary among coun-
tries 10 and individual hemophilia treatment centres, 11 compre-
hensive genetic counselling generally involves 9 : 
 ◦  collection and analysis of family and medical histories to as-
sess the chance of disease occurrence; 
 ◦  education about inheritance, genetic testing, treatment, pre-
vention, and available resources; and 
 ◦  counselling to promote informed choices and adaptation to 
the risk or condition. 
•  Genetic counselling should take into account the individual ' s 
experiences and perceptions, as well as the social, cultural, and 
religious factors and contexts that may influence decisions and 
options related to their genetic status. 
•  Genetic counsellors can help both obligate and potential carriers 
of hemophilia understand their bleeding and genetic risks and 
adapt to the medical, psychological, familial, and reproductive im-
plications and consequences of their genetic status. 9 
•  The primary role of genetic counsellors is to educate individuals on 
the natural history of hemophilia, establish their family tree/pedi-
gree, perform risk assessments related to the inheritance of hemo-
philia, facilitate genetic testing, help them process and integrate 
genetic information, and discuss relevant reproductive options. 9 
•  Where access to trained genetic counsellors is limited, the he-
mophilia treatment centre and the comprehensive care team 
members, specifically physicians, nurses, and/or psychosocial 
professionals, 9 often take responsibility for delivering important 
genetic information. 2 
 Psychosocial support 
•  Ongoing psychosocial assessment and counselling should be inte-
grated within case management and comprehensive care for car-
riers. Carriers may require referral to psychosocial professionals 
(e.g., psychologists) for further support to address psychological 
or emotional issues that may arise during the genetic counselling 
process or at different life stages. 
•  Collaboration between psychosocial professionals and genetic 
counsellors can enhance overall patient care. 
•  Carriers may experience a wide range of emotional and psycho-
social impacts, including feelings of guilt, sorrow, and self-blame 
related to reproductive choices or consequences such as passing 
on their genetic variant. 12 Such feelings run across generations of 
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a family and may also be experienced by grandmothers who were 
carriers and fathers with hemophilia. 12 
•  It is important for hemophilia treatment centres and healthcare 
providers (especially genetic counsellors and clinical geneticists), 
families, and patient organizations to be aware that the experi-
ence of being a hemophilia carrier may change with different life 
stages, and carriers may need genetic and/or psychosocial coun-
selling more than once during their lifetime. 12 
•  Comprehensive genetic counselling including a formalized system 
for the education, management, follow-up, and long-term medical 
and psychosocial support of carriers should be implemented. 10 
 Genetic testing 
•  Genetic testing facilitates identification of carriers and prenatal 
diagnosis. Where available, formal genetic testing should be of-
fered to potential carriers when they are mature enough to un-
derstand the consequences of the diagnosis and give consent. 13 
•  It is important to be aware of and abide by the relevant laws gov-
erning genetic testing and prenatal diagnosis procedures in the 
country where the service is being provided. 
•  See also Chapter 4: Genetic Assessment. 
 Recommendation 9.2.4: 
•  Carriers of hemophilia should be offered counselling that in-
cludes reproductive implications and choices.  CB 
 Prenatal diagnosis 
•  Prenatal diagnosis is usually offered to help with reproductive 
planning and risk assessment. Determination of whether a male 
fetus is affected by hemophilia assists parents and healthcare 
providers in making decisions regarding pregnancy management, 
such as caesarean delivery of a fetus with severe disease to re-
duce intracranial hemorrhage (ICH) and maternal anesthesia for 
childbirth. (See Chapter 4: Genetic Assessment.) 
 Pregnancy and prenatal planning 
 Management of care for all pregnant carriers should involve close 
cooperation between the hemophilia and obstetric teams. It is im-
portant to have a clear plan for delivery that is shared with the car-
rier and written in her medical file. 
 Factor levels during pregnancy 
•  During pregnancy, FVIII levels can increase significantly in car-
riers and may completely normalize in the later stages. Levels of 
FIX, however, do not usually change significantly. 14 
•  Even with factor levels above 50 IU/dL in the third trimester, 
carriers may experience abnormal bleeding during childbirth; 
therefore, it is critical to obtain a carrier ' s bleeding history and 
score, family history of bleeding, and history of bleeding with past 
childbirth prior to delivery 15 and, if possible, prior to pregnancy. 
 Recommendation 9.2.5: 
•  Pregnant carriers of hemophilia should have their FVIII/FIX lev-
els assayed in the third trimester of pregnancy to assess their 
bleeding risk during delivery and in the postpartum period.  CB 
 Labour and delivery 
•  Regional block anesthesia (epidural) in carriers of hemophilia is 
not contraindicated if the coagulation screen is normal and the 
relevant factor level is above 50 IU/dL or raised to above 50 IU/dL 
by prophylactic treatment. 16 The anesthesia should be performed 
by an expert anesthetist, taking into account the carrier ' s coagu-
lation parameters and factor levels, with arrangements for appro-
priate timing of treatment, if applicable. 
•  Factor replacement therapy, if required, should be administered 
to maintain factor levels above 50 IU/dL for labour and delivery 
and maintained in the normal range for at least 3 days after vagi-
nal delivery and at least 5 days after caesarean delivery. 16,17 Route 
of delivery for carriers with a fetus without hemophilia should be 
as per obstetric indications. Some suggest caesarean delivery to 
prevent intracranial hemorrhage in an infant expected to be born 
with severe hemophilia. 18 
•  Delivery of infants known or suspected to have hemophilia must 
be atraumatic, regardless of whether it is by vaginal or caesarean 
delivery, to decrease the risk of bleeding complications. 14 
•  Forceps and vacuum extraction vaginal delivery as well as inva-
sive procedures to the fetus such as fetal scalp blood sampling 
and internal fetal scalp electrodes should be avoided. 19 
•  See Chapter 7: Treatment of Specific Hemorrhages – Table 7-2 for 
CFC replacement for major and minor surgery. 
 Recommendation 9.2.6: 
•  For pregnant carriers of hemophilia, delivery should be in a hos-
pital with access to hemophilia specialists where complications 
during labour and delivery can be dealt with promptly to main-
tain the safety of mother and child.  CB 
 Recommendation 9.2.7: 
•  For pregnant carriers of hemophilia, the WFH recommends 
against instrumental delivery.  CB 
 Postpartum care 
•  Carrier FVIII and VWF levels fall off fairly rapidly after delivery, 5 
usually returning to baseline levels in 7-10 days, but sometimes 
earlier. 20 
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•  It is important to monitor and maintain factor levels post-deliv-
ery as carriers are at increased risk of primary and secondary 
postpartum hemorrhage. 21 If postpartum hemorrhage oc-
curs, factor replacement therapy, antifibrinolytics (tranexamic 
acid), and hormonal therapy are the first-line therapies for its 
management. 5 
•  Prophylactic hormonal therapy may be started immediately after 
delivery and continued for one month in selected carriers deemed 
to be at higher risk of bleeding. 5 
•  Desmopressin (DDAVP) is occasionally used in the postpar-
tum period for hemophilia A. 5 (See Chapter 5: Hemostatic 
Agents – Other pharmacological options – Desmopressin 
[DDAVP].) 
•  Hemoglobin levels in carriers at risk of late postpartum 
hemorrhage should be checked before discharge from 
hospital. 22 
•  Delayed bleeding up to 35 days postpartum is possible; carriers 
must be informed of this risk and should be seen 2 weeks post-
partum. Follow-up to monitor postpartum bleeding for approxi-
mately 1-2 months may be appropriate. 22 
 Recommendation 9.2.8: 
•  Carriers of hemophilia should be monitored for both primary and 
secondary postpartum hemorrhage, which should be treated 
with appropriate hemostatic measures.  CB 
 Newborn testing 
•  Cord blood should be collected from all male newborn infants 
of carriers of hemophilia to assess clotting factor levels for early 
identification and management of hemophilia. The test results 
should be conveyed to the parents by an appropriate member of 
the hemophilia team. 
•  Normally in newborn and pre-term infants without hemophilia, 
FVIII levels at birth are within the normal adult range or mildly 
increased. Therefore, it is possible to diagnose most cases of 
hemophilia A at birth; the exception being in mild hemophilia 
A, wherein a FVIII result at the lower end of the normal range 
should be repeated when the infant is around 6 months of 
age. 23 
•  In contrast to FVIII, FIX levels at birth are significantly lower than 
normal in newborns without hemophilia and even more so in pre-
term infants. 23 While it is usually possible to make a diagnosis 
of severe or moderate hemophilia B in the neonatal period, in-
fants who may be mildly affected will require repeat screening at 
3-6 months of age. 
 Recommendation 9.2.9: 
•  Male babies born to known or potential carriers of hemophilia 
should have cord blood testing of activated partial thromboplas-
tin time (APTT) or factor levels.  CB 
 Miscarriage management 
•  Miscarriage refers to a spontaneous abortion or pregnancy loss 
before 20 weeks of gestation 24,25 by complete or incomplete ex-
pulsion of the products of conception from the uterus, by failure 
of the embryo to develop, or by death of the fetus in utero. 25 
•  Once the determination has been made that the pregnancy has 
ended because the embryo or fetus has died or because a miscarriage 
is in progress, the obstetrician will surgically evacuate the uterus or 
await spontaneous expulsion of the products of conception. 
•  Surgical management of spontaneous abortion is preferred in 
patients with a pre-existing hemostatic abnormality such as an 
inherited bleeding disorder. 24 In such cases, adequate hemo-
static treatment is required in accordance with the recommended 
perioperative protocols. (See 9.5 Surgery and invasive procedures, 
below, and Chapter 7: Treatment of Specific Hemorrhages – Table 
7-2 for CFC replacement for major and minor surgery.) 
•  Since bleeding in pregnancy is almost always attributed to ob-
stetric bleeding, adequate obstetric management is required. In 
the case of bleeding in a pregnant carrier, appropriate hemostatic 
management may also be required. 
•  Hemostatic management consists of replacement of the deficient 
clotting factor or other treatment modalities in accordance with 
protocols for the management of bleeding complications in pa-
tients with hemophilia. 
 9.3  |  Circumcision 
•  Circumcision is a widely practiced surgical procedure; up to 30% 
of the male population in the world are circumcised. 26,27 
•  Medical benefits of circumcision include reduced risk of sexually 
transmitted diseases, reduced risk of carcinoma of the penis, and 
reduced risk of cervical cancer in sexual partners of circumcised 
males. 28 
•  The accepted medical indications include treatment of phimosis, 
paraphimosis, recurrent balanitis, and recurrent balanoposthi-
tis. 27,29 Non-medical reasons and indications may be social, cul-
tural, personal, or religious. 
•  In hemophilia, circumcision is associated with a number of com-
plications including prolonged bleeding, infection, delayed skin 
healing/increased morbidity, gangrene, human immunodeficiency 
virus (HIV) and hepatitis infection acquired through contaminated 
blood products to treat bleeding, risk of neonatal inhibitor devel-
opment, psychosocial scarring, and risk of mortality. 29,30 
•  The key considerations for circumcision in patients with hemo-
philia include individual patient factors such as inhibitor develop-
ment, venous access, and wound care, as well as the expertise and 
resources at the hospital/treatment centre. Patients will invariably 
bleed when stitches are removed, and this should be managed with 
clotting factor replacement. (See Chapter 7: Treatment of Specific 
Hemorrhages – Table 7-2 for CFC replacement for minor surgery.) 
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•  A risk–benefit ratio assessment should be performed and dis-
cussed with family and other caregivers. 
 Recommendation 9.3.1: 
•  In patients with hemophilia, the circumcision procedure should 
be performed electively by an experienced surgeon and hema-
tology team in a resourced hematology treatment centre with 
access to clotting factor concentrates.  CB 
 Recommendation 9.3.2: 
•  In patients with hemophilia, the plasma factor level should be 
raised to 80-100 IU/dL just prior to the procedure.  CB 
 Recommendation 9.3.3: 
•  In patients with hemophilia undergoing circumcision, intraoper-
ative care should be taken to cauterize all bleeding vessels.  CB 
 Recommendation 9.3.4: 
•  For patients with hemophilia undergoing circumcision, the WFH 
suggests use of topical fibrin sealant as an adjunctive therapy, 
using a product manufactured with robust viral reduction/inacti-
vation processes if available, to minimize the risk of bloodborne 
pathogen transmission.  CB 
 Recommendation 9.3.5: 
•  For patients with hemophilia undergoing circumcision, the WFH 
recommends adjusting clotting factor replacement to the clinical 
course of the procedure. If continued clotting factor replacement 
is required, the goal would be to maintain factor levels above 
50 IU/dL for the first 3 days, and above 30 IU/dL for the subse-
quent 4-8 days.  CB 
 Recommendation 9.3.6: 
•  In patients with hemophilia post-circumcision, inhibitor mea-
surement should be repeated if there is intractable bleeding that 
is poorly responsive to replacement therapy and local hemo-
static measures.  CB 
 Recommendation 9.3.7: 
•  In patients with hemophilia post-circumcision, non-dissolvable 
stitches (if used) should be removed 10-14 days postsurgery; the 
inevitable bleeding should be managed with clotting factor re-
placement.  CB 
 Recommendation 9.3.8: 
•  In hemophilia patients with intractable bleeding 
post-circumcision, all angles should be considered, including 
blood vessel bleeding, clotting factor deficiency, and platelet 
abnormalities.  CB 
 Recommendation 9.3.9: 
•  In hemophilia patients with intractable bleeding post-circum-
cision, adjunct and supportive therapy should be used; this 
includes transfusion and local hemostatic measures, such as the 
application of topical agents.  CB 
 9.4  |  Vaccinations 
•  Vaccination against communicable diseases is crucial for disease 
prevention. People with hemophilia should receive all immuniza-
tions recommended for their age group. 
•  Challenges associated with vaccinations include: 
 ◦  route of vaccine administration; and 
 ◦  vaccination of patients with compromised immunity (e.g., HIV 
infection). 
•  Live virus vaccines may be contraindicated in those with weak-
ened immunity. 
•  There has been no evidence that vaccinations result in inhibitor 
development. 31 
 Recommendation 9.4.1: 
•  Children and adults with hemophilia should be administered the 
same routine vaccines as the general population; however, they 
should preferably receive the vaccines subcutaneously rather 
than intramuscularly or intradermally, as it is as safe and effec-
tive as the latter and does not require clotting factor infusion. 
•  REMARK : If intramuscular injection must be the route of adminis-
tration, a dose of clotting factor concentrate should be given, and 
the smallest gauge needle available (25-27 gauge) should be used. 
•  REMARK : Additionally, an ice pack should be applied to the in-
jection site for 5 minutes before injection of the vaccine, and 
pressure should be applied to the site for at least 10 minutes to 
reduce bleeding and swelling.  CB 
 Recommendation 9.4.2: 
•  In children and adults with hemophilia and human immunode-
ficiency virus (HIV) infection, the WFH recommends standard 
immunizations, including pneumococcal and influenza vaccines 
and hepatitis A and B immunization.  CB 
 Recommendation 9.4.3: 
•  In children and adults with hemophilia and HIV infection, the 
WFH recommends that live virus vaccines (such as chicken-
pox, yellow fever, rotavirus, oral polio, and combined measles, 
mumps, and rubella [MMR] vaccines) should be avoided.  CB 
 9.5  |  Surgery and invasive procedures 
•  Surgery may be required for hemophilia-related complications or 
unrelated diseases. The issues discussed here are of prime impor-
tance when performing surgery on patients with hemophilia. 
•  Surgery for patients with hemophilia requires additional planning 
and interaction with the healthcare team compared to what is re-
quired for other patients. 
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•  The anesthesiologist should have experience treating patients 
with bleeding disorders. 
•  Neuraxial anesthesia requires factor levels above 50 IU/dL to 
avoid bleeding and ensuing neurological complications. 32 
•  Surgery should be scheduled early in the week and early in the 
day for optimal laboratory and blood bank support, if needed. 
•  Adequate quantities of CFCs (or bypassing agents for patients 
with inhibitors) should be available for the surgery itself and to 
maintain adequate coverage postoperatively for the length of 
time required for healing and/or rehabilitation. (For patients with 
inhibitors, see Chapter 8: Inhibitors to Clotting Factor – Surgery 
and invasive procedures.) 
•  If CFCs or bypassing agents are not available, adequate blood 
bank support for plasma components is needed. 
•  The dosage and duration of CFC or other hemostatic cover-
age depend on the type of surgery performed. (See Chapter 7: 
Treatment of Specific Hemorrhages – Table 7-2 for CFC replace-
ment for major and minor surgery.) 
•  Effectiveness of hemostasis for surgical procedures may be as-
sessed as per criteria defined by the Scientific and Standardization 
Committee of the International Society on Thrombosis and 
Haemostasis (see Table  9-1 ). 33 
•  Treatment with CFCs or other hemostatic agents should be con-
sidered before invasive diagnostic procedures such as lumbar 
puncture, arterial blood gas determination, or any endoscopy with 
biopsy. 
•  DDAVP may be useful hemostatic treatment for surgery and 
other invasive procedures in responsive patients with mild he-
mophilia A (without medical contraindications) for minor bleed-
ing or surgery. 34 Limitations of DDAVP include water retention, 
hyponatremia, and tachyphylaxis. Tachyphylaxis occurs when re-
peated dosages of DDAVP are given within short time intervals 
(12-24 hours), with approximately 30% decrease in FVIII activity 
response from the second dose onwards in the case of a 24-hour 
interval. Due to possible tachyphylaxis, DDAVP may not be a 
good option for those patients who require adequate hemostasis 
for longer periods of time, e.g., following major surgery. 35 
•  Combined administration of DDAVP and FVIII concentrate may 
be able to overcome several of the drawbacks of these separate 
treatment options; however, there is a lack of experience and 
knowledge with regard to the efficacy and safety of combination 
treatment. 35 
•  When needed, or if CFCs are not available, DDAVP and antifibri-
nolytics (tranexamic acid or epsilon-aminocaproic acid) are ther-
apeutic options as hemostatic support to the initial replacement 
treatment. 36 More potent and better tolerated among antifibrino-
lytics is tranexamic acid. This compound is particularly effective 
and useful in cases of mucosal bleeds. 
•  See Chapter 5: Hemostatic Agents – Other pharmacological op-
tions – Desmopressin (DDAVP). 
•  Inhibitors should be assessed prior to surgery and when there is 
suboptimal response to treatment in the postoperative period. 
(See Chapter 8: Inhibitors to Clotting Factor – Surgery and inva-
sive procedures.) 
 Recommendation 9.5.1: 
•  Patients with hemophilia A and B should have ready access to 
and be evaluated for acute and elective surgical procedures that 
could enhance their well-being or quality of life.  CB 
 Recommendation 9.5.2: 
•  The WFH recommends patients with hemophilia requiring sur-
gery should be managed at or in consultation with a comprehen-
sive hemophilia treatment centre.  CB 
 TA B L E   9 1     Definition of adequacy of hemostasis for surgical procedures 33 
 Excellent  Intraoperative and postoperative blood loss similar (within 10%) to that in the non- hemophilic patient. 
 • No extra (unplanned) doses of FVIII/FIX/bypassing agents needed  and 
 • Blood component transfusions required are similar to those in a non- hemophilic patient 
 Good  Intraoperative and/or postoperative blood loss slightly increased over expectation for the non- hemophilic patient (between 10% 
and 25% of expected), but the difference is judged by the involved surgeon/anesthetist to be clinically insignificant. 
 • No extra (unplanned) doses of FVIII/FIX/bypassing agents needed  and 
 • Blood component transfusions required are similar to those in the non- hemophilic patient 
 Fair  Intraoperative and/or postoperative blood loss increased over expectation (25%- 50%) for the non- hemophilic patient, and 
additional treatment is needed. 
 • Extra (unplanned) dose of FVIII/FIX/bypassing agents needed  or 
 • Increased blood component (within 2- fold) of the anticipated transfusion requirement 
 Poor/None  Significant intraoperative and/or postoperative blood loss that is substantially increased over expectation (>50%) for the non- 
hemophilic patient, requires intervention, and is not explained by a surgical/medical issue other than hemophilia. 
 • Unexpected hypotension or unexpected transfer to ICU due to bleeding  or 
 • Substantially increased blood component (>2- fold) of the anticipated transfusion requirement 
 Notes :  Apart from estimates of blood loss during surgery, data on pre- and postoperative hemoglobin levels and the number of packed red blood cell 
units transfused may also be used, if relevant, to estimate surgical blood loss. Surgical hemostasis should be assessed by an involved surgeon and/
or anesthetist, and records should be completed within 72 h post- surgery. Surgical procedures may be classified as major or minor. A major surgical 
procedure is defined as one that requires hemostatic support for periods exceeding 5 consecutive days. 
 Abbreviations: FIX, factor IX; FVIII, factor VIII; ICU, intensive care unit. 
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 Recommendation 9.5.3: 
•  For patients with hemophilia requiring surgery, sufficient 
quantities of clotting factor concentrates must be available 
for the surgery itself and to maintain adequate coverage post-
operatively for the duration required for recovery and/or 
rehabilitation.  CB 
 Recommendation 9.5.4: 
•  The WFH recommends centres providing surgery for patients 
with hemophilia should have adequate laboratory support for 
reliable monitoring of clotting factor levels in the perioperative 
period.  CB 
 Recommendation 9.5.5: 
•  For patients with mild hemophilia A undergoing surgery, the 
WFH recommends the use of DDAVP for hemostasis if the pa-
tient shows good therapeutic response to DDAVP in pre-surgery 
testing. 
•  REMARK : DDAVP is not recommended for surgical hemostasis in 
those patients with mild hemophilia A in whom the response to 
DDAVP (increase of plasma FVIII activity levels) is unsatisfactory 
or in whom DDAVP is contraindicated (e.g., in those with signifi-
cant cardiovascular disease). 
•  REMARK : Due to the risk of tachyphylaxis, DDAVP should not be 
given for more than 3-5 days unless the patient can be monitored 
closely and switched to clotting factor concentrate if this occurs. 
Therefore, if the anticipated treatment duration will be longer 
than 3-5 days (e.g., after major surgery), providers may choose to 
avoid the use of DDAVP from the outset. 
•  REMARK : DDAVP is the first choice for patients with mild hemo-
philia A to avoid the cost of CFCs and exposure to FVIII concen-
trates and the potential risk of inhibitor development, which 
increases with the number of exposures. 
•  REMARK : Given the need for close monitoring, an experienced he-
matology team should manage these patients.  CB 
 Recommendation 9.5.6: 
•  For patients with hemophilia undergoing surgery, antifibrinolyt-
ics and topical hemostatic agents should be considered if ancil-
lary therapies are required beyond factor replacement.  CB 
 Recommendation 9.5.7: 
•  Pre- and postoperative assessment of all patients with hemo-
philia A and B should include inhibitor screening and inhibitor 
assay.  CB 
 Recommendation 9.5.8: 
•  For patients with hemophilia undergoing surgery, the WFH ad-
vises against neuraxial anesthesia. If neuraxial anesthesia is 
required, it should be performed only under adequate clotting 
factor coverage as the safety of neuraxial procedures has not 
been established in patients with hemophilia. 
•  REMARK : It is recognized that in some centres, neuraxial anesthe-
sia is acceptable after restoring hemostasis in patients with he-
mophilia, whereas in other centres this procedure is discouraged 
and general anesthesia is preferred.  CB 
 Recommendation 9.5.9: 
•  Patients with mild hemophilia A and all patients with hemo-
philia receiving intensive factor replacement for the first time 
are at particular risk of inhibitor development, and therefore 
should be rescreened for inhibitor presence 4-12 weeks post-
operatively.  CB 
 Recommendation 9.5.10: 
•  In surgical patients with hemophilia B requiring intensive re-
placement therapy, the WFH recommends against use of pro-
thrombin complex concentrate (PCC) due to risk of accumulation 
of clotting factors II, VII, and X, which can be associated with 
higher risk of thrombotic complications.  CB 
 Recommendation 9.5.11: 
•  The WFH recommends replacement therapy for a duration of at 
least 3 days for minor surgical procedures, and at least 7-10 days 
for major surgical procedures.  CB 
 Recommendation 9.5.12: 
•  For patients with hemophilia A and B undergoing major surgery, 
the WFH recommends against routine use of pharmacologic 
thromboprophylaxis.  CB 
 9.6  |  Sexuality 
•  People with hemophilia are able to have entirely normal sexual 
lives. 37 Although sexual health has generally been inadequately 
assessed in routine care of people with hemophilia, recent studies 
have shown that the prevalence of difficulty with sexual activity is 
significantly higher compared to the general population. 38 
•  Complications of hemophilia can be accompanied by sexual dys-
function, such as lack of libido or impotence. Pain, fear of pain, 
or analgesia may affect sexual desire, and hemophilic arthropathy 
may place physical limitations on sexual intercourse. 
•  Older age, joint bleeding, and joint status contribute to poor sex-
ual health; in addition, poor sexual health is strongly associated 
with worse general health status. 38 
•  People with hemophilia have reported experiencing joint stiffness 
that affected their sexual life (53%), joint pain from sexual activ-
ity (53%), and not having adequate information regarding sexual 
activity. 39 
•  Muscle bleeding (e.g., iliopsoas) may sometimes arise from sexual 
activity, and this may require active management or specific coun-
selling to reduce recurrence. 40 (See Chapter 10: Musculoskeletal 
Complications.) 
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•  Sexuality may also be affected by viral complications such as 
chronic hepatitis C virus (HCV) and HIV infection. 40 
•  Age-related diseases such as hypertension and diabetes mellitus 
may also result in sexuality issues, as well as certain medications 
to treat comorbidities. 
•  In some cases, oral phosphodiesterase-5 inhibitors (sildenafil, 
tadalafil) may be helpful. Note that these medications mildly in-
hibit platelet aggregation in vitro and may cause epistaxis due to 
nasal congestion. 
•  In addition to the physical effects on sexuality, people with hemo-
philia may experience social and psychological issues surrounding 
sexual health. Worries about having a bleed due to sexual activ-
ity, lack of desire, body image issues, fear of rejection, medication 
side effects, pain, and tiredness have all been reported to affect 
the sexual lives of people with hemophilia. 40 
•  Cultural influences may play a role in a person ' s decision about 
whether to discuss sexual health issues with their healthcare 
provider. As some individuals may be reluctant to have such dis-
cussions, all members of the comprehensive care team should be 
proficient in initiating and engaging patients in a conversation 
about their sexual health and quality of life, and this approach 
should be integrated into routine care. 40 
•  Hematospermia (defined as the macroscopic presence of blood in 
the semen) is not uncommon in people with hemophilia and may 
cause considerable anxiety in some individuals and their partners. 
•  Hematospermia is rarely linked to serious dysfunctions; neverthe-
less, a more serious pathology may be underlying, consequently 
requiring further investigations. 
 Recommendation 9.6.1: 
•  Adult patients with hemophilia should be assessed for sexual 
health issues as part of routine care to address possible impacts 
related to age, joint bleeding, joint pain and stiffness, and muscle 
bleeding (e.g., iliopsoas), which can sometimes arise during sex-
ual activity.  CB 
 Recommendation 9.6.2: 
•  For patients with hemophilia with comorbidities who may ex-
perience complications of hemophilia accompanied by sexual 
dysfunction, the WFH recommends that healthcare providers at 
hemophilia treatment centres provide a multipronged psychoso-
cial approach that includes communicating openly about sexual 
activity and quality of life in a consistent and comprehensive 
manner.  CB 
 9.7  |  Psychosocial issues 
•  Severe hemophilia is associated with major psychological and 
economic burdens for people with hemophilia and their caregiv-
ers. 41 As hemophilia can impact many aspects of daily living and 
family life, psychological and social support are important compo-
nents of comprehensive care for hemophilia. 42 
•  Psychosocial care is an important aspect of healthcare services 
for individuals and families living with hemophilia and related 
complications. 
•  The hemophilia treatment centre social worker and/or other 
members of the comprehensive care team typically fulfill this role. 
Key functions include: 
 ◦  Provide as much information as possible about all aspects 
of care, including the physical, psychological, emotional, and 
economic dimensions of living with hemophilia, in terms the 
patient/family members can understand. 
 ◦  Provide psychosocial support and counselling to patients, 
their parents, and other family members (including unaffected 
siblings). 
 ◦  Interact and speak directly with children with hemophilia 
about their treatment, not just with their parents. 
 ◦  Assess and address issues related to adherence. 
 ◦  Help patients understand and deal with issues and challenges 
related to school or employment. 
 ◦  Encourage patients and family members to build a support 
network (e.g., by forming or joining support groups at their he-
mophilia treatment centre and patient organization). 
 ◦  Work in partnership with the patient organization to provide 
education to patients, families, and healthcare providers, and 
advocate for hemophilia care. 
 ◦  Enlist the assistance of local healthcare organizations where 
social workers are unavailable. 
 ◦  Encourage patients, family members and caregivers to discuss 
issues or challenges with regards to mental health such as de-
pression or anxiety. 
 ◦  Recognize warning signs of burnout and depression, which are 
common with chronic illness, and provide suggestions and re-
sources for coping. 
 ◦  Encourage patients to engage in productive and fulfilling ac-
tivities at home and in the workplace. 
•  See 9.9 Medical issues with aging – Psychosocial issues with 
aging, below. 
 Recommendation 9.7.1: 
•  For patients with severe hemophilia, the WFH recommends the 
provision of psychological and social support as part of compre-
hensive hemophilia care, with enlistment of assistance from local 
healthcare organizations wherever psychologists or social work-
ers are unavailable.  CB 
 Recommendation 9.7.2: 
•  For patients with hemophilia, the WFH recommends that hemo-
philia treatment centres assist patients and families in forming 
and joining support groups or networks, and encourage partici-
pation in their patient organizations.  CB 
 Recommendation 9.7.3: 
•  For patients with hemophilia, the WFH recommends appropri-
ate programming at hemophilia treatment centres and patient 
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organizations to assist in successful aging through assessment of 
their developmental progression, assessment and prevention of 
comorbidities and functional impairments, assessment of cogni-
tive and emotional function, identification of depression and refer-
ral for treatment, and reinforcement of social connectedness.  CB 
 9.8  |  Comorbidities 
•  The increase in life expectancy for people with hemophilia—due 
to major advances in hemophilia care, including the availability of 
safe and effective CFCs—is accompanied by a range of new chal-
lenges. An increasing number of people with hemophilia develop 
significant comorbidities, such as cardiovascular and metabolic 
diseases, renal disease, and cancer/malignancies. 43 
•  As a result, hemophilia treatment centres increasingly require the 
expertise of specialists rarely needed before, such as cardiolo-
gists, endocrinologists, and oncologists. 44 
•  In general, the comorbidities occurring in older patients with 
hemophilia should be treated in consultation with relevant spe-
cialists as they would in the unaffected population of the same 
age, but treatment should be adapted when the risk of bleeding is 
increased by the use of invasive procedures or medications that 
may cause bleeding. 44 
 Cancer/malignancy 
•  The risk of developing cancer increases with age, and the same 
holds true in aging patients with hemophilia. 45 
•  It has been well documented that older patients with hemophilia 
have a higher incidence of virus-related malignancies caused by 
HIV (e.g., non-Hodgkin lymphoma, basal cell carcinoma, Kaposi 
sarcoma) and HCV (e.g., hepatocellular carcinoma) infection. 46-48 
•  It is unclear whether hemophilia exerts an impact on the preva-
lence of other cancers among people with hemophilia, and it is un-
clear whether hemophilia exerts an impact on the clinical course 
of malignancy. 49-51 
•  More recent analyses suggest that, with the exception of hepa-
tocellular carcinoma due to chronic hepatitis infection, mortality 
rates from cancer are essentially the same among people with he-
mophilia and the general population. 52 
•  The risk of bleeding in people with hemophilia and cancer is exac-
erbated by factors including 44 : 
 ◦  use of invasive diagnostic and therapeutic procedures; 
 ◦  thrombocytopenia induced by chemotherapy and/or 
radiotherapy. 
•  Therefore, hemostatic therapy should be provided not only epi-
sodically at the time of invasive procedures, but also in the form 
of ongoing prophylaxis in cases of severe thrombocytopenia due 
to chemotherapy and/or radiotherapy. 44 
•  It is unknown which platelet count is safe in patients with hemophilia 
and malignancy. Some experts advise considering prophylaxis with 
replacement of the deficient clotting factor when platelet count is 
less than 30 G/L apart from management of thrombocytopenia, 44 
although previous studies have suggested that prophylaxis should 
be instituted when platelet counts fall below 50 because of the risk 
of central nervous system (CNS) and other serious bleeds. 53 (See 
Chapter 7: Treatment of Specific Hemorrhages – Table 7-2.) 
•  Since thrombocytopenia is in itself not antithrombotic, antithrom-
botic prophylaxis should be considered in those types of malig-
nancy that are associated with a high risk of thrombosis. 44 
•  For patients with hemophilia who are diagnosed with cancer, 
which in the general population is accompanied by an increased 
risk for developing venous thromboembolism (VTE), thromboem-
bolism prophylaxis may not be necessary as patients with clotting 
deficiencies are relatively protected from developing VTE. 53,54 
 Recommendation 9.8.1: 
•  In patients with hemophilia, the WFH recommends age-appro-
priate cancer screening.  CB 
 Recommendation 9.8.2: 
•  For diagnosis and treatment of malignancy in patients with he-
mophilia, the WFH recommends the provision of adequate factor 
replacement as necessary to minimize bleeding risk.  CB 
 Recommendation 9.8.3: 
•  In patients with hemophilia, if chemotherapy or radiotherapy is 
accompanied by severe long-lasting thrombocytopenia, the WFH 
recommends continuous prophylactic replacement therapy.  CB 
 Recommendation 9.8.4: 
•  Antineoplastic treatments for patients with hemophilia diag-
nosed with cancer should be the same as recommended for the 
general population.  CB 
 Recommendation 9.8.5: 
•  For hemophilia patients without inhibitors diagnosed with can-
cer, the WFH advises that venous thromboembolism prophylaxis 
management decisions should be based on evaluation of the indi-
vidual patient ' s bleeding and thrombotic risk. If used in patients 
receiving factor concentrates, it must be carefully managed to 
maintain factor levels below the risk range for VTE. 
•  REMARK : If pharmacologic thromboprophylaxis for hemophilia pa-
tients without inhibitors diagnosed with cancer is used, it should 
mimic what is recommended for the general population, pro-
vided that appropriate factor replacement therapy is adminis-
tered, taking into account that factor replacement to high factor 
levels above normal is a potential risk factor for VTE.  CB 
 Cerebrovascular accident/stroke 
•  Patients with hemophilia are prone to hemorrhagic stroke, 
the most serious type of bleeding in this population; however, 
     |  117
ischemic/thrombotic strokes have also been reported. 55,56 (See 
Chapter 7: Treatment of Specific Hemorrhages – Table 7-2.) 
 Atrial fibrillation 
•  Non-valvular atrial fibrillation (AF) is the most common type of 
arrhythmia, and it is associated with a significant increase in the 
risk of embolic stroke. Its prevalence in the general population 
increases with age, ranging from <0.1% in patients less than 
55 years of age to 3% in patients between 65 and 69 years of age, 
and up to 9% in patients over 80 years of age. 57-59 
•  Results of recent studies indicate that the prevalence of atrial 
fibrillation in patients with hemophilia is similar to that reported 
in their peers in the general population. 60 
•  There is no evidence to suggest that patients with hemophilia and 
atrial fibrillation are protected from thromboembolic complications. 
•  Management of non-valvular atrial fibrillation comprises rhythm 
control strategies such as cardioversion or ablation; however, 
these strategies do not always obviate the need for therapeutic 
anticoagulation. 54 
•  The selection of patients with hemophilia who have a high chance 
of successful cardioversion should involve a cardiologist at a he-
mophilia treatment centre. 44 
•  Left atrial appendage occlusion may be an option for patients 
with non-valvular atrial fibrillation at high risk of bleeding and 
cardioembolism. 61 
•  In patients without bleeding diathesis, treatment decisions re-
garding anticoagulation in atrial fibrillation are determined by 
weighing an individual ' s stroke risk as calculated by the CHA 2 DS 2 -
VASc score against an estimated bleeding risk occurring as a 
consequence of anticoagulation therapy (the risk of bleeding as-
sociated with anticoagulation for atrial fibrillation in the general 
population is calculated by the HAS-BLED score). 54 
•  There is no evidence to support or reject the hypothesis that the 
CHA 2 DS 2 -VASc and HAS-BLED scores are equally useful in pa-
tients with hemophilia. 54,60 
•  There are no evidence-based guidelines for the management of 
atrial fibrillation in patients with hemophilia. 
 Recommendation 9.8.6: 
•  Patients with hemophilia and non-valvular atrial fibrillation 
should be treated by medical teams composed of experienced 
hematologists and cardiologists.  CB 
 Recommendation 9.8.7: 
•  For patients with severe or moderate hemophilia and atrial fibril-
lation, the WFH recommends clinical management based on 
basal FVIII/FIX levels and stroke risk by weighing the patient ' s 
stroke risk as calculated by the CHA  2  DS  2  -VASc score against an 
estimated bleeding risk occurring as a consequence of anticoag-
ulation therapy, and withholding anticoagulation if stroke risk is 
deemed to be lower than bleeding risk.  CB 
 Recommendation 9.8.8: 
•  For patients with hemophilia and atrial fibrillation at high risk 
of bleeding and thromboembolism, the WFH recommends left 
atrial appendage occlusion, particularly if long-term replacement 
therapy with deficient clotting factor is not feasible. 
•  REMARK : Left atrial appendage occlusion for patients with hemo-
philia and atrial fibrillation should be preceded by assessments 
of the individual ' s risk of bleeding and thromboembolism and im-
plemented under the advisement of a cardiologist.  CB 
 Recommendation 9.8.9: 
•  For patients with hemophilia in whom the risk of non-valvular 
atrial fibrillation-associated stroke is high or outweighs the risk 
of bleeding complications, the WFH recommends careful consid-
eration of the use of anticoagulants. 
•  REMARK : The choice between direct oral anticoagulants and vita-
min K antagonists depends on the local protocols, availability of 
antidotes for reversal of anticoagulant activity, and feasibility of 
maintaining adequate trough levels of the deficient clotting factor. 
•  REMARK : Despite the scarcity of evidence-based data for this 
indication in patients with hemophilia, most experts suggest 
maintaining trough levels of the deficient clotting factor in the 
individual patient at ≥15-30 IU/dL while on anticoagulant ther-
apy for atrial fibrillation. 
•  REMARK : Because treatment responses to DOACs and VKAs may 
vary, decisions on anticoagulant therapy should be based on the 
individual patient in consultation with a cardiologist.  CB 
 Recommendation 9.8.10: 
•  In hemophilia patients with inhibitors, antithrombotic therapy is 
generally contraindicated.  CB 
•  More research is needed to better understand the safety of anti-
thrombotic therapy in patients with hemophilia A complicated by 
FVIII inhibitors who are treated with emicizumab. 
 Venous thromboembolism/thrombosis 
•  Patients with hemophilia are considered to be protected against 
venous thromboembolism (VTE) by virtue of their coagulation 
factor deficiency. 
•  Spontaneous VTE is uncommon among patients with hemophilia, 
including those with inherited thrombophilia; however, VTE asso-
ciated with surgical interventions (e.g., total knee or hip replace-
ment or major abdominal surgery for cancer) has been reported. 
It has been postulated that in this clinical setting, the natural pro-
tection against VTE is mitigated by administration of high doses of 
concentrates of the deficient clotting factor. 62-64 
•  Intensive replacement therapy with prothrombin complex con-
centrate (PCC) in patients with hemophilia B may result in accu-
mulation of clotting factors II, VII, and X, which may be associated 
with a higher risk of VTE development. 65 
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•  Intensive therapy with bypassing agents may also be associated 
with a higher risk of VTE development. 54,65 
•  Concomitant use of emicizumab and activated prothrombin com-
plex concentrate (aPCC) may also result in thrombotic compli-
cations, including VTE and thrombotic microangiopathy. 66 (See 
Chapter 8: Inhibitors to Clotting Factor.) 
•  There is currently a lack of evidence-based consensus on how to 
manage VTE in patients with hemophilia. It has been suggested 
that therapeutic doses of anticoagulants may be administered 
when deficient clotting factor levels are maintained above 30 IU/
dL 44 or above 15 IU/dL. 54 
•  Hemostatic response to bypassing agents is often unpredictable; 
therefore, antithrombotics should only be used in patients with 
hemophilia and high-responding inhibitors who are at the highest 
risk of developing thromboses. In rare cases, the risk of untreated 
thrombosis may outweigh the risk of bleeding complications and 
therefore justify the use of antithrombotic agents. (For patients 
with inhibitors, see Chapter 8: Inhibitors to Clotting Factor.) 
 Recommendation 9.8.11: 
•  In patients with hemophilia undergoing surgical procedures who 
carry a high risk of developing venous thromboembolism (e.g., 
in cases of major orthopedic surgery, major abdominal surgery 
for cancer, or long post-surgery immobilization), the WFH rec-
ommends an assessment of individual risk of VTE.  CB 
 Recommendation 9.8.12: 
•  For patients with hemophilia undergoing surgery associated with 
a high risk of venous thromboembolism and bleeding complica-
tions, the WFH recommends consideration of the use of mechan-
ical methods for thromboprophylaxis. 
•  REMARK : In contrast to pharmacological thromboprophylaxis, me-
chanical methods of thromboprophylaxis are not associated with 
the risk of bleeding complications.  CB 
 Recommendation 9.8.13: 
•  For patients with hemophilia in whom the balance of the risk of 
bleeding compared to the risk of developing venous thromboem-
bolism favours pharmacological thromboprophylaxis, the WFH 
recommends the same practice as that applied in the general popu-
lation, provided that adequate replacement therapy is administered. 
•  REMARK : Decisions on anticoagulant therapy in a patient with 
hemophilia should always be preceded by assessments of the 
individual ' s bleeding and thrombotic risk. In some patients with 
hemophilia, the risk of uncontrolled bleeding may outweigh the 
benefit of anticoagulation.  CB 
 Recommendation 9.8.14: 
•  For patients with hemophilia without inhibitors, the WFH recom-
mends the use of prophylactic doses of anticoagulants only after 
ensuring hemostatic control with adequate replacement therapy. 
•  REMARK : If the risk of uncontrolled bleeding outweighs the bene-
fit of anticoagulation, anticoagulants should not be used. 
•  REMARK : This recommendation does not apply to patients with 
hemophilia and inhibitors in whom anticoagulants are generally 
contraindicated.  CB 
 Recommendation 9.8.15: 
•  In hemophilia patients without inhibitors who experience an 
acute episode of venous thromboembolism, the WFH recom-
mends the use of high-intensity anticoagulation for the minimal 
duration and under clotting factor replacement protection and 
close clinical and laboratory monitoring. 
•  REMARK : This recommendation does not apply to hemophilia pa-
tients with inhibitors in whom anticoagulants are generally con-
traindicated.  CB 
•  More research is needed to better understand the safety of anti-
thrombotic therapy in patients with hemophilia A complicated by 
FVIII inhibitors who are treated with emicizumab. 
 Metabolic syndrome 
•  Metabolic syndrome is associated with obesity and physical in-
activity, both of which are common in older patients with hemo-
philia due to severe hemophilic arthropathy. 43 
•  Obesity (body mass index [BMI] ≥30 kg/m 2 ) is a major health con-
cern in developed countries in both the general population and in 
patients with hemophilia. 67 The number of patients with hemo-
philia who are overweight is also increasing. 68 
•  Obesity impacts physical activity in both children 69 and adults. 70 
Although few studies have assessed the effects of obesity on he-
mophilia-specific outcomes, there is evidence that excess weight 
has a significant impact on lower extremity joint range of motion 
and functional ability, as well as on joint pain, with potentially sig-
nificant effects on overall quality of life. 71,72 
•  Overweight and obesity can affect frequency of bleeding in 
different ways: some overweight/obese patients have reduced 
bleeding rates, but this may be due to lower levels of physical 
activity; conversely, obese patients with hemophilia tend to 
have more joint bleeds, compared to non-obese patients with 
hemophilia. 70 
•  Venous access is more complex in obese patients with hemophilia, 
which may inhibit their ability to self-infuse and therefore result 
in lower compliance with their prophylaxis regimen. 73 Lower com-
pliance with prophylaxis may result in more joint bleeding and 
ultimately worsen hemophilic arthropathy and osteoarthritis in 
obese patients with hemophilia. 70 
•  Factor recovery is different in patients with hemophilia who are 
overweight or obese. A median FVIII recovery has been observed 
in obese children (2.65), compared to those with normal weight 
(1.94). 74,75 
•  For some obese patients, lean body weight dosing may be effective 
while reducing cost of treatment based on body weight. However, 
each patient would have to be assessed by pharmacokinetic 
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studies, including trough and peak levels, and factor levels at ad-
ditional timepoints to establish ideal dosing. 
•  Weight management should be offered as part of health promo-
tion within hemophilia treatment centres for all patients. This 
should include: 
 ◦  nutritional education for parents of children as well as for 
adults with hemophilia; 
 ◦  weight management programs; 
 ◦  psychological support; 
 ◦  exercise programs (preferably monitored by the centre ' s phys-
ical therapist); 
 ◦  pharmacological therapy; 
 ◦  bariatric surgery; and 
 ◦  collaboration with or referral to obesity medical/surgical teams. 
•  Bariatric surgery is possible in morbidly obese people with 
hemophilia. 76 
 Recommendation 9.8.16: 
•  Patients with hemophilia should have regular height and weight 
measurements to monitor body mass index.  CB 
 Recommendation 9.8.17: 
•  Patients with hemophilia who are overweight or obese should be 
referred for dietary advice and/or weight management.  CB 
 Recommendation 9.8.18: 
•  Patients with hemophilia who are obese should have FVIII/FIX 
replacement therapy based on lean body weight after individual 
pharmacokinetic assessments.  CB 
 Diabetes mellitus 
•  Little is known about the prevalence of diabetes mellitus in people 
with hemophilia, but it has been found to be higher in the hemo-
philia population than in the general population. 43 
•  If treatment with insulin is indicated, subcutaneous injections can 
be administered without bleeding and without the need for factor 
replacement. 37 
•  Higher body weight/BMI is a major risk factor for not only the 
development of diabetes mellitus, but also for atherosclerosis, 
cardiovascular disease, and further damage to arthropathic joints. 
As a result, regular physical activity and physical therapy aimed at 
preventing further joint deterioration are advisable. 43 
 Recommendation 9.8.19: 
•  Patients with hemophilia should have the same screening for di-
abetes as the general population.  CB 
 Recommendation 9.8.20: 
•  Patients with hemophilia and diabetes should have the same 
management strategies to control their diabetes as the general 
population; if treatment with insulin is indicated, subcutaneous 
injections can be administered without bleeding and without 
the need for factor replacement.  CB 
 Renal disease 
•  A higher incidence of renal disease has been reported in people 
with hemophilia, compared with the general population. In addition, 
the likelihood of death from renal failure is about 50 times higher 
among patients with hemophilia than in the general population. 45 
•  The increasing frequency of renal disease in older patients with 
hemophilia is likely due to a number of concomitant risk factors 
including 44,45 : 
 ◦  older age; 
 ◦  non-white population; 
 ◦  hypertension; 
 ◦  history of renal bleeds and hematuria, potentially resulting in 
structural renal damage; 
 ◦  HIV infection and combined antiretroviral therapy; 
 ◦  use of antifibrinolytic amino acids. 
•  Therefore, the need for dialysis may be increasing in patients with 
hemophilia. 44 
•  In those patients who require renal replacement therapy, the 
choice between peritoneal dialysis and hemodialysis depends on 
patient-specific factors, such as the increased risk of infection in 
patients with cirrhosis and/or ascites. 45 
•  Theoretically, peritoneal dialysis is preferable to hemodialysis be-
cause it requires factor coverage only at the time of catheter in-
sertion; however, the procedure is associated with a high risk of 
peritoneal infections, particularly in HCV- and HIV-infected pa-
tients. Thus, hemodialysis using heparin and a single dose of CFC 
before and after each procedure is often preferred. 44 
•  If hemodialysis is selected, central venous access is mandatory. 
Before placement of the device, factor levels should be 80-100 IU/
dL and then maintained between 50 and 70 IU/dL for 3 days after 
the procedure. 45,77 
 Osteoporosis 
•  Bone mineral density (BMD) has been shown to be lower in peo-
ple with hemophilia. An increased number of arthropathic joints, 
loss of joint movement, and muscle atrophy leading to inactivity 
are associated with a lower BMD. 78,79 
•  It is not clear whether patients with hemophilia require routine 
monitoring of bone mass; it may be advisable in patients with high 
risk or multiple risk factors. 
•  Weight-bearing activities and suitable sports that promote devel-
opment and maintenance of good bone density should be encour-
aged for younger patients, if their joint health permits, to build 
bone mass and reduce the risk of later osteoporosis. 
•  Calcium and vitamin D supplements or bisphosphonates should 
be considered for patients with demonstrated osteopenia, and a 
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dental evaluation should be carried out before initiating long-term 
bisphosphonate therapy. 80,81 
 Degenerative joint disease 
•  Joint damage progresses with increasing age in a near-linear fash-
ion not only in patients with severe hemophilia but also in mod-
erate cases. 44 
•  Contributing factors include osteoporosis and osteopenia, a sed-
entary lifestyle, overweight, and obesity. 44 
•  Due to the increased rate of joint morbidity, preventive strate-
gies are necessary. While secondary prophylaxis reduces the in-
cidence of bleeding, its efficacy in improving orthopedic function 
has not been clearly established. 45 
•  See also Chapter 10: Musculoskeletal Complications. 
 Recommendation 9.8.21: 
•  All patients with hemophilia should be encouraged to engage in 
regular physical activity and to have adequate calcium and vita-
min D intake. 
•  REMARK : Hemophilia patients with musculoskeletal conditions 
and injuries should have physical therapy and rehabilitation su-
pervised by a physical therapist with hemophilia experience.  CB 
 Recommendation 9.8.22: 
•  Hemophilia patients with osteoporosis, fragility fractures, or 
who are at increased fracture risk should be treated with individ-
ually adjusted anti-osteoporotic medications.  CB 
 9.9  |  Medical issues with aging 
•  See also 9.8 Comorbidities, above, for discussion of cancer/malig-
nancy, cerebrovascular accident/stroke, atrial fibrillation, venous 
thromboembolism/thrombosis, metabolic syndrome, diabetes 
mellitus, renal disease, and degenerative joint disease. 
•  It is important to provide older patients with regular education 
and counselling on the importance of informing the hemophilia 
team of their health issues to ensure appropriate treatment. 
•  Aging patients with hemophilia require the same access as pa-
tients without hemophilia to health education and preventive 
strategies to reduce the risk or impact of age-related morbidity. 
•  The hemophilia team should be closely involved in managing as-
pects and complications of care related to aging, and ensure close 
consultation and agreement on treatment plans. 
•  Patients with mild hemophilia may require specific education and 
attention to highlight potential issues associated with hemophilia 
and other illnesses. 
 Recommendation 9.9.1: 
•  The WFH recommends that aging patients with hemophilia be 
granted the same access to health education and preventive 
strategies to reduce the risks or impacts of age-related morbidi-
ties as the general population.  CB 
 Recommendation 9.9.2: 
•  The WFH recommends the hemophilia team should be closely 
involved in managing aspects and complications of care related 
to aging and ensure close consultation and agreement on treat-
ment plans.  CB 
 Hypertension 
•  Studies have shown that people with hemophilia have higher 
mean blood pressure, are twice as likely to have hypertension, and 
use more antihypertensive medications compared to the general 
population. 82,83 
•  Hypertension is associated with the usual risk factors, such as 
older age, diabetes mellitus, dyslipidemia, or higher BMI and obe-
sity; however, the causes of the increased prevalence of hyper-
tension in patients with hemophilia remain unclear. 84,85 
•  Hypertension is a well-established risk factor for cardiovascular 
diseases, renal diseases, and intracranial hemorrhage, all of which 
may pose significant challenges in the management of care for 
patients with hemophilia. 84 
•  In view of the increased risk of bleeding, hypertensive patients 
with hemophilia should receive appropriate treatment and have 
their blood pressure checked regularly. 
•  In the absence of other cardiovascular risk factors, a systolic blood 
pressure ≤130 mm Hg and a diastolic blood pressure ≤80 mm Hg 
should be maintained. 
 Recommendation 9.9.3: 
•  For all patients with hemophilia, the WFH recommends regular 
blood pressure measurements as part of their standard care. 
•  REMARK : This recommendation is based on data indicating a 
higher prevalence of arterial hypertension among patients with 
hemophilia irrespective of age as compared with males in the 
general population.  CB 
 Recommendation 9.9.4: 
•  For patients with hemophilia, the WFH recommends the same 
management of arterial hypertension as that applied in the gen-
eral population. 
•  REMARK : Patients with hemophilia diagnosed with hypertension 
may be treated in a hemophilia treatment centre or referred to 
primary care providers depending on the local healthcare system 
and practices.  CB 
 Coronary artery disease 
•  There is evidence that people with hemophilia develop athero-
sclerosis at similar rates to those in the general population. 86,87 
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•  By contrast, patients with hemophilia have lower cardiovascu-
lar mortality rates compared with the general population (most 
likely because of lower thrombin generation at the point of plaque 
rupture). 87,88 
•  It is not known whether the increasing use of prophylaxis in aging 
patients with hemophilia will result in an increase in cardiovascu-
lar mortality. 89 
•  Individuals with severe, moderate, and mild hemophilia may de-
velop overt ischemic heart disease. The management of such 
cases should be individualized and requires close cooperation be-
tween the hemophilia and cardiology teams. 
•  Making a decision on antithrombotic therapy in a patient with in-
nate bleeding tendency is particularly difficult; a recent study found 
that antiplatelet and anticoagulant medications increased severe 
bleeding in patients with hemophilia (odds ratio [OR] = 3.5). 90 
•  When considering antithrombotic therapy in patients with hemo-
philia, the following aspects should be evaluated 54 : 
 ◦  patient bleeding phenotype; 
 ◦  intensity of the antithrombotic therapy; 
 ◦  duration of the planned therapy; and 
 ◦  characteristics of the antithrombotic agent. 
•  Healthcare providers working with patients with hemophilia 
should educate them on cardiovascular risk and encourage risk 
reduction (smoking, obesity, exercise) or optimization (hyperten-
sion, hyperlipidemia). 89 
 Recommendation 9.9.5: 
•  Patients with hemophilia should receive the same screening and 
management for individual cardiovascular disease risk factors as 
the general population.  CB 
 Recommendation 9.9.6: 
•  Patients with hemophilia and cardiovascular disease should re-
ceive routine care adapted to their individual situation in consul-
tation with a cardiologist.  CB 
 Recommendation 9.9.7: 
•  For patients with hemophilia without inhibitors who have been 
diagnosed with cardiovascular disease, the WFH recommends 
similar management as that applied to the general population, 
except for the necessary additional correction of impaired he-
mostasis with clotting factor concentrates. 
•  REMARK : Decisions on cardiovascular treatment strategy for pa-
tients with hemophilia should always be preceded by assess-
ments of the individual ' s bleeding and thrombotic risks and 
cardiac disease severity and implemented under the advisement 
of a cardiologist.  CB 
 Recommendation 9.9.8: 
•  Among patients with hemophilia and high-responding inhibi-
tors, the WFH recommends limiting the use of antithrombotics 
to those patients in whom the risk of untreated thrombosis out-
weighs the risk of bleeding complications. 
•  REMARK : This recommendation is based on the observation that 
hemostatic response to bypassing agents is often unpredictable. 
•  REMARK : More research is needed to better understand the 
safety of antithrombotic therapy in patients treated with emi-
cizumab.  CB 
 Recommendation 9.9.9: 
•  Given the scarcity of published data on antiplatelet therapy in 
patients with hemophilia, the WFH recommends careful evalua-
tion of an individual ' s bleeding and thrombotic risk. 
•  REMARK : It has been suggested that the trough level of the defi-
cient clotting factor be maintained at ≥15-30 IU/dL during dual 
antiplatelet therapy and at ≥1-5 IU/dL during single-agent anti-
platelet therapy; however, treatment strategy should be tailored 
to the individual. 
•  REMARK : The decision on use of antiplatelet therapy in a patient 
with hemophilia should always be made in consultation with a 
cardiologist.  CB 
 Recommendation 9.9.10: 
•  Given the scarcity of published data on patients with hemo-
philia undergoing percutaneous coronary intervention, the WFH 
recommends careful evaluation of an individual ' s bleeding and 
thrombotic risk.  CB 
•  REMARK : It has been suggested that in patients with hemophilia 
without inhibitors who are undergoing PCI, the deficient clotting 
factor be maintained at the peak level of 80-100 IU/dL for as 
long as therapeutic doses of antithrombotics are used; however, 
treatment strategy should be tailored to the individual. 
•  REMARK : The decision on use of antithrombotic therapy for this 
indication should always be made in consultation with a cardi-
ologist.  CB 
 Recommendation 9.9.11: 
•  Given the scarcity of published data on patients with hemophilia 
undergoing coronary artery bypass grafting, the WFH recommends 
careful evaluation of an individual ' s bleeding and thrombotic risk. 
•  REMARK : It has been suggested that in patients with hemophilia 
without inhibitors who are undergoing CABG, similarly to other 
major surgical procedures, the deficient clotting factor be main-
tained at the peak level of 80-100 IU/dL before, during, and after 
CABG until sufficient wound healing has taken place; however, 
treatment strategy should be tailored to the individual. 
•  REMARK : The decision on use of antithrombotic therapy for this 
indication should always be made in consultation with a cardi-
ologist.  CB 
 Recommendation 9.9.12: 
•  Given the scarcity of published data on patients with hemophilia 
and ST-elevation myocardial infarction in whom early percutane-
ous coronary intervention is not available, the WFH recommends 
careful evaluation of an individual ' s bleeding risk and cardiac dis-
ease severity. 
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•  REMARK : Use of fibrinolytic therapy may only be considered after 
complete correction of hemostasis with deficient clotting factor 
replacement. 
•  REMARK : The decision on use of fibrinolytic therapy for this indica-
tion should always be made in consultation with a cardiologist.  CB 
 Recommendation 9.9.13: 
•  When heart valve replacement is indicated in patients with he-
mophilia, a bioprosthetic valve should be the first choice to avoid 
the need for indefinite anticoagulation.  CB 
 Hypercholesterolemia 
•  Mean cholesterol levels in patients with hemophilia have been re-
ported to be lower than in the general population. 91 Cholesterol 
levels (total cholesterol, HDL, and LDL fraction) should be measured 
in aging patients with hemophilia at risk of cardiovascular disease. 
•  Treatment is indicated if cholesterol levels are high. As a general 
rule, the total cholesterol/HDL ratio should not be higher than 8. 
 Recommendation 9.9.14: 
•  In patients with hemophilia, the management of hypercholester-
olemia should be the same as for the general population.  CB 
 Psychosocial issues with aging 
•  For aging patients with hemophilia, crippling, painful arthropathy 
can affect quality of life and may lead to loss of independence. 92 
•  Aging patients may be confronted with unexpected emotional 
problems due to memories of negative experiences related to he-
mophilia (e.g., hospitalization) during their youth. 89 
•  Adaptations at home or at work and an appropriate pain manage-
ment regimen are indicated to improve quality of life and preserve 
independence. 
•  Active psychosocial support should be provided by a social 
worker, hemophilia nurse, physician, and/or psychologist. 
•  The patient ' s annual checkup at the hemophilia treatment centre 
is a good time to assess and address changing needs with age. 
Refer patients to appropriate services and resources as needed 
and as mutually agreed upon. 
 Recommendation 9.9.15: 
•  As adults with hemophilia experience many personal and social 
changes with aging, the WFH recommends active psychosocial 
assessments and support for their changing needs.  CB 
 Quality of life assessment 
•  People with hemophilia may face a variety of psychosocial issues 
which may impact their well-being. Quality of life assessments 
can help to: 
 ◦  identify patient perceptions of their health status and needs; 
 ◦  gather evidence on clinical findings that can lead to improved 
quality of care; 
 ◦  serve as a rapid screening to identify individual patients or 
populations who might require more detailed assessment of 
their health and quality of life needs; and 
 ◦  identify individual and overall patient needs in terms of 
gaps in knowledge and/or education to facilitate better 
self-management. 
•  See also Chapter 11: Outcome Assessment. 
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 All statements identified as recommendations are consensus based, 
as denoted by  CB . 
 10.1  |  Introduction 
•  Hemophilia is characterized by acute bleeds, over 80% of which 
occur in specific joints (most commonly the ankle, knee, and elbow 
joints, and frequently the hip, shoulder, and wrist joints) and in 
particular muscles (iliopsoas and gastrocnemius). 1,2 Spontaneous 
bleeding may occur depending on the severity of the disease (see 
Chapter 2: Comprehensive Care of Hemophilia – Table 2-1), or 
breakthrough bleeding may occur depending on the prophylactic 
treatment approach. 
•  In children with severe hemophilia, the first joint and muscle bleeds 
typically occur when they begin to crawl and walk, usually be-
tween 1 and 2 years of age, but sometimes in later toddler years. 3 
•  Recurrent joint bleeds cause progressive joint damage as a result 
of blood accumulation in the joint cavity and synovial inflamma-
tion. This leads to complications such as chronic synovitis and he-
mophilic arthropathy. 1,2 For discussion and recommendations on 
joint bleeds, see Chapter 7: Treatment of Specific Hemorrhages 
and Table 7-2. 
•  Inadequate treatment of intramuscular bleeds can lead to mus-
cle contractures, especially in bi-articular muscles (e.g., calf and 
psoas muscles), often within the first decades of life. 1,2 Other 
more serious complications such as compartment syndrome and 
pseudotumours may also develop. (See “ Clotting factor replace-
ment therapy ” and  10.5 Pseudotumours , below.) 
•  Prophylaxis to prevent bleeding episodes is considered the stan-
dard of care to the extent that resources permit. 4 
•  Successful treatment to achieve complete functional recovery 
generally requires a combination of clotting factor concentrate 
(CFC) replacement therapy or other hemostatic coverage (e.g., by-
passing agents for patients with inhibitors) and physical therapy. 
 Patient/caregiver education 
•  Patient education on musculoskeletal issues in hemophilia is crit-
ical and should encompass joint and muscle health, recognition 
and treatment of musculoskeletal bleeds, pain management, mus-
culoskeletal complications, and the importance of physical ther-
apy and rehabilitation. A multidisciplinary approach to addressing 
the bleed and its consequences is essential. 5 (See Chapter 2: 
Comprehensive Care of Hemophilia.) 
 10.2  |  Synovitis 
•  Following acute hemarthrosis, the synovium becomes inflamed, 
hyperemic, and friable. This acute synovitis can take several 
weeks to resolve. 2,6,7 
•  Failure to manage acute synovitis results in recurrent hemar-
throses and subclinical bleeds 1,2 ; the synovium becomes chron-
ically inflamed and hypertrophic, and the joint becomes prone to 
further bleeding. A vicious cycle of bleeding, loss of joint motion, 
and inflammation can ensue which ultimately leads to irreversible 
cartilage 7,8 and bone damage and impaired joint function. 6 
•  If this process exceeds 3 months, it is defined as chronic synovitis. 
•  Regular assessments are required until the joint and synovial con-
dition are fully rehabilitated, and there is no evidence of residual 
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blood and/or associated synovitis. 9 Physical examination for joint 
changes (e.g., in joint circumference, muscle strength, joint effu-
sion, joint angle, pain according to a visual analogue scale) should 
be conducted at all routine follow-ups. (See Chapter 11: Outcome 
Assessment.). However, in many cases, the synovium never re-
turns to its original state. 
•  Given that clinical signs do not always adequately represent the 
actual situation, ultrasound evaluation is advised. 9,10 Magnetic 
resonance imaging (MRI), while currently the gold standard for 
imaging, is expensive technology, time- consuming, and is not fea-
sible for very young children. 6 
 Recommendation 10.2.1: 
•  For people with hemophilia, the WFH recommends regular 
physical assessment of the synovial condition after every bleed, 
preferably using suitable imaging techniques such as ultrasound 
(when feasible) until the situation is controlled, as clinical assess-
ment alone is inadequate to detect early synovitis.  CB 
 Treatment of chronic synovitis 
•  The goal of chronic synovitis treatment is to suppress synovial ac-
tivation and reduce inflammation to preserve joint integrity and 
function. 11,12 
•  Nonoperative options include prophylaxis for 6-8 weeks (for 
those not on regular prophylaxis), physical therapy, and selective 
COX-2 inhibitors to reduce inflammation. 13,14 
 Recommendation 10.2.2: 
•  For patients with hemophilia who have chronic synovitis and no 
access to regular prophylaxis, the WFH recommends nonsurgi-
cal treatment, including short-term prophylaxis for 6-8 weeks to 
control bleeding; physical therapy to improve muscle strength 
and joint function; and selective COX-2 inhibitors to reduce pain 
and inflammation. 
•  REMARK : Physical therapy with individualized goals and exercises 
based on the patient ' s functional level should start slowly with 
increasing progression of weight-bearing activities. 
•  REMARK : For patients with acute pain and recurrent bleeding, 
bracing may stabilize the affected joint and limit motion, but 
caution is advised as prolonged immobilization leads to muscle 
weakness, so isometric exercises even within bracing are advised. 
•  REMARK : If unresponsive to nonsurgical interventions, treatment 
should be escalated to treat the synovitis directly, by the treat-
ment intervention of the local expert.  CB 
 Recommendation 10.2.3: 
•  For patients with hemophilia who have chronic synovitis (char-
acterized only by minimal pain and loss of range of motion) the 
WFH recommends consultation with an experienced musculo-
skeletal specialist in a hemophilia treatment centre.  CB 
 Physical therapy for synovitis 
•  Physical therapy 15,16 under the direction of a hemophilia treat-
ment centre is advised throughout the entire rehabilitation trajec-
tory, with progressive exercises to build up to full weight bearing 
and complete functional recovery. This may include daily exercises 
to improve muscle strength and restore joint range of motion. 17 
•  Functional training may commence based on practical goals for 
each individual. 18 
•  Bracing may be appropriate to stabilize the affected joint and limit 
movement in order to prevent recurrent bleeding and synovial 
impingement during movement. 19 (See Chapter 7: Treatment of 
Specific Hemorrhages – Joint hemorrhage – Physical therapy and 
rehabilitation.) 
•  In chronic cases that no longer respond to nonoperative mea-
sures, synovectomy/synoviorthesis may be indicated. 
 Synovectomy/synoviorthesis 
•  Synovectomy should be considered if chronic synovitis persists 
with frequent recurrent bleeding not controlled by other means. 
•  The procedure can be performed in several ways: chemical or ra-
dioisotope intra-articular injection (synoviorthesis); arthroscopic 
synovectomy; or open surgical synovectomy. 20,21 
•  Nonsurgical synovectomy should always be the first procedure of 
choice for all patients. 
•  Radiosynovectomy is indicated for synovitis (confirmed clinically 
or by point-of-care ultrasound) causing 2 or more bleeds in a par-
ticular joint over the last 6 months despite adequate treatment. 9 
•  Radioisotope synovectomy using a pure beta emitter (phospho-
rus-32, yttrium-90, rhenium-186, or rhenium-188) is highly ef-
fective, has few side effects, and can be accomplished in a single 
outpatient procedure. 9,22-30 
•  Choice and dose of radioisotope depend on the joint to be in-
jected, the condition of its synovium, and available radioisotopes. 
•  Prophylaxis should be administered prior to radiosynovectomy; 
one dose of CFC is usually sufficient for a single injection of the 
radioisotope. 
•  Where possible, simultaneous administration of intra-articular 
steroids is recommended. 31 
•  The joint should then be rested for at least 24-48 hours 31,32 in a 
splint or other immobilization device, after which rehabilitation 
can commence. 
•  Rehabilitation after radiosynovectomy is less intensive than after 
surgical synovectomy, but it is still required to help patients re-
gain strength, proprioception, and functional use of the joint. 15 
An individualized rehabilitation program for at least 3 weeks may 
be appropriate. 26 Intensive exercise and weight bearing should be 
avoided immediately following radiosynovectomy. 33 
•  The aim of treatment is to reduce synovitis and the frequency of 
bleeds, thereby indirectly reducing pain. It has no effect on articular 
degeneration. With the improvement in pain and the reduction of 
bleeds, the patient may regain function through appropriate rehabil-
itation. Pain reduction typically occurs 1-3 weeks postinjection. 31,32 
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•  The minimum interval between repeated treatments in the same 
joint is 6 months. 31 
•  If radioisotopes are not available, chemical synoviorthesis with 
either rifampicin or oxytetracycline chlorhydrate may be con-
sidered. Chemical synoviorthesis may be painful, and the scle-
rosant injection should be combined with an intra-articular local 
anesthetic to minimize pain, supplemented by oral analgesics (a 
combination of acetaminophen/paracetamol and an opioid) as 
required. 34-36 
•  Frequent injections may be required; typically, 5-6 weekly injec-
tions are needed until the synovitis is controlled. 34-36 
 Recommendation 10.2.4: 
•  For patients with hemophilia who have unresolved chronic sy-
novitis, the WFH recommends nonsurgical synovectomy as a 
first-line treatment option using radioisotope synovectomy with 
a pure beta emitter (phosphorus-32, yttrium-90, rhenium-186, or 
rhenium-188). One dose of CFC per dose of isotope should be 
used. 
•  REMARK : Choice of isotope depends on the joint being injected 
and isotope availability. 
•  REMARK : The joint should be immobilized for at least 24 hours, fol-
lowed by progressive rehabilitation for restoration of strength 
and function. 
•  REMARK : When radioisotopes are not available, chemical synov-
iorthesis with either rifampicin or oxytetracycline chlorhydrate 
(once weekly injection for 5-6 weeks) is an alternative, accom-
panied by one dose of CFC per treatment, a local anesthetic, and 
oral analgesics.  CB 
•  In cases where chronic synovitis is resistant to treatment with ra-
diosynovectomy, selective embolization of the blood vessels that 
supply the synovium may be performed. This procedure is to be 
performed only in specialized medical imaging centres. 37 
•  Surgical synovectomy may be considered when other less inva-
sive procedures have failed or when an additional procedure is 
required that must be performed through arthroscopy 38 such as 
removal of a tibial anterior osteophyte of the ankle. 
•  Arthroscopic synovectomy is suggested over open synovectomy. 39 
•  If surgical synovectomy (either open or arthroscopic) is necessary, 
ensure longer prophylaxis coverage with CFCs or other appropri-
ate hemostatic agents sufficient for the procedure and postop-
erative rehabilitation. The procedure must be performed by an 
experienced team at a dedicated hemophilia treatment centre. 
 Recommendation 10.2.5: 
•  For patients with hemophilia who have chronic synovitis that no 
longer responds to nonoperative interventions, the WFH recom-
mends surgical synovectomy (preferably arthroscopic, not open) 
only by an experienced team in a hemophilia treatment centre.  CB 
•  See also Chapter 7: Treatment of Specific Hemorrhages – Table 
7-2; Chapter 8: Inhibitors to Clotting Factor – Hemophilia A/
Hemophilia B – Surgery and invasive procedures; and Chapter 9: 
Specific Management Issues – Surgery and invasive procedures. 
 10.3  |  Hemophilic arthropathy 
•  Hemophilic arthropathy can result from a single bleed or recurrent 
bleeds. It generally evolves gradually from hemarthrosis to chronic 
synovitis and extended erosions of the articular surface, culminat-
ing in the final stage of joint destruction, chronic hemophilic ar-
thropathy, 40 which often manifests during the second decade of 
life, particularly if prophylactic therapy is unavailable or inadequate. 
•  Muscle bleeds can result in joint deformity and contracture, par-
ticularly with bleeds within the psoas muscle or gastrocnemius. 
Fixed flexion contractures result in loss of motion and significant 
functional impairment and thus need to be prevented. 
•  As the arthropathy worsens, range of motion and swelling of the 
joint often subside due to progressive fibrosis of the synovium 
and capsule. As the joint becomes ankylosed (stiffened), pain may 
diminish or disappear. 
•  The appropriate radiographic technique for assessing chronic he-
mophilic arthropathy depends on the stage of progression. 
•  MRI is useful to assess early arthropathy and will show early soft 
tissue and osteochondral changes. 41-43 
•  Ultrasound imaging is useful for assessing soft tissue and periph-
eral cartilage pathology in early hemophilic arthropathy. 44 
•  Plain radiographs are insensitive to early change and are used to 
assess late arthropathic changes. 45,46 
•  See Chapter 11: Outcome Assessment. 
 Treatment of chronic hemophilic arthropathy 
•  The goals of treatment are to reduce the incidence of hemar-
throses, improve joint function, relieve pain, and help the patient 
continue or resume normal activities of daily living. 
•  Treatment options for chronic hemophilic arthropathy depend on 
many factors including: 
 ◦  the stage of the condition; 
 ◦  the patient ' s symptoms; 
 ◦  the patient ' s age; 
 ◦  the impacts on the patient ' s lifestyle and functional abilities; 
 ◦  the resources available. 
•  Pain should be controlled with appropriate analgesics. 
•  See Chapter 2: Comprehensive Care of Hemophilia – Pain 
management. 
 Physical therapy for hemophilic arthropathy 
•  Physical therapy aimed at preserving muscle strength and func-
tional ability is an essential component of treatment of chronic 
hemophilic arthropathy. 
•  The intensity of physical therapy should be increased gradually 
and adapted according to prophylaxis coverage; physical therapy 
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should be less intense in patients with limited access to CFC 
replacement. 
•  In settings with limited resources and factor availability, physical 
therapy without factor coverage may be performed if the treat-
ment is coordinated by an experienced multidisciplinary team 
with musculoskeletal expertise. 47 
•  Intermittent prophylaxis coverage may be necessary if break-
through bleeding occurs as a result of physical therapy. 16 Other 
modes of therapy such as exercise therapy, manual therapy, elec-
trotherapy, and hydrotherapy have been used to complement 
physical therapy. 48 
 Recommendation 10.3.1: 
•  For the prevention and treatment of chronic hemophilic arthrop-
athy in people with hemophilia, the WFH recommends a com-
bination of regular replacement therapy to reduce frequency 
of bleeding and physical therapy aimed at preserving muscle 
strength and functional ability. Physical therapy may be done 
with or without factor coverage, depending on availability and 
the patient ' s response to therapy.  CB 
•  Other conservative management techniques include: 
 ◦  serial casting to correct deformities 49 ; 
 ◦  traction devices; 
 ◦  bracing and orthotics to support painful and unstable 
joints 19 ; 
 ◦  walking aids or mobility aids to decrease stress on weight-bear-
ing joints; 
 ◦  adaptations to the home, school, or work environment to 
allow participation in community activities and employment, 
and to facilitate activities of daily living. 50 
 Recommendation 10.3.2: 
•  For the prevention and treatment of the sequelae of joint ar-
thropathy in people with hemophilia, the WFH recommends 
nonsurgical measures such as bracing, orthotics, mobility aids, 
and serial casting and traction devices to aid in the correction 
of flexion contractures. This may be done with or without factor 
coverage.  CB 
 Surgical interventions 
•  If nonsurgical measures fail to provide satisfactory pain relief and 
improved function, surgical intervention may be necessary. 
•  Surgical procedures, depending on the specific condition, may 
include: 
 ◦  synovectomy and joint debridement, if required 38 ; 
 ◦  arthroscopy to release intra-articular adhesions and correct 
impingement, especially in the ankle or elbow joint 51 ; 
 ◦  extra-articular soft tissue release to treat contractures 52 ; 
 ◦  osteotomy to correct angular deformity; 
 ◦  external fixators to assist in deformity correction 53 ; 
 ◦  prosthetic joint replacement (knee, hip, shoulder, elbow, or 
ankle) 54 ; 
 ◦  radial head excision for select patients with radiocapitellar 
arthropathy 55 ; 
 ◦  arthrodesis for painful ankle joint arthropathy. 
•  Adequate resources, including prophylaxis (e.g., sufficient sup-
ply of CFCs) and postoperative rehabilitation, must be available 
to support and increase the likelihood of success of any surgical 
procedure. 56-58 
 Recommendation 10.3.3: 
•  For patients with hemophilia with chronic hemophilic arthropa-
thy for whom nonsurgical measures have failed to provide satis-
factory pain relief and improved function, the WFH recommends 
consultation with an orthopedic specialist on surgical interven-
tion options which may include: 
 ◦  synovectomy and joint debridement; 
 ◦  arthroscopy to release intra-articular adhesions and correct 
impingement; 
 ◦  extra-articular soft tissue release to treat contractures; 
 ◦  osteotomy to correct angular deformity; 
 ◦  arthrodesis (of the ankle); 
 ◦  joint replacement in end-stage arthritis. 
•  REMARK : Adequate resources including a sufficient supply of CFCs 
or other appropriate hemostatic agents (e.g., bypassing agents 
for patients with inhibitors) and postoperative rehabilitation ser-
vices must be available to increase the likelihood of success for 
any surgical procedure.  CB 
•  See also Chapter 7: Treatment of Specific Hemorrhages – Joint 
hemorrhage and Table 7-2; Chapter 8: Inhibitors to Clotting Factor 
– Hemophilia A/Hemophilia B – Surgery and invasive procedures; 
and Chapter 9: Specific Management Issues – Surgery and inva-
sive procedures. 
 10.4  |  Muscle hemorrhage 
•  Bleeds may occur in any muscle of the body, often as a result of 
injury or a sudden stretch. 
•  A muscle bleed is defined as an episode of bleeding into a mus-
cle, determined clinically and/or by imaging studies. It is generally 
associated with pain and/or swelling and functional impairment, 
e.g., a limp associated with a calf bleed. 59 
•  Early identification and proper management of muscle bleeds are 
important to prevent permanent contracture, re-bleeding, and 
possible later formation of pseudotumours. 60 
•  Symptoms of a muscle bleed include: 
 ◦  discomfort in the muscle and maintenance of the limb in a po-
sition of comfort; 
 ◦  severe pain if the muscle is actively contracted or stretched; 
 ◦  tension and tenderness upon palpation; and 
 ◦  swelling. 
•  Sites of muscle bleeding that are associated with neurovascular 
compromise, such as the deep flexor muscle groups of the limbs, 
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require immediate management to prevent permanent damage 
and loss of function. These groups include: 
 ◦  the iliopsoas muscle (risk of femoral nerve palsy); 
 ◦  the superficial and deep posterior compartments of the lower 
leg (risk of posterior tibial and deep peroneal nerve injury); and 
 ◦  the flexor group of forearm muscles (risk of Volkmann ' s isch-
emic contracture). 
•  Bleeding can also occur in more superficial muscles such as the 
biceps, hamstrings, quadriceps, and gluteal muscles. 
•  There is emerging evidence that suggests musculoskeletal ultra-
sound (MSKUS) may be useful in differentiating between muscle 
bleeds and other regional pain syndromes. 61,62 Nonetheless, if a 
patient or clinician suspects a muscle bleed or has difficulty as-
sessing whether a bleed is in progress, hemostatic treatment is 
advised immediately before performing confirmatory investiga-
tions or awaiting such results. 
 Clotting factor replacement therapy 
•  An untreated muscle bleed can result in compartment syndrome 
(a deep muscle bleed within a closed space) with secondary neu-
rovascular and tendon damage and muscle contracture and necro-
sis. In addition, an injured muscle that is not properly rehabilitated 
can exert secondary effects on the adjacent joints. 63 
•  The best practice to achieve the best outcomes is to treat muscle 
bleeds with CFC immediately, ideally when the patient recognizes 
the first signs of discomfort or right after trauma, to raise the pa-
tient ' s factor level to stop the bleed. Factor replacement therapy 
should continue until bleeding symptoms and signs resolve, gen-
erally for 5-7 days or longer, if symptoms indicate recurrent bleed-
ing or worsening neurovascular symptoms. 64-66 (See Chapter 7: 
Treatment of Specific Hemorrhages – Table 7-2.) 
•  Repeat infusions are often required, particularly if there is a po-
tential risk of compartment syndrome and/or if extensive rehabil-
itation is required. 2,67 
•  See Chapter 8: Inhibitors to Clotting Factor for the management 
of bleeds in patients with inhibitors. 
 Recommendation 10.4.1: 
•  All hemophilia patients with muscle bleeds should be given clot-
ting factor replacement therapy immediately and, where appli-
cable, be observed for neurovascular complications associated 
with the bleed.  CB 
 Clinical monitoring and management 
•  It is important to monitor the patient continuously for possible 
compartment syndrome. Symptoms of possible compartment 
syndrome include increasing pain, loss of sensation, loss of func-
tion, and poor blood supply in the distal area. If in doubt, measure 
the compartment pressure. 
•  Pain should be assessed frequently and regularly, as it is an indi-
rect measure of compartment pressure. 
•  Acute muscle bleeds may require escalating the analgesia pro-
tocol to obtain relief. (See Chapter 2: Comprehensive Care of 
Hemophilia – Pain management.) 
•  In addition to factor replacement therapy or other appropriate he-
mostatic therapy, clinicians may apply the following measures as 
adjunctive management of acute muscle bleeds: 
 ◦  Rest the injured muscle. 
 ◦  Where possible, elevate the affected area; this may help to 
reduce the associated swelling. 68 
 ◦  If appropriate, splint the affected limb in a position of comfort 
and adjust to a position of function as pain subsides. 
 ◦  Apply ice/cold packs around the muscle for 15-20 minutes 
every 4-6 hours for pain relief. Do not apply the ice directly 
on the skin. 
•  See also “ Physical therapy and rehabilitation for muscle bleeds ” 
below. 
 Recommendation 10.4.2: 
•  For all hemophilia patients with muscle bleeds, the WFH rec-
ommends detailed clinical assessment, grading, and monitoring 
of pain according to the WHO pain scale, as muscle bleed pain 
may be an early indicator of reversible neurovascular and tissue 
damage. 
•  REMARK : While many pain assessment scales exist, use of the 
WHO pain scale is preferred because it is a simple and universal 
tool that permits uniform measurement of pain in people with 
hemophilia and generates comparable population-level outcome 
data important to advancing hemophilia treatment and research. 
 Compartment syndrome 
•  Neurovascular compromise is a musculoskeletal emergency 
and requires direct, continuous observation and monitoring of 
the need for fasciotomy. Prophylaxis should be administered to 
raise and maintain factor levels for 5-7 days or longer as symp-
toms indicate, along with physical therapy and rehabilitation to 
restore baseline muscle function. 69-71 (See Chapter 7: Treatment 
of Specific Hemorrhages – Table 7-2.) 
•  If compartment syndrome is suspected on clinical grounds, mea-
sure the compartment pressure. If confirmed, fasciotomy should 
be performed within 12 hours of onset of the compartment syn-
drome. 72-74 Late fasciotomy has a very high incidence of complica-
tions and is contraindicated. 75 
•  Earlier fasciotomy is associated with improved patient outcomes, 
including decreased muscle and nerve injury. Once a motor nerve 
deficit has occurred, patients rarely recover fully after fasciotomy. 
•  In patients with hemophilia, if there is uncertainty regarding 
the adequacy of hemostatic response, as may occur in patients 
with high-responding inhibitors, a longer observation period 
may be warranted to possibly avoid fasciotomy and the risk of 
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uncontrolled bleeding after the procedure. However, any delay 
in performing fasciotomy once compartment syndrome is estab-
lished may lead to suboptimal outcomes in muscle recovery and 
subsequent loss of function. 76 
 Recommendation 10.4.3: 
•  In hemophilia patients with muscle bleeds with evidence of 
compartment syndrome and neurovascular compromise, a fas-
ciotomy is required within 12 hours from the time of onset of 
symptoms before irreversible damage sets in due to tissue ne-
crosis.  CB 
 Physical therapy and rehabilitation for muscle bleeds 
•  Physical therapy should begin as soon as pain subsides and should 
be progressed gradually to restore full muscle length, strength, 
and function. 15,73 Supervised physical therapy and rehabilitation 
directed by a physical therapist experienced in hemophilia man-
agement should be initiated: 
 ◦  Ensure appropriate prophylaxis coverage during physical ther-
apy and rehabilitation. In settings with limited resources and 
factor availability, physical therapy without factor coverage 
may be performed during the rehabilitation period if the treat-
ment is coordinated by an experienced multidisciplinary team 
with musculoskeletal expertise. 47 
 ◦  Use serial casting or splinting as required to correct any 
contracture. 
 ◦  Use supportive bracing if there has been nerve damage. 
 ◦  Regularly evaluate the patient for pain during physical therapy, 
which may suggest re-bleeding. 77 
 Iliopsoas hemorrhage 
•  Iliopsoas hemorrhages can potentially lead to musculoskeletal 
damage; therefore, early and effective factor replacement ther-
apy or other appropriate hemostatic therapies are essential to 
minimize and prevent the related complications. 65 
•  An iliopsoas hemorrhage has a particular presentation that can 
sometimes be misleading. 68 Signs may include pain in the lower 
abdomen, groin, and/or lower back, with inability to straighten or 
stand up from a seated position; and pain on extension, but not 
on rotation, of the hip joint. 64 The symptoms of iliopsoas hemor-
rhage may mimic those of acute appendicitis, including a positive 
Blumberg ' s sign (rebound tenderness). 9 It can also be mistaken for 
a hip joint bleed. 
•  There may be paresthesia in the medial aspect of the thigh or other 
signs of femoral nerve compression, such as loss of the patellar ten-
don reflex, quadriceps weakness, and ultimately muscle wasting. 9 
•  Patients with an iliopsoas bleed may need to be hospitalized for 
observation and pain control. 
•  Strict bed rest may be indicated. Ambulation with crutches should 
be avoided as muscle contractions may exacerbate pain and 
bleeding. 64-66 
•  It is useful to confirm the diagnosis and monitor patient recovery 
using imaging studies (ultrasound, CT scan, 59 or MRI 78 ). 64-66 
•  Physical activity should be restricted until pain resolves and hip 
extension improves. A carefully supervised program of physical 
therapy is essential to restore complete hip extension and full ac-
tivity and function, and prevent re-bleeding. 64-66 
•  If residual neuromuscular deficits persist, further orthotic support 
may be necessary, particularly to prevent flexion of the knee due 
to quadriceps weakness. 
•  See also Chapter 7: Treatment of Specific Hemorrhages – Table 
7-2, and Chapter 8: Inhibitors to Clotting Factor. 
 10.5  |  Pseudotumours 
•  A pseudotumour is a potentially limb- and life-threatening condi-
tion unique to hemophilia. 
•  It develops as a result of inadequately treated soft tissue bleeds, 
usually in muscle adjacent to bone, which can be secondarily 
involved. 
•  If untreated, a pseudotumour can become massive, causing pres-
sure on the adjacent neurovascular structures and possibly result-
ing in pathologic fractures. 
•  A fistula can develop through the overlying skin. 
•  Pseudotumours may be assessed and serially followed up using 
ultrasound imaging. 
•  A more detailed and accurate evaluation of a pseudotumour can 
be obtained with a CT scan and MRI. 
 Recommendation 10.5.1: 
•  For hemophilia patients with soft tissue bleeding and signs of a 
possible pseudotumour, the WFH recommends clinical assess-
ment and radiological confirmation using X-ray, ultrasound, and 
magnetic resonance imaging, as appropriate. 
•  REMARK : While ultrasound is useful for serial assessment of a soft 
tissue pseudotumour, MRI provides more detailed information 
prior to surgical intervention. 
•  REMARK : A CT scan or CT angiogram may be indicated, especially 
for a large pseudotumour and/or pre-operative planning.  CB 
•  Management of a pseudotumour depends on its site, size, growth 
rate, and effect on adjoining structures. Options include factor re-
placement therapy and monitoring, aspiration, radiation, surgical 
excision, and surgical ablation. 
•  For small early pseudotumours, a short course (6-8 weeks) of 
factor replacement therapy can be attempted, and the pseudo-
tumour can be monitored using serial ultrasound screening. If 
the pseudotumour is shown to be shrinking, continue factor 
replacement therapy in combination with repeat ultrasound 
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evaluation for 4-6 months. 79,80 (See Chapter 7: Treatment of 
Specific Hemorrhages – Table 7-2.) 
 Recommendation 10.5.2: 
•  For patients with hemophilia who have developed small early 
pseudotumours (prior to acquiring a pseudocapsule) and have 
no access to regular prophylaxis, the WFH recommends a short 
course (6-8 weeks) of clotting factor replacement therapy with 
possible continuation of therapy if serial ultrasound evaluations 
indicate that the pseudotumour is shrinking, with repeat evalua-
tion after 4-6 months.  CB 
•  The management of pseudotumours is complex and associated 
with a high rate of potential complications. Therapeutic alterna-
tives include embolization, radiation, percutaneous management, 
surgical removal, and filling of the dead cavity. 9 
•  Aspiration of the pseudotumour followed by injections of fibrin 
sealant, arterial embolization, or radiotherapy may heal some 
smaller lesions. 81,82 
•  Surgical excision may be necessary for large pseudotumours. 
Removal of the pseudotumour with the pseudocapsule—rather 
than evacuation of the hematoma—is required. 
•  Surgical resection of large abdominal/pelvic pseudotumours, 
which present a special challenge in the surgical management of 
hemophilia, must only be performed by a surgical team with expe-
rience in hemophilia. Preoperative embolization has been found 
to be useful in excision of these large tumours. 
 Recommendation 10.5.3: 
•  For patients with hemophilia who have developed large 
pseudotumours, the WFH recommends surgical excision of the 
pseudotumour with the pseudocapsule, performed only by a 
surgical team with experience in hemophilia, in a hemophilia 
treatment centre wherever possible, followed by close mon-
itoring and long-term prophylaxis to prevent recurrence of 
bleeding. 
•  REMARK : Fluctuations in factor levels during the first postop-
erative year may increase the likelihood of bleed recurrence. 
Therefore, close monitoring and optimal correction of factor lev-
els are of paramount importance.  CB 
•  See also Chapter 7: Treatment of Specific Hemorrhages – Table 
7-2; Chapter 8: Inhibitors to Clotting Factor – Hemophilia A/
Hemophilia B – Surgery and invasive procedures; and Chapter 9: 
Specific Management Issues – Surgery and invasive procedures. 
 10.6  |  Fractures 
•  Fractures are not frequent in patients with hemophilia despite a 
high incidence of osteopenia and osteoporosis, possibly due to 
lower levels of ambulation and intensity of activities. 83 
•  However, a patient with hemophilic arthropathy may be at risk 
for fractures around a joint with significant loss of motion and in 
bones that are osteoporotic. 
•  Treatment of a fracture requires immediate factor replacement 
therapy. 83-85 Ideally, patients should be on continuous prophy-
laxis (e.g., high doses of CFC) and factor levels of at least 50 IU/
dL should be maintained for at least a week. 11,83-85 Subsequently, 
lower levels may be maintained for 10-14 days while the frac-
ture becomes stabilized and to prevent soft tissue bleeding. (See 
Chapter 7: Treatment of Specific Hemorrhages – Table 7-2.) 
 Recommendation 10.6.1: 
•  For people with hemophilia who incur fractures, the WFH recom-
mends immediate treatment with clotting factor concentrates or 
other hemostatic agents, and continued treatment to maintain 
sufficiently high factor levels for bleed control for a week or lon-
ger, depending on the likelihood of bleeding due to fracture site 
or stability. Subsequently, lower factor levels may be maintained 
for 10-14 days to prevent soft tissue bleeding while the fracture 
becomes stabilized. Clinical monitoring is paramount due to the 
risk of compartment syndrome.  CB 
•  The management plan should be devised for the specific fracture 
and include appropriate prophylaxis coverage if surgical proce-
dures are necessary. 
•  Avoid full circumferential plaster and split casts if possible, es-
pecially in the early stages; splints are preferred. 83 Monitoring, 
especially of forearm fractures, is mandatory in order to avoid 
complications such as compartment syndrome. 
•  Consider external fixators for open/infected fractures. 86 
•  Avoid prolonged immobilization if possible as it can lead to signifi-
cant limitation of range of motion in the adjacent joints. 83,84 
•  Arrange for physical therapy as soon as the fracture is stabilized 
to restore range of motion, muscle strength, and function. 33 
 Recommendation 10.6.2: 
•  For people with hemophilia who incur fractures, the WFH rec-
ommends splints over full casts to avoid compartment syndrome 
(especially in the early stages), and external fixators for open or 
infected fractures.  CB 
 Recommendation 10.6.3: 
•  For people with hemophilia who incur fractures, the WFH rec-
ommends avoiding prolonged immobilization and advises super-
vised physical therapy and rehabilitation as soon as the fracture 
is stabilized to restore range of motion, muscle strength, and 
function.  CB 
•  See also Chapter 7: Treatment of Specific Hemorrhages – Table 
7-2; Chapter 8: Inhibitors to Clotting Factor – Hemophilia A/
Hemophilia B – Surgery and invasive procedures; and Chapter 9: 
Specific Management Issues – Surgery and invasive procedures. 
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 10.7  |  Orthopedic surgery in hemophilia 
•  For patients with hemophilia undergoing orthopedic surgery, best 
results are achieved in dedicated hemophilia centres where skill-
ful multidisciplinary teams are prepared to manage these patients 
using tailored approaches. 5,11 
•  Multiple-site elective surgery with simultaneous or staggered 
procedures may simultaneously allow for a more expedient re-
covery of gait and overall function, as well as for judicious use 
of factor replacement therapy 87 or other hemostatic agents. (See 
Chapter 7: Treatment of Specific Hemorrhages – Table 7-2.) 
•  Use of local coagulation enhancers may be appropriate. Wound 
infiltration with local anesthetic agents (lignocaine/lidocaine 
and/or bupivacaine) with an adrenaline and fibrin sealant/spray 
is useful to control oozing when operating in extensive surgical 
fields. 56,88,89 
•  Postoperative care in patients with hemophilia requires, in ad-
dition to factor replacement therapy (continuous infusion pre-
ferred) or other prophylaxis, close monitoring of pain, and often 
higher doses of analgesics in the immediate postoperative 
period. 56 
•  Good communication with the postoperative rehabilitation team 
is essential. 33 Knowledge of the details of the surgery performed 
and intra-operative joint status will facilitate planning of an ap-
propriate rehabilitation program. 
•  As part of comprehensive care, both pre- and postoperative phys-
ical therapy is needed to achieve optimal functional outcome. 33 
 Recommendation 10.7.1: 
•  For patients with hemophilia requiring orthopedic surgery, espe-
cially in cases where oozing is present at closure as well as dead 
space or cavities, the WFH suggests the use of local coagulation 
enhancers and wound infiltration with local anesthetic agents 
(lignocaine/lidocaine and/or bupivacaine) with an adrenaline and 
fibrin sealant or spray to control blood oozing when operating in 
extensive surgical fields.  CB 
 Recommendation 10.7.2 
•  For patients with hemophilia requiring orthopedic surgery, the 
WFH recommends factor replacement therapy and close pain 
control and monitoring, with higher doses of analgesics in the 
immediate postoperative period.  CB 
 Recommendation 10.7.3: 
•  For patients with hemophilia in the postoperative period fol-
lowing orthopedic surgery, the WFH recommends gradual re-
habilitation by a physical therapist experienced in hemophilia 
management.  CB 
•  See also Chapter 7: Treatment of Specific Hemorrhages – Table 
7-2; Chapter 8: Inhibitors to Clotting Factor – Hemophilia A/
Hemophilia B – Surgery and invasive procedures; and Chapter 9: 
Specific Management Issues – Surgery and invasive procedures. 
 10.8  |  Joint replacement 
•  Joint replacement is indicated in cases of established hemophilic 
arthropathy with associated pain and functional impairment not 
responsive to nonsurgical or other surgical treatments. 
•  Joint replacement should be performed only in recognized hemo-
philia treatment centres with experienced orthopedic surgeons 
and appropriate hematological and laboratory support. 
•  Such centres will have a multidisciplinary team including a nurse, 
social worker, and physical therapist familiar with the require-
ments of hemophilia patients undergoing arthroplasty. 90 
 Hemostasis during the perioperative period 
•  Meticulous hemostasis is critical for the success of the surgical 
procedure. The specific plasma factor levels needed during dif-
ferent phases of surgery are described in Chapter 7: Treatment 
of Specific Hemorrhages – Table 7-2. Some centres use contin-
uous infusion of factor replacement therapy, particularly during 
the first 72 hours, which more consistently maintains a protective 
factor trough level. 91 
•  The use of perioperative antifibrinolytics and fibrin sealants has 
been shown to reduce blood loss. However, there is no consensus 
on the duration of postoperative treatment. 92 
•  There is usually no need for deep vein thrombosis prophylaxis in 
those undergoing arthroplasty under factor coverage unless very 
high plasma levels are maintained during the postoperative pe-
riod. 93 (For venous thromboembolism and thromboprophylaxis 
considerations for surgery, see Chapter 9: Specific Management 
Issues – Surgery and invasive procedures.) 
 Surgical considerations 
•  In the knee, there is often an anteroposterior/medio-lateral mis-
match, which should be anticipated. Occasionally, a custom im-
plant may be required. Significant angular deformity, patellar 
subluxation, and posterior subluxation of the tibia are often en-
countered, all of which may require extensive soft tissue release. 
•  Bilateral simultaneous knee replacement has been recommended 
in some instances, and consideration should be given to undertak-
ing additional procedures if indicated. 87 
•  The principles of knee replacement are the same as in the general 
population. Most often, posterior-stabilized implants or implants 
with stems and augments for associated bony defects are used. 
•  Antibiotic-loaded cement should be used in all cases where ce-
ment fixation is performed. 
•  Wound closure should be meticulous. 
•  There is no consensus on the use of drains. 
•  There is no consensus on the best type of fixation for hip 
replacement. 94 
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 Postoperative physical therapy 
•  Physical therapy should be started as soon as possible, ideally on 
the day of the surgery. Therapy sessions need to focus on regain-
ing body functions such as range of motion and muscle strength 
before increasing functional training and endurance. 
•  To prevent the formation of joint adhesions, early mobilization 
and dedicated work on regaining motion are critical. 95 During 
this phase, attention to delayed wound and tissue healing and 
risks for re-bleeds is also required. Functional rehabilitation 
should be the goal, but only when all possible body functions 
are restored. 
•  Physical therapists at the hemophilia treatment centre are gen-
erally the best resource for devising a safe and comprehensive 
outpatient program. Alternatively, the hemophilia physical thera-
pist can contact a physical therapist in the patient ' s community to 
arrange for postoperative care. 57 
 Recommendation 10.8.1: 
•  For patients with hemophilia, the WFH recommends joint re-
placement only in cases of established hemophilic arthropathy 
that is not responsive to nonsurgical or other surgical treat-
ments, and that is accompanied by associated pain, functional 
impairment, and loss of participation in activities of daily living. 
•  REMARK : Perioperatively, tranexamic acid and fibrin sealants may 
be used to reduce blood loss. 
•  REMARK : Physical therapy should ideally start on the day of sur-
gery with early mobilization and appropriately progressive exer-
cises to regain motion and muscle strength.  CB 
 Complications and long- term considerations 
•  Patients with hemophilia tend to have less favourable knee func-
tional scores and more postoperative complications following 
knee replacement, compared to the general population. This is 
mainly due to complicating factors and multijoint involvement. 96-98 
•  Knee surgery should not be delayed for too long, as preoperative 
flexion deformity has a significant effect on postoperative out-
come. Knees with flexion deformity of more than 25 degrees have 
a higher risk of a poor outcome and of developing postoperative 
flexion deformities. 99 
•  Historically, infection rates following arthroplasty in hemophilia 
patients were higher than those seen in the general population. 
However, these infection rates have decreased over the past de-
cade. Today, they are reported to be almost the same as in the 
general population. 54 
•  Patients with hemophilia are at a higher risk of contracting a de-
layed secondary infection. 100 
•  Patients with HIV or HCV infection may have a higher risk for 
prosthetic joint infection. 
•  The long-term survival of joint replacement implants may be 
the same as in the general population, depending on the level of 
expertise of the hemophilia care team, the type of implant used, 
and the severity of musculoskeletal disease of the joint. 54,101 
•  See also Chapter 8: Inhibitors to Clotting Factor – Hemophilia A/
Hemophilia B – Surgery and invasive procedures, and Chapter 9: 
Specific Management Issues – Surgery and invasive procedures. 
 10.9  |  Psychosocial impacts of musculoskeletal 
complications 
•  Despite great strides in hemophilia care in recent years, people 
with hemophilia continue to face psychosocial challenges with he-
mophilia-related musculoskeletal complications. In particular, this 
affects those who grew up prior to prophylaxis and those who do 
not have access to prophylaxis. 102 
•  A study of people with moderate and severe hemophilia found 
that those with more significant arthropathy experienced a lower 
quality of life, especially in the physical domain. 103 
•  Psychosocial limitations from hemophilic arthropathy may be 
compounded by 104 : 
 ◦  gait changes; 
 ◦  multiple joints being affected; 
 ◦  chronic pain. 
•  The psychosocial impacts of these compounding factors may re-
sult in 104 : 
 ◦  lost time from school or work; 
 ◦  limitations in sports participation; 
 ◦  decreased socialization and/or increased isolation; 
 ◦  negative self-perceptions related to body image, masculinity, 
and/or self-esteem; 
 ◦  lack of a sense of normalcy; 
 ◦  limited physical flexibility with sexual positioning; 
 ◦  challenges in personal relationships; 
 ◦  role loss and/or role changes; 
 ◦  increase in fatigue; 
 ◦  negative coping behaviours. 
•  In people with hemophilia, disability from joint disease frequently 
occurs at an earlier age than in the general population and may 
impair their ability to perform reliably in the workplace. This may 
cause individuals to retire earlier than planned, result in unwanted 
role loss or shifts in all aspects of life, and negatively impact 
finances. 104 
•  Psychosocial interventions should be tailored to meet the specific 
circumstances and needs of each individual, including their physi-
cal, emotional, social, educational, and cultural needs. 105 
•  Individual psychosocial intervention strategies may be aimed at 
helping individuals adapt to pain and functional impairment 105 
and develop coping strategies such as: 
 ◦  identifying/recognizing stressors and strengths; 
 ◦  partializing concerns (i.e., setting goals and priorities and de-
veloping strategies to address issues one by one); 
 ◦  examining options; 
 ◦  seeking information; 
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 ◦  strengthening support systems; 
 ◦  communicating effectively; 
 ◦  reframing the situation; 
 ◦  using distraction techniques; 
 ◦  using coping self-statements. 106 
•  Psychosocial intervention strengthens patient resilience by fos-
tering self- and health efficacy, cognitive flexibility, hardiness, op-
timism, and self-advocacy. 
•  Peer mentoring and group learning opportunities help foster sup-
port, reduce isolation, enhance receptivity to information, and 
strengthen resilience. 107 
 Recommendation 10.9.1: 
•  For patients with hemophilia who have chronic musculoskeletal 
pain or functional limitations, the WFH recommends psychoso-
cial interventions tailored to meet the specific needs of each in-
dividual based on their physical, emotional, social, educational, 
and cultural circumstances.  CB 
 Recommendation 10.9.2: 
•  For patients with hemophilia who have chronic musculoskeletal 
pain or functional limitations, the WFH recommends specific 
individualized psychosocial assessments and intervention strat-
egies aimed at achieving better quality of life, including psycho-
social counselling, educational and employment counselling, and 
financial planning.  CB 
 Recommendation 10.9.3: 
•  For patients with hemophilia who have chronic musculoskeletal 
pain or functional limitations, the WFH recommends the promo-
tion of support networks, peer mentoring, and group educational 
opportunities to support their ability to cope with musculoskeletal 
complications, reduce social isolation, and strengthen resilience.  CB 
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 11.1  |  Introduction 
•  In order to optimize treatment and make economically sound clin-
ical decisions, objective evidence of both short- and long-term 
outcomes of treatment regimens is required. 1 
•  Outcome refers to the condition of a patient that results from a 
disease or medical intervention. It is assessed by clinical evalua-
tion including the use of generic and disease-specific health-re-
lated quality of life (HRQoL) assessment instruments, measures 
of patient-reported outcomes (PROs), and laboratory tests includ-
ing imaging studies. 2-7 These instruments measure a variety of 
parameters including activities and participation, body structure 
and function, burden of disease, and subjective health status, as 
described later in this chapter. 
•  Both generic and hemophilia-specific assessment instruments 
make it possible to evaluate the nature of the physical impair-
ments and functional limitations and their impacts on the lives of 
people with hemophilia and their families. 1 
•  The increasing use of these instruments will standardize assess-
ment and permit comparison of data between individuals and 
cohorts. 8-10 
 Purposes of outcome assessment 
•  Outcome assessment may be used to follow an individual ' s dis-
ease course, obtain information to guide routine clinical care, 
measure response to therapy, and determine whether there is a 
need to modify therapy. Outcome assessment may also be used to 
quantify the health of a group of patients, measure quality of care, 
and advocate for resources. 
•  In addition, outcome assessment may be used for research pur-
poses such as to document the natural history of the disease, test 
new therapies, or compare different therapies. 
•  Health outcome research may be used to inform decisions regard-
ing expenditures on treatment. 
 11.2  |  Outcome assessment in hemophilia 
•  Outcome assessment in hemophilia should cover two aspects: 
disease-related and therapy-related outcomes. 
•  Disease-related outcomes pertain to the effectiveness of hemo-
static therapy and are reflected in outcomes such as: 
 ◦  frequency of bleeding; and 
 ◦  impact of bleeding on the musculoskeletal system and other 
systems in the short and long term, including the psychosocial 
impact of hemophilia. 
•  Therapy-related outcomes need to be monitored using a prospec-
tive and systematic plan and should include screening and testing 
of people with hemophilia treated with clotting factor concen-
trates (CFCs) for inhibitor development. (See Chapter 8: Inhibitors 
to Clotting Factor.) 
•  Other less common complications of CFC replacement therapy 
include thrombosis and allergic/anaphylactic reactions. (See 
Chapter 9: Specific Management Issues.) 
 Frequency of bleeding 
•  Frequency of bleeding (particularly joint and muscle bleeds) and 
response to treatment have been the most important indicators 
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of the effectiveness of hemostatic therapy and the best surrogate 
predictors of long-term musculoskeletal outcomes. 
•  All bleeds must be documented by patients/caregivers in real 
time as they occur using manual or electronic diaries or other 
reporting systems, and analyzed periodically (at least once a 
year) by their hemophilia treater using a standard protocol. (See 
Chapter 2: Comprehensive Care of Hemophilia – Home therapy 
– Self-management.) 
•  In particular, bleeding into the central nervous system (CNS) re-
quires documentation because of its potential impact on neuro-
logical and musculoskeletal functions. 
•  Given the potential difficulties in clinical determination of joint 
and muscle bleeding and to bring consistency into document-
ing this important parameter, criteria defined by the Scientific 
and Standardization Committee of the International Society on 
Thrombosis and Haemostasis should be followed. 11 
•  A joint bleed is defined as an unusual sensation “aura” in the joint, 
in combination with any of the following 11 : 
 ◦  increasing swelling or warmth of the skin over the joint; 
 ◦  increasing pain; or 
 ◦  progressive loss of range of motion or difficulty in using the 
limb as compared with baseline. 
•  A muscle bleed is defined as an episode of bleeding into a mus-
cle, determined clinically and/or by imaging studies, generally 
associated with pain and/or swelling and loss of movement over 
baseline. 11 
•  In infants and young children, reluctance to use the limb alone 
may be indicative of a joint or muscle bleed. 11 
•  Definitions for effectiveness of hemostatic therapy for joint and 
muscle bleeds have been developed and should be used when 
documenting treatment outcomes. (See Chapter 7: Treatment of 
Specific Hemorrhages – Table 7-1.) 
 Recommendation 11.2.1: 
•  For providers of care for people with hemophilia, the WFH 
recommends ensuring that the frequency of all bleeds is 
documented in real time by patients/caregivers and re-
viewed together at least annually, with particular reference 
to intra-articular, intramuscular, and central nervous system 
bleeds, including their recovery status. Standard criteria de-
fined by the Scientific and Standardization Committee of the 
International Society on Thrombosis and Haemostasis should 
be used.  CB 
 Pain assessment in hemophilia 
•  Pain in hemophilia can be either acute (as in an acute bleed) or 
chronic (as a result of arthropathy), or both may occur concurrently. 
•  Hemophilia-related pain can be assessed using single-dimen-
sional numerical or visual rating scales 12 such as the Wong-
Baker FACES Scale, 13,14 or multi-dimensional pain questionnaires 
like the generic McGill Pain Questionnaire 15 or the Brief Pain 
Inventory (BPI), 16,17 or disease-specific instruments like the 
Multidimensional Haemophilia Pain Questionnaire (MHPQ). 
•  Pain can also be scored through subscales within quality-of-life 
questionnaires—both generic 18 and disease-specific 19 question-
naires—and also within specific joint assessment instruments 
such as the Gilbert Score 20 and the Hemophilia Joint Health Score 
(HJHS). 21 
•  Pain is best assessed and addressed in the context of a compre-
hensive care setting. 16 
 Domains to assess the impact of bleeding on the 
musculoskeletal and other systems 
•  In conditions like hemophilia, it is recommended that outcomes 
be assessed according to the domains in the International 
Classification of Functioning, Disability and Health (ICF) model of 
the World Health Organization (WHO). 22,23 
•  According to the ICF, evaluation of disability and health 4,24 should 
focus on the impact of the disease on body structures and func-
tions, activities, and participation. 
•  These domains can be affected by individual contextual factors, 
which represent a person ' s circumstances and background, and 
include both environmental and personal factors. 
•  Environmental factors comprise the physical, social, and attitudi-
nal environments in which an individual lives and conducts day-
to-day activities. 
•  Personal factors include aspects that are not necessarily part of 
an individual ' s health condition or health status, such as age, sex, 
and indigenous status. 
•  See Figure  11-1 for an overview of the ICF model and outcome 
assessment instruments by domain. 
•  The concept of quality of life (QoL) is complex and encompasses 
many characteristics of an individual ' s social, cultural, economic, 
and physical environments as well as physical and mental health 
state. 4,22 
•  Health-related quality of life (HRQoL) is a synonym for self-re-
ported health state; HRQoL measurements generally include sev-
eral aspects of the ICF model. 25 To be meaningful, this is best not 
used in isolation but in addition to assessment of body structure, 
function, and activities. 
•  While most outcome assessment instruments have been val-
idated for older children, there is a paucity of validated dis-
ease-specific instruments to assess outcomes in very young 
children with severe hemophilia (i.e., younger than 4 years of age) 
during the period when they are typically started on long-term 
prophylaxis and the chances of inhibitor development are at their 
highest. 
•  The ability of the instruments to detect subtle changes following 
treatment interventions in children with good joint status and low 
bleeding frequency is limited and needs further attention. 26 
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 11.3  |  Body structure and function 
•  Body structure refers to anatomical structures and bodily parts, 
such as organs, limbs, and their components. 22,24 
•  Body function refers to the physiologic functions of these sys-
tems, such as range of motion, strength, and joint stability. 
•  In hemophilia, this refers to, for example, the status of joints and 
specific muscle groups, assessed both clinically and radiologically. 
 Recommended measures of body structure and 
function in hemophilia 
•  The Hemophilia Joint Health Score (HJHS) is the best studied 
of the physical examination instruments in both children and 
adults. 21,27,28 (See Figure  11-2 .) 
•  The radiological Pettersson score 29 is the most widely used imag-
ing measure of joint structure. This score is not sensitive to early 
changes; therefore, more sensitive instruments have been devel-
oped to assess arthropathy. (See Table  11-1 .) 
•  Magnetic resonance imaging (MRI) is likely the most sensitive 
measure of joint structure. There are a number of scales that can 
be used to quantify arthropathy on MRI 30,31 ; however, this modal-
ity is expensive, time consuming, and difficult to perform in small 
children. (See Table  11-2 .) 
•  Ultrasound (US) scoring systems to assess hemophilic arthropathy 
are now available 32-35 and can detect joint effusion, 36 early joint 
disease, 37 and subclinical joint disease, 38 and promote medication 
adherence. 39 (See Table  11-3 .) 
•  US scoring algorithms can be relatively subjective, but their reli-
ability can be improved if the assessment is performed by a hemo-
philia provider trained in musculoskeletal US. 35 
•  There is emerging evidence that suggests musculoskeletal ul-
trasound (MSKUS) may be useful in the clinical assessment 
and management of painful hemophilic arthropathy as it can 
differentiate between joint bleeds and joint inflammation and 
between muscle bleeds and other regional pain syndromes. 40,41 
Nonetheless, in any circumstance, if a patient or clinician sus-
pects an acute joint or muscle bleed or has difficulty assessing 
whether a bleed is in progress, hemostatic treatment is advised 
immediately before performing confirmatory investigations or 
awaiting such results. 
 11.4  |  Activities and participation 
•  Activity refers to the execution of a task or action by an individ-
ual. 4 In the context of hemophilia, activity generally refers to in-
strumental activities of daily living (e.g., walking, climbing steps, 
brushing teeth, toileting). 
 F I G U R E   11 1     International Classification of Functioning and Health ( ICF ) model, with domain- related outcome assessment instruments. 
 COPM , Canadian Occupational Performance Measure;  FISH , Functional Independence Score in Hemophilia;  HAEMO - QoL- A, hemophilia- 
specific quality- of- life questionnaire for adults;  HAL , Haemophilia Activities List;  HJHS , Hemophilia Joint Health Score;  MRI , magnetic 
resonance imaging; Paed HAL , Haemophilia Activities List for children;  PROBE , Patient- Reported Outcomes, Burdens and Experiences;  SF - 
36, 36- Item Short Form Survey Instrument;  US , ultrasound 
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 F I G U R E   11 2     Hemophilia Joint Health Score 2.1 – Summary Score Sheet. 42 Available at:  http://www1.wfh.org/docs/en/Publi catio ns/
Asses sment_Tools/ HJHS_Summa ry_Score.pdf 
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•  Participation refers to involvement in life situations in the context 
of social interactions. 
•  It is often difficult to distinctly categorize items and outcome 
assessment instruments as belonging to only one of these two 
domains; therefore, the two domains are often combined in out-
come assessment. 
•  In hemophilia, measurements of activities are defined as either 
self-reported or performance-based (i.e., observed). 22 
 Recommended instruments for measuring 
activities and participation 
•  The Haemophilia Activities List (HAL) 15,44 is a disease-specific 
measurement instrument. It is the best-studied measure of 
self-reported activities for adults 45 and has been translated into 
many languages. The three subscores (upper extremity, basic 
lower extremity, and complex lower extremity) have been proven 
useful in the United States and the United Kingdom. 15,16,46 (See 
Table  11-4 .) 
•  The Paediatric Haemophilia Activities List (PedHAL) 47 is derived 
from the HAL. It is a self-reported measure for children with he-
mophilia. 45 (See Table  11-5 .) 
•  Both the HAL and PedHAL were developed by hemophilia treat-
ers in the Netherlands; thus, they may not apply as well when 
used in other cultural settings. 48,49 
•  The Functional Independence Score in Hemophilia (FISH) 48,50 is 
the best-studied observed performance measure for people with 
hemophilia, 45 with many reports of its use in different countries 
and age groups. (See Table  11-6 .) 
•  The Patient-Reported Outcomes, Burdens and Experiences 
(PROBE) questionnaire also includes metrics that assess activities 
and participation, such as school/education, employment, family 
life, and impact on activities of daily living. 6,7 (See 11.8 Patient-
reported outcomes, below.) 
•  The Canadian Occupational Performance Measure (COPM) 51 
and the McMaster Toronto Patient Disability Questionnaire 
(MACTAR) 52 are generic instruments that have been used for 
day-to-day assessment of a person ' s perception of changes in the 
domains of activities and participation. They can be used for goal 
attainment scaling. 
 11.5  |  Environmental and personal factors 
 Environmental factors 
•  While environmental factors are part of the ICF model, they are 
not often considered “outcomes”  per se but can be the major inter-
vention in the rehabilitation process. 4 
•  Environmental factors that influence outcome include facilitators 
and barriers to treatment. These might include access to a com-
prehensive hemophilia care centre, availability of CFCs, medical 
understanding, medical insurance coverage, 53 and travel distance 
to a hemophilia treatment centre. 54 
•  For children with hemophilia, family support and, if needed, addi-
tional psychosocial support and assessment provided by the he-
mophilia care team, may be an important facilitating factor. 
 Personal factors 
•  An individual ' s personal strengths and deficiencies may signifi-
cantly influence treatment outcomes. 
•  Assessment of factors, such as the locus of control, and psycho-
logical characteristics, such as anger, depression, and optimism, 
can be used to guide and inform individual care or research. 55 
•  Another important and measurable influence on treatment out-
comes is patient/family treatment adherence. 56,57 
 11.6  |  Economic factors 
•  The costs and associated benefits of medical care can be quanti-
fied and used in research, program development, and advocacy. 
 TA B L E   11 1     Radiological Pettersson score 29 
 Radiologic change  Finding 
 Score a  
(points) 
•  Osteoporosis  Absent  0 
 Present  1 
•  Enlargement of epiphysis  Absent  0 
 Present  1 
•  Irregularity of 
subchondral surface 
 Absent  0 
 Slight  1 
 Pronounced  2 
•  Narrowing of joint space  Absent  0 
 <50%  1 
 >50%  2 
•  Subchondral cyst 
formation 
 Absent  0 
 1 cyst  1 
 >1 cyst  2 
•  Erosions at joint margin  Absent  0 
 Present  1 
•  Incongruence between 
joint surfaces 
 Absent  0 
 Slight  1 
 Pronounced  2 
•  Deformity (angulation 
and/or displacement of 
articulating bones) 
 Absent  0 
 Slight  1 
 Pronounced  2 
 a Possible joint score: 0- 13 points for each joint (total possible score, 
6 × 13 = 78).  
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 Direct costs 
•  Direct costs include the cost of medical treatments, health ser-
vices, and surgical and medical supplies. 
•  CFCs for patients with severe hemophilia usually account for 
more than 90% of treatment-related costs. 58 
 Indirect costs 
•  Indirect costs arise from loss of work productivity of adult pa-
tients and of parents of pediatric patients due to the time they 
spend managing their child ' s hemophilia care. 
•  The costs that result from illness or seeking medical care are 
sometimes similar but often vary by country. 59 
 11.7  |  Health- related quality of life 
•  Health-related quality of life is a synonym for subjective (self- or 
family-reported) health status. 25 
•  HRQoL measurements are usually questionnaires that aim to 
quantify a patient ' s health in a global way. 
•  Given their global nature, HRQoL measures are often more su-
perficial in their scope than individual measures of the different 
domains listed above; therefore, they are best applied in combi-
nation with specific assessments of the ICF domains rather than 
in isolation. 60 
•  An additional challenge in their use is that they must be val-
idated in the language and social and cultural contexts of their 
application. 
 Instruments most used for measurement of health- 
related quality of life 
•  The EQ-5D 2,3 and SF-36 61,62 are widely used generic instruments 
for assessing QoL in hemophilia. (See Tables  11-7 and  11-8 .) 
•  The PROBE questionnaire assesses QoL in addition to burden of 
disease in people with hemophilia. 6,63-65 
•  For children with hemophilia, the Canadian Hemophilia 
Outcomes-Kids Life Assessment Tool (CHO-KLAT) has been ex-
tensively used. 4,66 
•  For adults with hemophilia, the Hemophilia Well-Being Index 67 
and the hemophilia-specific QoL questionnaire for adults 
(HAEMO-QoL-A) have been widely used. 4,5 
 TA B L E   11 2     IPSG MRI Scale to Assess Hemophilic Arthropathy 43 
 Soft tissue changes  Effusion/hemarthrosis  Small  (1)__ 
 Moderate  (2)__ 
 Large  (3)__ 
 Synovial hypertrophy  Small  (1)__ 
 Moderate  (2)__ 
 Large  (3)__ 
 Hemosiderin  Small  (1)__ 
 Moderate  (2)__ 
 Large  (3)__ 
 Soft tissue changes subscore   Maximum 9 points  ___ 
 Osteochondral changes  Surface erosions involving 
subchondral cortex or 
joint margins 
 Any surface erosion  (1)__ 
 Half or more of the articular surface eroded in at least one bone  (1)__ 
 Subchondral cysts  At least one subchondral cyst  (1)__ 
 Subchondral cysts in at least two bones, or cystic changes involving 
a third or more of the articular surface in at least one bone 
 (1)__ 
 Cartilage degradation  Any loss of joint cartilage height  (1)__ 
 Loss of half or more of the total volume of joint cartilage in at least 
one bone 
 (1)__ 
 Full- thickness loss of joint cartilage in at least some area in at least 
one bone 
 (1)__ 
 Full- thickness loss of joint cartilage including at least one half of the 
joint surface in at least one bone 
 (1)__ 
 Osteochondral changes subscore   Maximum 8 points  ___ 
 Abbreviations: IPSG, International Prophylaxis Study Group; MRI, magnetic resonance imaging. 
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 Recommendation 11.7.1: 
•  The WFH recommends assessing and documenting the musculo-
skeletal and overall health of each patient at least annually. This 
should include an assessment of body structure and function, ac-
tivity levels, participation and health-related quality of life as per 
the World Health Organization ' s International Classification of 
 TA B L E   11 3     HEAD- US Scoring Method 32 
 Disease activity (synovitis)  Scale 
 Hypertrophic synovium 
 0. Absent/minimal  0 
 1. Mild/moderate  1 
 2. Severe  2 
 Disease damage (articular surfaces) 
 Cartilage 
 0. Normal  0 
 1. Echotexture abnormalities, focal partial- /full- 
thickness loss of the articular cartilage involving 
<25% of the target surface a  
 1 
 2. Partial- /full- thickness loss of the articular 
cartilage involving ≤50% of the target surface a  
 2 
 3. Partial- /full- thickness loss of the articular 
cartilage involving >50% of the target surface a  
 3 
 4. Complete cartilage destruction or absent 
visualization of the articular cartilage on the 
target bony surface a  
 4 
 Bone 
 1. Normal  0 
 2. Mild irregularities of the subchondral bone 
with/without initial osteophytes around the joint 
 1 
 3. Deranged subchondral bone with/without 
erosions and presence of prominent osteophytes 
around the joint 
 2 
 Abbreviations: HEAD- US, Haemophilia Early Arthropathy Detection 
with Ultrasound. 
 a Elbow, anterior aspect of the distal humeral epiphysis; knee, femoral 
trochlea; ankle, anterior aspect of the talar dome.  
 TA B L E   11 4     Haemophilia Activities List (HAL) 2005 15 
  Items (n) 
 HAL overall  42 
 HAL domains 
 Lying/sitting/kneeling/standing  8 
 Functions of the legs  9 
 Functions of the arms  4 
 Use of transportation  3 
 Self- care  5 
 Household tasks  6 
 Leisure activities and sports  7 
 HAL components 
 Upper extremity (HAL upper )  9 
 Basic lower extremity (HAL lowbas )  6 
 Complex lower extremity (HAL lowcom )  9 
 Note :  Available in multiple languages at:  http://elear ning.wfh.org/resou 
rce/hemop hilia-activ ities-list-hal/  





 PedHAL overall  53 
 PedHAL domains 
 Lying/sitting/kneeling/standing  10 
 Functions of the legs  11 
 Functions of the arms  6 
 Use of transportation  3 
 Self- care  9 
 Household tasks  3 
 Leisure activities and sports  11 
 Note :  Available at:  http://elear ning.wfh.org/resou rce/haemo philia-activ 
ities-list-pedia tric-pedha l/  
 TA B L E   11 6     Functional Independence Score in Hemophilia 
(FISH) 48 
 List of activities tested 
 Self- care  Transfers  Locomotion 
 Eating  Chair transferring  Walking 
 Grooming  Squatting  Climbing stairs 
 Bathing   Running 
 Dressing   
 Notes :  Scores range from 1 to 4 for each activity depending on the 
degree of independence: 1, unable to perform; 2, requires the help of 
an assistant/aid; 3, able to perform the activity without an aid but not 
like a healthy subject; 4, able to perform the activity like other healthy 
subjects. Available at:  http://elear ning.wfh.org/resou rce/funct ional-
indep enden ce-score-in-hemop hilia-fish/ . 
 TA B L E   11 7     EQ- 5D Instrument 68 
 EQ- 5D description 
system a   EQ- VAS 
 Mobility •  Records the respondent ' s self- rated 
health on a vertical, visual analogue 
scale ranging from 0 (worst imaginable 
health state) to 100 (best imaginable 
health state) 
 Self- care 
 Usual activities 
 Pain/discomfort 
 Anxiety/depression 
 Abbreviations: EQ, EuroQoL; VAS, visual analogue scale. 
 a Three- item, five- item, and youth versions are available.  
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Functioning, Disability and Health (WHO ICF), as much as possi-
ble, in the right clinical context. 
•  REMARK : Standard definitions and validated tools should be used 
as much as possible, including the following: 
 ◦  For body structure and function, clinical assessment of joints 
is (most) commonly done using the Hemophilia Joint Health 
Score (HJHS) in both children and adolescents. 
 ◦  Under the same domain, early structural changes in joints are 
best assessed using ultrasound (US) or magnetic resonance 
imaging (MRI). Late osteochondral changes may be assessed 
on plain radiographs. 
 ◦  Functional activity levels should be assessed using the most 
appropriate option available for that individual, including the 
Haemophilia Activities List (HAL), the Haemophilia Activities 
List for children (PedHAL), or the Functional Independence 
Score in Hemophilia (FISH). 
 ◦  HRQoL is an important aspect of outcome measurement that 
may be assessed using either generic or disease-specific tools, but 
only in combination with the other domains of the WHO ICF.  CB 
 11.8  |  Patient- reported outcomes 
•  Patient-reported outcomes (PROs) provide a report of the status 
of a patient ' s health condition that comes directly from the pa-
tient, without interpretation of the patient ' s response by a clini-
cian or anyone else. 70 
•  It encompasses both single-dimensional and multi-dimensional 
measures of symptoms, HRQoL, health status, adherence to 
treatment, satisfaction with treatment, and other measures. 71 
•  PROs include generic instruments such as EQ-5D-5L, Brief Pain 
Inventory v2 (BPI), International Physical Activity Questionnaire 
(IPAQ), Short Form 36 Health Survey v2 (SF-36v2), Patient-
Reported Outcomes Measurement Information System 
(PROMIS), 71,72 and disease-specific instruments such as the 
HAL, 73 HRQoL measures such as CHO-KLAT, 66 HAEMO-QoL-A, 5 
and burden of disease questionnaires such as PROBE. 6 
•  While data generated by a PRO instrument can provide evidence 
of a treatment benefit from the patient perspective, the choice of 
instrument should be tailored to the study design or clinical need 
for specific outcome assessment, rather than just psychometric 
properties of the instrument. 74 
 11.9  |  Core set of measures for use in the clinic or 
research setting 
•  In health care, the focus is increasingly shifting from the volume 
of services delivered to the value created for patients. In this con-
text, value is defined as outcomes achieved relative to costs. 75 
•  While many outcome assessment options have been described 
here, in practice, hemophilia treatment centres and clinicians 
may select the instruments most appropriate for their patients. 
Outcome assessment instruments may be classified as manda-
tory, recommended, and optional. 1 
•  To extract the potential of value-based health care, standardized 
outcome measures must be encouraged. 
•  This will mean committing to measuring a minimum sufficient set 
of outcomes for every major medical condition, with well-defined 
methods for their collection, which will then need to be applied 
universally. 
•  The WFH World Bleeding Disorders Registry (WBDR) provides a 
platform for hemophilia treatment centres to collect uniform and 
standardized patient data and outcomes globally to guide clini-
cal practice (http://www.wfh.org/en/our-work-research-data/
world-bleeding-disorders-registry). 8,9 
•  Defining a standardized core set of outcome measures for 
specific clinical settings within which hemophilia is man-
aged worldwide is key to advancing the clinical care of peo-
ple with hemophilia and conducting further studies on 
treatment options. 1 A selection of outcome assessment in-
struments can be accessed at the WFH Compendium of 
Assessment Tools webpage (http://elearning.wfh.org/resource/
compendium-of-assessment-tools/). 10 
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 12.1  |  Background 
 The World Federation of Hemophilia (WFH) developed the first edi-
tion of the Guidelines for the Management of Hemophilia in 2005. 1 
These guidelines were updated in 2012 2 and have since seen global 
print and online distribution of more than one million (including 
downloads from the  Haemophilia journal and WFH websites, WFH 
print distributions, and WFH and National Member Organization 
translations). For this third edition, the WFH decided to adopt a 
different method for development, incorporating evidence-based 
and Trustworthy Consensus-Based Statement (TCBS) 3 approaches 
in conformance with established international standards for clinical 
practice guidelines. 4,5 
I n rare diseases such as hemophilia, 6 there are limitations in 
developing evidence-based guidelines due to gaps in the evidence 
base related to small sample sizes and the paucity of methodolog-
ically rigorous data stemming from randomized controlled trials. 
The wide range of hemophilia treatments and practices used glob-
ally also contributes to the disparate research foci in the current 
state of hemophilia science. Quantitative analyses of the data for 
several aspects of management (e.g., direct meta-analyses or net-
work meta-analyses) are not feasible under these circumstances. 
 When the evidence is not sufficiently evolved to support quan-
titative analyses for evidence-based recommendations, it is import-
ant to provide physicians and other healthcare providers, people 
with hemophilia, and advocates with advice they can trust. 4,7 The 
TCBS approach 3 produces unbiased, scientifically valid, and trust-
worthy recommendations through a transparent process that incor-
porates both the available evidence, identified using a systematic 
approach to reduce biases, and expert clinical advice. 
 This chapter describes the methodology used to develop 
the third edition of the WFH Guidelines for the Management of 
Hemophilia. 
 12.2  |  Methodology 
 The TCBS process produces evidence-informed recommendations 
supported by a comprehensive and systematic search for relevant 
scientific literature, which is first screened based on predetermined 
inclusion/exclusion criteria, then followed by data extraction of the 
available and relevant evidence. The Delphi technique is a widely 
used and well-accepted process for soliciting feedback and achiev-
ing consensus. 8 There are several variations, 9-12 but the modified 
Delphi approach for guideline recommendations allows considera-
tion of the evidence base as well as expert opinion while suppressing 
the introduction of group interaction bias. The WFH adopted the 
TCBS approach, already in use by several medical professional socie-
ties, 13,14 as this type of guideline brings thoroughness and transpar-
ency to the guideline development process for the expert panel ' s 
evidence-informed and consensus-based recommendations. 7 As 
with fully evidence-based guidelines, the TCBS approach includes 
a rigorous review of both methods and content by internal and ex-
ternal stakeholders of all types. This approach is based on five im-
portant pillars: 
 ◦  confidence in the panel composition and screening; 
 ◦  systematic and comprehensive evidence searches; 
 ◦  formal consensus achievement; 
 ◦  transparency of data and methods throughout; and 
 ◦  rigorous review process. 
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 Composition of the panels: structure and review 
 The WFH appointed an overall content lead (AS) and an assistant 
content lead (GP), both highly experienced in the field of hemophilia, 
and a methodology consultant (SZL) with extensive experience in 
developing guidelines and expertise in the TCBS approach. A WFH 
Guidelines Process Task Force (GPTF) was established to provide 
objective oversight of the process. The GPTF was composed of 
members of the WFH Education Committee, including patients and 
a hematologist not involved in the development of the guidelines. 
 The content lead and the previous WFH Vice President, Medical, 
offered initial invitations to the expert and representative panel to 
meet the criteria described below. An important goal, not always 
achieved by guideline and research organizations, 15 was to ensure 
that no serious topic-related conflicts of interest existed for the leads 
and to minimize the percentage of the panel with relevant conflicts. 
 This third edition of the WFH guidelines comprises an extensive 
revision of the existing seven chapters of the 2012 edition, as well as 
several new chapters. Each chapter was assigned to a panel composed 
of 7-10 members, including a chapter lead, healthcare professionals 
with clinical expertise, and patients/caregivers, with the latter making 
up at least 25% of each chapter panel. A total of 50 panelists were 
assigned to the 11 content chapters, with some panelists serving on 
more than one panel. The WFH drew upon its international volun-
teers and wide stakeholder network to recruit experts from diverse 
healthcare disciplines (hematologists, orthopedic surgeons and other 
musculoskeletal specialists, physical and occupational therapists, lab-
oratory scientists, nurses, dentists, and psychosocial professionals). 
The panel also included a broad representation of people living with 
hemophilia including those with related complications such as inhib-
itors, musculoskeletal complications, and diverse comorbidities, as 
well as parents of children living with these conditions. Panelists were 
recruited from diverse demographic, geographic, and socioeconomic 
contexts to ensure the global relevance of these guidelines. 
 Process for panel workflow and oversight 
 The content and chapter leads guided the panels through the chapter 
development process and provided content expertise. The responsi-
bilities of the chapter leads, with help from other healthcare profes-
sionals on their panels, included developing a comprehensive set of 
important subtopics per chapter, advising the medical librarians on rel-
evant search terms, drafting initial recommendations, and developing 
the manuscripts including citation of important research. The respon-
sibilities of the chapter leads also included ensuring that the patient/
caregiver panelists’ perspectives were solicited and addressed. Even 
though the vast majority of recommendations address the care and 
management of patients, rather than treatments, content and chapter 
leads also ensured that no specific products or brand names were men-
tioned; with the exception of the Laboratory Diagnosis and Monitoring 
chapter, wherein the therapeutic products may not be recognized by 
their international nonproprietary names (INN) by the community and 
brand names were included for all products, without which medical 
errors could inadvertently be made. For the diagnostic reagents, the 
specific brand names for which published evidence of assay validation 
is available were included within each category of the reagents. 
 All panelists were involved throughout topic organization, evi-
dence generation, consensus achievement of recommendations, and 
manuscript drafting and reviews. Meetings, communications, and 
trainings were conducted via videoconferences, emails, and elec-
tronic surveys. Recordings and slides of training sessions and calls 
were made available to all members afterward. All panelists were 
afforded the opportunity to review all of the chapters before final-
ization and external reviews. 
 The equal status of all panelists (whether healthcare professional 
or patient/caregiver), the importance of each individual ' s expertise, 
and the imperative for all panelists to work together to solicit and 
validate all perspectives were emphasized in the trainings. Under 
the direction of the GPTF, a patient partner facilitator was hired to 
contribute training on the value that this approach adds to guide-
line development and the practicalities of its application, and assist 
with the implementation of this philosophy. The patient partner fa-
cilitator supported the patient/caregiver panelists throughout the 
guideline development process with monthly calls and guidance and 
non-financial support as needed. 
 Funding 
 The sole source of funding for these guidelines was the World 
Federation of Hemophilia. 
 12.3  |  Evidence generation 
 A team of qualified and experienced medical librarians, screeners, 
methodologists, and data extractors was assembled to update the 
evidence base. Separate systematic reviews of the published litera-
ture were conducted on 10 of the 11 content chapters. A review of 
the literature was deemed not relevant for one chapter, Principles of 
Care, which focuses on ideal goals and aspirations given the current 
understanding of hemophilia and available science and technologies. 
Additional searches were developed specifically to target dental proce-
dures, planned and emergent surgical and invasive procedures, and the 
emerging area of genetic assessment, resulting in a total of 11 reviews 
conducted. Details of the search strategies, the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA), and the 
extracted evidence are provided in the online supplemental materials. 
 Study eligibility criteria 
 Population, interventions, comparisons, and outcomes 
 For all chapters, studies that included patients with hemophilia A 
or B were retained. Additional population criteria were established 
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for each chapter. There were no exclusions based on sex or age. 
Eligibility of included studies was not restricted by interventions, 
comparisons, or outcomes for any content area. 
 Search strategies and information sources 
 All search strategies were developed by a medical librarian in col-
laboration with content experts involved in each of the chapters 
and the overall content lead. All searches were restricted to English 
language and human-only studies. No exclusions based on geogra-
phy or type of care setting were implemented. Searches were run 
in PubMed, the Cochrane Database of Systematic Reviews (CDSR), 
the Cochrane Central Register of Controlled Trials (CENTRAL), and 
EMBASE, covering the period from January 1, 2000, to the date of 
the search between May and November 2019. The complete search 
strategies can be found in the online supplemental materials. 
 No crawling or searching of reference lists of identified system-
atic reviews was conducted. One exception was made for the new 
review on Outcome Assessment, for which the reference list of one 
generally well-respected landmark paper was crawled. Chapter leads 
and panelists were invited to propose any directly relevant literature 
that was not identified through formal searching to be reviewed for 
inclusion. 
 Setting and study designs 
 Due to the volume of literature identified, post hoc restrictions on 
included studies (e.g., by publication year and study design) were 
applied without knowledge of the literature identified. Most stud-
ies selected for extractions were limited to publication dates after 
January 1, 2010 (preceding the search date limit for the previous 
edition of the guidelines), with the exception of the new chapter on 
Outcome Assessment, for which the inclusion date extended back 
to January 1, 2005. Additional papers and qualitative reviews were 
referenced when relevant, but data extraction was not performed. 
Study designs retained were randomized controlled trials, quasi-
randomized controlled trials, and prospective comparative studies. 
In some cases, retrospective studies were included at the request 
of individual chapter leads. Some included studies were later con-
firmed as retrospective during extraction. These were retained in 
the evidence tables and marked as retrospective in the study design 
column. Cross-sectional studies were included in the evidence base 
for the Laboratory Diagnosis and Monitoring chapter. Systematic re-
views were included for reference only. 
 Study selection 
 For each of the 11 search strategies, screening criteria were devel-
oped based on pre-specified criteria as defined during the chapter ' s 
search development calls and in collaboration with the chapter leads. 
Identified references were screened for chapter-specific eligibility 
using the reference management software Distiller SR ® . 
 A team of seven trained reviewers screened titles and abstracts. 
Pilot testing was conducted prior to screening of each chapter, with 
all reviewers screening the same 50 references, followed by dis-
cussions and modifications to the screening forms when required 
for clarification. The remainder of title and abstract screening was 
completed by single review for all chapters. Dual screenings were 
not performed. For 8 of the 11 chapters, a secondary round of title 
and abstract screening of those studies deemed potentially eligible 
was conducted for two reasons. First, as the screening team be-
came more familiar with the literature identified by the searches 
and through further discussions with the chapter and content leads, 
additional screening criteria were applied for subsequent rounds 
of review. Screening decisions were made without the panelists’ 
knowledge of the identified literature to avoid biasing the results. 
Second, a secondary title and abstract screening allowed the team 
to efficiently eliminate irrelevant references, providing time- and 
cost-saving measures. References not eliminated during title and ab-
stract screening were reviewed for eligibility at full-text screening. 
 For further details related to the flow of references in PRISMA 
diagrams, please see the online supplemental materials. 
 Data extraction and development of evidence tables 
 Evidence tables were created for each chapter. Relevant outcomes 
were determined with the help of the chapter leads. 
 A senior methodologist (TS) provided oversight and organiza-
tion of the evidence tables. A team of 15 methodologists and data 
analysts extracted the relevant data from all included studies. Dual 
extractions were not performed. The evidence tables and the un-
derlying research articles for each chapter were shared with the 
entire chapter panel and used by the chapter leads and healthcare 
professionals to inform the recommendations. The evidence tables 
are available in the online supplemental materials. 
 Risk of bias in individual studies 
 No formal quantitative analyses were conducted, and no critical as-
sessments were made of individual study quality. It should be noted 
that hemophilia is classified 6 as a rare disease which results in inher-
ent limitations of primary research studies; thus, most assessments 
would have resulted in low or very low levels of evidence. Other 
than the study design limitations placed on the literature search and 
screenings, no additional exclusions were made based on methodo-
logical quality of the research studies. 
 By design, no recommendations were graded as the vast majority 
of the evidence base in the field, given the barriers to clinical re-
search and data collection in rare diseases, is insufficient to support 
meta-analyses. Grading is based on two components, the quality of 
the evidence and the balance of benefits to harms and/or risks. The 
former is an assessment of the quality of the evidence supporting 
the recommendations specific to each outcome. When low-level evi-
dence is partitioned by outcomes, the remaining data are not feasible 
to support quantitative analyses. Attempting to grade such recom-
mendations can be misleading to the target audience of healthcare 
providers. 16 The second component is not explicit in the absence of 
the quality assessments, so we did not assign a level of strength to 
the recommendations. Therefore, in the interest of transparency, 
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the WFH guideline recommendations were not graded but were 
clearly marked “CB” for consensus-based. 
 12.4  |  Formal consensus achievement through 
Delphi techniques 
 A priori rules and processes 
 Following the drafting of the recommendations by the assigned 
healthcare professionals, each set of recommendations went 
through the modified Delphi consensus process. 
 Several  a priori decisions guiding the modified Delphi process 
were determined by the GPTF: 
 ◦  Up to three rounds of Delphi surveys were permitted to 
achieve consensus. 
 ◦  The minimum response rate for each survey round was set at 
75% of eligible voting panelists. 
 ◦  The threshold for achieving consensus was 80% of the re-
spondents indicating agreement or strong agreement. 
 ◦  Statements achieving consensus in the first or second round 
were not subjected to subsequent rounds. 
 ◦  No minority reports were permitted. 
 Drafted recommendations that did not achieve consensus after 
three rounds do not appear as recommendations in the final guide-
lines. However, the underlying topics may be included in the relevant 
chapter text, often with a call for additional research in these areas 
to help resolve some of the controversies. 
 Delphi surveys 
 The modified Delphi surveys were conducted using SurveyMonkey, 
with all responses remaining anonymous except to the independent 
administrator (MG) who created and managed the process. All pan-
elists received two trainings on the TCBS approach, written remind-
ers of the Delphi process and rules, and instructions on the first page 
of the surveys. 
 The initial recommendations were drafted by the healthcare pro-
fessionals, as assigned by the chapter leads. Recommendations were 
based on the evidence provided in the evidence tables and articles, 
as well as on the experience and expertise of the panelists. Panelists 
were trained in writing recommendations. The consultant and edi-
tors provided advice and edited the recommendations to make them 
specific and actionable. 
 Before the modified Delphi process began, the entire chapter 
panel, including the patients/caregivers, convened via teleconfer-
ence to discuss the evidence as a group and receive instructions on 
the Delphi process. They were not permitted to discuss the drafted 
recommendations so as to avoid the occurrence or even perception 
of group interaction bias. Panelists were permitted to suggest topics 
for additional recommendations that did not appear in the list. When 
new topics were suggested, the assigned healthcare professionals for 
that chapter ' s section were tasked with drafting new recommenda-
tions to address the identified gaps. 
 Panelists were encouraged to respond completely to all rec-
ommendations in every round of the surveys. The healthcare 
professionals were advised to base their level of agreement or dis-
agreement on the evidence and their experience treating patients 
with hemophilia. The patient/caregiver panelists were asked to make 
similar judgments based on the evidence and their experience as he-
mophilia patients/family caregivers in the healthcare system. These 
guidelines benefitted from the experiences of patient/caregiver 
panelists. However, some expressed hesitation about being asked to 
vote on recommendations for which they did not have any expertise 
or experience. Therefore, if the recommendation addressed an area 
in which the patient/caregiver panelists were not familiar, they could 
opt out of the denominator by voting neutral and adding the phrase 
“No experience in this area” in the comments field. This signaled that 
their neutral vote should not be added to the denominator when the 
votes were tallied. Across all chapters, 53 of 344 recommendations 
(15%) achieved consensus with at least one patient/caregiver pan-
elist selecting this option. These choices were made selectively by 
individual patient/caregiver panelists on a recommendation-by-rec-
ommendation basis and did not impact the votes of others. 
 For recommendations that did not achieve consensus in the first 
or second round, the chapter leads drafted revisions based on the 
comments provided by the respondents. The revised recommenda-
tions were submitted for the next round of voting. The topics of any 
recommendations that did not achieve consensus by the end of the 
third round could be noted in the manuscripts along with calls for 
future research in the respective areas. After all Delphi rounds were 
completed, consensus was not achieved for 13 (<4%) of the recom-
mendations. Research funding agencies are encouraged to prioritize 
these areas to address knowledge gaps. 
 Survey tallies with the degree of consensus for each recommen-
dation are available upon request ( research@wfh.org ). 
 Diversions from the process 
 There were a few diversions from the described process requir-
ing additional surveys after the third round. One recommendation 
in the muscle hemorrhage section of the Treatment of Specific 
Hemorrhages chapter was resubmitted for voting because new evi-
dence (albeit low level) was brought forth that raised doubts about 
the timeframe specified in the recommendation. Due to inadvert-
ent group discussion of this recommendation, this section with all 
three recommendations was then moved to the Musculoskeletal 
Complications chapter, which was composed of different panelists, 
to avoid the introduction of group interaction bias. The panelists 
were informed of the full set of evidence, provided with the relevant 
papers and extracted data, and voting on the updated recommen-
dation took place. During reviews for consistency and gaps, three 
additional recommendations (one from the Treatment of Specific 
Hemorrhages chapter and two from the Inhibitors to Clotting Factor 
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chapter) required additional revisions or the addition of remarks. 
One recommendation was inadvertently excluded from the original 
surveys for the Prophylaxis in Hemophilia chapter. All were rectified 
through additional survey rounds. 
 12.5  |  Finalization of the recommendations and 
manuscript development 
 At the conclusion of the final round of the modified Delphi sur-
veys, the chapter leads finalized the manuscripts for their assigned 
chapters. All recommendations that achieved consensus were in-
corporated within the relevant section of the manuscript, bolded, 
and numbered accordingly. All remarks are considered integral to 
the recommendations themselves and therefore included as part of 
the recommendations.  The WFH advises that as recommendations are 
uploaded into digital platforms, incorporated into separate lists, or oth-
erwise removed from this full guideline publication, the remarks should 
always be kept with the rest of the recommendation as a single unit. 
 These guidelines have an intrinsic navigation system for the 
chapters, sections, recommendations, and supplemental materials. 
The numbering system uses the chapter number as the initial num-
ber, followed by the section numbers. Recommendations are num-
bered according to the chapter and section in which they appear. 
This will help readers locate the background information that builds 
the case for the recommendations themselves. For example, a rec-
ommendation numbered 4.2.3 represents the third recommenda-
tion in Chapter 4, section 2. 
 Review and finalization 
 Each chapter manuscript underwent extensive review. Final manu-
scripts were reviewed by the chapter lead and panelists; the content 
lead and co-lead; the GPTF; key members of the WFH senior man-
agement team; followed by an external team of highly experienced 
healthcare professionals with expertise in the care of people with 
hemophilia, and well-informed expert people with hemophilia from 
around the world, ensuring a global perspective. Finally, the entirety 
of the guidelines was submitted to several organizations for their 
review and consideration for endorsement. Comments at each stage 
of review were considered by the chapter leads, and modifications 
were made when relevant. No editing or changes to the recommen-
dations or remarks were permitted. A final independent peer review 
was also done through the  Haemophilia journal and the extensive 
comments were addressed. 
 12.6  |  Methodology limitations 
 As is common in guideline development, methodological processes 
have to be pragmatically adjusted to accommodate challenges with 
the available evidence, organizational matters, and other constraints. 
Similarly, with these guidelines, compromises were required in order 
to provide the best guidance possible in a clinical area with limita-
tions in the evidence base. 
 The panels were organized by invitation and without a declared 
review of conflicts of interest (although current disclosures accom-
pany this publication). All panelists were invited to participate in the 
scope of the chapter searches, which was accepted as a proxy for 
 a priori established PICO (Population/Intervention/Comparators/
Outcomes paradigm) questions. 
 Search strategies were then developed by highly experienced 
medical librarians based on the scope discussions and early drafts, 
although they were not peer-reviewed. Since the last guidelines 
were published in 2012, the searches were restricted to the years 
2010-2019 for the chapters which are revisions from the previous 
edition. However, since that edition did not include a formal system-
atic review, future searches may have to be extended further back 
in time. 
 Studies identified as retrospective by the screeners were ex-
cluded, except where specified above. For a rare disease, especially 
for the more subjective topics, a more comprehensive and reliable 
evidence base would have included these reviews. 
 Due to the high yield of references from the searches for the 
Prophylaxis in Hemophilia chapter, references were limited to stud-
ies with a minimum sample size of 40. Sample size is not a proxy for 
quality, but alternative options to limit the number of studies to meet 
the timeframe did not exist. 
 Both single screening, rather than dual screening with adjudica-
tion, and single data extractions, rather than dual extractions with 
adjudication, were necessary compromises. 
 There were no critical appraisals of the quality of the evidence 
or assessments of the feasibility of quantitative analyses as these 
had been ruled out in advance due to previous efforts to conduct 
systematic reviews in this rare disease. 
 Considerable support was provided to reduce the burden on 
the volunteer panelists in the literature searches, screenings, data 
extractions, and drafting of the manuscripts. Like all multi-chapter 
guidelines, the level of consistency of writing varied across chap-
ters, but the medical editors strove to reduce duplication and ensure 
standardization. This helped to ensure a final consistent format in 
these important guidelines for all users. 
 12.7  |  Future plans for updates 
 With this third edition, the WFH Guidelines for the Management 
of Hemophilia have advanced considerably and comply with current 
standards for guideline development using the TCBS approach. 3 
As additional research is conducted in the field of hemophilia, as 
methods standardize, and knowledge grows, published data should 
become more homogeneous and quantifiable, permitting more evi-
dence-based guideline updates by the WFH in many of the content 
areas. This will also increase the methodological rigor and allow the 
evolving science to guide future recommendations, especially in 
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areas where the research is growing, such as diagnostic methods, 
hemostatic agents, regular replacement strategies, and management 
of inhibitors apart from curative treatments. Additional efforts will 
follow the advancing work of several international initiatives to pro-
vide recommendations for digital platforms and repositories and to 
increase implementation, especially at the point of care. 
 12.8  |  Conclusion 
 Even though this third edition of the WFH Guidelines for the 
Management of Hemophilia is primarily intended for use by health-
care professionals, it will also be useful for people living with he-
mophilia and healthcare agencies and advocates around the world. 
These are trustworthy, reliable, evidence-informed, and expert-
driven recommendations that should inform and empower medical 
professionals, patients and their caregivers so that they can be bet-
ter informed and active participants in shared decision-making guid-
ing hemophilia treatment and management plans. 
 The WFH, guideline panelists, staff, and consultants did not re-
ceive any external funding for these guidelines. 
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 Acronyms and Abbreviat ions 
 AAV  adeno- associated virus 
 ABR   annualized bleeding rate 
 AJBR  annualized joint bleeding rate 
 ACMG  American College of Medical Genetics 
and Genomics 
 AF  atrial fibrillation 
 aPCC  activated prothrombin complex 
concentrate 
 APTT  activated partial thromboplastin time 
 ASA  acetylsalicylic acid 
 AVF  arteriovenous fistula 
 BDD  B- domain–deleted 
 BMD  bone mineral density 
 BMI  body mass index 
 BPI  Brief Pain Inventory 
 BT  bleeding time 
 BU  Bethesda unit 
 CABG  coronary artery bypass grafting 
 CDC  Centers for Disease Control (U.S.) 
 CDSR  Cochrane Database of Systematic 
Reviews 
 CENTRAL  Cochrane Central Register of Controlled 
Trials 
 CFC  clotting factor concentrate 
 CHAMP  CDC Hemophilia A Mutation Project 
 CHBMP  CDC Hemophilia B Mutation Project 
 CHO- KLAT  Canadian Hemophilia Outcomes- Kids Life 
Assessment Tool  
 CNS  central nervous system 
 CNV  copy number variation 
 COPM  Canadian Occupational Performance 
Measure 
 COX- 2  cyclooxygenase- 2  
 CSGE  conformation sensitive gel 
electrophoresis 
 CT  computed tomography  
 CV  coefficient of variation 
 CVAD  central venous access device 
 DDAVP  1- deamino- 8- D- arginine vasopressin, also 
known as desmopressin 
 DNA   deoxyribonucleic acid 
 DOAC  direct oral anticoagulant 
 EACA  epsilon aminocaproic acid 
 EAHAD  European Association for Haemophilia 
and Allied Disorders 
 EHL  extended half- life 
 EMA  European Medicines Agency 
 EQ  EuroQoL 
 EQA  external quality assessment 
 EQAS  external quality assessment scheme 
 EQ- VAS  EuroQoL Visual Analogue Scale 
 EQ- 5D  EuroQoL 5 Dimensions 
 FDA  Food and Drug Administration (U.S.) 
 FFP   fresh frozen plasma 
 FII, FIIa  factor II, activated factor II 
 FISH   Functional Independence Score in 
Hemophilia 
 FIX, FIXa  factor IX, activated factor IX 
 FIX:C  factor IX activity 
 FV  factor V 
 FVII, FVIIa  factor VII, activated FVII 
 FVIII  factor VIII 
 FVIII:C  factor VIII activity 
 FX, FXa  factor X, activated factor X 
 FXI  factor XI 
 FXIII  factor XIII 
 GenQA  Genomics Quality Assessment 
 GI  gastrointestinal 
 GMP  Good Manufacturing Practices 
 GPTF  Guidelines Process Task Force 
 HAL  Haemophilia Activities List 
 HAV  hepatitis A virus 
 HAEMO- QoL- A  Hemophilia- specific quality of life 
questionnaire for adults 
 HBsAg  surface antigen of the hepatitis B virus 
 HBV   hepatitis B virus 
 HCCC  Hemophilia comprehensive care centre 
 HCV   hepatitis C virus 
 HDL  high density lipoprotein 
 HEAD- US  Haemophilia Early Arthropathy Detection 
with Ultrasound 
 HGVS  Human Genome Variation Society 
 HIV  human immunodeficiency virus 
 HJHS  Hemophilia Joint Health Score 
 HMWK  high- molecular- weight kininogen 
 HRQoL  health- related quality of life 
 HTC   hemophilia treatment centre 
 ICF  International Classification of 
Functioning, Disability and Health 
(WHO) 
 ICH  intracranial hemorrhage; intracerebral 
hemorrhage 
 ICU  intensive care unit 
 IDB  inferior alveolar dental block, inferior 
alveolar nerve block 
 IEQAS  International External Quality 
Assessment Scheme 
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 IgG  immunoglobulin G (IgG1, IgG2, IgG3, 
IgG4) 
 Inv1  intron 1 inversion 
 IPAQ  International Physical Activity 
Questionnaire 
 IPSG  International Prophylaxis Study Group 
 IQC  internal quality control 
 ISTH  International Society on Thrombosis and 
Haemostasis 
 ITI  immune tolerance induction  
 IU  international unit 
 IUD  intrauterine device 
 IV  intravenous 
 LA  lupus anticoagulant 
 LDL  low density lipoprotein 
 MACTAR  McMaster Toronto Patient Disability 
Questionnaire 
 MLPA  multiplex ligation- dependent probe 
amplification 
 MMR  measles, mumps, rubella 
 MPS  massively parallel sequencing 
 MRI  magnetic resonance imaging 
 MSK  musculoskeletal 
 MSKUS  musculoskeletal ultrasound 
 NAT  nucleic acid testing 
 NGC  National Guideline Clearinghouse 
 NGS  next generation sequencing 
 NMO  national member organization 
 NSAIDs  nonsteroidal anti- inflammatory drugs 
 OR  odds ratio 
 PCC  prothrombin complex concentrate 
 PCI  percutaneous coronary intervention 
 PCR  polymerase chain reaction 
 PedHAL  Paediatric Haemophilia Activities List 
 PEG  polyethylene glycol  
 PGD  pre- implantation genetic assessment 
 PICO  Population/Intervention/Comparators/
Outcomes 
 PK  pharmacokinetics 
 PND  prenatal diagnosis 
 PNP  pooled normal plasma 
 POLICE  protection, optimum loading, ice, 
compression, elevation 
 PPP  platelet- poor plasma 
 PRICE  protection, rest, ice, compression, 
elevation 
 PRISMA  Preferred Reporting Items for Systematic 
Reviews and Meta- Analyses 
 PRO  patient- reported outcome 
 PROBE  Patient- Reported Outcomes, Burdens and 
Experiences 
 PT  prothrombin time 
 PUPs  previously untreated patients  
 QA  quality assurance 
 QoL   quality of life  
 rFIX  recombinant factor IX 
 rFIXFc  recombinant FIX- Fc 
 rFVIIa  recombinant activated factor VII 
 rFVIII  recombinant factor VIII 
 rIX- RFP  recombinant FIX fusion protein 
 rFVIIIFc  recombinant FVIII–Fc 
 rVIII- SingleChain  single- chain recombinant FVIII 
 RICE  rest, compression, ice, elevation 
 RNA  ribonucleic acid 
 SF- 36  36- Item Short Form Survey Instrument 
 SHL  standard half- life 
 siRNA- AT  small interfering RNA agent targeting 
antithrombin 
 SNV  single nucleotide variant 
 SSC  Scientific and Standardization Committee 
of the ISTH 
 STEMI  ST segment elevation myocardial 
infarction 
 STR  short tandem repeat 
 SV  structural variant 
 t½  half- life 
 TCBS  Trustworthy Consensus- Based Statement 
 TFPI  tissue factor pathway inhibitor 
 UK NEQAS  U.K. National External Quality 
Assessment Service 
 US  ultrasonography, ultrasound 
 VAS  visual analogue scale 
 vCJD  variant Creutzfeldt- Jakob disease 
 VKA  vitamin K antagonist 
 VTE  venous thromboembolism 
 VWD  von Willebrand disease 
 VWF  von Willebrand factor 
 WBDR  World Bleeding Disorders Registry 
 WFH  World Federation of Hemophilia 
 WGS  whole genome sequencing 
 WHO  World Health Organization 
 XCI  X chromosome inactivation 
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 Symbols and Measurements 
 μg  microgram (mcg) 
 °C  Celsius degrees 
 >  greater than 
 <  less than 
 =  equal to 
 ≥  greater than or equal to 
 ≤  less than or equal to 
 ±  plus or minus 
 ×  multiplied by (times) 
 BU  Bethesda Unit 
 cm  centimetre 
 dL  decilitre 
 g  gram 
 IU  international unit 
 kDa  kilodalton 
 kg  kilogram 
 m  metres 
 mcg  microgram, also known as μg 
 mg  milligram 
 mL  millilitre 
